Scenario,PMID,QID,Question,Type,Human Answer,GPT-5 base Answer,GPT-5 base Correct,GPT-4o base Answer,GPT-4o base Correct,GPT-4o FT Answer,GPT-4o FT Correct,GPT-4o AP Before Answer,GPT-4o AP Before Correct,GPT-4o AP Answer,GPT-4o AP Correct,GPT-4o AP After Answer,GPT-4o AP After Correct,GPT-4o BM25 5-shot Answer,GPT-4o BM25 5-shot Correct,GPT-4o BM25 10-shot Answer,GPT-4o BM25 10-shot Correct,Llama3.1-70B base Answer,Llama3.1-70B base Correct,Llama3.1-70B FT Answer,Llama3.1-70B FT Correct,Llama3.1-70B AP Before Answer,Llama3.1-70B AP Before Correct,Llama3.1-70B AP Answer,Llama3.1-70B AP Correct,Llama3.1-70B AP After Answer,Llama3.1-70B AP After Correct,Llama3.1-70B BM25 5-shot Answer,Llama3.1-70B BM25 5-shot Correct,Llama3.1-70B BM25 10-shot Answer,Llama3.1-70B BM25 10-shot Correct,Llama3.1-8B base Answer,Llama3.1-8B base Correct,Llama3.1-8B FT Answer,Llama3.1-8B FT Correct,Llama3.1-8B AP Before Answer,Llama3.1-8B AP Before Correct,Llama3.1-8B AP Answer,Llama3.1-8B AP Correct,Llama3.1-8B AP After Answer,Llama3.1-8B AP After Correct,Llama3.1-8B BM25 5-shot Answer,Llama3.1-8B BM25 5-shot Correct,Llama3.1-8B BM25 10-shot Answer,Llama3.1-8B BM25 10-shot Correct
Human Answer,18715920,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — sequences derive from in vitro–selected laboratory strains and recombinant constructs, not from patient samples.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer,18715920,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes — the paper reports in vitro antiviral susceptibility (EC50) and fold-change phenotypic data for selected and recombinant viruses against multiple integrase inhibitors.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,18715920,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report deposition of sequences in public databases or provide GenBank accession numbers.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,18715920,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1,Not reported,1
Human Answer,18715920,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero — no human individuals' samples were sequenced; sequencing was performed on laboratory virus stocks and recombinant viruses.,1,0,1,0,1,0,1,0,1,Not reported.,1,Not reported,1,600,0,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,9,0,Not reported,1,Not reported,1,600,0
Human Answer,18715920,6,From which countries were the sequenced samples obtained?,List,No,"Not applicable — sequences derive from laboratory virus stocks and in vitro experiments, not from patient samples in specific countries.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,"Japan, France",0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,United States,0,Not reported,1,Not reported,1,Japan,0
Human Answer,18715920,7,From what years were the sequenced samples obtained?,List,No,Not reported / Not applicable — the paper describes passages and days of in vitro selection but does not report calendar years for sample collection.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,2018-2021,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2004-2007,0,Not reported,1,Not reported,1,2018-2021,0
Human Answer,18715920,8,Were samples cloned prior to sequencing?,Boolean,No,"Population-based (direct) Sanger sequencing was used for virus populations (no cloning); separately, site-directed mutant (SDM) constructs were generated in plasmids and confirmed by sequencing (these constructs were cloned).",1,Yes,0,No,1,Yes,0,Yes,0,No.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1
Human Answer,18715920,9,Which HIV genes were reported to have been sequenced?,List,IN,"The integrase (IN) coding region of pol was sequenced (cDNA for reverse transcriptase and IN was generated, and the IN region was amplified and genotyped).",1,"Integrase, IN",1,"RT, IN",1,Pol,0,IN,1,IN.,1,IN,1,IN,1,No,0,IN,1,IN,1,IN,1,IN,1,IN,1,IN,1,Integrase (IN),1,No,0,IN,1,"PR, RT",0,Not reported,0,IN,1,"PR, RT, IN",1
Human Answer,18715920,10,What method was used for sequencing?,List,Sanger sequencing,Sanger (dideoxy) sequencing using ABI Prism BigDye Terminator cycle sequencing for PCR products (population-based full-sequence analysis); plasmid SDMs were confirmed by dideoxyribose sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not reported.,0,Sanger sequencing,1,"Sanger sequencing, Automated sequencing",1,No,0,No,0,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1,Yes,0,Sanger sequencing,1,Illumina sequencing,0
Human Answer,18715920,11,What type of samples were sequenced?,List,No,Viral RNA from culture supernatants/virus stocks of in vitro–infected MT4 cell cultures (selected virus populations and recombinant/site-directed mutant virus stocks) was sequenced.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,Virus stock,1,Viral RNA from culture supernatant or virus stock,1,Viral RNA,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Culture supernatant or virus stock,1,Plasma,0,Not reported,1,Not reported,1,Plasma,0
Human Answer,18715920,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — the sequences derive from in vitro–selected laboratory viruses and recombinant constructs, not from patients with virologic failure.",1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Not reported,1,Not reported,1,Yes,0
Human Answer,18715920,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients in this study; the work was performed using cell lines and laboratory virus strains in vitro.,1,No,1,No,1,Not Reported,1,No,1,Not reported.,1,No,1,Yes,0,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,No,1,Not reported,1,Yes,0
Human Answer,18715920,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report sequences from treated individuals; sequences are from in vitro-selected viruses and recombinant constructs.,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,Not reported,1,Yes,0
Human Answer,18715920,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable — no individuals were sampled; there is no reporting of patient drug exposure. The study exposed laboratory viruses to integrase inhibitors (and used other ARV compounds experimentally).,1,No,1,No,1,,1,,1,None.,1,Not reported,1,"INSTI (Integrase Strand Transfer Inhibitors), NRTI (Nucleoside Reverse Transcriptase Inhibitors), NNRTI (Non-nucleoside Reverse Transcriptase Inhibitors), CCR5 antagonist",0,INSTI,0,No,1,IN inhibitors (EVG and RAL),0,INSTI,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,"NRTI, NNRTI, INSTI",0,"NRTIs, NNRTIs, PIs",0,No,1,Not reported,1,"NRTI, NNRTI, INSTI, CCR5 antagonist",0
Human Answer,18715920,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable — no human participants were part of this study; the manuscript does not report patient drug exposures. Experimentally, the study used integrase inhibitors such as elvitegravir (EVG) and raltegravir (RAL) and other compounds.",1,No,1,No,1,Not Reported,1,,1,None.,1,Not reported,1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL)",0,"RAL, EVG, DTG, BIC, CAB, LEN",0,No,1,EVG and RAL,0,EVG,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,"AZT, 3TC, FTC, TDF, ATV, DRV, RAL, EVG, DTG, BIC, CAB, LEN",0,No,1,Not reported,1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0
Human Answer,19104010,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — the reported HIV sequences were derived from in vitro tissue-culture selections and cloned viral DNA, not from patient samples.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,19104010,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes — extensive in vitro antiviral activity and phenotypic resistance (EC50/IC50) data are reported.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,19104010,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report deposition of sequences in public databases or provide accession numbers.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,19104010,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported — no GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,MN234327 - MN235714,0
Human Answer,19104010,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero patient individuals — sequencing was performed on tissue-culture–derived viral DNA; 24 plasmid clones were sequenced.,1,0,1,0,1,Not reported,1,0,1,Not reported.,1,42,0,51,0,0,1,0,1,Not reported.,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,600,0,600,0
Human Answer,19104010,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — sequences originated from laboratory viral strains and in vitro selections (no country-of-origin of patient samples reported).,1,No,1,No,1,USA,0,Not Reported,1,Not reported.,1,Not reported,1,France,0,No,1,No,1,Not reported.,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,United States,0,Not reported,1,Japan,0,France,0
Human Answer,19104010,7,From what years were the sequenced samples obtained?,List,No,Not reported — the paper does not provide collection years for sequenced material.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2004-2007,0,Not reported,1,Not reported,1,Not reported,1
Human Answer,19104010,8,Were samples cloned prior to sequencing?,Boolean,Yes,Yes — PCR products were cloned into a plasmid and individual plasmid clones were sequenced.,1,No,0,No,0,Yes,1,Not Reported,0,Not reported.,0,Yes,1,No,0,No,0,No,0,Not reported.,0,Not reported,0,Not Reported,0,Not reported,0,Not reported,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0
Human Answer,19104010,9,Which HIV genes were reported to have been sequenced?,List,IN,"The integrase (IN) gene was sequenced; the amplified fragment spanned from RT nucleotide 372 to Vpr nucleotide 127 (i.e., included the IN coding region).",1,No,0,No,0,IN,1,Not reported,0,IN.,1,IN,1,IN,1,"Integrase, IN",1,No,0,Not reported.,0,Pol,0,IN,1,IN,1,IN,1,Integrase (IN),1,No,0,IN,1,"Pol, PR, RT",0,"Pol, PR, RT",0,"PR, RT, IN",1,IN,1
Human Answer,19104010,10,What method was used for sequencing?,List,Sanger,Sanger (cycle) sequencing using the BigDye terminator v3.1 kit and analysis on an ABI Prism 3100 genetic analyzer.,1,No,0,No,0,Sanger sequencing,1,Not Reported,0,Not reported.,0,Sanger sequencing,1,Sanger sequencing,1,No,0,No,0,Not reported.,0,Sanger sequencing,1,Not Reported,0,Sanger sequencing,1,Not reported,0,No,0,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Illumina sequencing,0,Illumina sequencing,0
Human Answer,19104010,11,What type of samples were sequenced?,List,No,Viral DNA extracted from infected tissue-culture cells; PCR amplicons were cloned and plasmid clones were sequenced.,1,No,1,No,1,PBMC,0,Not Reported,1,Not reported.,1,Not reported,1,Plasma samples,0,No,1,No,1,Not reported.,1,Plasma,0,Primary human T lymphocytes,0,Not reported,1,Not reported,1,Viral DNA,0,No,1,Laboratory strain,0,Plasma,0,Plasma,0,Plasma,0,Plasma,0
Human Answer,19104010,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the sequences were from in vitro–selected viruses in tissue culture; there were no sequences reported from patients failing therapy.,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,Yes,0,No,1,No,1,No.,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,19104010,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the study used cell lines, primary cells from healthy donors, and in vitro experiments; it did not involve patients enrolled in a clinical trial.",1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer,19104010,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the sequences were from laboratory-selected viruses and not from individuals with prior ARV exposure.,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,Yes,0,Yes,0,No,1,No.,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,19104010,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not applicable — no individuals were sampled; sequencing was performed on in vitro–selected viruses. (The study did test and discuss multiple drug classes in vitro: NRTIs, NNRTIs, and PIs.)",1,No,1,No,1,,1,,1,None.,1,"NRTI, NNRTI, PI",0,"INSTIs, NRTIs, NNRTIs",0,INSTI,0,No,1,Not reported.,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,"NRTI, NNRTI, PI",0,No,1,Not reported,1,,1,"NRTI, PI, NNRTI, INSTI",0,"NRTI, NNRTI, INSTI, CCR5 antagonist",0,"NRTI, NNRTI, INSTI, CCR5 antagonist",0
Human Answer,19104010,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable — no individuals were sequenced. (Experimentally, the study used/mentioned drugs such as 3TC, EFV, APV for selections and tested combinations with LPV, atazanavir, nelfinavir, TDF, AZT, FTC, 3TC, and others.)",1,No,1,No,1,Not reported,1,Not Reported,1,None.,1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Raltegravir (RAL)",0,"GS-9160, L-870,810, GS-9137, MK-0518",0,No,1,Not reported.,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,"NRTI (Nucleoside Reverse Transcriptase Inhibitor), including Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV); NNRTI (Non-Nucleosid Reverse Transcriptase Inhibitor), including Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR); PI (Protease Inhibitor), including Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV)",0,No,1,Not reported,1,Not reported,1,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0
Human Answer,21115794,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,21115794,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,21115794,3,Were sequences from the paper made publicly available?,Boolean,No,No (no deposition or accession numbers are reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer,21115794,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"FJ800379–FJ800386, GQ477441-GQ477451",0,Not reported,1,Not reported,1
Human Answer,21115794,5,How many individuals had samples obtained for HIV sequencing?,Number,0,None (0 individuals; sequencing was performed on lab/cell-culture material).,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,8,0,Not reported,1,0,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not Reported,1,50,0,50,0,8,0,8,0
Human Answer,21115794,6,From which countries were the sequenced samples obtained?,List,No,"Not applicable — sequences derived from laboratory strains and cell cultures, not from patient samples in any country.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,"France, Greece, Italy, Portugal, Spain",0,"France, Greece, Italy, Portugal, Spain",0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,United States,0,"United States, Japan, Europe",0,"France, Greece, Italy, Portugal, Spain",0,"France, Greece, Italy, Portugal, Spain",0
Human Answer,21115794,7,From what years were the sequenced samples obtained?,List,No,Not applicable — sequencing was of in vitro/cell-culture material and no collection years for patient samples are reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,2018-2021,0,2018-2021,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,2008-2010,0,2004-2007,0,2018-2021,0,2018-2021,0
Human Answer,21115794,8,Were samples cloned prior to sequencing?,Boolean,No,"No for the integrase PCR products (sequencing was performed on PCR products); cloning was performed when constructing recombinant molecular clones for mutagenesis, but PCR products from infected cells were directly sequenced.",1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,21115794,9,Which HIV genes were reported to have been sequenced?,List,IN,The integrase (IN) region was sequenced; RT- and protease-region mutants were used in susceptibility testing but sequencing focus described is integrase.,1,No,0,No,0,Not reported,0,Not reported,0,IN,1,IN,1,IN,1,No,0,No,0,IN,1,Integrase,1,IN,1,IN,1,"PR, RT, IN",1,No,0,No,0,IN,1,"PR, RT",0,"Pol, Integrase",1,"PR, RT, IN",1,IN,1
Human Answer,21115794,10,What method was used for sequencing?,List,No,Sequencing was performed by Operon Biotechnologies' sequencing service (the paper does not specify the exact sequencing technology).,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Sanger sequencing and NGS,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0
Human Answer,21115794,11,What type of samples were sequenced?,List,No,"Proviral DNA amplified from infected cell pellets (DNA extracted from infected cell cultures); additionally, plasmid/molecular-clone fragments were manipulated and used for mutagenesis and virus generation.",1,No,1,No,1,Not reported,1,Not reported,1,PBMC,0,Not reported,1,Plasma,0,No,1,No,1,Not reported,1,Plasma,0,Cell line,0,Not reported,1,Not reported,1,No,1,No,1,Plasma and PBMCs,0,Plasma,0,Plasma,0,Plasma,0,Plasma,0
Human Answer,21115794,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer,21115794,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this publication reports preclinical in vitro work, not a clinical trial with patients.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,21115794,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer,21115794,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable — no individuals' clinical samples were sequenced in this study.,1,No,1,No,1,,1,,1,,1,Not reported,1,Not reported,1,INSTI,0,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,"NRTI, NNRTI, and PI",0,"NRTIs, NNRTIs, PIs",0,"NRTIs, NNRTIs, PIs",0,,1,"NRTI, NNRTI, PI, INSTI",0
Human Answer,21115794,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable — no patient-derived sequenced samples, so no patient drug histories are reported.",1,No,1,No,1,,1,,1,,1,Not reported,1,Not reported,1,"Raltegravir (RAL), Elvitegravir(EVG)",0,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,"Lamivudine, Efavirenz, and Lopinavir",0,"AZT, 3TC, EFV, ATV, DRV",0,"AZT, 3TC, EFV, LPV/r, ATV/r",0,,1,"Etravirine, Rilpivirine",0
Human Answer,23749954,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — the study used laboratory-generated NL4-3 recombinant viruses and cell culture selections, not patient-derived sequences.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,,1
Human Answer,23749954,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No — the paper reports in vitro drug selection experiments (selection of resistance mutations) but does not present quantitative phenotypic drug susceptibility (e.g., IC50) data.",1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,We recently reported the preferential selection of the K65R resistance,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,,1
Human Answer,23749954,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report deposition of sequences or provide GenBank accession numbers.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,Yes,0,,1
Human Answer,23749954,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"KX233975 to KX234077, KX377087 to KX377116",0,,1
Human Answer,23749954,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero — no individual/patient samples were obtained or sequenced in this study.,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,103,0,103,0,Not specified,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not Reported,1,4,0,Not reported,1,133,0,,1
Human Answer,23749954,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no patient-derived samples or country-origin clinical sequences were obtained in this study.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Kenya,0,South Africa,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,"Kenya, Uganda",0,,1
Human Answer,23749954,7,From what years were the sequenced samples obtained?,List,No,Not applicable — no clinical/temporal patient-derived sequences were obtained or reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,2018-2021,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,2018-2021,0,,1
Human Answer,23749954,8,Were samples cloned prior to sequencing?,Boolean,Yes,"Yes, laboratory clones (mutant NL4-3 plasmids/viruses) were generated by site-directed mutagenesis; however, no patient sample cloning prior to sequencing applies because no patient samples were sequenced.",1,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,No,0,No,0,Not reported,0,Yes,1,Yes,1,Not reported,0,No,0,Yes,1,No,0,Yes,1,Not Reported,0,Yes,1,No,0,,0
Human Answer,23749954,9,Which HIV genes were reported to have been sequenced?,List,RT,"The study focused on the reverse transcriptase region of pol (RT) — mutations at codons K65, 64/65 and TAM sites 70, 210 and 219 were studied.",1,No,0,No,0,RT,1,Not reported,1,Not reported,1,"Gag, protease",0,"Gag, PR",0,Not specified,0,No,0,RT,1,RT,1,RT,1,IN,0,RT,1,No,0,No,0,Not Reported,1,Pol,0,Pol,0,"PR, RT, IN",1,,0
Human Answer,23749954,10,What method was used for sequencing?,List,No,Not specified — the paper does not describe a sequencing method for determining mutation identities.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,,1
Human Answer,23749954,11,What type of samples were sequenced?,List,No,"Laboratory-derived NL4-3 plasmids/viruses and viral populations from MT2 cell culture selections were analyzed (i.e., recombinant lab viruses rather than clinical specimens).",1,No,1,No,1,Not reported,1,Not reported,1,No,1,Blood (or PBMC),0,Plasma,0,No,1,No,1,Cell culture,1,"Plasma, PBMCs",0,Cell culture,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Plasma,0,Plasma,0,"Plasma, PBMC",0,,1
Human Answer,23749954,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the study did not include patient samples or sequences from individuals with virological failure.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,,1
Human Answer,23749954,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients enrolled in this study; it was an in vitro laboratory study using recombinant viruses.,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,Yes,0,Yes,0,,1
Human Answer,23749954,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report sequences from treated individuals; it discusses clinical findings from other studies but presents laboratory data from recombinant viruses.,1,No,1,No,1,Yes,0,No,1,,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Not reported,1,Not reported,1,Not reported,1,Yes,0,No,1,Not Reported,1,Yes,0,Yes,0,No,1,,1
Human Answer,23749954,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable — no individuals were sampled/sequenced in this study.,1,No,1,No,1,NRTIs,0,,1,,1,Not applicable (as they were treatment-naive),1,NNRTI,0,NRTI,0,No,1,N(t)RTIs,0,"NRTIs, NNRTIs",0,Not reported,1,Not reported,1,Not reported,1,NRTI,0,No,1,Not Reported,1,NRTI,0,"NRTI, PI",0,,1,,1
Human Answer,23749954,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable — no individuals were sampled; the study used in vitro drug selections with tenofovir, didanosine, stavudine, apricitabine and abacavir on laboratory viruses.",1,No,1,No,1,Stavudine,0,,1,,1,Not applicable (as they were treatment-naive),1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",0,"Tenofovir, didanosine, stavudine, apricitabine, and abacavir",0,No,1,"Tenofovir, didanosine, stavudine, apricitabine, and abacavir",0,"Tenofovir, didanosine, stavudine, apricitabine, abacavir",0,Not reported,1,Not reported,1,Not reported,1,"Tenofovir, Didanosine, Stavudine, Apricitabine, Abacavir",0,No,1,Not Reported,1,Abacavir,0,"Raltegravir, Dolutegravir, Elvitegravir, Bictegravir, Maraviroc, Lenacapavir",0,,1,,1
Human Answer,24227862,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — the study reports experiments with site-directed mutant proviral clones and in vitro selections using CBMCs, not sequences derived from patient samples.",1,No,1,No,1,No,1,Yes,0,** Yes,0,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,24227862,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes — the paper reports in vitro phenotypic susceptibility assays in TZM-bl cells and biochemical assays with recombinant RT enzymes.,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,24227862,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report making sequences publicly available (no GenBank accession numbers or data-deposition statement are provided).,1,No,1,No,1,No,1,No,1,** No,1,Yes,0,Yes,0,No,1,No,1,No.,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,24227862,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,** Not reported,1,"MW484893, MW484894, MW484895, DQ380549, AF492618",0,MN234327 - MN235714,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,The GenBank accession numbers are not provided in the text.,1,Not reported,1,"MW484893, MW484894, MW484895, DQ380549, AF492618, OQ336290, OQ336291, OQ336292, OQ336293, OQ336294, MW48492, AF324493",0
Human Answer,24227862,5,How many individuals had samples obtained for HIV sequencing?,Number,0,None — no patient-derived HIV sequences were obtained; experimental work used cell lines and cord blood mononuclear cells (CBMCs).,1,0,1,0,1,Not reported,1,Not reported,1,** Not reported,1,6,0,6,0,0,1,0,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,100,0,Not reported,1,6,0,6,0
Human Answer,24227862,6,From which countries were the sequenced samples obtained?,List,No,"Not applicable for patient-derived sequences; experimental CBMCs were obtained in Canada (Montreal, Canada).",1,No,1,No,1,Not reported,1,Canada,0,** Canada,0,Canada,0,"Australia, USA",0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Canada,0,United States,0,Not reported,1,"United States, Australia",0,"United States, Australia",0
Human Answer,24227862,7,From what years were the sequenced samples obtained?,List,No,Not reported / not applicable — no patient sequence sample dates are provided.,1,No,1,No,1,Not reported,1,Not reported,1,** Not reported,1,2018-2021,0,2018 - 2021,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2004-2007,0,Not reported,1,2018-2021,0,2018-2021,0
Human Answer,24227862,8,Were samples cloned prior to sequencing?,Boolean,Yes,Yes for the engineered constructs: proviral and RT expression plasmids were generated by site-directed mutagenesis and then sequenced to verify mutations; no patient-derived clones were described.,1,No,0,No,0,No,0,Not reported,0,** Not reported,0,Not reported,0,Not reported,0,No,0,No,0,Not reported.,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0
Human Answer,24227862,9,Which HIV genes were reported to have been sequenced?,List,RT,The reverse transcriptase (RT) coding region (including the connection domain) was sequenced/verified.,1,No,0,No,0,Not reported,1,RT,1,** Not reported,1,RT,1,RT,1,"Reverse transcriptase, RT",1,RT,1,RT.,1,Pol,0,No,0,IN,0,IN,0,No,0,No,0,RT,1,"Pol, PR, RT",1,Not reported,1,IN,0,IN,0
Human Answer,24227862,10,What method was used for sequencing?,List,Not reported,"The paper states that DNA sequencing was performed to verify constructs, but it does not specify the sequencing technology or method (e.g., Sanger) used.",0,No,1,No,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1,Sanger sequencing,0,No,1,No,1,Not reported.,1,Sanger sequencing,0,Sanger sequencing,0,Not reported,1,Not reported,1,No,1,No,1,Sanger sequencing,0,Sanger sequencing,0,Yes,0,Sanger sequencing,0,"Sanger sequencing, Illumina sequencing",0
Human Answer,24227862,11,What type of samples were sequenced?,List,No,Engineered plasmid constructs/proviral clones and viruses derived from those constructs (recombinant NL4.3 proviral clones and RT expression plasmids) were sequenced/verified; no patient-derived samples were sequenced.,1,No,1,No,1,Not reported,1,PBMC,0,** PBMC,0,Clinical samples,0,PBMCs,0,PBMC,0,No,1,Plasma.,0,Plasma,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,PBMC,0,Plasma,0,"NRTIs, NNRTIs, PIs, and INSTIs",0,PBMC,0,PBMC,0
Human Answer,24227862,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the study did not obtain sequences from clinical patients with virological failure; experiments were laboratory-based.,1,No,1,No,1,Not reported,1,Yes,0,** Not reported,1,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,"Efavirenz, nevirapine, lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, and lenacapavir",1,Yes,0,Yes,0
Human Answer,24227862,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients enrolled in this study; it is an in vitro/biochemical study. (Clinical trials like ECHO and THRIVE are cited for context but are not the source of study participants.),1,No,1,No,1,No,1,No,1,** Not reported,1,Not reported,1,Yes,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0
Human Answer,24227862,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the study does not report patient-derived HIV sequences from individuals with prior ARV exposure; it is based on engineered viruses and in vitro selections, though it discusses prevalence of mutations in treatment-experienced patients.",1,No,1,No,1,Not reported,1,Yes,0,** Not reported,1,Yes,0,Yes,0,Yes,0,No,1,Yes.,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0
Human Answer,24227862,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not applicable — no individuals were sampled or sequenced; however, the study focuses on interactions involving NNRTIs and NRTIs (e.g., ETR, RPV, NVP, EFV as NNRTIs; ZDV, 3TC/FTC as NRTIs) in the experimental work.",1,No,1,No,1,Not reported,1,"NRTI, NNRTI",0,** None,1,"NRTI, NNRTI",0,"NRTI, NNRTI, INSTI",0,NNRTI,0,No,1,"NRTIs, NNRTIs.",0,"NRTI, PI, INSTI",0,Not reported,1,Not reported,1,Not reported,1,NNRTI,0,No,1,"NRTI, NNRTI",0,"NRTI, NNRTI",0,No,1,Not reported,1,"NRTI, NNRTI, INSTI, CCR5 antagonist",0
Human Answer,24227862,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable — no individuals were sampled or sequenced. The experimental agents used in this study included NNRTIs (etravirine, rilpivirine, nevirapine, efavirenz) and NRTIs mentioned in context (zidovudine, lamivudine/3TC, emtricitabine/FTC), but these were used experimentally or discussed, not 'received' by study participants.",1,No,1,No,1,Not reported,1,Not reported,1,** Not reported,1,"Zidovudine (ZDV), Nevirapine (NVP)",0,"Darunavir (DRV), Ritonavir (RTV), Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT)",0,"Nevirapine (NVP), Etravirine (ETR), Rilpivirine (RPV)",0,No,1,"ZDV, NVP.",0,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0,Not reported,1,Not reported,1,Not reported,1,"Etravirine (ETR), Rilpivirine (RPV)",0,No,1,"ZDV, NVP",0,"AZT, 3TC, EFV",0,No,1,Not reported,1,"Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)",0
Human Answer,25637519,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,25637519,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,25637519,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report any public sequence deposition.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,25637519,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"MW484893, MW484894, MW484895, DQ380549, AF492618, OQ336290, OQ336291, OQ336292, OQ336293, OQ336294, MW48492, AF324493",0,GQ344955-GQ345003,0
Human Answer,25637519,5,How many individuals had samples obtained for HIV sequencing?,Number,0,None (no patient-derived sequencing reported).,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,1,0,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,100,0,265,0,265,0
Human Answer,25637519,6,From which countries were the sequenced samples obtained?,List,No,Not reported / Not applicable.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,China,0,China,0,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,China,0,China,0,Netherlands,0,Cameroon,0
Human Answer,25637519,7,From what years were the sequenced samples obtained?,List,No,Not reported / Not applicable.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,2007,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2010-2015,0,2004-2007,0,2007-2010,0,2007-2010,0
Human Answer,25637519,8,Were samples cloned prior to sequencing?,Boolean,Yes,Yes — mutated RT sequences were generated in plasmid clones and positive clones were identified and sequenced.,1,No,0,No,0,Not reported,0,No,0,Not reported,0,No,0,Yes,1,Yes,1,No,0,Not reported,0,No,0,Not reported,0,Not reported,0,Not reported,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0
Human Answer,25637519,9,Which HIV genes were reported to have been sequenced?,List,RT,Reverse transcriptase (RT) gene — specifically the RT region including the connection subdomain (positions covering RT 1–560 amino acids in modelling).,1,No,0,No,0,RT,1,RT,1,RT,1,RT,1,RT (Reverse Transcriptase),1,"Reverse transcriptase, RT",1,RT,1,"Pol, RT",1,Pol,0,Pol,0,RT,1,Not reported,1,Pol gene,0,Full genome,0,RT,1,Pol,0,Pol,0,"PR, RT, IN",1,"PR, RT, IN",1
Human Answer,25637519,10,What method was used for sequencing?,List,No,DNA sequencing of plasmid clones (method not explicitly specified; implied conventional Sanger sequencing).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Not reported,1,Not reported,1,No,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0
Human Answer,25637519,11,What type of samples were sequenced?,List,No,Plasmid/infectious clone constructs (pBRGX) containing wild-type or site-directed mutant RT sequences derived from a prior clinical isolate.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Plasma,0,Virus isolates,0,Other,0,No,1,Plasma,0,Not reported,1,Plasma,0,Not reported,1,Not reported,1,No,1,Plasma,0,Not reported,1,Plasma,0,Plasma,0,Plasma,0,Plasma,0
Human Answer,25637519,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — this study did not sequence samples from treatment-failure patients (although it cites other studies that found D404N in treatment-failure patients).,1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,25637519,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients enrolled or described in a clinical trial in this study.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer,25637519,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — this study did not report sequences from treated individuals (it only references other reports of D404N in ART-experienced patients).,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,25637519,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable / Not reported (no patient samples sequenced in this study).,1,No,1,No,1,"NRTI, NNRTI",0,,1,Not reported,1,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NRTI, NNRTI",0,No,1,"NNRTI, NRTI, PI, INSTI",0,"NRTI, NNRTI, PI",0,"NRTIs, NNRTIs, PIs",0,Not reported,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,No,1,Not reported,1,NRTIs,0,"NRTIs, NNRTIs",0,NRTI,0,"NRTI, NNRTI",0
Human Answer,25637519,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not applicable / Not reported (no patient samples sequenced in this study).,1,No,1,No,1,"Nevirapine, efavirenz",0,Not reported,1,Not reported,1,"Nevirapine, Efavirenz",0,"Lamivudine (3TC), Stavudine (d4T), Nevirapine (NVP), Zidovudine (AZT), Efavirenz (EFV)",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR)",0,No,1,"nevirapine, efavirenz, rilpivirine, zidovudine, abacavir, lamivudine, emtricitabine, tenofovir",0,"zidovudine, abacavir, lamivudine, efavirenz, nevirapine, ritonavir",0,"Zidovudine, lamivudine, efavirenz",0,Not reported,1,Not reported,1,"NRTI (Abacavir, Zidovudine, Zalcitabine, Didanosine, Lamivudine, Stavudine, Emtricitabine, Tenofovir); NNRTI (Nevirapine, Delavirdine, Efavirenz, Etravirine, Rilpivirine, Doravirine); PI (Amprenavir, Lopinavir, Atazanavir, Derunavir); INSTI (Raltegravir, Elvitegravir, Dolutegravir, Bictegravir, cabotegravir, Lenacapavir)",0,No,1,Not reported,1,"zidovudine/AZT, lamivudine/3TC, emtricitabine/FTC, tenofovir TDF/TAF, abacavir/ABC, stavudine/d4T, didanosine/ddI",0,"AZT, 3TC, EFV, NVP",0,"Tenofovir, Emtricitabine",0,"Lamivudine (3TC), Stavudine (d4T), Nevirapine (NVP), Zidovudine (AZT), Efavirenz (EFV)",0
Human Answer,26246578,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,,1
Human Answer,26246578,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0
Human Answer,26246578,3,Were sequences from the paper made publicly available?,Boolean,No,No (not reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,,1
Human Answer,26246578,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,MN234327 - MN235714,0,No,1,No,1,Not reported.,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported (no specific accession numbers mentioned),1,Not reported in the provided text,1,Not reported,1,,1
Human Answer,26246578,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero — no individuals sampled.,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,600,0,0,1,0,1,Not reported.,1,Not reported,1,Not reported,1,600,0,Not reported,1,0,1,0,1,Not Reported,1,Not reported (no specific number mentioned),1,Not reported,1,600,0,,1
Human Answer,26246578,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no patient-derived samples or sequences were obtained.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Japan,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Japan,0,Not reported,1,No,1,No,1,Not Reported,1,Canada,0,Not reported,1,Japan,0,,1
Human Answer,26246578,7,From what years were the sequenced samples obtained?,List,No,Not applicable — no samples from patients were sequenced.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,2008–2021,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,2015-2018,0,Not reported,1,Not reported,1,,1
Human Answer,26246578,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable for patient samples; laboratory plasmid constructs and viral clones were generated by cloning for experiments.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported.,1,Yes,0,Not reported,1,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,,1
Human Answer,26246578,9,Which HIV genes were reported to have been sequenced?,List,IN,No sequencing of HIV genes from patient samples was reported; the study investigated the integrase (IN) gene by engineered mutagenesis and expression.,1,No,0,No,0,Not reported,0,Not reported,0,IN,1,IN,1,"IN, PR, RT",1,No,0,No,0,Integrase.,1,"Integrase, Pol",1,IN,1,IN,1,Not reported,0,Integrase (IN),1,No,0,Integrase (IN),1,Pol,0,Not reported,0,IN,1,,0
Human Answer,26246578,10,What method was used for sequencing?,List,No,Not applicable — the paper does not describe performing sequencing of HIV samples.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Sanger sequencing,0,No,1,No,1,Not reported.,1,Sanger sequencing,0,Not reported,1,Illumina sequencing,0,Not reported,1,No,1,No,1,Sanger sequencing,0,Sanger sequencing,0,Yes,0,Illumina sequencing,0,,1
Human Answer,26246578,11,What type of samples were sequenced?,List,No,"Not applicable — no samples were sequenced; experimental materials were plasmid constructs, recombinant proteins, and cell-culture-produced viral stocks.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Plasma; Whole Blood,0,No,1,No,1,Not reported.,1,"Plasma, PBMC",0,Not reported,1,Plasma,0,Not reported,1,No,1,No,1,Cell culture,1,Plasma,0,Not reported,1,Plasma,0,,1
Human Answer,26246578,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — the study did not obtain or report sequences from individuals, including those with virological failure.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Not reported.,1,Yes,0,Yes,0,Yes,0,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Not reported,1,Yes,0,,1
Human Answer,26246578,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients in this study.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,No,1,No,1,,1
Human Answer,26246578,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the paper does not report sequences from individuals, regardless of treatment history.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported.,1,Yes,0,Yes,0,Yes,0,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,,1
Human Answer,26246578,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not applicable — no individuals or patient samples were included in this study; the drugs used in the experiments were integrase strand transfer inhibitors (INSTIs: dolutegravir, raltegravir, elvitegravir).",1,No,1,No,1,,1,,1,Not reported,1,Not reported,1,INSTI,0,INSTI,0,No,1,INSTIs.,0,"INSTI, NRTI",0,INSTI,0,"NRTI, NNRTI, INSTI, CCR5 antagonist",0,Not reported,1,No,1,No,1,Not Reported,1,"NRTI, NNRTI, PI, INSTI, CAI",0,No,1,"NRTI, NNRTI, INSTI, CCR5 antagonist",0,,1
Human Answer,26246578,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable — no individuals were sampled; experimentally the study used dolutegravir (DTG), raltegravir (RAL), and elvitegravir (EVG).",1,No,1,No,1,,1,,1,Not reported,1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Raltegravir (RAL)",0,"RAL, EVG, DTG",0,No,1,"DTG, RAL, EVG.",0,"Raltegravir, Elvitegravir, Dolutegravir",0,DTG,0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0,Not reported,1,No,1,No,1,Not Reported,1,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0,No,1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0,,1
Human Answer,26311878,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No. The study used lab-derived plasmids and viruses and sequenced PCR products from tissue-culture samples rather than patient-derived clinical samples.,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1
Human Answer,26311878,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,"Yes. The paper reports in vitro susceptibility (IC50) data for DTG, RAL, and EVG using cell-based assays.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,26311878,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report deposition of sequences to public databases or provide accession numbers.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,26311878,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported in the provided text,1,Not reported,1,Not reported,1
Human Answer,26311878,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero. No human patient samples were sequenced in this study.,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,6,0,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,1,0,12,0,Not reported in the provided text,1,1,0,Not reported,1
Human Answer,26311878,6,From which countries were the sequenced samples obtained?,List,No,"Not applicable for patient-derived samples; cord blood was obtained in Montréal, Canada. The sequenced material was laboratory-derived (NL4-3 plasmids/viruses) rather than clinical samples from countries.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Canada,0,Canada,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Canada,0,Canada,0,Not reported,1,Not reported,1,Not reported,1
Human Answer,26311878,7,From what years were the sequenced samples obtained?,List,No,Not applicable / not reported. The paper does not provide years for any sequenced samples because sequences derive from laboratory constructs and culture selections.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2004–2007,0,Not reported,1,Not reported,1,Not reported,1
Human Answer,26311878,8,Were samples cloned prior to sequencing?,Boolean,No,"For the constructs used, yes: plasmids were generated by site-directed mutagenesis and verified by sequencing; clinical sample cloning was not performed because no patient samples were used.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Yes,0,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,26311878,9,Which HIV genes were reported to have been sequenced?,List,No,Integrase (the integrase coding region of pol) was the sequenced region examined for mutations.,0,No,1,No,1,IN,0,IN,0,IN,0,IN (Integrase),0,IN,0,Integrase,0,No,1,Integrase,0,"IN, RT",0,IN,0,IN,0,IN,0,No,1,No,1,Integrase (IN),0,"PR, RT, IN",0,Pol,0,IN,0,IN,0
Human Answer,26311878,10,What method was used for sequencing?,List,No,PCR amplification (RT-PCR for viral RNA or sequencing of plasmids) followed by sequencing; the specific sequencing technology is not specified in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Illumina sequencing,0,Illumina sequencing,0,No,1,No,1,Not reported,1,Sanger sequencing,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Site-directed mutagenesis,0,Sanger sequencing,0,"Sanger sequencing, Illumina sequencing, and MiSeq",0,Illumina sequencing,0,Illumina sequencing,0
Human Answer,26311878,11,What type of samples were sequenced?,List,No,PCR products derived from viral RNA from culture supernatants (tissue-culture selections in CBMCs) and plasmid DNA constructs were sequenced.,1,No,1,No,1,Not reported,1,Not reported,1,PBMC,0,Plasma,0,PBMC,0,Other,0,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Cord blood and CBMCs,0,Plasma,0,"Plasma, serum, PBMCs, proviral DNA, and dried blood spots",0,Plasma,0,Plasma,0
Human Answer,26311878,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. The sequences reported were from laboratory constructs and tissue-culture selections, not from individuals experiencing virological failure.",1,No,1,No,1,Not reported,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,26311878,13,Were the patients in the study in a clinical trial?,Boolean,No,No. There were no patients in this study and no clinical trial involvement.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer,26311878,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The paper does not present sequences from individuals with prior ARV exposure; it focuses on laboratory-generated viruses and in vitro selections.,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,26311878,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable. No individuals were sampled or had drug histories in this study.,1,No,1,No,1,"NRTI, INSTI",0,,1,Not reported,1,INSTI (Integrase Strand Transfer Inhibitors),0,"NRTI, NNRTI",0,INSTI,0,No,1,Not reported,1,"INSTI, NNRTI",0,INSTI,0,Not reported,1,Not reported,1,No,1,No,1,INSTI (Integrase Strand Transfer Inhibitors),0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI, INSTI, CAI, and CCR5 antagonist",0,INSTI,0,"NRTI, NNRTI, PI, INSTI",0
Human Answer,26311878,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not applicable. There were no individuals in the study and thus no pre-sequencing drug exposures recorded for participants.,1,No,1,No,1,Dolutegravir,0,Not reported,1,Not reported,1,"Dolutegravir (DTG), Raltegravir (RAL), Elvitegravir (EVG)",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",0,"RAL, EVG, DTG",0,No,1,Not reported,1,"Raltegravir, elvitegravir, dolutegravir",0,"RAL, DTG",0,Not reported,1,Not reported,1,No,1,No,1,EVG (Elvitegravir),0,"AZT, 3TC, EFV, LPV/r, ATV/r",0,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, EVG, DTG, BIC, CAB, LEN, and MVC",0,Dolutegravir (DTG),0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC), Etravirine, Rilpivirine",0
Human Answer,26559830,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the study used lab-derived molecular clones and cell culture; no patient-derived HIV sequences are reported.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,26559830,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes — the paper reports in vitro phenotypic protease inhibitor (PI) susceptibility data (EC50s) using single-cycle cell culture assays.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** No,0,No,0
Human Answer,26559830,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report public deposition of sequences (no GenBank accession numbers); only that clones were sequenced and that primer sequences are available on request.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,26559830,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported (the paper does not provide specific accession numbers),1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,** HQ694834 to HQ694845,0,HQ694834 to HQ694845,0
Human Answer,26559830,5,How many individuals had samples obtained for HIV sequencing?,Number,0,None — no human individuals were sampled; sequencing was performed on laboratory molecular clones/plasmids.,1,0,1,0,1,0,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,1,0,Not reported (the paper does not provide a specific number),1,Not reported,1,** 7,0,7,0
Human Answer,26559830,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — sequences derive from laboratory clones rather than clinical samples; the clones were obtained from US-based labs (United States).,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,United States,0,"Botswana, Uganda, USA, Zimbabwe",0,Not reported,1,** France,0,France,0
Human Answer,26559830,7,From what years were the sequenced samples obtained?,List,No,Not reported / Not applicable — no patient-derived samples with collection years are described.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2004-2007,0,Not reported,1,** Not reported,1,1994-2019,0
Human Answer,26559830,8,Were samples cloned prior to sequencing?,Boolean,No,Yes — the study used molecular cloning and site-directed mutagenesis to create and sequence full-length plasmid clones.,0,No,1,No,1,Yes,0,Not reported,1,Yes.,0,Yes,0,No,1,Yes,0,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,** No,1,Yes,0
Human Answer,26559830,9,Which HIV genes were reported to have been sequenced?,List,No,Full-length viral genomes (entire genome) were sequenced; the protease gene (pol/protease region) in particular was examined and mutated.,0,No,1,No,1,PR,0,Not reported,1,PR.,0,PR (protease),0,Not reported,1,Protease,0,Protease,0,Not reported,1,Protease,0,Protease,0,Not reported,1,Not reported,1,Protease,0,Protease,0,Pol,0,Pol,0,"Pol, RT, IN, Gag, Env",0,"** PR, RT, IN",0,"PR, RT, IN",0
Human Answer,26559830,10,What method was used for sequencing?,List,No,Not specified — the paper states that clones were sequenced across the genome but does not describe the sequencing technology or protocol.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,** Sanger sequencing,0,Illumina sequencing,0
Human Answer,26559830,11,What type of samples were sequenced?,List,No,Plasmid DNA representing full-length infectious molecular clones (engineered HIV-2 and HIV-1 clones) were sequenced.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported.,1,Not applicable,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Molecular clones,1,Molecular clones,1,Cell culture,1,Plasma,0,Cell culture samples,1,** Plasma,0,Plasma; cultured viral stocks; lab-adapted strains,0
Human Answer,26559830,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the study did not sequence viruses from treated individuals or from cases of virological failure.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,26559830,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients in the study; experiments used laboratory cell lines and molecular clones.,1,No,1,No,1,Not Reported,1,No,1,Not reported.,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,No,1,** No,1,Yes,0
Human Answer,26559830,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the sequences reported derive from laboratory clones and not from individuals with prior ARV exposure.,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,26559830,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not applicable — there were no individuals sampled, so no antiretroviral drug exposures to report.",1,No,1,No,1,,1,,1,None.,1,Not reported,1,Not reported,1,PI,0,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,PI,0,No,1,,1,"NRTI, PI, NNRTI, INSTI",0,"NRTI, NNRTI, PI",0,"** NRTI, PI",0,"NRTI, PI",0
Human Answer,26559830,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not applicable — no human individuals were sampled and thus no prior drug exposures were reported.,1,No,1,No,1,,1,,1,None.,1,Not reported,1,Not reported,1,"Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Darunavir (DRV), Nelfinavir (NFV)",0,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,PI,0,No,1,,1,"AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",0,"AZT, 3TC, EFV, ATV, DRV, RTV",0,"** Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)",0,"Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV)",0
Human Answer,27009474,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,"Yes
```",1,** Yes,1
Human Answer,27009474,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,"Yes
```",1,** Yes,1
Human Answer,27009474,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,"Yes
```",1,** Yes,1
Human Answer,27009474,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,KU761565,KU761565.,1,KU761565,1,KU761565,1,KU761565,1,KU761565,1,KU761565,1,KU761565,1,KU761565,1,KU761565,1,KU761565,1,KU761565,1,KU761565,1,KU761565,1,KU761565,1,KU761565,1,KU761565,1,KU761565,1,No,0,KU761565,1,KU761565,1,"KU761565
```",1,** KU761565,1
Human Answer,27009474,5,How many individuals had samples obtained for HIV sequencing?,Number,1,One individual (the reported patient).,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,No,0,1,1,1,1,"1
```",1,** 1,1
Human Answer,27009474,6,From which countries were the sequenced samples obtained?,List,No,Not specified in the paper.,1,No,1,United States,0,Not reported,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,USA,0,Not Reported,1,Not Reported,1,Not reported,1,Not Found,0,Not reported,1,No,1,United States,0,No,1,Not Reported,1,Not Reported,1,"Not Found
```",0,** Not Found,0
Human Answer,27009474,7,From what years were the sequenced samples obtained?,List,2014,2014 (the patient sample was obtained in August 2014).,1,No,0,2014,1,2014,1,Not reported,0,2014,1,2014,1,2014,1,2014,1,2014,1,2014,1,2014,1,2014,1,2014,1,2014,1,2014,1,2014,1,No,0,2014,1,2014,1,"2014
```",1,** 2014,1
Human Answer,27009474,8,Were samples cloned prior to sequencing?,Boolean,Yes,"Yes, infectious molecular clones were created and sequenced (clinical clone).",1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not Reported,0,Not Reported,0,Yes,1,No,0,Yes,1,No,0,Yes,1,No,0,Yes,1,Yes,1,"Yes
```",1,** Yes,1
Human Answer,27009474,9,Which HIV genes were reported to have been sequenced?,List,IN,"Integrase was explicitly sequenced; protease and reverse transcriptase regions were also assessed via baseline genotypic resistance testing (i.e., protease and RT regions of pol).",1,"Integrase, IN",1,IN,1,IN,1,IN,1,IN,1,IN (Integrase),1,IN,1,"Integrase, IN",1,"PR, RT, IN",1,Pol,0,IN,1,IN,1,"PR, RT, IN",1,IN,1,No,0,Pol,0,No,0,Pol,0,IN,1,"IN
```",1,"** RT, PR",0
Human Answer,27009474,10,What method was used for sequencing?,List,No,Not specified (the paper does not state the sequencing platform or method).,1,No,1,No,1,Not reported,1,Not Reported,1,Not Reported,1,Genotypic resistance testing methods (likely Sanger sequencing),0,Infectious molecular cloning and phenotypic susceptibility testing,0,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,Sanger sequencing,0,No,1,NGS,0,NGS,0,"Molecular Cloning
```",0,** Molecular cloning,0
Human Answer,27009474,11,What type of samples were sequenced?,List,Plasma,Plasma-derived HIV-1 (the patient's August 2014 plasma sample) and infectious molecular clones derived from that clinical sample.,1,No,0,Plasma,1,Not reported,0,Not Reported,0,Not Reported,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Molecular clones,0,Plasma,1,Plasma,1,No,0,Plasma,1,Plasma,1,"Plasma
```",1,** Plasma,1
Human Answer,27009474,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the patient reported in this paper was virologically suppressed (HIV-1 RNA <50 copies/ml) on therapy at the time of the INSTI resistance test.,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,No,1,"Yes
```",0,** Yes,0
Human Answer,27009474,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,"Yes
```",0,** Yes,0
Human Answer,27009474,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"The primary sequenced individual was treatment-naive at the time of sampling (transmitted resistance), but the paper references other sequences from raltegravir-experienced individuals in GenBank.",0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,"Yes
```",1,** Yes,1
Human Answer,27009474,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, INSTI",For the primary patient sample: none prior to the sampled baseline (treatment-naive). The paper references other individuals in GenBank who were raltegravir-experienced (INSTI class).,0,"NRTI, INSTI",1,"NRTI, INSTI",1,"NRTI, INSTI",1,"NRTI, INSTI",1,"NRTI, INSTI",1,"NRTI, INSTI",1,"NRTI, NNRTI, PI",0,"INSTI, NRTI",1,"NRTI, INSTI",1,"INSTI, NRTI, NNRTI",1,"NRTI, INSTI",1,INSTI,0,"NRTI, NNRTI, PI, INSTI",1,INSTI,0,INSTI,0,No,0,No,0,"NRTI, NNRTI, INSTI",1,"NRTI, INSTI, PI",1,"NRTI, NNRTI, INSTI
```",1,"** NRTI, NNRTI, INSTI",1
Human Answer,27009474,16,Which drugs were received by individuals in the study before sample sequencing?,List,"Tenofovir, Emtricitabine, Elvitegravir","The primary patient had not received antiretroviral drugs prior to the sampled baseline (treatment-naive). The patient was started on tenofovir/emtricitabine/elvitegravir/cobicistat after the baseline sample, and the paper references other (GenBank) sequences from raltegravir-experienced individuals.",1,"Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",1,"Tenofovir (TFV), Emtricitabine (FTC), Elvitegravir (EVG), Cobicistat",1,"Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",1,"Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",1,"Tenofovir, Emtricitabine, Elvitegravir",1,"Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",1,"Tenofovir (TDF), Emtricitabine (FTC), Elvitegravir (EVG), Cobicistat",1,"Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",1,"Tenofovir (TFV), Emtricitabine (FTC), Elvitegravir (EVG)",1,"Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",1,"Tenofovir, emtricitabine, elvitegravir, cobicistat",1,"Tenofovir, emtricitabine, elvitegravir, cobicistat",1,"Zidovudine (AZT), Tenofovir (TFV), Nevirapine (NVP), Lopinavir (LPV), Indinavir (IDV), Dolutegravir (DTG)",0,Tenofovir/emtricitabine/elvitegravir/cobicistat,1,"Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,0,No,0,"Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",1,"Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",1,"Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",1,"** Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",1
Human Answer,27124362,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,27124362,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,27124362,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report making sequences publicly available.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,27124362,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported (the paper does not provide specific accession numbers),1,Not reported,1,** Not reported,1,Not reported,1
Human Answer,27124362,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero (no patient samples were sequenced in this study).,1,0,1,0,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,7,0,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,0,1,Not Reported,1,Not reported (the paper does not provide a specific number),1,Not reported,1,** 7,0,7,0
Human Answer,27124362,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no patient-derived sequences were reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,"France, Greece, Italy, Portugal, Spain",0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported (the paper does not provide specific countries),1,Not reported,1,** Spain,0,Spain,0
Human Answer,27124362,7,From what years were the sequenced samples obtained?,List,No,Not applicable — no patient-derived sequencing was reported in this paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,2018-2021,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported (the paper does not provide specific years),1,Not reported,1,** 2018-2019,0,2018-2019,0
Human Answer,27124362,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — no sequencing was performed on patient-derived samples.,1,No,1,No,1,No,1,Not reported,1,Not reported.,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,27124362,9,Which HIV genes were reported to have been sequenced?,List,No,No genes were newly sequenced in this study; the gene analyzed functionally and structurally is reverse transcriptase (RT).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,RT,0,No,1,No,1,Not reported,1,Not reported,1,"Pol, RT",0,Not reported,1,Not reported,1,No,1,No,1,RT,0,"Pol, PR, RT",0,Pol,0,** RT,0,RT,0
Human Answer,27124362,10,What method was used for sequencing?,List,No,Not applicable — the paper does not report performing sequencing.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Sanger sequencing,0,Not reported,1,Not reported,1,No,1,No,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,** Not reported,1,Sanger sequencing,0
Human Answer,27124362,11,What type of samples were sequenced?,List,No,Not applicable — no sequencing of patient samples was performed; the experimental material consisted of HIV-1 viral vectors/viruses (engineered or cell-culture-selected mutants).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"Plasma, PBMC",0,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"Plasma, PBMC",0,Plasma,0,** Plasma,0,Plasma,0
Human Answer,27124362,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — the paper did not generate or report patient-derived sequences, although it discusses mutations that are observed in virological failures in prior studies.",1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,27124362,13,Were the patients in the study in a clinical trial?,Boolean,No,No — this study is an in vitro and structural study and did not involve patients or clinical trial participants.,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,27124362,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report any patient-derived sequences; it discusses and tests mutations that have been observed in individuals on ARV therapy in prior studies.,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,27124362,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable — no individuals were sampled or sequenced in this study. The manuscript does refer to antiretroviral drug classes such as NNRTIs and NRTIs in the discussion/context.,1,No,1,No,1,,1,,1,None.,1,"NNRTI, NRTI",0,"NRTI, NNRTI, INSTI",0,NNRTI,0,No,1,Not reported,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,Not reported,1,Not reported,1,No,1,No,1,NNRTIs,0,"NRTI, PI, NNRTI, INSTI, CAI, CCR5 antagonist",0,Not reported,1,"** NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0
Human Answer,27124362,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable — no patients were sampled or sequenced. The paper references several specific ARV drugs in context (e.g., RPV, DOR, ETR, 3TC, FTC, tenofovir).",1,No,1,No,1,,1,,1,None.,1,"Doravirine (DOR), Lamivudine (3TC), Tenofovir (TFV)",0,"Doravirine (DOR), NRTIs",0,"RPV, DOR",0,No,1,Not reported,1,Not reported,1,"3TC, FTC, AZT, TDF, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, RAL",0,Not reported,1,Not reported,1,No,1,No,1,RPV and DOR,0,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0,Not reported,1,"** DOR, 3TC, TDF",0,"Doravirine (DOR), Abacavir (ABC), Lamivudine (3TC), Emtricitabine (FTC), Tenofovir (TFV), Darunavir (DRV)",0
Human Answer,28559249,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,No — the paper reports patient-derived viral isolates and recombinant clones but does not present nucleotide sequence data in the text.,0,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes.,1,Yes,1,No,0,Yes,1,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,28559249,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,28559249,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report that sequences were deposited or provide accession numbers.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,Not Reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,28559249,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,,1,"The paper reports that sequences were submitted to GenBank and provides accession numbers for these sequences. However, the specific accession numbers are not provided in the paper.",1,HQ694834 to HQ694845,0,"KP226396-KP226481, MW697236-MW697343, MW697344-MW697444, KP226314-KP226501, MW714050-MW714124",0
Human Answer,28559249,5,How many individuals had samples obtained for HIV sequencing?,Number,1,The paper tested 10 HIV-1 and 14 HIV-2 isolates (24 patient-derived strains total) in the single-cycle assays.,1,0,0,0,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,0,0,0,0,Not Reported.,0,Not reported,0,Not reported,0,7,0,Not reported,0,0,0,0,0,Not reported,0,No,0,24,0,7,0,7,0
Human Answer,28559249,6,From which countries were the sequenced samples obtained?,List,No,Not specified; the only country explicitly mentioned in the paper with respect to sample collection oversight is Senegal (ethics committee).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Not reported,1,France,0,France,0
Human Answer,28559249,7,From what years were the sequenced samples obtained?,List,No,Not reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Not reported,1,1994-2019,0,1994-2019,0
Human Answer,28559249,8,Were samples cloned prior to sequencing?,Boolean,No,"Some viruses used in the study were derived from full-length plasmid molecular clones and a recombinant clone was constructed from a treated patient, but the paper does not report sequencing workflows or whether patient-derived samples were cloned specifically for sequencing.",1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not Reported.,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1
Human Answer,28559249,9,Which HIV genes were reported to have been sequenced?,List,RT,The study focuses on reverse transcriptase (RT)/pol region changes; RT (a component of pol) is the gene region discussed.,1,No,0,RT,1,RT,1,Not reported,1,Not reported,1,Not reported,1,RT,1,No,0,No,0,Pol.,0,"Pol (PR, RT)",1,"Pol, PR, RT",1,IN,0,Not reported,1,No,0,No,0,Not reported,1,No,0,Protease and reverse transcriptase,1,"PR, RT, IN",1,"PR, RT, IN",1
Human Answer,28559249,10,What method was used for sequencing?,List,No,Not reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported.,1,Not reported,1,Not reported,1,Sanger sequencing,0,Not reported,1,No,1,No,1,Not reported,1,No,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0
Human Answer,28559249,11,What type of samples were sequenced?,List,No,"Clinical isolates (patient-derived viral strains) and laboratory molecular/recombinant clones were used; the specific clinical specimen type (e.g., plasma, PBMC) is not specified.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Patient-derived strains,0,No,1,No,1,Not Reported.,1,Not reported,1,Not reported,1,Plasma,0,Not reported,1,No,1,No,1,Not reported,1,No,1,Plasma and PBMC,0,Plasma,0,Plasma,0
Human Answer,28559249,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Yes — a recombinant clone (designated 4.7a) was derived from a patient receiving AZT, lamivudine (3TC), and ritonavir-boosted lopinavir (i.e., treatment-experienced).",0,No,1,Yes,0,Not reported,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0
Human Answer,28559249,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there is no indication that the patients providing samples were enrolled in a clinical trial; sample collection was approved by institutional and national ethics committees.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not Reported.,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,Not reported,1,No,1,No,1
Human Answer,28559249,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"Yes — the recombinant clone 4.7a was derived from a patient receiving AZT, lamivudine (3TC), and ritonavir-boosted lopinavir, indicating prior ARV exposure.",0,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0
Human Answer,28559249,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Nucleoside reverse transcriptase inhibitors (NRTIs) and a protease inhibitor (boosted PI).,0,NRTI,0,NRTI,0,NRTI,0,,1,Not reported,1,Not reported,1,NRTI,0,No,1,No,1,"NRTIs, PIs.",0,Not reported,1,NRTI,0,"NRTI, PI",0,Not reported,1,No,1,No,1,,1,No,1,"NRTI, NNRTI, PI, INSTI, and CAI",0,"NRTI, PI, INSTI",0,"NRTI, PI, INSTI",0
Human Answer,28559249,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Zidovudine (AZT), lamivudine (3TC), and ritonavir-boosted lopinavir.",0,No,1,No,1,"AZT, 3TC, ritonavir-boosted lopinavir",0,,1,Not reported,1,Not reported,1,"Darunavir, Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT)",0,No,1,No,1,"AZT, 3TC, lopinavir.",0,Not reported,1,"3TC, FTC",0,"Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)",0,Not reported,1,No,1,No,1,,1,No,1,The paper does not provide specific information on the ARV drugs received by the individuals in the study.,0,"Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)",0,"Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)",0
Human Answer,29373677,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The paper reports genotypic analysis of the integrase gene from patient samples (PBMC DNA and plasma RNA) and identifies specific mutations (N155H, K156N, K211R, E212T).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,29373677,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes. The paper reports both cell-free and cell-based (culture) assays measuring IC50/EC50 for raltegravir and dolutegravir and other susceptibility readouts.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,29373677,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report deposition of sequences or provide public accession numbers.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer,29373677,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. The paper does not provide GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451",0,Not reported,1,MZ568467-MZ568625,0
Human Answer,29373677,5,How many individuals had samples obtained for HIV sequencing?,Number,1,One individual (a single patient case).,1,0,0,1,1,1,1,1,1,1,1,51,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,Not reported,0,10,0,1,1,1,1
Human Answer,29373677,6,From which countries were the sequenced samples obtained?,List,No,Not reported. The paper does not specify the country of origin for the patient/sample in the provided text.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,France,0,France,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,Not reported,1,France,0
Human Answer,29373677,7,From what years were the sequenced samples obtained?,List,2015,"Samples were obtained during the patient's clinical follow-up around 2014–2015 (treatment history spans 2008–2015, with dolutegravir monotherapy started in 2014 and viral rebound five months later).",1,2008-2015,1,No,0,2008–2015,1,Not reported,0,2008–2015,1,2008-2015,1,2008-2014,0,No,0,No,0,2008-2015,1,2008-2015,1,Not reported,0,Not reported,0,2014,0,2008-2015,1,2008-2014,0,2008-2015,1,Not reported,0,2014-2015,1,2008-2015,1,2008-2015,1
Human Answer,29373677,8,Were samples cloned prior to sequencing?,Boolean,No,No. The paper does not report cloning of patient samples prior to genotypic analysis.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,29373677,9,Which HIV genes were reported to have been sequenced?,List,IN,The integrase (IN) gene (HIV-1 integrase region) was sequenced/genotyped.,1,"Integrase, IN",1,IN,1,IN,1,IN,1,IN,1,IN,1,IN,1,"Integrase, IN",1,IN,1,IN,1,IN,1,No,0,IN,1,IN,1,"Integrase, IN",1,Integrase,1,IN,1,"Integrase, Pol",1,Integrase,1,"PR, RT, IN",1,"PR, RT, IN",1
Human Answer,29373677,10,What method was used for sequencing?,List,No,Not reported. The paper states genotypic analysis was performed but does not specify the sequencing method.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0
Human Answer,29373677,11,What type of samples were sequenced?,List,"PBMC, Plasma","DNA from peripheral blood mononuclear cells (PBMCs) and plasma RNA were analyzed (i.e., PBMC DNA and plasma viral RNA).",1,PBMC,0,"Plasma, PBMC",1,"PBMC, Plasma",1,"Plasma, PBMC",1,PBMC,0,"Plasma, PBMCs",1,Plasma and PBMCs,1,PBMC,0,PBMC,0,"PBMC, Plasma",1,PBMC,0,Plasma,0,"Plasma, PBMC",1,DNA from PBMCs and plasma RNA,1,Plasma,0,PBMC,0,PBMCs,0,"Plasma, PBMC",1,Plasma,0,Plasma,0,Plasma,0
Human Answer,29373677,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes. Sequences/genotypic data were obtained from a patient who experienced virological failure on dolutegravir monotherapy (viral load became detectable).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,29373677,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The paper reports a single patient case and does not indicate enrollment in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,Yes,0
Human Answer,29373677,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. The patient had prior antiretroviral therapy including raltegravir and tenofovir/emtricitabine before the dolutegravir monotherapy and sequencing.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,29373677,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"INSTI, NRTI",Integrase strand-transfer inhibitors (INSTIs) and nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs).,1,"INSTI, NRTI",1,"NRTI, INSTI",1,INSTI,0,"NRTI, INSTI",1,"NRTI, INSTI",1,INSTIs (Integrase Strand Transfer Inhibitors),0,"INSTI, NRTI",1,INSTI,0,INSTI,0,"INSTI, NRTI",1,INSTI,0,"NRTI, PI, INSTI",1,"INSTI, other ARV targets",0,INSTI,0,INSTI,0,INSTI,0,INSTIs,0,INSTI,0,INSTIs,0,INSTI,0,INSTI,0
Human Answer,29373677,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TFV, FTC, RAL, DTG",Raltegravir and tenofovir/emtricitabine (Truvada); subsequently the patient received dolutegravir monotherapy (the failure occurred on dolutegravir).,1,"Raltegravir, Tenofovir, Emtricitabine",0,"Raltegravir (RAL), Tenofovir (TFV), Emtricitabine (FTC), Dolutegravir (DTG)",1,"Raltegravir, Tenofovir, Emtricitabine",0,"Tenofovir, Emtricitabine, Raltegravir",0,"Raltegravir, Tenofovir, Emtricitabine",0,"Raltegravir, Tenofovir, Emtricitabine",0,"Raltegravir (RAL), Tenofovir (TF), Emtricitabine (FTC)",0,"Dolutegravir (DTG), Raltegravir (RAL)",0,"Raltegravir, Dolutegravir",0,"Raltegravir, Tenofovir, Emtricitabine, Dolutegravir",1,"Raltegravir, dolutegravir",0,Dolutegravir,0,"Raltegravir, Dolutegravir",0,"Raltegravir (RAL), Dolutegravir (DTG)",0,"Raltegravir, Tenofovir/emtricitabine",0,"Raltegravir, Dolutegravir",0,Raltegravir,0,Dolutegravir,0,Dolutegravir,0,"Raltegravir (RAL), Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC)",0,Raltegravir (RAL),0
Human Answer,30053052,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports patient-derived HIV sequences used to create chimeric viruses and to clone RT genes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,30053052,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes. The paper reports both cell-based phenotypic drug susceptibility assays (ex vivo) and cell-free biochemical (in vitro) susceptibility/IC50 assays.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,30053052,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report GenBank accession numbers or state that sequences were deposited in a public database.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,30053052,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. The paper does not provide any GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,"MW484893, MW484894, MW484895, DQ380549",0,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"The paper reports the following GenBank accession numbers: FJ800379–FJ800386, GQ477441-GQ477451, KP170487.",0,"MW484893, MW484894, MW484895, DQ380549, AF492618, OQ336290, OQ336291, OQ336292, OQ336293, OQ336294, MW48492",0,Not reported,1
Human Answer,30053052,5,How many individuals had samples obtained for HIV sequencing?,Number,51,51 individuals had stored plasma samples selected (42 therapy-naive and 9 with virological failure); sequencing/cloning yielded 24 replication-competent viruses from treatment-naive individuals and 3 from therapy-failure patients (27 replication-competent viruses total).,1,51,1,51,1,51,1,27,0,51,1,51,1,51,1,51,1,51,1,51,1,51,1,27.,0,51,1,51,1,51,1,0,0,51,1,24,0,24,0,51,1,51,1
Human Answer,30053052,6,From which countries were the sequenced samples obtained?,List,Sweden,"Sweden (samples were from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden).",1,Sweden,1,Sweden,1,Sweden,1,Sweden,1,Sweden,1,Sweden,1,Sweden,1,Sweden,1,Sweden,1,Sweden,1,Sweden,1,Not reported.,0,Sweden,1,Sweden,1,Sweden,1,No,0,Sweden,1,Sweden,1,Sweden,1,Sweden,1,Sweden,1
Human Answer,30053052,7,From what years were the sequenced samples obtained?,List,No,Not reported. The manuscript does not specify the years of sample collection.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2008-2010,0,2014-2018,0,Not reported,1,Not reported,1
Human Answer,30053052,8,Were samples cloned prior to sequencing?,Boolean,No,"Yes. The gag-pol fragment was cloned into pNL43 to produce chimeric viruses, and RT genes were PCR-amplified and cloned for protein expression.",0,No,1,No,1,Yes,0,Yes,0,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Not reported.,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1
Human Answer,30053052,9,Which HIV genes were reported to have been sequenced?,List,RT,gag-pol (HXB2 coordinates 0702-5798) was cloned and used; RT genes (part of pol) were specifically PCR-amplified and cloned for enzymatic assays. A previously published near full-length sequencing protocol was also referenced.,1,"Reverse transcriptase, RT",1,"Full length Genome, Gag, Pol, RT",1,"Gag, Pol",0,"PR, RT",1,Not reported,1,gag-pol,0,"*gag-pol*, RT",1,Capsid,0,"Gag, Pol",0,Gag-pol,0,Pol,0,"Gag, Pol.",0,gag-pol,0,"gag, pol",0,gag and pol,0,No,0,"Gag, Pol",0,Pol,0,"Gag, Pol",0,gag-pol,0,gag-pol,0
Human Answer,30053052,10,What method was used for sequencing?,List,No,"Not explicitly specified. The paper references a previously published near full-length sequencing protocol and describes PCR amplification and cloning of viral fragments, but it does not state the sequencing platform or approach (e.g., Sanger or NGS).",0,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Sanger sequencing,0,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Phenotypic assay,0,Not reported,1,No,1,No,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Cloning and sequencing,0,Not reported,1
Human Answer,30053052,11,What type of samples were sequenced?,List,Plasma,Plasma samples (viral RNA extracted from plasma) were used to obtain sequences and produce chimeric viruses.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,Plasma,1,No,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,30053052,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Sequences (replication-competent viruses) were obtained from three patients with virological treatment failure, and those isolates harbored resistance mutations.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,30053052,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The patients were sampled from an HIV cohort at Karolinska University Hospital; there is no indication that they were participants in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1
Human Answer,30053052,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. Sequences were obtained from individuals with virological treatment failure (i.e., previously treated), and those isolates contained resistance mutations consistent with prior ARV exposure.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,30053052,15,Which drug classes were received by individuals in the study before sample sequencing?,List,Not reported,The paper implies prior exposure to NRTIs and NNRTIs based on the detected resistance mutations; specific class exposure is not explicitly listed for each patient.,0,"NRTI, NNRTI",0,No,1,"NRTI, NNRTI",0,"NRTI, NNRTI",0,Not reported,1,"NRTIs, NNRTIs",0,NRTI,0,"NNRTI, NRTI",0,"NRTI, NNRTI",0,"NRTIs, NNRTIs",0,Not reported,1,"NRTIs, NNRTIs, PIs.",0,Not reported,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,No,1,"NRTI, NNRTI",0,NRTI,0,"NRTI, NNRTI",0,"NRTIs, NNRTIs, PIs",0,"NRTI, NNRTI, PI",0
Human Answer,30053052,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not explicitly reported. The manuscript does not list the specific antiretroviral drugs taken by patients; based on resistance mutations, likely exposures include NRTIs such as tenofovir and lamivudine/emtricitabine and NNRTIs such as efavirenz or nevirapine, but these are inferred rather than stated.",0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,"Etravirine, Rilpivirine",0,"Etravirine, Rilpivirine",0,"Nevirapine, Efavirenz, Etravirine, Rilpivirine, Tenofovir alafenamide",0,"Tenofovir, Lamivudine, Nevirapine, Efavirenz, Etravirine, Rilpivirine",0,"Tenofovir alafenamide, nevirapine, efavirenz, etravirine, rilpivirine",0,Not reported,1,"Tenofovir alafenamide, nevirapine, efavirenz, etravirine, rilpivirine, and other ARV drugs.",0,Not reported,1,Not reported,1,"Abacavir (ABC), Zidovudine (AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir (EVG), Dolutegravir (DTG), Bictegravir (BIC), Cabotegravir (CAB), Lenacapavir (LEN)",0,No,1,Not reported,1,"AZT, 3TC, FTC",0,"AZT, 3TC, TDF, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC.",0,"Etravirine, Rilpivirine",0,Not reported,1
Human Answer,30803972,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No. The paper does not report nucleotide sequence data from patient-derived samples; it reports phenotypic drug-susceptibility testing of virus isolates and site-directed mutant clones.,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,,1
Human Answer,30803972,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes. The paper reports in vitro drug susceptibility data (EC50 values and fold-resistance) obtained in a single-cycle culture-based assay.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,,0
Human Answer,30803972,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report that any sequences were deposited in public databases.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,,1
Human Answer,30803972,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. The paper does not provide any GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences, but the specific accession numbers are not provided in the text.",1,"KP226396-KP226481, MW697236-MW697343, MW697344-MW697444, KP226314-KP226501, MW714050-MW714124",0,,1
Human Answer,30803972,5,How many individuals had samples obtained for HIV sequencing?,Number,0,"Not applicable for sequencing (no sequencing reported). For the phenotypic assays, the study tested 9 HIV-1 isolates and 15 HIV-2 isolates.",1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Yes,0,0,1,24,0,15,0,24,0,6,0,,1
Human Answer,30803972,6,From which countries were the sequenced samples obtained?,List,No,Not specified. The paper does not provide country-level origins for sequenced samples (no sequencing reported) or for most isolates.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,United States,0,Not Reported,1,France,0,,1
Human Answer,30803972,7,From what years were the sequenced samples obtained?,List,No,Not specified. The paper does not report years of sample collection or sequencing.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,1994-2019,0,,1
Human Answer,30803972,8,Were samples cloned prior to sequencing?,Boolean,No,"Not applicable for sequencing. The study used existing molecular clones and generated site-directed mutant clones, but it did not report cloning patient-derived sequences for sequencing.",1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,,1
Human Answer,30803972,9,Which HIV genes were reported to have been sequenced?,List,No,"Not applicable — the paper does not report sequencing gene regions; however, the study focused on the integrase-encoding region of pol (site-directed mutations were constructed and tested).",1,No,1,IN,0,IN,0,IN,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,IN,0,IN,0,IN,0,IN,0,No,1,No,1,Integrase,0,"PR, RT",0,Not Reported,1,IN,0,,1
Human Answer,30803972,10,What method was used for sequencing?,List,No,Not applicable. The paper does not describe any sequencing methods because it does not report sequence data.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Single-cycle assay,0,Not reported,1,Yes,0,Sanger sequencing,0,,1
Human Answer,30803972,11,What type of samples were sequenced?,List,No,Not applicable. No sequencing of samples was reported. The study used cell-free virus stocks generated from plasmid molecular clones and virus isolates obtained from reagent sources.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Cell-free stocks,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Plasma,0,"NRTIs, NNRTIs, PIs, INSTIs",0,Plasma,0,,1
Human Answer,30803972,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. The isolates tested in this study were from ART-naive individuals, and no sequences from treatment-failure patients were reported here.",1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,"TDF, FTC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB",1,Yes,0,,1
Human Answer,30803972,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. The study was an in vitro laboratory investigation using isolates and molecular clones, not a clinical trial.",1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,Not Reported,1,No,1,,1
Human Answer,30803972,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No. The isolates tested were from ART-naive individuals, and the paper does not report sequences from ARV-experienced individuals.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,Not reported,1,Not reported,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,,1
Human Answer,30803972,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable. The individuals from whom isolates were obtained were ART-naive and thus had not received antiretroviral drug classes prior to sampling.,1,No,1,No,1,,1,,1,,1,Not reported,1,Not reported,1,INSTI,0,No,1,Not reported,1,Not reported,1,INSTI,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,NRTI,0,"NRTIs, NNRTIs, PIs, INSTIs",0,"NRTI, PI, INSTI",0,,1
Human Answer,30803972,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not applicable. The study samples came from ART-naive individuals who had not received antiretroviral drugs prior to sampling.,1,No,1,No,1,,1,,1,,1,Not reported,1,Not reported,1,Bictegravir,0,No,1,Not reported,1,Not reported,1,Raltegravir,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"TDF, FTC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB",0,"Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)",0,,1
Human Answer,31988104,1,Does the paper report HIV sequences from patient samples?,Boolean,No,Yes. The study used patient-derived HIV isolates (patient samples) to generate viruses for phenotypic testing.,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer,31988104,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes. The paper reports extensive in vitro phenotypic drug susceptibility data (EC50 fold-changes and viral breakthrough assays).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,31988104,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report GenBank accession numbers for patient-derived sequences; only GenBank numbers for reference plasmid clones are given.,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer,31988104,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,No GenBank accession numbers are reported for patient-derived HIV isolates. The only GenBank accession numbers given are for reference plasmids: K03455 (pLAI3.2-derived) and AF324493 (NL4.3-derived).,1,No,1,No,1,"K03455, AF324493",0,K03455,0,Not reported,1,Not reported,1,MN234327 - MN235714,0,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,K03455,0,Not reported (the paper does not provide specific accession numbers),1,Not reported in the provided text,1,Not reported,1,Not reported,1
Human Answer,31988104,5,How many individuals had samples obtained for HIV sequencing?,Number,0,"Samples from 14 patient-derived isolates were used (i.e., 14 patient-derived samples).",0,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,6,0,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,42,0,42,0,0,1,0,1,Not Reported,1,110,0,110,0,42,0,42,0
Human Answer,31988104,6,From which countries were the sequenced samples obtained?,List,No,Not reported. The paper does not specify the countries of origin for the patient-derived isolates.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,"France, Greece, Italy, Portugal, Spain",0,"France, Greece, Italy, Portugal, Spain",0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,"France, Greece, Italy, Portugal, Spain",0,Not reported,1
Human Answer,31988104,7,From what years were the sequenced samples obtained?,List,No,Not reported. The manuscript does not state the years when patient samples were collected.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,2018-2021,0,2018-2021,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,2008-2017,0,Not reported,1,2018-2021,0,Not reported,1
Human Answer,31988104,8,Were samples cloned prior to sequencing?,Boolean,No,Yes. DNA fragments (from SDM and PCR of patient isolates) were cloned into plasmid backbones (pKSHX and pXXLAI) to generate viruses used in assays.,0,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer,31988104,9,Which HIV genes were reported to have been sequenced?,List,RT,The study focused on the reverse transcriptase (RT) region within the pol gene (RT mutations/TAMs and M184V were the targets).,1,No,0,RT,1,Pol,0,Pol (indicating a focus on the *pol* region including protease and reverse transcriptase),1,Not reported,1,RT,1,RT (Reverse Transcriptase),1,No,0,No,0,Not reported,1,"Pol, RT",1,Pol,0,RT,1,RT,1,No,0,No,0,RT,1,"PR, RT",1,"Pol, PR, RT",1,Not reported,1,RT,1
Human Answer,31988104,10,What method was used for sequencing?,List,No,"Not specified in the main text. The paper describes PCR, site-directed mutagenesis, cloning, and plasmid-based virus production but does not describe a sequencing method (e.g., Sanger or NGS) used to generate or confirm sequences in the main text.",1,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,Sanger sequencing,0,No,1,No,1,Not reported,1,Sanger sequencing,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Not reported,1
Human Answer,31988104,11,What type of samples were sequenced?,List,No,"Patient-derived clinical isolates (ART-experienced patient isolates) were used; the manuscript does not specify the clinical specimen type (e.g., plasma) from which isolates were derived.",0,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,Plasma,0,No,1,No,1,Not reported,1,Plasma,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Patient isolates,0,Plasma,0,"Plasma, serum, PBMC, proviral DNA, dried blood spots",0,Plasma,0,Patient samples,0
Human Answer,31988104,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not explicitly reported. The isolates are described as ART-experienced and many contain TAMs, but the paper does not state whether donors were experiencing virological failure at time of sampling.",1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer,31988104,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The experiments used laboratory-created viruses and patient-derived isolates; the patient samples used to generate isolates are not described as coming from a clinical trial in this study.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,Not reported,1,Not reported,1,Yes,0,No,1
Human Answer,31988104,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,Yes. The paper explicitly states that patient-derived isolates were from ART-experienced individuals.,0,No,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer,31988104,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not explicitly reported. The paper does not list prior treatment regimens by drug class for the donors, though the mutations studied (TAMs and M184V) indicate prior exposure to NRTIs (thymidine analogs and 3TC/FTC).",0,No,1,No,1,Not reported,1,,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0,No,1,Not reported,1,"NRTI, NNRTI, INSTI",0,"NRTIs, NNRTIs, PIs",0,Not reported,1,Not reported,1,No,1,No,1,"NRTIs, NNRTIs, and INSTIs",0,"NRTI, NNRTI",0,NRTI,0,"NRTI, NNRTI, PI, INSTI, CAI",0,"NRTI, NNRTI, PI, INSTI",0
Human Answer,31988104,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not specified. The manuscript does not report individual patients' prior drugs; based on the mutations present (TAMs and M184V), donors likely received thymidine analog NRTIs (e.g., AZT/d4T) and 3TC/emtricitabine, but this is an inference, not explicitly stated.",1,No,1,No,1,Not reported,1,,1,Not reported,1,"Tenofovir (TFV), Emtricitabine (FTC), Darunavir (DRV), Dolutegravir (DTG), Doravirine (DOR), Ibalizumab (IBA)",0,"Tenofovir, Emtricitabine, Darunavir, Dolutegravir",0,"Abacavir (ABC), Zidovudine (AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir (EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,1,Not reported,1,"TAF, TFV, AZT, RAL",0,"TDF, FTC, EFV, ATV",0,Not reported,1,Not reported,1,No,1,No,1,"Elvitegravir, cobicistat, emtricitabine, and TAF",0,"TAF, TDF",0,Not reported,1,"Tenofovir (TFV), Emtricitabine (FTC), Darunavir (DRV), Dolutegravir (DTG), Doravirine (DOR), Ibalizumab (IBA), Lenacapavir (LEN)",0,"Tenofovir (TFV), Emtricitabine (FTC), Darunavir (DRV), Dolutegravir (DTG), Doravirine (DOR), Ibalizumab (IBA)",0
Human Answer,32601157,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — the study did not report sequencing of primary patient samples; it used engineered IN mutants, recombinant vectors, and some references to patient-derived IN sequences introduced into laboratory constructs, but no primary patient sequence datasets were reported.",1,No,1,No,1,No,1,Yes,0,No.,1,No,1,No,1,No,1,No,1,Yes.,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,32601157,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes — extensive in vitro drug susceptibility (antiviral potency) data are reported using single-round infectivity assays.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,32601157,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report making sequences publicly available (no accession numbers or database deposits are provided).,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,32601157,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,"AF009409, AB253428, AY713409, AY173956, AY173952, AY173955, AF067158, AY444801, AF484502, AF484477, AY713424, AY713421",0,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported (the paper does not provide specific accession numbers),1,"The paper reports the following GenBank accession numbers: FJ800379–FJ800386, GQ477441-GQ477451, KP170487.",0,Not reported,1,"AF009409, AB253428, AY713409, AY173956, AY173952, AY173955, AF067158, AY444801, AF484502, AF484477, AY713424, AY713421",0
Human Answer,32601157,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Not applicable / none reported — the study did not report sequencing of samples from individual patients.,1,0,1,0,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,50,0,0,1,0,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported (the paper does not provide a specific number),1,21,0,Not reported,1,8,0
Human Answer,32601157,6,From which countries were the sequenced samples obtained?,List,No,Not reported / not applicable.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,"France, Greece, Italy, Portugal, Spain",0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,United States,0,United States,0,Not reported,1,"France, Greece, Italy, Portugal, Spain",0
Human Answer,32601157,7,From what years were the sequenced samples obtained?,List,No,Not reported / not applicable.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,2018-2021,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,2004-2007,0,Not reported,1,2018-2021,0
Human Answer,32601157,8,Were samples cloned prior to sequencing?,Boolean,No,Yes — IN coding sequences and mutant constructs were prepared in plasmid vectors (cloned/subcloned) and then sequenced to verify the constructs.,0,No,1,No,1,No,1,No,1,Not reported.,1,Not reported,1,No,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1
Human Answer,32601157,9,Which HIV genes were reported to have been sequenced?,List,No,Integrase (IN) coding sequences were sequenced/verified.,0,No,1,No,1,IN (Integrase),0,IN,0,Not reported.,1,IN,0,IN,0,No,1,No,1,IN.,0,Pol,0,IN,0,"PR, RT, IN",0,Not reported,1,No,1,No,1,IN,0,Pol,0,Pol,0,IN,0,IN,0
Human Answer,32601157,10,What method was used for sequencing?,List,No,Not specified — the paper states constructs were 'verified by sequencing' but does not specify the sequencing technology or method.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Sanger sequencing,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Not reported,1,Sanger sequencing,0
Human Answer,32601157,11,What type of samples were sequenced?,List,No,Plasmid DNA constructs containing IN coding sequences (cloned in pBluescript KS+ and subcloned into pNLNgoMIVR-ΔEnv.LUC) were sequenced to verify mutant constructs.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Viral sequences from patients,0,No,1,No,1,Not reported.,1,Plasma,0,Viral vectors,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Plasma,0,Plasma,0,Not reported,1,Plasma,0
Human Answer,32601157,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the study itself did not report sequencing of samples from individuals with virological failure; references are made to INSTI-experienced or clinical isolates in prior reports but no new patient failure-derived sequences are presented.,1,No,1,No,1,No,1,Not reported,1,No.,1,No,1,No,1,No,1,No,1,Yes.,0,Yes,0,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,32601157,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients enrolled in a clinical trial in this study; the work was laboratory-based using viral vectors and engineered mutants.,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0
Human Answer,32601157,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the paper does not report sequences obtained from individuals with known prior ARV exposure; it focuses on engineered mutants and in vitro selections, though it discusses INSTI-experienced patients in the literature context.",1,No,1,No,1,Not reported,1,Not reported,1,No.,1,No,1,No,1,No,1,No,1,Yes.,0,Yes,0,Not reported,1,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,32601157,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable / not reported — no individuals were sequenced in this study; however the paper discusses integrase strand transfer inhibitors (INSTIs) and nucleoside reverse transcriptase inhibitors (NRTIs) in the clinical background.,1,No,1,No,1,,1,Not reported,1,None.,1,Not reported,1,Not reported,1,INSTI,0,No,1,"INSTIs, NRTIs.",0,"NRTI, PI, INSTI, CAI",0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,INSTI,0,NRTI,0,NRTIs and NNRTIs,0,Not reported,1,Not reported,1
Human Answer,32601157,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable / not reported — no patient sequencing with documented treatment histories was reported. The manuscript studies DTG, BIC, CAB and other INSTIs in vitro but does not report drugs received by sequenced individuals.",1,No,1,No,1,Not reported,1,Not reported,1,None.,1,Not reported,1,Not reported,1,"Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,1,"DTG, BIC, CAB.",0,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,"DTG, BIC, and CAB",0,AZT,0,"AZT, 3TC, and EFV",0,Not reported,1,Not reported,1
Human Answer,33855437,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,33855437,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes. Cell-based in vitro phenotypic assays measuring EC50 and fold-resistance were performed.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,33855437,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. Several isolates are listed with GenBank accession numbers.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0
Human Answer,33855437,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,"MW484894, MW484895, MW484893, DQ380549, AF492618, MW48492","As reported in the paper: MW484894, MW484895, MW484893, DQ380549, AF492618, MW48492, AF324493.",1,"MW484894, MW484895, MW484893, DQ380549, AF492618",0,"MW484894, MW484895, MW484893, DQ380549, AF492618, MW48492, AF324493",1,"MW484894, MW484895, MW484893, DQ380549",0,"MW484894, MW484895, MW484893, DQ380549, AF492618",0,"MW484894, MW484895, MW484893, DQ380549",0,"MW484893, MW484894, MW484895, DQ380549, AF492618, MW48492, AF324493",1,"MW484893, MW484894, MW484895, DQ380549, AF492618",0,"MW484894, MW484895, MW484893, DQ380549, AF492618, MW48492, AF324493",1,"MW484894, MW484895, MW484893, DQ380549, AF492618, MW48492, AF324493",1,"MW484894, MW484895, MW484893, DQ380549, MW48492, AF324493",0,"MW484894, MW484895, MW484893, DQ380549, AF492618, MW48492, AF324493",1,"MW484894, MW484895, MW484893, DQ380549, AF492618, MW48492, and AF324493",1,"MW484893, MW484894, MW484895, DQ380549, AF492618",0,"MW484893, MW484894, MW484895, DQ380549, AF492618, OQ336290, OQ336291, OQ336292, OQ336293, OQ336294, MW48492, AF324493",1,"AF492618, MW48492, AF324493",0,"MW484894, MW484895, MW484893, DQ380549, MW48492, AF324493",0,"MW484892, MW484893, MW484894, MW484895, AF492618, MW48492, AF324493",0,"MW484894, MW484895, MW484893, DQ380549, AF492618",0,"MW484894, MW484895, MW484893, DQ380549, and AF492618",0,"MW484893, MW484894, MW484895, DQ380549, AF492618, OQ336290, OQ336291, OQ336292, OQ336293, OQ336294, MW48492, AF324493",1,"MW484893, MW484894, MW484895, DQ380549",0
Human Answer,33855437,5,How many individuals had samples obtained for HIV sequencing?,Number,6,Six individuals (three subtype B and three non-B clinical isolates).,1,6,1,6,1,4,0,6,1,Not reported,0,5,0,7,0,6,1,0,0,6,1,7,0,6,1,10,0,10,0,6,1,4,0,6,1,6,1,6,1,Not reported,0,6,1
Human Answer,33855437,6,From which countries were the sequenced samples obtained?,List,"Canada, Ethiopia",Explicitly reported origin: Ethiopia (isolate 4742). Other patient isolates were from 'Clinique Actuel' (location not specified in the paper) and additional isolates/reagents were obtained from the NIH repository (USA).,0,"Canada, Ethiopia",1,"Canada, Ethiopia, United States",1,Ethiopia,0,Ethiopia,0,Ethiopia,0,Ethiopia,0,Ethiopia,0,Ethiopia,0,"Canada, Ethiopia",1,"Canada, Ethiopia",1,Ethiopia,0,"Botswana, Uganda, USA, Zimbabwe, Ethiopia, and Israel",0,Not reported,0,Not reported,0,"Ethiopia, Israel",0,Canada,0,Ethiopia,0,"Canada, Ethiopia",1,Ethiopia,0,Not reported,0,Not reported,0
Human Answer,33855437,7,From what years were the sequenced samples obtained?,List,No,Not reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,2018-2021,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,33855437,8,Were samples cloned prior to sequencing?,Boolean,No,No evidence of cloning prior to sequencing was reported.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,33855437,9,Which HIV genes were reported to have been sequenced?,List,RT,"The reverse transcriptase (RT) region of pol (RT) was analyzed (i.e., RT-associated drug resistance mutations).",1,No,0,RT,1,Pol,0,"PR, RT",1,Not reported,1,RT,1,RT,1,No,0,RT,1,Not reported,1,Pol,0,Pol,0,RT,1,RT,1,"Protease, RT, IN",1,RT,1,Pol,0,"Pol, PR, RT",1,Pol,0,RT,1,RT,1
Human Answer,33855437,10,What method was used for sequencing?,List,No,"Genotypic analyses of viral RNA were performed, but the paper does not specify the sequencing technology or platform (e.g., Sanger vs. NGS).",0,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Sanger sequencing,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Sanger sequencing,0,No,1,Sanger sequencing,0,Not reported,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0
Human Answer,33855437,11,What type of samples were sequenced?,List,No,Viral RNA from patient-derived clinical isolates propagated in cell culture; RNA was extracted from stored cell culture supernatants following serial passage in cord blood mononuclear cells.,1,PBMC,0,No,1,Not Reported,1,Not reported,1,Not reported,1,Plasma samples,0,Plasma,0,PBMC,0,No,1,Clinical isolates,0,"Plasma, PBMC",0,Plasma,0,Not reported,1,Plasma,0,Plasma,0,Cell culture,1,Blood,0,Plasma,0,"Plasma, serum, PBMC, and dried blood spots",0,Plasma,0,Plasma,0
Human Answer,33855437,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No clear evidence of sequencing from individuals with virological failure on treatment; most patient-derived isolates were from drug‑naive individuals, though one isolate (96USSN20) had baseline thymidine-analogue mutations.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0
Human Answer,33855437,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The paper does not report that patients were enrolled in a clinical trial; samples were obtained with ethics approval and informed consent.,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Yes,0,No,1
Human Answer,33855437,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,Mostly no — the primary patient-derived isolates were from drug‑naive individuals; however one named isolate (96USSN20) had baseline thymidine-analogue mutations suggesting prior ARV exposure or transmitted resistance.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0
Human Answer,33855437,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not generally reported for study participants; however the presence of thymidine-analogue mutations (D67N, T69D, K70R) in isolate 96USSN20 suggests exposure to thymidine-analogue NRTIs (a subclass of NRTIs).",0,No,1,No,1,,1,,1,,1,"NRTI, NNRTI, PI",0,"NRTIs, NNRTIs, Protease Inhibitors (PIs)",0,NNRTI,0,No,1,"NNRTIs, NRTIs",0,"NNRTIs, NRTIs",0,"NRTIs, NNRTIs, and PIs",0,Not reported,1,Not reported,1,No,1,No,1,,1,,1,NRTIs and NNRTIs,0,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0
Human Answer,33855437,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Specific drug names are not reported. The paper only notes thymidine-analogue-associated resistance mutations for isolate 96USSN20 (indicative of prior exposure to thymidine-analogue NRTIs), but it does not list drug names.",1,No,1,No,1,,1,,1,,1,"Etravirine, Rilpivirine",0,"Etravirine, Rilpivirine",0,"Doravirine, Rilpivirine",0,No,1,"Doravirine, rilpivirine, lamivudine, islatravir",0,"Doravirine, Rilpivirine",0,"Doravirine, rilpivirine, lamivudine, and islatravir",0,Not reported,1,Not reported,1,No,1,No,1,,1,,1,"AZT, 3TC, EFV, and RPV",0,"Etravirine, Rilpivirine",0,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c",0
Human Answer,34516245,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No. The paper reports sequences derived from laboratory virus stocks and cell culture passaging, not from patient samples.",1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,34516245,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,"Yes. The paper reports in vitro dose-response and EC50 data for EFdA and susceptibility testing against TDF and FTC, as well as in vitro biochemical assays.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,34516245,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. Mutation sequences were deposited in GenBank under accession numbers OK263149 to OK263162.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,34516245,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,OK263149 to OK263162,OK263149 to OK263162.,1,OK263149 to OK263162,1,OK263149 to OK263162,1,OK263149 to OK263162,1,OK263149 to OK263162,1,OK263149 to OK263162,1,OK263149 to OK263162,1,OK263149 to OK263162,1,No,0,OK263149 to OK263162,1,OK263149 to OK263162,1,OK263149 to OK263162,1,OK263149 to OK263162,1,Not reported,0,Not reported,0,OK263149 to OK263162,1,No,0,OK263149 to OK263162,1,OK263149 to OK263162,1,OK263149 to OK263162,1,MN234327 - MN235714,0,MN234327 - MN235714,0
Human Answer,34516245,5,How many individuals had samples obtained for HIV sequencing?,Number,0,None—no human individuals; sequencing was performed on laboratory virus stocks and cell-culture-derived material.,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,1,0,14,0,14,0,265,0,6,0
Human Answer,34516245,6,From which countries were the sequenced samples obtained?,List,No,Not applicable / Not reported. The sequences derive from laboratory viruses and cell culture; no country-of-origin for patient samples is provided.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Netherlands,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not Reported,1,Netherlands,0,Netherlands,0
Human Answer,34516245,7,From what years were the sequenced samples obtained?,List,No,"Not reported / Not applicable. The manuscript does not provide collection years for sequences, as they derive from in vitro experiments rather than dated patient samples.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,2007-2010,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2004-2007,0,2010-2017,0,2007-2010,0,2007-2010,0
Human Answer,34516245,8,Were samples cloned prior to sequencing?,Boolean,Yes,"Yes. PCR products spanning the full-length reverse transcriptase were cloned into pGEM-T and individual clones were sequenced (clonal sequencing), in addition to population sequencing.",1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,Not reported,0,Not reported,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0
Human Answer,34516245,9,Which HIV genes were reported to have been sequenced?,List,RT,The full-length reverse transcriptase (RT) gene was sequenced (PCR product spanning RT).,1,"Reverse transcriptase, RT",1,RT,1,RT,1,RT,1,RT,1,"Gag, RT",1,RT,1,"Reverse transcriptase, RT",1,RT,1,Pol,0,Pol,0,Reverse transcriptase,1,Not reported,1,Not reported,1,Reverse transcriptase (RT),1,RT,1,Reverse transcriptase,1,"Pol, IN, RT",1,Pol,0,"Gag, PR, RT",1,"Gag, PR, RT",1
Human Answer,34516245,10,What method was used for sequencing?,List,Sanger sequencing,"Sanger population sequencing of PCR products (submitted to ACGT, Inc.) and clonal Sanger sequencing of pGEM-T plasmid inserts (sequencing of individual clones).",1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Not reported,0,Sanger sequencing,1,PCR amplification,0,Clonal sequencing,0,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Not reported,0,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Sanger sequencing,1
Human Answer,34516245,11,What type of samples were sequenced?,List,No,Viral RNA purified from cell-culture supernatants (from MT-2 cell passages) was reverse-transcribed and PCR-amplified; PCR products and cloned plasmid inserts were sequenced.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Laboratory-generated viruses,0,Clinical samples from treatment-naive individuals,0,No,1,No,1,Plasma,0,"Plasma, Proviral DNA",0,Supernatants,0,Not reported,1,Not reported,1,Viral RNA from cell culture supernatants,1,No,1,Plasma,0,"Plasma, PBMC",0,Plasma,0,Plasma,0,PBMC,0
Human Answer,34516245,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. The sequences were derived from laboratory-generated and passaged viruses, not from patients experiencing virological failure on treatment.",1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,34516245,13,Were the patients in the study in a clinical trial?,Boolean,No,No. There were no patients in this study and no clinical trial involvement; the work was laboratory-based.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not Reported,1,No,1,Yes,0
Human Answer,34516245,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No. The sequences are from lab-generated or passaged viruses; while some starting viruses carried resistance-associated mutations (e.g., K65R, M184V, AZT-resistance mutations), these were engineered or defined laboratory strains, not sequences from treated individuals.",1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,34516245,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not applicable; no human individuals provided samples. The study did use viruses carrying nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)-associated mutations (e.g., K65R, M184V, AZT-resistance mutations) for in vitro experiments.",1,No,1,No,1,Not reported,1,,1,,1,NRTIs,0,"NRTI, NNRTI, INSTI",0,NRTI,0,No,1,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI",0,Not reported,1,Not reported,1,Not reported,1,NRTI,0,No,1,NRTIs,0,,1,NRTIs,0,NRTI,0,NRTI,0
Human Answer,34516245,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable; no human individuals. The study modeled resistance to tenofovir (TFV/TDF), emtricitabine/lamivudine (FTC/3TC), and zidovudine (AZT) by using viruses with associated resistance mutations.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,"Tenofovir, Emtricitabine, Lamivudine, Zidovudine",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",0,EFdA,0,No,1,"EFdA, TDF, FTC, AZT, 3TC",0,"EFdA, TDF, FTC",0,Not reported,1,Not reported,1,Not reported,1,EFdA,0,No,1,"AZT, 3TC, and FTC",0,Not Reported,1,"AZT, 3TC, and TDF",0,"Tenofovir, Emtricitabine",0,"Tenofovir, Emtricitabine",0
Human Answer,35730213,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,35730213,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer,35730213,3,Were sequences from the paper made publicly available?,Boolean,No,No,1,No,1,"NRTI, NNRTI",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** Yes,0,No,1
Human Answer,35730213,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported / Not applicable,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"The paper reports that sequences were submitted to GenBank and accession numbers have been provided, but the specific accession numbers are not provided in the text.",1,** MN234327 - MN235714,0,Not reported,1
Human Answer,35730213,5,How many individuals had samples obtained for HIV sequencing?,Number,0,None (no HIV sequencing reported),1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,1131,0,0,1,0,1,1131,0,Not reported,1,1131,0,** 6,0,1131,0
Human Answer,35730213,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no sequencing; study participants were from Lesotho,1,No,1,No,1,Lesotho,0,Lesotho,0,Lesotho,0,Lesotho,0,Lesotho,0,No,1,No,1,Not reported,1,Lesotho,0,Lesotho,0,Not reported,1,Lesotho,0,No,1,No,1,Lesotho,0,Lesotho,0,Lesotho,0,** Malawi,0,Lesotho,0
Human Answer,35730213,7,From what years were the sequenced samples obtained?,List,No,Not applicable — no sequencing; cohort enrollment occurred in 2020 with follow-up into 2021,1,No,1,No,1,2020,0,2020,0,2020,0,2020,0,2020-2021,0,No,1,No,1,Not reported,1,2020,0,2020,0,Not reported,1,2020,0,No,1,No,1,2020,0,Not reported,1,2020,0,** 2019,0,2020,0
Human Answer,35730213,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — no sequencing or cloning reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,** No,1,No,1
Human Answer,35730213,9,Which HIV genes were reported to have been sequenced?,List,No,Not applicable — no HIV genes sequenced or reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,"** Gag, PR, RT",0,Not reported,1
Human Answer,35730213,10,What method was used for sequencing?,List,No,Not applicable — no sequencing methods reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing,0,Yes,0,** Sanger sequencing,0,Not reported,1
Human Answer,35730213,11,What type of samples were sequenced?,List,No,Not applicable — no samples were sequenced (study used interviews and routine clinical data),1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Plasma,0,Not reported,1,Not reported,1,Yes,0,No,1,Blood or other bodily fluids,0,Plasma,0,"Pol, RT, IN",0,** Plasma,0,Blood or plasma samples,0
Human Answer,35730213,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,Not applicable — no sequences reported; virologic failure was uncommon in cohort,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Yes,0,Not reported,1,No,1,No,1,No,1,Yes,0,No,1,No,1,** Yes,0,No,1
Human Answer,35730213,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — they were enrolled in a prospective, registered cohort study (DO-REAL)",1,No,1,No,1,Not reported,1,No,1,Not reported,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,"NRTI, NNRTI",1,** No,1,No,1
Human Answer,35730213,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — no sequences reported; participants included ART-experienced individuals transitioning from EFV to DTG,1,No,1,No,1,Not reported,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,EFV,1,** Yes,0,Yes,0
Human Answer,35730213,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, INSTI","Not applicable for sequencing; participants prior to transition were on NRTIs (tenofovir, lamivudine) plus an NNRTI (efavirenz) — some transitions also involved nevirapine (an NNRTI).",0,"NNRTI, INSTI",1,No,0,"NRTI, NNRTI",0,Not reported,0,NNRTI,0,"NNRTI, NRTI",0,"NRTI, NNRTI",0,"NNRTI, INSTI",1,No,0,"NNRTI, INSTI",1,"NNRTIs, NRTIs",0,NNRTI,0,Not reported,0,"NRTI, NNRTI, INSTI",1,No,0,No,0,"NRTI, NNRTI, PI",0,NRTI,0,Yes,0,"** NRTI, NNRTI, INSTI",1,"NRTIs, NNRTIs",0
Human Answer,35730213,16,Which drugs were received by individuals in the study before sample sequencing?,List,"EFV, DTG, TDF, 3TC","Not applicable for sequencing; prior to transition participants were on tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and efavirenz (EFV); some transitions involved nevirapine.",0,"Efavirenz (EFV), Dolutegravir (DTG)",0,No,0,"TDF, 3TC, EFV",0,Not reported,0,Efavirenz,0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",0,"Tenofovir (TDF), Lamivudine (3TC)",0,"EFV, DTG",0,No,0,"Efavirenz, Dolutegravir",0,"EFV, NRTIs",0,Efavirenz,0,Not reported,0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",0,No,0,No,0,"EFV, TDF, 3TC",0,Not reported,0,"NRTI, NNRTI",0,"** Dolutegravir (DTG), Emtricitabine (FTC), Tenofovir alafenamide (TAF), Tenofovir disoproxil fumarate (TDF), Efavirenz (EFV)",0,"EFV, TDF, 3TC",0
Human Answer,35913500,1,Does the paper report HIV sequences from patient samples?,Boolean,Uncertain,No. The paper does not report HIV sequence data or sequence alignments from patient samples; it reports clinical resistance testing results (a detected mutation) but provides no sequence files or sequence data.,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** No,1,No,1
Human Answer,35913500,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not report any in vitro phenotypic drug susceptibility assays or results.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer,35913500,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not indicate that any HIV sequences were deposited in public repositories.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,** Yes,0,No,1
Human Answer,35913500,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. No GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported in the provided text,1,** OP539111–OP539272,0,Not reported,1
Human Answer,35913500,5,How many individuals had samples obtained for HIV sequencing?,Number,51,Not applicable / none reported. The paper does not report HIV sequencing of samples; it reports clinical resistance testing in routine care but does not specify sequencing sample counts.,0,0,0,0,0,39,0,Not reported,0,Not reported,0,Not reported,0,39,0,0,0,0,0,Not reported,0,39,0,Not reported,0,39,0,Not reported,0,0,0,0,0,Not Reported,0,39,0,39,0,** 51,1,Not reported,0
Human Answer,35913500,6,From which countries were the sequenced samples obtained?,List,US,"Not applicable for sequencing. The clinical population was drawn from a single clinic in the United States (San Francisco, California, USA).",1,No,0,No,0,USA,1,United States,1,Not reported,0,United States,1,United States,1,No,0,No,0,Not reported,0,USA,1,United States,1,Not reported,0,Not reported,0,No,0,No,0,Not Reported,0,United States,1,United States,1,** Not reported,0,Not reported,0
Human Answer,35913500,7,From what years were the sequenced samples obtained?,List,2021-2022,Not applicable for sequencing. Clinic data and samples (for viral loads/resistance testing) were obtained during 202162022 (referrals from Feb 2021 and injections between June 2021 and April 2022).,0,No,0,No,0,2021–2022,1,2021–2022,1,Not reported,0,2021-2022,1,2021-2022,1,No,0,No,0,Not reported,0,2021-2022,1,2021-2022,1,2021-2022,1,Not reported,0,No,0,No,0,2021-2022,1,2021-2022,1,2021-2022,1,** 2021-2022,1,2021-2022,1
Human Answer,35913500,8,Were samples cloned prior to sequencing?,Boolean,No,"No. There is no report of cloning of samples prior to sequencing; in fact, no sequencing was reported.",1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer,35913500,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN","Not explicitly reported. The manuscript reports detection of an N155H mutation (an integrase mutation) and references RPV-associated resistance (rilpivirine, an NNRTI affecting reverse transcriptase), implying assessment of integrase and reverse transcriptase regions, but no genes are explicitly stated as sequenced.",1,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,Not reported,0,IN,0,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,Not Reported,0,Not reported,0,Not reported,0,** Not reported,0,Not reported,0
Human Answer,35913500,10,What method was used for sequencing?,List,No,Not reported. The paper does not describe any sequencing methods.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,NGS,0,Not reported,1,** Not reported,1,Not reported,1
Human Answer,35913500,11,What type of samples were sequenced?,List,No,"Not explicitly stated as 'sequenced.' Clinical viral load testing and resistance testing were performed on blood draws (plasma), so sample type for resistance testing would be patient blood/plasma.",0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Plasma,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Plasma,0,Plasma,0,** Not reported,1,Not reported,1
Human Answer,35913500,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes in the sense that clinical resistance testing detected a mutation in a viremic patient (one patient had the N155H mutation at baseline), but the paper does not provide sequence data files.",1,No,0,No,0,Yes,1,Not reported,0,No,0,Yes,1,Yes,1,No,0,No,0,Not reported,0,Yes,1,Yes,1,Yes,1,Not reported,0,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,35913500,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. This was a clinical demonstration project conducted in routine care, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer,35913500,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Indirectly yes: the paper reports a detected resistance mutation (N155H) in a patient who was treatment experienced, but it does not provide sequence data.",0,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,Yes,1,Yes,1,No,0,No,0,Not reported,0,Yes,1,Yes,1,Yes,1,Not reported,0,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,35913500,15,Which drug classes were received by individuals in the study before sample sequencing?,List,Not reported,"Reported or implied drug classes include integrase strand transfer inhibitors (INSTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs, e.g., rilpivirine), and nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs, e.g., tenofovir/emtricitabine).",0,No,1,No,1,,1,Not reported,1,Not reported,1,"NRTI, INSTI",0,"NRTI, NNRTI, PI",0,INSTI,0,No,1,Not reported,1,"INSTI, NNRTI",0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,** Not reported,1,"NRTI, NNRTI, PI, INSTI",0
Human Answer,35913500,16,Which drugs were received by individuals in the study before sample sequencing?,List,Not reported,"Specifically mentioned drugs include cabotegravir and rilpivirine (the long-acting regimen studied, CAB/RPV-LA) and oral tenofovir/emtricitabine-containing regimens; prior exposure to rilpivirine and INSTI-class drugs is discussed conceptually (e.g., RPV-associated resistance, N155H integrase mutation).",0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,"Cabotegravir (CAB), Rilpivirine (RPV)",0,"Abacavir (ABC), Lamivudine (3TC), Tenofovir (TDF), Efavirenz (EFV), among others.",0,CAB/RPV-LA,0,No,1,Not reported,1,"Cabotegravir, Rilpivirine",0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,** Not reported,1,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF), Emtricitabine (FTC), Lopinavir (LPV), Darunavir (DRV), Dolutegravir (DTG), Rilpivirine (RPV)",0
Human Answer,35945163,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,No — the paper reports genotypic resistance-associated mutations/ART resistance profiles but does not report or deposit patient HIV sequences.,0,No,0,Yes,1,Yes,1,Not reported,0,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,No,0
Human Answer,35945163,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro phenotypic susceptibility assays.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** Yes,0,No,1
Human Answer,35945163,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not indicate that sequences were made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,** No,1,No,1
Human Answer,35945163,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,** Not reported,1,Not reported,1
Human Answer,35945163,5,How many individuals had samples obtained for HIV sequencing?,Number,6,"35 individuals were included in the compassionate use programme (clinical/resistance data available for 35), but the paper does not specify how many had sequencing performed.",0,0,0,35,0,35,0,35,0,Not reported,0,35,0,35,0,0,0,0,0,35,0,35,0,35,0,35,0,35,0,0,0,0,0,35,0,35,0,35,0,** 35,0,Not reported,0
Human Answer,35945163,6,From which countries were the sequenced samples obtained?,List,"UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain","Participants were from the UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain; the paper does not state which countries provided sequenced samples specifically.",1,No,0,No,0,"UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain",1,"UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain",1,Not reported,0,"UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain",1,"UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain",1,No,0,No,0,"UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain",1,"UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain",1,"UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain",1,"UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain",1,"UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain",1,No,0,No,0,"The sequenced samples were obtained from the UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain.",1,"UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain",1,"10 countries (UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain)",1,"** UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain",1,Not reported,0
Human Answer,35945163,7,From what years were the sequenced samples obtained?,List,2016-2020,The compassionate use data cover February 2016 through July 2020; the paper does not specify exact sample collection dates for sequencing separately.,1,No,0,2016-2020,1,2016–2020,1,2016–2020,1,Not reported,0,2016-2020,1,2016-2020,1,No,0,No,0,2016-2020,1,2016-2020,1,2016-2020,1,2016-2020,1,2016-2020,1,No,0,No,0,2016-2020,1,2016-2020,1,2016-2020,1,** 2016-2020,1,Not reported,0
Human Answer,35945163,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,** No,1,No,1
Human Answer,35945163,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",Reverse transcriptase (RT) and integrase (IN) — the paper reports reverse transcriptase (NNRTI-associated) and integrase mutations.,1,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,"RT, IN",1,"Reverse Transcription (RT), Integrase (IN)",1,No,0,No,0,Not reported,0,Not reported,0,Pol,0,Not reported,0,"RT, IN",1,No,0,No,0,Not reported,0,Pol,0,No,0,** Integrase,0,Not reported,0
Human Answer,35945163,10,What method was used for sequencing?,List,No,Not reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,Not reported,1,Sanger sequencing,0,No,1,No,1,Not reported,1,Not reported,1,Yes,0,** Not reported,1,Not reported,1
Human Answer,35945163,11,What type of samples were sequenced?,List,Plasma,"Not explicitly reported; the paper reports plasma viral load data and ART resistance profiles, so sequencing (if performed) was likely based on plasma-derived virus, but sample type is not specified.",1,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,Plasma,1,Plasma,1,No,0,No,0,Not reported,0,Not reported,0,"Plasma, PBMCs",1,Not reported,0,Plasma,1,No,0,No,0,Plasma,1,Plasma,1,Not Reported,0,** Plasma,1,Not reported,0
Human Answer,35945163,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — the paper reports resistance-associated mutations detected at discontinuation in individuals with incomplete virological response (virological failure).,1,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Not Reported,0,** Yes,1,No,0
Human Answer,35945163,13,Were the patients in the study in a clinical trial?,Boolean,No,No — participants were enrolled in a compassionate use programme and were explicitly ineligible for phase III clinical trials.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** Yes,0,No,1
Human Answer,35945163,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — many participants had prior ART exposure and resistance-associated mutations were reported; the paper includes participants with prior multiple ART regimens.,1,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,No,0,** Yes,1,No,0
Human Answer,35945163,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"INSTI, NNRTI","Reported drug classes include NNRTIs (non-nucleoside reverse transcriptase inhibitors), INSTIs (integrase strand transfer inhibitors), NRTIs (nucleoside/nucleotide reverse transcriptase inhibitors), and PIs (protease inhibitors; e.g., boosted darunavir).",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,Not reported,0,"NRTI, NNRTI",0,Not reported,0,"NRTI, NNRTI, INSTI",1,"NRTI, NNRTI, INSTI",1,"INSTI, NNRTI",1,No,0,Not reported,0,"INSTI, NNRTI",1,"NRTIs, NNRTIs, PIs",0,"INSTI, NNRTI",1,"NRTI, NNRTI, INSTI",1,No,0,No,0,"NRTI, NNRTI",0,"NRTI, NNRTI, and INSTI",1,No,0,"** NRTI, NNRTI, INSTI",1,Not reported,0
Human Answer,35945163,16,Which drugs were received by individuals in the study before sample sequencing?,List,"CAB, RPV","The manuscript explicitly names cobicistat-boosted darunavir, tenofovir alafenamide (TAF), emtricitabine (FTC), and dolutegravir as drugs used by some individuals; it also discusses resistance to rilpivirine and mentions integrase inhibitor resistance (e.g., cabotegravir resistance-associated mutations).",1,"cabotegravir, rilpivirine",1,"Cabotegravir (CAB), Rilpivirine (RPV), Darunavir (DRV), Tenofovir (TFV), Emtricitabine (FTC)",1,Not reported,0,"Cabotegravir, Rilpivirine",1,Not reported,0,"Cabotegravir, Rilpivirine, Dolutegravir, Abacavir, Lamivudine",1,"Cabotegravir (CAB), Rilpivirine (RPV), Maraviroc (MVC), Tenofovir (TDF), Emtricitabine (FTC), Dolutegravir (DTG), Efavirenz (EFV)",1,"Cabotegravir, Rilpivirine",1,No,0,Not reported,0,"Cabotegravir, Rilpivirine",1,"Cabotegravir, rilpivirine, and other ARV drugs",1,"Cabotegravir, Rilpivirine",1,"Abacavir (ABC), Lamivudine (3TC), Efavirenz (EFV), Tenofovir disoproxil (TDF), Dolutegravir (DTG)",0,No,0,No,0,"Cabotegravir, Rilpivirine",1,"Cabotegravir, rilpivirine, and other ARV drugs",1,No,0,"** Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC), Cabotegravir (CAB), Rilpivirine (RPV)",1,Not reported,0
Human Answer,36415058,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No. The paper reports an interview-based study and does not report HIV sequences from patient samples.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer,36415058,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not report any in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,36415058,3,Were sequences from the paper made publicly available?,Boolean,No,"No. There were no sequences generated or deposited, so none were made publicly available.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1
Human Answer,36415058,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. The paper does not include any GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,36415058,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero; no samples were obtained for HIV sequencing. The study involved interviews of 486 individuals.,1,0,1,0,1,Not reported,1,Not reported,1,0,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not Reported,1,Not reported,1,Not reported,1,486,0,Not reported,1
Human Answer,36415058,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no samples were sequenced. The study was conducted at an outpatient clinic in Italy (references to an Italian patient advocacy group indicate an Italian context).,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,36415058,7,From what years were the sequenced samples obtained?,List,No,Not applicable — no samples were sequenced. The interviews took place during 2021.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2021,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,2021,0,Not reported,1
Human Answer,36415058,8,Were samples cloned prior to sequencing?,Boolean,No,No — not applicable. The study did not perform sequencing or cloning.,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1
Human Answer,36415058,9,Which HIV genes were reported to have been sequenced?,List,No,None. The paper does not report sequencing of any HIV genes.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,36415058,10,What method was used for sequencing?,List,No,Not applicable — no sequencing was performed and no sequencing methods are reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,36415058,11,What type of samples were sequenced?,List,No,Not applicable — no samples were sequenced. The study used clinical chart review and patient interviews.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,36415058,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. The study selected individuals with HIV-RNA <50 copies/ml and no previous failure, so there were no sequences from individuals with virological failure (and no sequencing was performed).",1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1
Human Answer,36415058,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. The patients interviewed in this study were clinic outpatients, not participants in a clinical trial; the paper references the CARISEL Phase 3b trial as a separate study.",1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,Yes,0,No,1
Human Answer,36415058,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No sequences are reported. The paper does state that many individuals had long histories of ART (median 12.5 years), but no sequencing was performed on those individuals.",1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,Yes,0
Human Answer,36415058,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"The manuscript references regimens based on NNRTIs, integrase strand transfer inhibitors (InSTIs), and protease inhibitors, but no sequencing was performed.",1,No,1,No,1,Not reported,1,,1,,1,"NNRTI, INSTI",0,"NRTI, NNRTI, INSTI",0,"INSTI, NNRTI, PI",0,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,36415058,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Specific individual drugs are not reported. The paper mentions drug classes (NNRTI-, InSTI-, and protease inhibitor–based regimens) and discusses cabotegravir and rilpivirine as the LA regimen under consideration, but does not list specific drugs used by participants.",1,No,1,No,1,Not reported,1,Not reported,1,,1,"Cabotegravir (CAB), Rilpivirine (RPV), Dolutegravir (DTG)",0,"Cabotegravir (CAB), Rilpivirine (RPV)",0,"Cabotegravir, Rilpivirine",0,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,36454248,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV-1 pol sequences recovered from patient plasma samples (sequences obtained from 67 of 76 children/adolescents).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,36454248,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports predicted antiretroviral susceptibility based on genotypes (Stanford HIVdb), not in vitro phenotypic susceptibility assays.",1,Yes,0,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,Yes,0,No,1,No.,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,** No,1,No,1
Human Answer,36454248,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. The sequences were submitted to GenBank.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,36454248,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,OM201778 - OM201846,OM201778 -- OM201846.,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846.,1,OM201778 -- OM201846,1,No,0,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,** OM201778 -- OM201846,1,OM201778 -- OM201846,1
Human Answer,36454248,5,How many individuals had samples obtained for HIV sequencing?,Number,76,"Plasma samples were collected from 76 individuals, and HIV-1 pol sequences were successfully recovered from 67 of those individuals.",1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,67,0,76.,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,** 76,1,76,1
Human Answer,36454248,6,From which countries were the sequenced samples obtained?,List,Panama,Panama.,1,Panama,1,Panama,1,Panama,1,Panama,1,Panama,1,Panama,1,Panama,1,Panama,1,Panama,1,Panama.,1,Panama,1,No,0,Panama,1,Panama,1,Panama,1,Panama,1,Panama,1,Panama,1,Panama,1,** Panama,1,Panama,1
Human Answer,36454248,7,From what years were the sequenced samples obtained?,List,2018-2019,Samples were collected during 2018–2019.,1,2018-19,1,2018--2019,1,2018–2019,1,2018-2019,1,2018–2019,1,2018-2019,1,2018-2019,1,2018-2019,1,2018-2019,1,2018-2019.,1,2018-2019,1,2018-2019,1,2018-2019,1,2018-2019,1,2018--19,0,2018--19,0,2018-2019,1,2018-2019,1,2018--19,0,** 2018-2019,1,2018-2019,1
Human Answer,36454248,8,Were samples cloned prior to sequencing?,Boolean,No,No. PCR amplicons were purified and directly sequenced; there is no mention of cloning prior to sequencing.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported.,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer,36454248,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol","Protease (PR), reverse transcriptase (RT) and integrase (IN) regions of the pol gene were sequenced (complete PR codons 1–99, partial RT 1–345, IN 48–285).",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",0,"PR, RT, IN",0,"Pol (PR, RT, IN).",1,"Pol (PR, RT, IN)",1,Pol,0,"PR, RT, IN",0,"PR, RT, IN",0,"Protease, RT, and IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,Pol,0,"** PR, RT, IN",0,"PR, RT",0
Human Answer,36454248,10,What method was used for sequencing?,List,No,"RT-PCR and nested PCR amplification of HIV-1 RNA followed by purification of PCR amplicons and sequencing by Macrogen Inc (i.e., Sanger sequencing of PCR products with sequence assembly/editing).",0,Sanger sequencing,0,Sanger sequencing,0,Not Reported,1,Sanger sequencing,0,Not Reported,1,RT-PCR and nested PCR followed by sequencing (Macrogen Inc.),0,Sanger sequencing,0,No,1,Sanger sequencing,0,Not Reported.,1,Not Reported,1,Sanger sequencing,0,Not reported,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing and Illumina sequencing,0,Sanger sequencing,0,** Sanger sequencing,0,Not reported,1
Human Answer,36454248,11,What type of samples were sequenced?,List,Plasma,Plasma samples (HIV-1 RNA extracted from plasma) were sequenced.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,** Plasma,1,Plasma,1
Human Answer,36454248,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Most treated individuals with sequences were experiencing virological failure (VL >50 copies/mL); specifically, 62 treated subjects were under virological failure and sequences were recovered from treated patients exhibiting virological failure.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,36454248,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The patients were under routine clinical follow-up at a hospital and enrolled with informed consent; they were not participants in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,** No,1,No,1
Human Answer,36454248,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. The study includes sequences from ART-experienced (treated) individuals; 71 were treated at sampling and sequences were recovered from 62 treated individuals.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,36454248,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI","Nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs).",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTIs, NNRTIs, PIs, INSTIs",1,"NRTI, NNRTI, PI, INSTI",1,"NRTIs, NNRTIs, PIs, INSTIs",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTIs, NNRTIs, PIs, INSTIs.",1,"NRTIs, NNRTIs, PIs, INSTIs",1,"NRTIs, NNRTIs, PIs, INSTIs",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, and PI",0,No,0,"NRTIs, NNRTIs, PIs, INSTIs",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"** NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0
Human Answer,36454248,16,Which drugs were received by individuals in the study before sample sequencing?,List,"3TC, TDF, AZT, D4T, ABC, DDI, FTC, EFV, LPV, DRV, NFV, RAL","Commonly reported drugs included lamivudine and zidovudine (most patients), lopinavir/ritonavir, efavirenz, and raltegravir for INSTI-experienced patients; other mentioned drugs include emtricitabine, tenofovir (used in older patients), darunavir, and various prophylaxis regimens of zidovudine alone or zidovudine+lamivudine.",0,"Lamivudine, Zidovudine, Lopinavir/Ritonavir, Efavirenz",0,"Lamivudine (3TC), Zidovudine (AZT), Lopinavir (LPV), Ritonavir (RTV), Efavirenz (EFV), Darunavir (DRV), Raltegravir (RAL), Emtricitabine (FTC), Tenofovir (TFV), Dolutegravir (DTG), Abacavir (ABC), Etravirine (ETR), Rilpivirine (RPV), Nevirapine (NVP), Nelfinavir (NFV), Stavudine (D4T), Didanosine (DDI), Lamivudine (3TC), Zidovudine (ZDV), Doravirine (DOR), Bictegravir (BIC), Cabotegravir (CAB), Elvitegravir (EVG), Raltegravir (RAL)",1,"Lamivudine, Zidovudine, Lopinavir/Ritonavir, Efavirenz",0,"Lamivudine, Zidovudine, Lopinavir/Ritonavir, Efavirenz",0,"Lamivudine, Zidovudine, Lopinavir/Ritonavir, Efavirenz",0,"Lamivudine (3TC), Zidovudine (AZT), Lopinavir/ritonavir (LPV/r), Efavirenz (EFV)",0,"Lamivudine, Zidovudine, Lopinavir/Ritonavir, Efavirenz",0,"Lamivudine, Zidovudine, Lopinavir, Ritonavir, Raltegravir",0,"Lamivudine, Zidovudine, Lopinavir/ritonavir, Efavirenz, Raltegravir",0,"Lamivudine, zidovudine, lopinavir/ritonavir, efavirenz.",0,"Lamivudine, zidovudine, lopinavir/ritonavir, efavirenz",0,"Zidovudine, lamivudine, efavirenz",0,Not reported,0,"Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), Efavirenz (EFV), Abacavir (ABC), Lopinavir (LPV), Atazanavir (ATZ), Dolutegravir (DTG), Tenofovir (TDF)",0,"Lamivudine, Zidovudine, Lopinavir/Ritonavir, and Efavirenz",0,No,0,"NRTIs, NNRTIs, PIs, INSTIs",0,"AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, RAL, EVG, DTG, BIC, CAB, LEN, MVC",0,"NRTIs, NNRTIs, PIs, INSTIs",0,"** Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), Efavirenz (EFV)",0,"Zidovudine (AZT), Nevirapine (NVP)",0
Human Answer,36519389,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,** Yes,0,** Yes,0
Human Answer,36519389,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report any in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,** Yes,0
Human Answer,36519389,3,Were sequences from the paper made publicly available?,Boolean,No,No — no sequences were reported or made publicly available in this paper.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,** No,1
Human Answer,36519389,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not applicable — no GenBank accession numbers are reported because no sequences were reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,** Not reported,1,** Not reported,1
Human Answer,36519389,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Not applicable / Not reported — the paper does not report obtaining samples for HIV sequencing.,1,0,1,0,1,Not reported,1,0,1,Not reported,1,6,0,172,0,0,1,0,1,Not reported,1,172,0,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,172 + 71 + 31 = 274,0,Not reported,1,Not reported,1,** Not reported,1,** 27,0
Human Answer,36519389,6,From which countries were the sequenced samples obtained?,List,No,"Not applicable — no sequenced samples are reported. Participant origins are described: mostly South Africa with some from Zimbabwe, Malawi, Mozambique, and other regions.",1,No,1,No,1,"South Africa, Zimbabwe, Malawi, Mozambique",0,Not reported,1,Not reported,1,"South Africa, Zimbabwe, Malawi, Mozambique",0,"South Africa, Zimbabwe, Malawi, Mozambique",0,South Africa,0,No,1,"South Africa, Zimbabwe, Malawi, Mozambique, and other regions",0,"South Africa, Zimbabwe, Malawi, Mozambique",0,South Africa,0,Not reported,1,Not reported,1,No,1,No,1,"South Africa, Zimbabwe, Malawi, and Mozambique",0,South Africa,0,South Africa,0,"** South Africa, Zimbabwe, Malawi, Mozambique",0,"** Spain, Switzerland, USA",0
Human Answer,36519389,7,From what years were the sequenced samples obtained?,List,No,Not applicable / Not reported — the paper does not report sequenced samples or years of sequencing. The study enrolled participants from July to November 2022.,1,No,1,No,1,2022,0,Not reported,1,Not reported,1,Not reported,1,Not reported,1,2022,0,No,1,2022,0,2022,0,2022,0,Not reported,1,Not reported,1,No,1,No,1,2022,0,2022,0,2022,0,** Not reported,1,** 2007-2010,0
Human Answer,36519389,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable / Not reported — no sequencing (and thus no cloning) is described.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,** No,1,** No,1
Human Answer,36519389,9,Which HIV genes were reported to have been sequenced?,List,No,Not applicable / Not reported — no HIV genes or gene regions are reported as sequenced.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"Pol, PR, RT",0,Not reported,1,** Not reported,1,** Full length genome,0
Human Answer,36519389,10,What method was used for sequencing?,List,No,Not applicable / Not reported — no sequencing methods are described in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,NGS,0,Not reported,1,** Next-generation sequencing,0,** Illumina sequencing,0
Human Answer,36519389,11,What type of samples were sequenced?,List,No,Not applicable / Not reported — no samples were reported as sequenced.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Plasma,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Plasma,0,Not reported,1,** PBMC,0,** PBMC,0
Human Answer,36519389,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the paper does not report obtaining sequences; it does report HIV RNA elevations in some participants but no sequence data.,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** Yes,0,** Yes,0
Human Answer,36519389,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes — participants were randomized in the ADVANCE trial and CHARACTERISE is an extension evaluating switches; the trial received ethics and regulatory approvals.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Not reported,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,** Yes,1
Human Answer,36519389,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report any HIV sequences. The participants had received and been randomized to specific ART regimens prior to switching.,1,No,1,No,1,Yes,0,Not reported,1,Not reported,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Not reported,1,** Yes,0,** Yes,0
Human Answer,36519389,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Sequencing was not performed, but participants had received the following antiretroviral drug classes: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and integrase strand transfer inhibitors (INSTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs).",1,No,1,No,1,"NRTI, INSTI",0,Not reported,1,Not reported,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,"INSTI, NRTI, NNRTI",0,No,1,"NRTI, NNRTI, INSTI",0,"NRTIs, NNRTIs, INSTIs",0,"NRTIs, NNRTIs, INSTIs",0,Not reported,1,Not reported,1,No,1,No,1,"NRTI, NNRTI, and PI",0,"NRTI, NNRTI, PI",0,Not reported,1,"** NRTI, NNRTI, PI, INSTI",0,"** NRTI, NNRTI, PI, INSTI",0
Human Answer,36519389,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Sequencing was not performed, but the study reports participants received TAF, FTC, DTG, TDF, 3TC (lamivudine), and EFV (efavirenz).",1,No,1,No,1,"Tenofovir Alafenamide, Emtricitabine, Dolutegravir, Tenofovir Disoproxil Fumarate, Efavirenz",0,Not reported,1,Not reported,1,"TAF, FTC, DTG",0,"Stavudine, Lamivudine, Nevirapine, Efavirenz, Zidovudine",0,"Dolutagravir (DTG), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV)",0,No,1,"TAF, FTC, DTG, TDF, EFV",0,"TDF, FTC, EFV",0,"TAF, FTC, TDF, EFV, DTG",0,Not reported,1,Not reported,1,No,1,No,1,"TAF, FTC, DTG, TDF, FTC, and EFV",0,Not reported,1,Not reported,1,"** Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",0,"** 3TC, NVP, EFV, D4T, AZT, LPV, ABC, ATZ, DTG, TDF",0
Human Answer,36571282,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,36571282,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer,36571282,3,Were sequences from the paper made publicly available?,Boolean,No,No — sequences were not made openly public; data are available upon reasonable request.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Not reported,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,36571282,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"The paper reports that sequences were submitted to GenBank and provides accession numbers, but the specific accession numbers are not provided in the text.",1,** Not reported,1,Not reported,1
Human Answer,36571282,5,How many individuals had samples obtained for HIV sequencing?,Number,2705,2705 individuals.,1,2705,1,2705,1,2705,1,2705,1,2705,1,2705,1,2705,1,2705,1,2705,1,2705.,1,2705,1,2705,1,50,0,50,0,2705,1,2705,1,2705,1,2705,1,2705,1,** 2705,1,50,0
Human Answer,36571282,6,From which countries were the sequenced samples obtained?,List,"France, Greece, Italy, Portugal, Spain","France, Greece, Italy, Portugal, and Spain (MeditRes consortium countries).",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, and Spain.",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, and Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, and Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, and Spain",1,"** France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1
Human Answer,36571282,7,From what years were the sequenced samples obtained?,List,2018-2021,2018–2021.,1,2018-2021,1,2018-2021,1,2018–2021,1,2018–2021,1,2018–2021,1,2018-2021,1,2018–2021,1,2018-2021,1,2018-2021,1,2018-2021.,1,2018-2021,1,2018-2021,1,2018-2021,1,2018-2021,1,2018--2021,1,"2018, 2019, 2020, 2021",0,2018-2021,1,2018-2021,1,2018-2021,1,** 2018-2021,1,2018-2021,1
Human Answer,36571282,8,Were samples cloned prior to sequencing?,Boolean,No,No evidence of cloning; samples were sequenced by Sanger or NGS without cloning.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,** No,1,No,1
Human Answer,36571282,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",Integrase and reverse transcriptase (RT).,1,"Integrase, IN",0,"RT, IN",1,IN (Integrase),0,IN,0,"RT, IN",1,"RT, IN",1,"RT, IN",1,"Integrase, Reverse transcriptase",1,"RT, IN",1,Integrase and Reverse Transcriptase.,1,"RT, INSTI",1,"Integrase, Reverse Transcriptase",1,RT,0,"RT, IN",1,"Integrase, IN",0,"Integrase, RT",1,Integrase,0,"Integrase, RT",1,Pol,0,** Integrase,0,RT,0
Human Answer,36571282,10,What method was used for sequencing?,List,"Sanger sequencing, NGS",Sanger sequencing-based assays and next-generation sequencing (NGS) assays (NGS sequences analyzed using a 20% consensus threshold).,1,Sanger sequencing; Next-generation sequencing,1,Sanger sequencing; NGS,1,Sanger sequencing and NGS,1,"Sanger sequencing, NGS",1,"Sanger sequencing, NGS",1,Sanger sequencing; NGS,1,"Sanger sequencing, Next-Generation Sequencing",1,"Sanger sequencing, Next-generation sequencing",1,NGS,0,Sanger sequencing and Next-Generation Sequencing (NGS).,1,"Sanger sequencing, NGS",1,Not reported,0,"Sanger sequencing, NGS",1,"Sanger sequencing, NGS",1,"Sanger sequencing, NGS",1,"Sanger sequencing, NGS sequencing",1,Sanger sequencing and NGS,1,"Sanger sequencing, NGS",1,Sanger sequencing,0,"** Sanger sequencing, NGS",1,NGS,0
Human Answer,36571282,11,What type of samples were sequenced?,List,Plasma,"Viral sequences (FASTA) encoding HIV integrase and RT obtained from patients at inclusion; the specific specimen type (e.g., plasma vs. PBMC) is not specified.",1,No,0,No,0,Plasma,1,Not reported,0,Plasma,1,Plasma,1,Plasma; Whole Blood,1,Plasma,1,No,0,Not reported.,0,Plasma,1,Plasma,1,Plasma,1,Plasma; Whole Blood,1,No,0,"Plasma, PBMC",1,Not Reported,0,"Plasma, PBMC",1,"Plasma, serum, PBMC, and dried blood spots",1,** Plasma,1,Plasma,1
Human Answer,36571282,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,36571282,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,** No,1,Yes,0
Human Answer,36571282,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,36571282,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None — study participants were ART-naive and had not received antiretroviral drug classes prior to sequencing.,1,No,1,No,1,,1,,1,,1,NRTI,0,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,No,1,Not reported.,1,Not reported,1,"NRTIs, NNRTIs, INSTIs",0,,1,,1,No,1,"NRTI, INSTI",0,Not Reported,1,"NRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0,"** NRTI, NNRTI, PI, INSTI, CAI",0,"NRTI, NNRTI, INSTI, CAI",0
Human Answer,36571282,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None — participants were ART-naive and had not received any antiretroviral drugs prior to sequencing.,1,No,1,No,1,,1,,1,,1,Not reported,1,Not reported,1,"Abacavir, Zidovudine, Zalcitabine, Didanosine, Lamivudine, Stavudine, Emtricitabine, Tenofovir, Nevirapine, Delavirdine, Efavirenz, Etravirine, Rilpivirine, Doravirine, Amprenavir, Lopinavir, Atazanavir, Derunavir, Raltegravir, Elvitegravir, Dolutagravir, Bictegravir, Cabotegravir, Lenacapavir",0,No,1,Not reported.,1,Not reported,1,"Tenofovir, Lamivudine, Dolutegravir",0,,1,,1,No,1,No,1,Not Reported,1,"Tenofovir, Lamivudine, Abacavir, Raltegravir",0,"AZT, 3TC, FTC, TDF, EFV, NVP, RAL, DTG, BIC, CAB, LEN",0,"** Tenofovir (TFV), Emtricitabine (FTC), Darunavir (DRV), Dolutegravir (DTG), Doravirine (DOR), Ibalizumab (IBA), Lenacapavir (LEN), Raltegravir (RAL), Elvitegravir (EVG)",0,"Tenofovir (TFV), Emtricitabine (FTC), Darunavir (DRV), Dolutegravir (DTG), Doravirine (DOR), Ibalizumab (IBA), Lenacapavir (LEN), Raltegravir (RAL), Elvitegravir (EVG)",0
Human Answer,36597160,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes — the paper reports HIV genotypes (Sanger sequencing) performed on patient samples, including genotypes at baseline and at virologic failure.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36597160,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro phenotypic drug susceptibility testing data; it reports genotypic resistance (sequence-based) results only.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,36597160,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not indicate that sequences were deposited in a public database and states that study data will not be shared publicly.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,36597160,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1
Human Answer,36597160,5,How many individuals had samples obtained for HIV sequencing?,Number,6,152 individuals had an HIV resistance genotype available before the switch; genotypic resistance at virologic failure was available for 6 patients (of 13 failures).,1,6,1,6,1,382,0,382,0,6,1,382,0,382,0,0,0,0,0,382,0,382,0,382,0,382,0,Not reported,0,0,0,0,0,382,0,382,0,382,0,382,0,382,0
Human Answer,36597160,6,From which countries were the sequenced samples obtained?,List,France,France (multicenter cohort in the Paris area).,1,No,0,France,1,France,1,France,1,France,1,France,1,Not reported (specifically by country),0,No,0,No,0,Not reported,0,France,1,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,Not reported,0,France,1,France,1,Africa,0,Not reported,0
Human Answer,36597160,7,From what years were the sequenced samples obtained?,List,2014,Patients switched (and samples collected) between February 2014 and August 2015; follow-up genotypes would have been obtained during the subsequent follow-up period (up to ~48 weeks thereafter).,1,No,0,2014,1,2014–2015,1,2014–2015,1,2014–2015,1,2014-2015,1,2014-2015,1,No,0,No,0,2014-2015,1,2014-2015,1,Not reported,0,2014-2015,1,Not reported,0,No,0,No,0,2014-2015,1,2014-2015,1,2014-2015,1,2014-2015,1,2014-2015,1
Human Answer,36597160,8,Were samples cloned prior to sequencing?,Boolean,No,No indication of cloning; genotyping was performed by Sanger sequencing without mention of cloning.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,36597160,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",Pol region genes relevant to NRTI and INSTI resistance were sequenced — specifically reverse transcriptase (where NRTI mutations like M184V occur) and integrase (where INSTI mutations like N155H and Q148H occur).,1,"Integrase, NRTI",1,"PR, RT, IN",1,Pol,0,Not reported,0,"RT, IN",1,"NRTI, INSTI",1,"NRTI, INSTI",1,No,0,No,0,"Pol, IN",0,Not reported,0,Not reported,0,Not reported,0,"RT, PR, IN",1,No,0,No,0,Not reported,0,Pol,0,No,0,"RT, IN",1,"PR, RT, IN",1
Human Answer,36597160,10,What method was used for sequencing?,List,Sanger sequencing,Sanger sequencing (genotypic testing by Sanger).,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Sanger sequencing,1,Sanger sequencing,1,No,0,No,0,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Sanger sequencing,1,Not reported,0,No,0,No,0,Sanger sequencing,1,Sanger sequencing,1,Yes,0,Sanger sequencing,1,"Sanger sequencing, Illumina sequencing",1
Human Answer,36597160,11,What type of samples were sequenced?,List,Plasma,Plasma samples (plasma HIV-1 RNA for genotyping in case of virologic failure).,1,No,0,Plasma,1,Plasma,1,Plasma,1,Not reported,0,Blood/plasma samples,1,Plasma,1,No,0,No,0,"Plasma, PBMC",1,Plasma,1,Plasma,1,Not reported,0,Not reported,0,No,0,No,0,Not reported,0,Plasma,1,"NRTIs, NNRTIs, PIs, INSTIs",0,Plasma,1,Plasma,1
Human Answer,36597160,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — genotypic resistance results at the time of virologic failure were available for 6 of the 13 patients who experienced virologic failure.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,"Tenofovir, emtricitabine, efavirenz, lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir",0,Yes,1,Yes,1
Human Answer,36597160,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a retrospective multicenter observational (non-interventional) cohort study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,No,1
Human Answer,36597160,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes — the study enrolled treatment-experienced patients and reports genotypes from individuals with prior ARV exposure (many had prior NRTI, PI/r, NNRTI, or INSTI regimens).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,36597160,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI, NNRTI, INSTI","NRTIs (two-NRTI backbone), boosted protease inhibitors (PI/r), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs).",1,"NRTI, PI, NNRTI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, PI, INSTI",0,"NRTI, NNRTI, PI",0,Not reported,0,"NRTI, PI, NNRTI, INSTI",1,"NRTI, NNRTI, INSTI, PI",1,"NRTI, NNRTI, PI, INSTI",1,No,0,"NRTI, NNRTI, PI, INSTI",1,"NRTIs, NNRTIs, PIs, INSTIs",1,"NRTIs, NNRTIs, PIs",0,"NRTI, PI, NNRTI, INSTI",1,"NRTI, NNRTI, INSTI",0,INSTI,0,No,0,"NRTI, PI/r, NNRTI, and INSTI",1,"NRTI, NNRTI, PI, INSTI",1,No,0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1
Human Answer,36597160,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF,FTC,EVG","Specific drugs are not comprehensively listed for all patients; the paper indicates most patients received a two-NRTI backbone (including agents such as emtricitabine and tenofovir disoproxil fumarate in many cases as implied by resistance patterns) plus a third agent that was a ritonavir-boosted protease inhibitor, an NNRTI, or an INSTI (prior INSTI exposure is noted). The manuscript also discusses elvitegravir (the study drug), and mentions other INSTIs (raltegravir, dolutegravir, bictegravir) in the Discussion as comparators.",1,"Tenofovir disoproxil fumarate, Emtricitabine, Ritonavir-boosted Protease Inhibitors, NNRTIs, Integrase Inhibitors",0,No,0,"ritonavir-boosted PI, NNRTI, INSTI",0,"Ritonavir-boosted PIs, NNRTIs",0,Not reported,0,Not reported,0,"Dolutegravir (DTG), Emtricitabine (FTC), Tenofovir alafenamide (TAF), Tenofovir disoproxil fumarate (TDF), Efavirenz (EFV)",0,"Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate",1,No,0,"Emtricitabine, tenofovir, elvitegravir",1,"Emtricitabine, tenofovir, elvitegravir",1,"3TC, FTC, TDF, ATV/r",0,"Ritonavir-boosted PI, NNRTI, INSTI",0,"Efavirenz (EFV), Tenofovir (TFV), Emtricitabine (FTC), Lamivudine (3TC), Nevirapine (NVP), Zidovudine (AZT), Dolutegravir (DTG)",0,"Elvitegravir (EVG), Raltegravir (RAL), Dolutegravir (DTG), Bictegravir (BIC), cabotegravir (CAB), Lenacapavir (LEN)",0,No,0,"Ritonavir-boosted PI (PI/r), NNRTI, and INSTI",0,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, EVG, DTG, BIC, CAB, LEN, MVC",1,No,0,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c",1,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c",1
Human Answer,36645792,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports genotypic antiretroviral resistance testing (GART) performed on patient plasma samples (baseline and as needed during follow-up).,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes.,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36645792,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance testing and computational susceptibility prediction, but no in vitro phenotypic (laboratory) drug susceptibility assays are described.",1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,36645792,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported. The paper does not state that sequences or accession numbers were deposited in public repositories.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No.,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer,36645792,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. The paper does not provide any GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported in the provided text,1,Not reported,1,MZ568467-MZ568625,0
Human Answer,36645792,5,How many individuals had samples obtained for HIV sequencing?,Number,"120 * 76% = 95, or 120 or 129","120 participants had successful baseline GART; additionally, six participants met protocol-defined criteria for GART by week 24 (used for on-study resistance testing).",1,0,0,6,0,130,0,130,0,Not reported,0,130,0,130,0,0,0,130,0,130.,0,130,0,130.,0,Not reported,0,130,0,0,0,0,0,130,0,130,0,130,0,130,0,130,0
Human Answer,36645792,6,From which countries were the sequenced samples obtained?,List,South Africa,South Africa.,1,No,0,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,No,0,South Africa,1,South Africa.,1,South Africa,1,South Africa.,1,Not reported,0,South Africa,1,No,0,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,"South Africa, Colombia, Ukraine, Brazil",1
Human Answer,36645792,7,From what years were the sequenced samples obtained?,List,No,Samples were obtained during 2020–2021 (participants recruited between 28 August 2020 and 10 November 2021).,0,No,1,2020-2021,0,2020–2021,0,2020–2021,0,2020–2021,0,2020-2021,0,2020-2021,0,No,1,2020-2021,0,2020-2021.,0,2020-2021,0,2020-2021.,0,Not reported,1,2020-2021,0,2020-2021,0,No,1,2020-2021,0,2020-2021,0,2020-2021,0,2020-2021,0,2020-2021,0
Human Answer,36645792,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported. There is no mention of cloning of samples prior to sequencing.,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported.,1,No,1,No.,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer,36645792,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",Reverse transcriptase (RT) and integrase regions were sequenced (genotypic testing detected RT mutations associated with tenofovir/lamivudine resistance and reported integrase resistance results).,1,No,0,IN,0,"RT, IN",1,Not reported,0,Not reported,0,IN,0,"NRTI, IN",1,No,0,"PR, RT, IN",1,Not reported.,0,Not reported,0,Pol.,0,Not reported,0,Not reported,0,No,0,No,0,Not Reported,0,Pol,0,Yes,0,"RT, IN",1,IN,0
Human Answer,36645792,10,What method was used for sequencing?,List,No,"Genotypic antiretroviral resistance testing (GART) was used, with drug susceptibility interpretation by the Stanford algorithm; the specific sequencing platform and laboratory sequencing method are not described.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Sanger sequencing,0,Yes,0,Not reported,1,Sanger sequencing,0
Human Answer,36645792,11,What type of samples were sequenced?,List,Plasma,Plasma samples (stored at enrollment).,1,No,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,No,0,Plasma,1,Plasma.,1,Plasma,1,Plasma.,1,Not reported,0,Plasma,1,Plasma,1,No,0,Dried Blood Spots,0,Plasma,1,"NRTIs, NNRTIs",0,Plasma,1,Plasma,1
Human Answer,36645792,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes. The study enrolled adults with virologic failure on first-line tenofovir-emtricitabine (or lamivudine)-efavirenz (TEE) and performed baseline and on-study GART for such participants.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Tenofovir, Emtricitabine, Efavirenz",0,Yes,1,Yes,1
Human Answer,36645792,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes. This was a randomized, double-blind, placebo-controlled, phase 2 clinical trial (ARTIST; ClinicalTrials.gov NCT03991013).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,36645792,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. Participants had previously received first-line antiretroviral therapy (tenofovir plus emtricitabine/lamivudine plus efavirenz) and sequencing was performed on their samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,36645792,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI",Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI).,1,NRTI,0,"NRTI, INSTI",0,"NRTI, NNRTI",1,"NRTI, NNRTI",1,Not reported,0,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI, INSTI",1,"NRTI, NNRTI",1,"NRTIs, NNRTIs.",1,"NRTI, NNRTI",1,"NRTIs, NNRTIs.",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI",1,"NRTIs, NNRTIs",1,"NRTIs, NNRTIs",1,No,0,"NRTI, NNRTI",1,"NRTI, NNRTI",1
Human Answer,36645792,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, EFV","Tenofovir, emtricitabine (or lamivudine), and efavirenz.",1,"Tenofovir, Lamivudine, Efavirenz",1,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG)",0,"Tenofovir, Emtricitabine, Efavirenz",0,"Tenofovir, Emtricitabine, Efavirenz",0,Not reported,0,"Tenofovir, Emtricitabine, Efavirenz",0,"Tenofovir (TFV), Emtricitabine (3TC), Efavirenz (EFV)",1,"Tenofovir, lamivudine, dolutegravir, efavirenz",1,"Tenofovir (TFV), Emtricitabine (FTC), Efavirenz (EFV)",0,"Tenofovir, emtricitabine/lamivudine, efavirenz.",1,"Tenofovir, emtricitabine, efavirenz",0,"Tenofovir, emtricitabine, efavirenz.",0,"Tenofovir, Emtricitabine, Efavirenz",0,"Tenofovir, Emtricitabine, Efavirenz",0,"ABC, AZT, DDC, DDI, 3TC, D4T, FTC, TFV, NVP, DLV, EFV, ETR, RPV, DOR, APV, LPV, ATV, DRV",1,"Tenofovir (TDF), Emtricitabine (FTC), Efavirenz (EFV)",0,"Tenofovir, Emtricitabine, Efavirenz",0,"Tenofovir, Emtricitabine, Efavirenz",0,No,0,"Tenofovir, Emtricitabine, Lamivudine, Efavirenz",1,"Efavirenz (EFV), Tenofovir (TFV), Emtricitabine (FTC), Lamivudine (3TC), Nevirapine (NVP), Zidovudine (AZT)",1
Human Answer,36659824,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the study performed baseline HIV-1 resistance genotyping on participant samples.,1,No,0,No,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,,0
Human Answer,36659824,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report newly generated in vitro drug susceptibility (phenotypic) assay results; it only references published in vitro IC95 values used to interpret plasma concentrations.,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,,1
Human Answer,36659824,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report depositing sequences in public repositories or provide accession numbers.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,,1
Human Answer,36659824,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported (the paper does not provide specific accession numbers),1,Not reported in the provided text,1,Not reported,1,,1
Human Answer,36659824,5,How many individuals had samples obtained for HIV sequencing?,Number,14,Not specified in the paper (number of genotyped samples is not reported explicitly).,0,0,0,0,0,112,0,112,0,Not reported,0,112,0,112,0,0,0,0,0,112,0,112,0,112,0,0,0,0,0,0,0,112,0,112,0,112,0,112,0,0,0,,0
Human Answer,36659824,6,From which countries were the sequenced samples obtained?,List,France,France.,1,No,0,No,0,France,1,France,1,France,1,France,1,France,1,No,0,No,0,France,1,France,1,Not reported,0,Not reported,0,Not reported,0,No,0,France,1,Not reported,0,France,1,France,1,Not reported,0,,0
Human Answer,36659824,7,From what years were the sequenced samples obtained?,List,2019-2020,Between November 2019 and September 2020.,1,No,0,No,0,2019–2020,1,2019–2020,1,2019–2020,1,2019-2020,1,2019-2020,1,No,0,No,0,2019-2020,1,2019-2020,1,2019-2020,1,Not reported,0,Not reported,0,No,0,2019-2020,1,2019-2020,1,2019-2020,1,2019-2020,1,2019-2020,1,,0
Human Answer,36659824,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / no indication that samples were cloned prior to sequencing.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,,1
Human Answer,36659824,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",Pol region genes are implied — at least reverse transcriptase and integrase (mutations M184V and E157Q are discussed); protease sequencing is not explicitly described.,1,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,"PR (Protease), RT (Reverse Transcriptase), IN (Integrase)",1,No,0,No,0,Pol,0,Not reported,0,Pol,0,Not reported,0,Not reported,0,No,0,No,0,Not reported,0,Pol,0,No,0,"RT, IN",1,,0
Human Answer,36659824,10,What method was used for sequencing?,List,No,"Not reported — the paper does not specify the sequencing technology or genotyping method (e.g., Sanger or NGS).",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Sanger sequencing,0,No,1,No,1,Not reported,1,Not reported,1,Sanger sequencing,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing,0,Yes,0,Not reported,1,,1
Human Answer,36659824,11,What type of samples were sequenced?,List,No,Blood-derived samples (plasma) collected at baseline for routine testing and HIV resistance genotyping.,0,No,1,No,1,Plasma,0,Not reported,1,Not reported,1,Not reported,1,Plasma,0,No,1,No,1,Plasma,0,Plasma,0,Plasma,0,Not reported,1,Not reported,1,No,1,No,1,Plasma,0,Plasma,0,Not reported,1,Plasma,0,,1
Human Answer,36659824,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes — resistance genotypic testing was recommended and performed in cases of virological non-response/failure, and the study reports no emergent resistance-associated mutations in those individuals.",1,No,0,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,No,0,No,0,Yes,1,Not reported,0,Yes,1,,0
Human Answer,36659824,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes — the study was a registered, prospective, multicentre, open-label single-arm clinical study (ClinicalTrials.gov NCT03858478).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,Yes,1,,0
Human Answer,36659824,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,No — previously treated individuals were excluded from the main ITT analyses and sequences from pretreated individuals are not reported in the results.,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,Yes,1,No,0,No,0,No,0,No,0,No,0,Yes,1,No,0,Yes,1,,0
Human Answer,36659824,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, INSTI",Not reported — the manuscript does not specify which antiretroviral drug classes (if any) prior-treated participants had received.,0,No,0,No,0,,0,,0,,0,"NNRTI, PI",0,None (participants were ART-naive),0,No,0,No,0,"INSTI, NRTI",1,Not reported,0,"NRTIs, NNRTIs, INSTIs",1,Not reported,0,Not reported,0,No,0,No,0,,0,"NRTIs, PIs, and INSTIs",1,No,0,"NRTI, NNRTI, PI, INSTI",1,,0
Human Answer,36659824,16,Which drugs were received by individuals in the study before sample sequencing?,List,"BIC, FTC, TAF",Not reported — specific prior antiretroviral drugs for pretreated individuals are not provided in the paper.,0,No,0,No,0,,0,,0,,0,Not reported,0,None (participants were ART-naive),0,No,0,No,0,"BIC, FTC, TAF",1,Not reported,0,"Tenofovir, emtricitabine, bictegravir",0,Not reported,0,Not reported,0,No,0,No,0,,0,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, and RAL",0,No,0,"BIC, FTC, TAF, and other drugs.",1,,0
Human Answer,36660819,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Not reported.,0,No,0,Not reported,0,Yes,1,No,0,No,0,Yes.,1,Yes,1,Yes,1,No,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,** No,0,Yes,1
Human Answer,36660819,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not present in vitro phenotypic susceptibility data.,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,Yes,0,No,1,No,1,No.,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,36660819,3,Were sequences from the paper made publicly available?,Boolean,No,No — sequences or accession numbers are not reported as publicly available.,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,36660819,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not reported.,1,No,1,No,1,Not reported,1,Not reported.,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,KP170487,0,Not reported,1,** Not reported,1,Not reported,1
Human Answer,36660819,5,How many individuals had samples obtained for HIV sequencing?,Number,8 and 10,Not specified in the manuscript.,0,0,0,1045,0,1045,0,Not reported.,0,Not reported,0,1045,0,1045,0,0,0,0,0,1045.,0,1045,0,1045,0,Not reported,0,Not reported,0,0,0,0,0,1045,0,1045,0,1045,0,** Not reported,0,1045,0
Human Answer,36660819,6,From which countries were the sequenced samples obtained?,List,No,Not reported.,1,No,1,No,1,Not reported,1,Not reported.,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"USA, Botswana, Uganda, Zimbabwe",0,Not reported,1,** Not reported,1,Not reported,1
Human Answer,36660819,7,From what years were the sequenced samples obtained?,List,No,Not reported.,1,No,1,No,1,Not reported,1,Not reported.,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2008-2017,0,48-152 weeks,0,** Not reported,1,Not reported,1
Human Answer,36660819,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / no indication that cloning was performed.,1,No,1,No,1,Not reported,1,Not reported.,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No.,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,36660819,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",Integrase and reverse transcriptase (pol region) were sequenced/reported.,1,No,0,"PR, RT, IN",1,Not reported,0,Not reported.,0,Not Reported,0,Not reported,0,Not reported,0,No,0,No,0,Not reported.,0,"Pol, IN",0,Pol,0,Not reported,0,IN,0,No,0,No,0,Not reported,0,Pol,0,Yes,0,** Not reported,0,RT,0
Human Answer,36660819,10,What method was used for sequencing?,List,No,Not reported.,1,No,1,No,1,Not reported,1,Not reported.,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Sanger sequencing,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing,0,Yes,0,** Not reported,1,Not reported,1
Human Answer,36660819,11,What type of samples were sequenced?,List,No,Plasma viral samples (SVF/plasma) and peripheral blood mononuclear cells (PBMCs) were used for sequencing.,0,No,1,PBMC,0,Not reported,1,Not reported.,1,Not Reported,1,Not reported,1,Plasma,0,No,1,No,1,Plasma.,0,"Plasma, PBMC",0,"Plasma, PBMC",0,Not reported,1,Plasma,0,No,1,No,1,Blood,0,Plasma,0,INSTI and NNRTI,0,** Plasma,0,Plasma,0
Human Answer,36660819,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes.,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,No,0,Yes,1,Yes,1,CAB and RPV,0,** Yes,1,Yes,1
Human Answer,36660819,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,36660819,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,36660819,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NNRTI, INSTI",Integrase strand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are explicitly indicated; participants had prior exposure to CAB (an INSTI) and RPV (an NNRTI).,1,No,0,"NRTI, NNRTI, INSTI",1,Not reported,0,"INSTI, NNRTI.",1,Not reported,0,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",0,"INSTI, NNRTI",1,No,0,"INSTI, NNRTI.",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,Not reported,0,"INSTI, NNRTI",1,No,0,No,0,Not reported,0,"NRTIs, NNRTIs, PIs",0,INSTI and NNRTI,1,"** INSTI, NNRTI",1,"NRTI, NNRTI, PI, INSTI",1
Human Answer,36660819,16,Which drugs were received by individuals in the study before sample sequencing?,List,"CAB, RPV",Cabotegravir and rilpivirine were received prior to and during the study; specific other individual prior drugs are not detailed in the manuscript.,1,No,0,"CAB, RPV",1,Not reported,0,"Cabotegravir, Rilpivirine.",1,Not reported,0,"Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine, Lamivudine, Nevirapine, Zidovudine",0,"Efavirenz, Tenofovir disoproxil fumarate, Emtricitabine, Lamivudine",0,"Cabotegravir (CAB), Rilpivirine (RPV)",1,No,0,"Cabotegravir, Rilpivirine.",1,"Cabotegravir, Rilpivirine",1,"Cabotegravir, rilpivirine, dolutegravir",1,Not reported,0,"Cabotegravir (CAB), Rilpivirine (RPV)",1,No,0,No,0,Not reported,0,"AZT, 3TC, FTC, TDF, ABC, EFV, RPV, DRV",0,CAB and RPV,1,"** Cabotegravir (CAB), Rilpivirine (RPV)",1,"DOR, 3TC, TDF, EFV, TFV, FTC, NVP, AZT, DTG, CAB, RPV, LEN",1
Human Answer,36694270,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer,36694270,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"No
```",1,No,1
Human Answer,36694270,3,Were sequences from the paper made publicly available?,Boolean,No,No (not reported).,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,"Yes, but the accession numbers are not provided.",0,"Yes
```",0,No,1
Human Answer,36694270,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported (the actual accession numbers are not provided in the main text),1,Not reported,1,Not reported,1,"Not reported
```",1,Not reported,1
Human Answer,36694270,5,How many individuals had samples obtained for HIV sequencing?,Number,62,62 individuals.,1,62,1,62,1,62,1,62,1,62,1,62,1,62,1,62,1,62,1,62,1,62,1,62,1,62,1,62,1,62,1,62,1,62,1,62,1,62,1,"62
```",1,62,1
Human Answer,36694270,6,From which countries were the sequenced samples obtained?,List,China,"China (Chongqing, China).",1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,Not reported,0,Not reported,0,China,1,China,1,China,1,China,1,China,1,"China
```",1,China,1
Human Answer,36694270,7,From what years were the sequenced samples obtained?,List,2019-2022,June 2020 to June 2022 (samples collected 2020–2022).,0,2019-2022,1,2019-2022,1,2020–2022,0,2020–2022,0,2019–2022,1,2019-2022,1,2020-2022,0,2019-2022,1,2019-2022,1,2020-2022,0,2019-2022,1,2019-2022,1,2020-2022,0,2020-2022,0,2019-2022,1,2020-2022,0,2020-2022,0,2020-2022,0,2019-2022,1,"2019-2022
```",1,2020-2022,0
Human Answer,36694270,8,Were samples cloned prior to sequencing?,Boolean,No,No (no cloning reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"No
```",1,No,1
Human Answer,36694270,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Protease, reverse transcriptase, and integrase genes.",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease (PI), Reverse Transcriptase (RT), Integrase (IN)",1,"PR, RT, IN",1,"Protease, Reverse transcriptase, Integrase",1,"PR, RT, IN",1,"Protease, Reverse Transcriptase, Integrase",1,"Protease, Reverse Transcriptase, Integrase",1,"Protease, Reverse Transcriptase, Integrase",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease, RT, IN",1,"PR, RT, IN",1,"Protease, Reverse Transcriptase, Integrase",1,"Protease, Reverse Transcriptase, Integrase",1,"Protease, Reverse Transcriptase, Integrase",1,"PR, RT, IN
```",1,"PR, RT, IN",1
Human Answer,36694270,10,What method was used for sequencing?,List,Sanger sequencing,RT-PCR followed by nested PCR amplification and sequencing of the PCR products (method of sequencing platform not specified).,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Not reported,0,Nested PCR,0,Nested PCR,0,Sanger sequencing,1,No,0,Sanger sequencing,1,Not Reported,0,Sanger sequencing,1,Not reported,0,Not reported,0,Sanger sequencing,1,No,0,PCR,0,PCR,0,Sanger sequencing,1,"Sanger sequencing
```",1,Not reported,0
Human Answer,36694270,11,What type of samples were sequenced?,List,"Plasma, CSF",Matched cerebrospinal fluid (CSF) and plasma samples (viral RNA-derived sequences).,1,Plasma; Other,0,"CSF, Plasma",1,"Plasma, CSF",1,"Plasma, CSF",1,"Plasma, CSF",1,"Plasma, Cerebrospinal Fluid (CSF)",1,Plasma; CSF,1,"CSF, Plasma",1,"CSF, Plasma",1,"Plasma, CSF",1,"Plasma, CSF",1,"Plasma, CSF",1,Plasma; CSF,1,"CSF, Plasma",1,"Plasma, CSF",1,"CSF, Plasma",1,"Plasma, CSF",1,"Plasma, CFS",0,"Plasma, CSF",1,"Plasma; CSF
```",1,"CSF, Plasma",1
Human Answer,36694270,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer,36694270,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"No
```",1,No,1
Human Answer,36694270,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer,36694270,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI, NNRTI, INSTI","Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).",0,NRTI; NNRTI,0,NRTI,0,"NRTIs, NNRTIs",0,"NRTI, NNRTI",0,"NNRTI, NRTI, PI",0,NRTI,0,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,NRTIs,0,"NRTIs, NNRTIs, PIs",0,"NRTIs, NNRTIs, PIs",0,NRTI; NNRTI; PI,0,Not reported,0,NRTI,0,"NRTI, NNRTI, PI",0,NRTIs,0,NRTIs,0,"NRTIs, NNRTIs, PIs",0,"NRTI
```",0,NRTI,0
Human Answer,36694270,16,Which drugs were received by individuals in the study before sample sequencing?,List,"3TC, TDF, EFV, LPV/r, EVG, ABC, DTG","Regimens included NRTIs such as lamivudine (3TC) and tenofovir (TDF), NNRTIs such as efavirenz (EFV), and protease inhibitor lopinavir/ritonavir (LPV/r); specific regimen details are not fully enumerated for each patient.",0,3TC; TDF,0,No,0,NRTIs,0,Not reported,0,Not reported,0,"3TC, TDF",0,"Lamivudine (3TC), Various NNRTIs",0,"3TC, TDF, EFV, LPV/r",0,No,0,"3TC, TDF",0,Not Reported,0,Not Reported,0,"Lamivudine (3TC), Tenofovir (TDF), Efavirenz (EFV), Lopinavir/Ritonavir (LPV/r)",0,Not reported,0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV)",0,"NRTI, NNRTI, PI",0,"3TC, TDF",0,Not reported,0,"NRTIs, NNRTIs, PIs",0,"3TC, TDF
```",0,"3TC, TDF",0
Human Answer,36706364,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports genotypic resistance testing (patient-derived sequences) from participants.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,36706364,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro phenotypic drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,36706364,3,Were sequences from the paper made publicly available?,Boolean,No,No — public availability of sequences is not reported in the paper.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** No,1,Yes,0
Human Answer,36706364,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,** Not reported,1,MF957336-MF957707,0
Human Answer,36706364,5,How many individuals had samples obtained for HIV sequencing?,Number,62 or 3,56 participants had baseline genotypic resistance results; additionally three resistance tests were conducted during follow-up (including the two with virological failure).,1,0,0,0,0,62,1,62,1,62,1,62,1,62,1,62,1,0,0,62,1,62,1,62,1,Not reported,0,62,1,0,0,0,0,62,1,62,1,62,1,** 62,1,62,1
Human Answer,36706364,6,From which countries were the sequenced samples obtained?,List,South Africa,"South Africa (Khayelitsha, South Africa).",1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,No,0,South Africa,1,South Africa,1,South Africa,1,Not reported,0,Not reported,0,No,0,South Africa,1,South Africa,1,South Africa,1,South Africa,1,** South Africa,1,South Africa,1
Human Answer,36706364,7,From what years were the sequenced samples obtained?,List,2019-2020,Samples were obtained from participants enrolled between August 2019 and July 2020.,1,No,0,2019-2020,1,2019–2020,1,2019–2020,1,Not reported,0,2019-2020,1,2019-2020,1,2019-2020,1,No,0,2019-2020,1,2019-2020,1,2019-2020,1,Not reported,0,2019-2020,1,No,0,No,0,2019-2020,1,2019-2020,1,2019-2020,1,** 2019-2020,1,2019-2020,1
Human Answer,36706364,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No evidence of cloning prior to sequencing.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,** No,1,No,1
Human Answer,36706364,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",Reverse transcriptase (RT) was assessed (mutations K65R and M184V/I reported); integrase was also assessed for resistance (no integrase resistance mutations detected).,1,No,0,No,0,Pol,0,Not reported,0,Not reported,0,"PR, RT, IN",1,RT,0,No,0,No,0,Not reported,0,"Pol, IN",0,Not Reported,0,Not reported,0,Not reported,0,No,0,No,0,Pol,0,Pol,0,Yes,0,"** PR, RT",0,NRTI,0
Human Answer,36706364,10,What method was used for sequencing?,List,No,Not specified in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing,0,Yes,0,** Sanger sequencing,0,Not reported,1
Human Answer,36706364,11,What type of samples were sequenced?,List,Plasma,Not explicitly stated in the paper (sample type not reported).,0,No,0,Plasma,1,Not reported,0,Plasma,1,Not reported,0,Plasma,1,Plasma,1,No,0,No,0,Plasma or whole blood,1,Plasma,1,Not Reported,0,Not reported,0,Not reported,0,No,0,No,0,Plasma,1,Plasma,1,"NRTIs, NNRTIs",0,** Plasma,1,Plasma,1
Human Answer,36706364,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes — three participants underwent resistance testing during follow-up, including the two participants who met criteria for virological failure.",1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,No,0,Yes,1,Yes,1,"Tenofovir, Lamivudine/Emtricitabine, NNRTI",0,** Yes,1,Yes,1
Human Answer,36706364,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes — participants were enrolled in a single-arm, prospective, interventional study registered on ClinicalTrials.gov (NCT03991013).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,No,0,** Yes,1,Yes,1
Human Answer,36706364,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes — participants had failed first-line ART consisting of tenofovir, lamivudine/emtricitabine and an NNRTI prior to switching to TLD, and genotypic resistance reflective of prior ARV exposure was reported.",1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,** Yes,1,Yes,1
Human Answer,36706364,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, INSTI",Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).,0,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI",0,No,0,NRTIs and NNRTIs,0,"NRTIs, NNRTIs, PIs",0,"INSTI, NRTI",0,Not reported,0,"NRTI, INSTI",0,"NRTI (Nucleoside Reverse Transcriptase Inhibitor), NNRTI (Non-Nucleosid Reverse Transcriptase Inhibitor), PI (Protease Inhibitor), INSTI (Integrase Inhibitor)",1,"NRTI, NNRTI",0,NNRTI,0,"NRTI, NNRTI",0,No,0,"** NRTI, NNRTI, PI",0,"NRTI, NNRTI",0
Human Answer,36706364,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, FTC, EFV, NVP, DTG","Tenofovir and lamivudine or emtricitabine (XTC), and an NNRTI: efavirenz or nevirapine.",0,"Tenofovir, Lamivudine, Emtricitabine, NNRTI (Efavirenz or Nevirapine)",0,"Tenofovir (TFV), Lamivudine (3TC), Emtricitabine (FTC), Efavirenz (EFV), Nevirapine (NVP), Dolutegravir (DTG)",1,"Tenofovir, lamivudine, emtricitabine, efavirenz, nevirapine",0,"Tenofovir, Lamivudine/Emtricitabine, Efavirenz/Nevirapine",0,"Tenofovir, Lamivudine, Emtricitabine",0,"Stavudine (D4T), Lamivudine (3TC), Nevirapine (NVP), Efavirenz (EFV)",0,"Tenofovir, Lamivudine, Efavirenz, Nevirapine, Abacavir, etc.",0,"Tenofovir, lamivudine/emtricitabine, efavirenz, nevirapine",0,No,0,"Tenofovir, lamivudine, and an NNRTI",0,"Tenofovir, XTC, efavirenz, nevirapine",0,"Dolutegravir, Tenofovir, Lamivudine",0,Not reported,0,"Dolutegravir, Tenofovir, Lamivudine",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",1,"Tenofovir, Lamivudine, Efavirenz, Nevirapine",0,"Efavirenz, Nevirapine",0,"Tenofovir, Lamivudine, Efavirenz",0,No,0,"** Tenofovir, XTC, Efavirenz, Nevirapine",0,"Tenofovir, XTC, Efavirenz, Nevirapine",0
Human Answer,36738248,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The paper reports HIV sequences obtained from patient plasma samples, including both Sanger (SS) and next-generation (NGS, Illumina) sequences from participants in the Swiss HIV Cohort Study and Zurich Primary HIV Cohort.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36738248,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic resistance interpretation (in silico) using the Stanford database but does not report in vitro phenotypic (laboratory) drug susceptibility assays.,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,36738248,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported as publicly deposited in GenBank; sequences are stored in internal cohort databases (SwissHIVGenomeDB and SHCS Drug Resistance Database).,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,No.,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,36738248,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not reported in the manuscript text provided; no GenBank accession numbers are listed.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,"KY558407 - KY558462, KY766062, KY558463 - KY558518, KY766063",0
Human Answer,36738248,5,How many individuals had samples obtained for HIV sequencing?,Number,527,"The primary analysis included 527 people living with HIV (PLHIV), corresponding to 594 SS/NGS sample pairs.",1,527,1,527,1,527,1,527,1,527,1,527,1,527,1,527,1,527,1,527.,1,527,1,527,1,527,1,Not reported,0,527,1,527,1,527,1,527,1,527,1,527,1,527,1
Human Answer,36738248,6,From which countries were the sequenced samples obtained?,List,Switzerland,Switzerland (participants were enrolled in the Swiss HIV Cohort Study and the Zurich Primary HIV Cohort).,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland.,1,Switzerland,1,Switzerland,1,Not reported,0,Not reported,0,Switzerland,1,Switzerland,1,Not Reported,0,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1
Human Answer,36738248,7,From what years were the sequenced samples obtained?,List,No,Specific sample collection years are not provided in the manuscript text supplied; counts and cohort descriptions are given as of August 2021 but exact collection years for the analyzed samples are not reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,2002-2021,0,No,1,Not reported.,1,Not reported,1,2002-2021,0,Not reported,1,Not reported,1,2021,0,No,1,Not Reported,1,2002-2021,0,2002-2021,0,2002-2021,0,Not reported,1
Human Answer,36738248,8,Were samples cloned prior to sequencing?,Boolean,No,No. The methods describe direct RT-PCR amplification of viral RNA into overlapping amplicons for sequencing (Sanger and Illumina) and do not describe cloning of samples prior to sequencing.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,36738248,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","The pol region was the focus, including protease (PR), reverse transcriptase (RT) and integrase (IN); NGS often provided (near) whole-genome sequences while SS primarily covered partial pol (PR, RT, IN) regions.",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN, Near full length genome",1,"PR, RT, IN.",1,"Pol (PR, RT, IN)",1,"Protease, Reverse Transcriptase, Integrase",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease, Reverse transcriptase, and Integrase",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT",0,No,0,"PR, RT",0,"PR, RT",0
Human Answer,36738248,10,What method was used for sequencing?,List,"Sanger sequencing, NGS",Sanger sequencing (population SS) and next-generation sequencing (Illumina MiSeq or HiSeq). NGS reads were assembled with de novo assembly (velvet) and iteratively aligned using the SmaltAlign pipeline.,1,Illumina sequencing,0,Sanger sequencing; NGS,1,"Sanger sequencing, NGS",1,Sanger sequencing and NGS,1,Sanger sequencing and NGS,1,Illumina sequencing,0,Illumina sequencing,0,Illumina sequencing,0,Sanger sequencing; Illumina sequencing,0,Sanger sequencing and next-generation sequencing.,1,Sanger sequencing and NGS (Illumina MiSeq/HiSeq),1,Sanger and Next-Generation Sequencing,1,"Sanger sequencing, NGS",1,"Sanger sequencing, Illumina sequencing",0,Illumina sequencing,0,"Sanger sequencing, Illumina sequencing",0,NGS,0,NGS,0,Yes,0,Sanger sequencing,0,"Sanger sequencing, Illumina sequencing",0
Human Answer,36738248,11,What type of samples were sequenced?,List,Plasma,Plasma/blood samples: viral RNA was manually extracted from blood/plasma samples collected from cohort participants.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,"NRTI, NNRTI, PI, INSTI",0,Plasma,1,Plasma,1
Human Answer,36738248,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Not reported,"Not explicitly reported. The paper reports ART status at sampling (20.4% on ART, 76.3% ART-naive) and analyzes resistance, but it does not explicitly state which sequences came from individuals with documented virological failure.",1,No,1,No,1,Not reported,1,No,1,Not reported,1,Yes,0,No,1,Yes,0,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,"TDF, FTC, EFV, NVP, ATV, DRV, RAL, DTG, BIC, CAB, LEN",1,Not reported,1,Yes,0
Human Answer,36738248,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Participants were enrolled in observational cohort studies (the Swiss HIV Cohort Study and the Zurich Primary HIV Cohort), not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,36738248,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. The study includes ART-experienced individuals and assesses prior ARV exposure in relation to detected drug-resistance mutations.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Not reported,0,Yes,1
Human Answer,36738248,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Protease inhibitors (PIs), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs) were considered; integrase inhibitors (INSTIs) are mentioned but SS coverage of integrase was limited.",0,"NRTI, NNRTI, PI",0,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI",0,Not reported.,1,Not reported,1,Not Reported,1,"NRTI, NNRTI, PI, INSTI",0,Not reported,1,"NRTI, NNRTI, PI",0,No,1,"NRTIs, NNRTIs, PIs, INSTIs",0,"NRTI, PI, NNRTI, INSTI",0,No,1,Not reported,1,NRTI,0
Human Answer,36738248,16,Which drugs were received by individuals in the study before sample sequencing?,List,Not reported,"Specific antiretroviral drug names are not listed in the provided manuscript text; the paper reports drug-class level analyses and refers to supplemental tables (e.g., Table S3) for drug-level resistance interpretations but does not enumerate individual drug names in the main text.",0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,"Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,1,Not reported.,1,Not reported,1,Not Reported,1,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.",0,Not reported,1,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,1,"Tenofovir, lamivudine, efavirenz, raltegravir",0,"AZT, 3TC, FTC, TDF, EFV, NVP, RAL, DTG, CAB, LEN",0,No,1,Not reported,1,"Zidovudine (AZT), Lamivudine (3TC), Didanosine (DDI)",0
Human Answer,36751650,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36751650,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,36751650,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No accession information provided.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,Not reported,1
Human Answer,36751650,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1,Not reported,1
Human Answer,36751650,5,How many individuals had samples obtained for HIV sequencing?,Number,1653,1653 individuals/samples were successfully sequenced.,1,1653,1,1653,1,1653,1,1653,1,1653,1,1653,1,1653,1,1653,1,1653,1,1653,1,1653,1,1608,0,1653,1,1653,1,1653,1,1653,1,1653,1,1653,1,1653,1,1653,1,1653,1
Human Answer,36751650,6,From which countries were the sequenced samples obtained?,List,China,China (Guangxi province).,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,Not Reported,0,China,1,China,1,China,1,China,1
Human Answer,36751650,7,From what years were the sequenced samples obtained?,List,2016-2020,Samples were obtained from January 2016 to December 2020.,1,2016-2020,1,2016-2020,1,2016–2020,1,2016–2020,1,2016–2020,1,2016-2020,1,2016 to 2020,1,2016-2020,1,2016-2020,1,2016-2020,1,2016-2020,1,2016-2020,1,2016-2020,1,2016-2020,1,2016-2020,1,2016-2020,1,2016-2020,1,2016-2020,1,2016-2020,1,2016-2020,1,2016-2020,1
Human Answer,36751650,8,Were samples cloned prior to sequencing?,Boolean,No,No; samples were amplified by nested PCR and directly Sanger-sequenced (no cloning reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer,36751650,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol",A 1316 bp fragment of the pol gene encompassing the protease region and the first 299 residues of reverse transcriptase was sequenced.,1,"Protease, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"Protease, Reverse transcriptase",0,"PR, RT",0,Pol,0,Pol,0,Pol,0,pol,0,"PR, RT",0,Protease and Reverse transcriptase,0,Pol,0,Pol,0,Pol,0,No,0,"PR, RT",0,"PR, RT",0
Human Answer,36751650,10,What method was used for sequencing?,List,Sanger sequencing,Nested PCR amplification of pol followed by Sanger sequencing of PCR products.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,36751650,11,What type of samples were sequenced?,List,Plasma,Plasma samples (from peripheral blood) were used for viral RNA extraction and sequencing.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,,0,Plasma,1,Plasma,1
Human Answer,36751650,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,,1,No,1,No,1
Human Answer,36751650,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1
Human Answer,36751650,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No; participants had not received ART prior to sampling.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1
Human Answer,36751650,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"None — participants were ART-naive, so no drug classes were received before sequencing.",1,"NRTI, NNRTI, PI, INSTI",0,No,1,,1,,1,,1,,1,Not applicable,1,"NNRTI, PI, NRTI",0,No,1,,1,Not reported,1,"NRTIs, NNRTIs, PIs, INSTIs",0,Not reported,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,No,1,,1,Not reported,1,No,1,Not reported,1,Not reported,1
Human Answer,36751650,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None — no specific ARV drugs were received prior to sequencing (participants were ART-naive).,1,No,1,No,1,,1,,1,,1,,1,Not applicable,1,"Fosamprenavir, Nelfinavir, Tipranavir, Abacavir, Zidovudine, Stavudine, Emtricitabine, Lamivudine, Tenofovir disoproxil fumarate, Doravirine, Efavirenz, Etravirine, Nevirapine, Rilpivirine, Bictegravir, Dolutegravir, Elvitegravir, Raltegravir",0,No,1,Not reported,1,Not reported,1,"3TC, FTC, AZT, TDF, ABC, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",0,Not reported,1,Not reported,1,"Abacavir (ABC), Zidovudine (AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir (EVG), Dolutegravir (DTG), Bictegravir (BIC), cabotegravir (CAB), Lenacapavir (LEN)",0,No,1,Not Reported,1,Not reported,1,No,1,Tenofovir (TDF),0,Not reported,1
Human Answer,36779485,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,** Yes,1
Human Answer,36779485,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** Yes,0,** Yes,0
Human Answer,36779485,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No accession information provided.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,** Yes,0
Human Answer,36779485,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not provided / Not reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Not reported,1,** Not reported,1
Human Answer,36779485,5,How many individuals had samples obtained for HIV sequencing?,Number,1649,277 patients initiating ART and 1372 patients failing NNRTI-based ART (total 1649 individuals).,1,1649,1,1649,1,1649,1,1649,1,1649,1,1649,1,1649,1,1649,1,1649,1,1649,1,277 + 1372 = 1649,1,1649,1,Not reported,0,Not reported,0,1649,1,1649,1,1649,1,277 (for ART-naive patients) and 1372 (for patients experiencing NNRTI-treatment failure),0,1649,1,** 1649,1,** 1649,1
Human Answer,36779485,6,From which countries were the sequenced samples obtained?,List,South Africa,South Africa.,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,Not reported,0,Not reported,0,South Africa,1,South Africa,1,South Africa,1,South Africa,1,Not reported,0,** Not reported,0,** Not reported,0
Human Answer,36779485,7,From what years were the sequenced samples obtained?,List,No,Not specified / Not reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Not reported,1,** Not reported,1
Human Answer,36779485,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No indication that samples were cloned prior to sequencing.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,** No,1,** No,1
Human Answer,36779485,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol",The pol gene.,0,"Reverse transcriptase, RT",0,Pol,0,Pol,0,Pol,0,Pol,0,Not reported,0,Pol gene (including protease and reverse transcriptase),1,"Protease, Reverse transcriptase, Integrase",0,"PR, RT, IN",0,Pol,0,Pol,0,Pol,0,Not reported,0,Not reported,0,Reverse transcriptase (RT),0,"PR, RT, IN",0,Pol,0,Pol,0,Pol,0,** Pol,0,** Pol,0
Human Answer,36779485,10,What method was used for sequencing?,List,No,Not specified / Not reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Sanger sequencing,0,Sanger sequencing,0,Not reported,1,** Not reported,1,** Not reported,1
Human Answer,36779485,11,What type of samples were sequenced?,List,Plasma,Not specified / Not reported.,0,No,0,No,0,Not reported,0,Not Reported,0,Not reported,0,Plasma,1,Patient plasma samples,1,Plasma,1,No,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,Plasma (from patients) and Peripheral Blood Mononuclear Cells (PBMC) (from patients),1,"Plasma, PBMC, Whole Blood, Serum, Semen, CSF, Other, Unknown",1,Not reported,0,Plasma,1,Not reported,0,** Plasma,1,** Plasma,1
Human Answer,36779485,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,** Yes,1
Human Answer,36779485,13,Were the patients in the study in a clinical trial?,Boolean,No,"No (retrospective cohort analysis, not a clinical trial).",1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,** No,1,** No,1
Human Answer,36779485,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes (the cohort of patients failing NNRTI-based ART had prior ARV exposure).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,** Yes,1
Human Answer,36779485,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI",Non-nucleoside reverse transcriptase inhibitors (NNRTIs) were received (NNRTI-based ART).,1,NNRTI,1,"NRTI, NNRTI",1,Not reported,0,Not reported,0,Not reported,0,NNRTI,1,"NRTI, NNRTI",1,NNRTI,1,NNRTI,1,NNRTI,1,NNRTI,1,"NNRTI, NRTI",1,Not reported,0,Not reported,0,NNRTI,1,NNRTI,1,NNRTI,1,NNRTI,1,Not reported,0,"** NRTI, NNRTI, INSTI",1,"** NRTI, NNRTI",1
Human Answer,36779485,16,Which drugs were received by individuals in the study before sample sequencing?,List,RPV,Specific antiretroviral drug names are not reported; only NNRTI-class exposure is described (rilpivirine DRMs were assessed).,1,Rilpivirine,1,Rilpivirine,1,Not reported,0,Not reported,0,Not reported,0,Not reported,0,"Stavudine (D4T), Lamivudine (3TC), Nevirapine (NVP), Efavirenz (EFV)",0,Rilpivirine,1,NNRTI,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,Rilpivirine (RPV),1,"NVP, EFV, RPV, CAB",1,Not reported,0,Not reported,0,Not reported,0,"** Dolutegravir, Abacavir, Lamivudine, Cabotegravir, Rilpivirine, Maraviroc, Darunavir, Tenofovir, Emtricitabine, Etravirine",1,** Not reported,0
Human Answer,36795586,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No. The paper does not report HIV sequences from patient samples; HIV genotype testing was not available routinely and only sporadically available on a limited basis.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,36795586,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not report any in vitro drug susceptibility (phenotypic) data.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,36795586,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not indicate that any sequences were made publicly available.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not Reported,1,No,1,No,1
Human Answer,36795586,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. No GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,None.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1
Human Answer,36795586,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Not reported. The paper does not provide a count of individuals who had samples obtained specifically for sequencing.,1,0,1,0,1,0,1,Not reported,1,0.,1,Not reported,1,9419,0,0,1,0,1,Not reported,1,9419,0,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,9419,0,9419,0,9419,0,9419,0,9419,0
Human Answer,36795586,6,From which countries were the sequenced samples obtained?,List,No,"If any genotyping was performed, samples would have come from the study countries: Botswana, Eswatini, Lesotho, Malawi, Tanzania (Mbeya and Mwanza) and Uganda.",0,No,1,No,1,"Botswana, Eswatini, Lesotho, Malawi, Tanzania, Uganda",0,"Botswana, Eswatini, Lesotho, Malawi, Tanzania, Uganda",0,Not Reported.,1,"Botswana, Eswatini, Lesotho, Malawi, Tanzania, Uganda",0,"Botswana, Eswatini, Lesotho, Malawi, Tanzania, Uganda",0,"Botswana, Eswatini, Lesotho, Malawi, Tanzania, Uganda",0,No,1,Not reported,1,"Botswana, Eswatini, Lesotho, Malawi, Tanzania, Uganda",0,"Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda",0,Not reported,1,"Botswana, Eswatini, Lesotho, Malawi, Tanzania, Uganda",0,No,1,No,1,"Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda",0,"Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda",0,"Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda",0,"Botswana, Eswatini, Lesotho, Malawi, Tanzania-Mbeya, Tanzania-Mwanza, Uganda",0,"Botswana, Eswatini, Lesotho, Malawi, Tanzania-Mbeya, Tanzania-Mwanza, Uganda",0
Human Answer,36795586,7,From what years were the sequenced samples obtained?,List,No,"Not explicitly reported; the study period was January 2017 to December 2020, so any sporadic genotyping would have occurred within 2017–2020.",0,No,1,No,1,2017–2020,0,2017–2020,0,Not Reported.,1,2017 to 2020,0,2017 to 2020,0,2017-2020,0,No,1,Not reported,1,2017-2020,0,2017-2020,0,Not reported,1,2017-2020,0,No,1,No,1,2017-2020,0,2017-2020,0,2017-2020,0,2017-2020,0,2017-2020,0
Human Answer,36795586,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported. The paper provides no information about cloning of samples prior to sequencing.,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,No,1
Human Answer,36795586,9,Which HIV genes were reported to have been sequenced?,List,No,Not reported. The paper does not specify any HIV genes that were sequenced.,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Pol,0,Not Reported,1,"HIV genes (specifically, the genes involved in drug resistance mutations)",0,Not reported,1
Human Answer,36795586,10,What method was used for sequencing?,List,No,Not reported. No sequencing methodology is described in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,NGS,0,Yes,0,HIV genotype testing,0,Not reported,1
Human Answer,36795586,11,What type of samples were sequenced?,List,No,Not reported. The paper does not specify the biological sample type used for sequencing.,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Plasma,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Blood,0,Plasma,0,"NRTI, NNRTI, PI, INSTI",0,Plasma samples,0,Plasma,0
Human Answer,36795586,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Possibly yes but limited: targeted HIV genotype testing was sporadically available for CALHIV failing second-line ART, so some genotypes (and thus sequences) may have originated from individuals with virological failure, but these were limited and not reported in detail.",1,No,1,No,1,No,1,Not reported,1,No.,1,Not reported,1,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,"AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN, MVC",1,Yes,0,Yes,0
Human Answer,36795586,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. The study was a retrospective real-world cohort analysis of patients in routine clinical care, not a clinical trial.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1
Human Answer,36795586,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No sequences are reported. However, the cohort included many ART-experienced individuals and targeted genotyping (when done) was sometimes for those failing second-line ART.",1,No,1,No,1,Yes,0,Not reported,1,Not Reported.,1,Yes,0,Yes,0,Yes,0,No,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,36795586,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Reported prior drug classes in the cohort include NRTIs (as backbone), NNRTIs and protease inhibitors (PIs); many patients were shifted from NNRTI-based regimens or had prior PI-based ART.",0,"NRTI, NNRTI, PI",0,No,1,"NRTI, NNRTI",0,Not reported,1,Not reported.,1,"NNRTI, NRTI, PI",0,"NRTI, NNRTI, PI, INSTI",0,"INSTI (Integrase Inhibitor), including Dolutagravir (DTG)",0,No,1,Not reported,1,"NRTIs, NNRTIs, PIs, INSTIs",0,INSTI,0,Not reported,1,Not reported,1,No,1,No,1,NRTIs,0,NRTI,0,No,1,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI",0
Human Answer,36795586,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"The paper reports specific commonly used drugs/regimens in the cohort: tenofovir-lamivudine-dolutegravir (TLD) was widely used; NRTI backbones prior to DTG included abacavir-based, tenofovir-based and zidovudine-based regimens. Prior anchor drugs included NNRTIs and protease inhibitors (specific NNRTIs or PIs are not listed).",0,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,"Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT)",0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG)",0,Dolutagravir (DTG),0,No,1,Not reported,1,"Dolutegravir (DTG), tenofovir (TDF), lamivudine (3TC), and other ARV drugs",0,DTG,0,Not reported,1,Not reported,1,No,1,No,1,Lamivudine and tenofovir,0,DTG,0,No,1,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF), Emtricitabine (FTC), Lopinavir (LPV), Darunavir (DRV), Dolutegravir (DTG)",0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG)",0
Human Answer,36851704,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36851704,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,36851704,3,Were sequences from the paper made publicly available?,Boolean,No,No (not reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1
Human Answer,36851704,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not Reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451",0,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"MH062016-MH062024, MH062026-MH062029, MH062125-MH062138, MK931539-MK931547, MK931784, MK931789-MK931801, MK931912-MK931931, MK931933, MK931934, MK931937, MK931939, MK931940, MK931942, MK931943, MK931945, MK931947-MK931964, MK931996, MK931997, MK931999-MK932016, and MW483846-MW484805",0,Not reported,1
Human Answer,36851704,5,How many individuals had samples obtained for HIV sequencing?,Number,206,206 individuals were enrolled; genotyping success yielded 204 protease/RT sequences and 205 integrase sequences used for analysis.,1,206,1,206,1,206,1,206,1,206,1,206,1,206,1,206,1,206,1,206.,1,206,1,206.,1,206,1,206,1,206,1,206,1,206,1,206,1,206,1,206,1,206,1
Human Answer,36851704,6,From which countries were the sequenced samples obtained?,List,Uruguay,Uruguay.,1,Uruguay,1,Uruguay,1,Uruguay,1,Uruguay,1,Uruguay,1,Uruguay,1,Uruguay,1,Uruguay,1,Uruguay,1,Uruguay.,1,Uruguay,1,Uruguay.,1,Uruguay,1,Uruguay,1,No,0,Uruguay,1,Uruguay,1,Uruguay,1,Uruguay,1,Uruguay,1,Uruguay,1
Human Answer,36851704,7,From what years were the sequenced samples obtained?,List,2018-2019,Samples were obtained from October 2018 to October 2019.,1,2018-2019,1,2018-2019,1,2018–2019,1,2018-2019,1,2018–2019,1,2018-2019,1,2018-2019,1,2018-2019,1,2018-2019,1,2018-2019.,1,2018-2019,1,2018-2019.,1,2018-2019,1,2018-2019,1,2018-2019,1,2018-2019,1,2018-2019,1,2018-2019,1,2018-2019,1,2018-2019,1,2018-2019,1
Human Answer,36851704,8,Were samples cloned prior to sequencing?,Boolean,No,No (not reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Not Reported,1,No.,1,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,36851704,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Protease, reverse transcriptase, and integrase.",1,"Protease, Reverse transcriptase, Integrase",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease, Reverse transcriptase, Integrase",1,"PR, RT, IN",1,"Protease, reverse transcriptase, and integrase.",1,"Protease, Reverse Transcriptase, Integrase",1,"Protease, reverse transcriptase, and integrase.",1,"PR, RT, IN",1,"Protease, reverse transcriptase, integrase",1,"Protease, Reverse transcriptase, and Integrase",1,"PR, RT, IN",1,"Protease, Reverse Transcriptase, Integrase",1,"Pol, including protease and reverse transcriptase",1,"Protease, Reverse Transcriptase, Integrase",1,"Protease, Reverse Transcriptase, Integrase",1,"PR, RT, IN",1
Human Answer,36851704,10,What method was used for sequencing?,List,Sanger sequencing,Sanger sequencing (3730xl Genetic Analyser).,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,36851704,11,What type of samples were sequenced?,List,Whole Blood,Plasma specimens (HIV RNA extracted from plasma obtained from whole blood collected in EDTA tubes).,1,Whole Blood,1,Plasma,0,"Plasma, Whole Blood",1,Whole Blood,1,Whole Blood,1,Plasma,0,Plasma,0,Plasma,0,Plasma,0,Whole blood.,1,Plasma,0,Whole blood.,1,Plasma,0,Plasma,0,Whole Blood,1,Plasma,0,Whole blood,1,Plasma,0,Whole blood,1,Plasma,0,"Plasma, Whole blood",1
Human Answer,36851704,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not explicitly reported; sequences were from individuals initiating or reinitiating ART with viral load >1000 copies/mL, some of whom reported prior ARV exposure, but the paper does not state that sequences came from people failing a current regimen.",1,No,1,Yes,0,Not reported,1,Not reported,1,Yes,0,Yes,0,Not reported,1,No,1,No,1,No.,1,Yes,0,Yes.,0,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1
Human Answer,36851704,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Not Reported,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,36851704,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36851704,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI","Not specifically detailed for prior exposure; the paper reports types of prior exposure (e.g., prior ART, PrEP, PEP, PMTCT) and reports the regimens prescribed at ART initiation in the cohort (NNRTI-based, dolutegravir-based INSTI regimens, and boosted protease inhibitor regimens).",0,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI",0,Not reported,0,Not reported,0,Not fully reported,0,Not reported,0,"NRTI, NNRTI, PI, INSTI",1,No,0,Not reported.,0,"NRTIs, NNRTIs, PIs, INSTIs",1,NNRTIs and PIs.,0,"NNRTI, INSTI, PI",1,"NNRTI, INSTI, PI",1,"NRTI, NNRTI, PI, INSTI",1,No,0,Not reported,0,"NRTIs, NNRTIs",0,"NRTIs, NNRTIs, PIs, INSTIs",1,Not reported,0,Not reported,0
Human Answer,36851704,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not reported in detail for prior exposures; individual prior drugs are not listed. The paper discusses resistance to specific drugs (e.g., efavirenz, nevirapine, tenofovir, emtricitabine/lamivudine, dolutegravir, bictegravir, cabotegravir, raltegravir, elvitegravir, atazanavir/ritonavir, lopinavir/ritonavir) in the resistance analyses, and reports that prior exposure types included PrEP, PEP, PMTCT, or prior ART interruption.",1,"Efavirenz (EFV), Nevirapine (NVP), Tenofovir disoproxil fumarate (TDF)",0,"TDF, FTC, 3TC, DTG, ATV/r, LPV/r",0,"Efavirenz, Nevirapine",0,Not reported,1,Not reported,1,"Efavirenz, Nevirapine, Tenofovir (TDF)",0,"Zidovudine (ZDV), Lamivudine (3TC), Lopinavir/ritonavir (LPV/RTV)",0,"Abacavir, Zidovudine, Lamivudine, Emtricitabine, Tenofovir, Nevirapine, Efavirenz, Raltegravir, Elvitegravir, Dolutagravir",0,No,1,Not reported.,1,"Efavirenz, Nevirapine, Dolutegravir",0,Efavirenz and nevirapine.,0,"Zidovudine (ZDV), Lamivudine (3TC), Lopinavir/ritonavir (LPV/RTV)",0,"Efavirenz (EFV), Nevirapine (NVP), Dolutegravir (DTG), Atazanavir (ATV), Lopinavir (LPV)",0,"Abacavir (ABC), Zidovudine (AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir (EVG), Dolutegravir (DTG), Bictegravir (BIC), cabotegravir (CAB), Lenacapavir (LEN)",0,No,1,Not reported,1,"Efavirenz, tenofovir",0,"Efavirenz, Nevirapine, Lopinavir/Ritonavir, Atazanavir/Ritonavir, Darunavir/Ritonavir, Raltegravir, Elvitegravir, Dolutegravir, Bictegravir, Cabotegravir, Lenacapavir",0,Not reported,1,Not reported,1
Human Answer,36851760,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer,36851760,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"No
```",1,No,1
Human Answer,36851760,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer,36851760,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,OQ435656-OQ435729,OQ435656-OQ435729.,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,"OQ435656-OQ435729
```",1,OQ435656-OQ435729,1
Human Answer,36851760,5,How many individuals had samples obtained for HIV sequencing?,Number,107,107 individuals had DBS samples obtained; 75 samples were successfully sequenced.,1,107,1,107,1,107,1,107,1,107,1,107,1,107,1,107,1,107,1,107,1,107,1,107,1,107,1,107,1,107,1,107,1,107,1,75,0,107,1,"107
```",1,107,1
Human Answer,36851760,6,From which countries were the sequenced samples obtained?,List,"Mali, Benin",Benin and Mali.,1,"Mali, Benin",1,"Benin, Mali",1,"Mali, Benin",1,"Mali, Benin",1,"Benin, Mali",1,"Mali, Benin",1,"Mali, Benin",1,"Benin, Mali",1,"Benin, Mali",1,"Benin, Mali",1,"Mali, Benin",1,"Mali, Benin",1,"Mali, Benin",1,"Benin, Mali",1,Mali and Benin,1,"Benin, Mali",1,Mali and Benin,1,"Benin, Mali",1,Mali and Benin,1,"Mali, Benin
```",1,"Mali, Benin",1
Human Answer,36851760,7,From what years were the sequenced samples obtained?,List,2015-2020,"2015–2016 (Benin, ART-treated) and 2018–2020 (Mali, ART-naïve).",0,2015-2020,1,2015-2020,1,2015–2020,1,2015–2020,1,2015–2020,1,2015-2020,1,2015-2020,1,"2015-2016, 2018-2020",0,"2015-2016, 2018-2020",0,"2015-2016, 2018-2020",0,2015-2020,1,"2015-2016, 2018-2020",0,"2015-2016, 2018-2020",0,Not reported,0,"2015-2016, 2018-2020",0,"2015-2016, 2018-2020",0,2015-2016 (Benin) and 2018-2020 (Mali),0,"2015-2016 (Benin), 2018-2020 (Mali)",0,2015-2016 and 2018-2020,0,"2015-2016, 2018-2020
```",0,"2015-2016, 2018-2020",0
Human Answer,36851760,8,Were samples cloned prior to sequencing?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"No
```",1,No,1
Human Answer,36851760,9,Which HIV genes were reported to have been sequenced?,List,IN,The integrase gene (HIV-1 integrase).,1,"Integrase, IN",1,IN,1,IN,1,IN,1,IN,1,Integrase (IN),1,Integrase,1,Integrase,1,IN,1,Integrase,1,Integrase,1,IN,1,IN,1,IN,1,Integrase,1,IN,1,Integrase,1,Integrase,1,No,0,"Integrase
```",1,Integrase,1
Human Answer,36851760,10,What method was used for sequencing?,List,Sanger sequencing,Sanger sequencing of RT‑PCR and nested PCR amplicons (genotypic sequencing).,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger method,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Yes,0,"Sanger sequencing
```",1,Sanger sequencing,1
Human Answer,36851760,11,What type of samples were sequenced?,List,DBS,Dried blood spots (DBS) collected on Whatman 903 filter paper (50 µL blood per circle).,1,Other,0,DBS,1,DBS,1,DBS,1,DBS,1,Dried blood spots (DBS),1,Dried blood spots (DBS),1,DBS,1,DBS,1,Dried blood spots (DBS),1,Dried blood spots (DBS),1,DBS,1,Dried blood spots (DBSs),1,Dried blood spots (DBSs),1,DBS,1,DBS,1,DBS,1,DBSs,1,"NRTI, NNRTI, and INSTI",0,"Dried blood spots (DBSs)
```",1,Blood,0
Human Answer,36851760,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — sequences include samples from ART-treated children with virological failure; specifically 31 sequenced samples from ART-treated children with virological failure (20 from Benin and 11 from Mali).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Not Reported,0,"Yes
```",1,Yes,1
Human Answer,36851760,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,"No
```",1,No,1
Human Answer,36851760,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,"Yes
```",1,Yes,1
Human Answer,36851760,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NNRTI, NRTI, PI",Primarily non-nucleoside reverse transcriptase inhibitors (NNRTIs); some received nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs) as part of combined regimens.,1,"NNRTI, NRTI, PI",1,"NRTI, NNRTI, PI",1,"NNRTI, NRTI, PI",1,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NNRTI, NRTI, PI",1,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",1,No,0,"NNRTI, NRTI, PI",1,Not reported,0,Not reported,0,"NNRTI, NRTI, PI",1,NNRTI,0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INST",1,ART,0,"NRTI, NNRTI, PI, INSTI",1,No,0,"ART
```",0,NNRTI,0
Human Answer,36851760,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Specific antiretroviral drug names are not reported in the paper; only drug classes (NNRTI-based regimens and some NRTI+PI regimens) are specified.,1,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,"Efavirenz (EFV), Tenofovir (TDF), Lamivudine (3TC)",0,"Tenofovir disoproxil fumarate (TDF), Emtricitabine (FTC), Raltegravir (RAL)",0,"Abacavir, Zidovudine, Zalcitabine, Didanosine, Lamivudine, Stavudine, Emtricitabine, Tenofovir, Nevirapine, Delavirdine, Efavirenz, Etravirine, Rilpivirine, Doravirine, Amprenavir, Lopinavir, Atazanavir, Derunavir, Nelfinavir, Raltegravir, Elvitegravir, Dolutagravir, Bictegravir, cabotagravir, Lenacapavir",0,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,1,Not reported,1,Not reported,1,No,1,"ART drugs
```",0,"NNRTIs were not specified, but the paper mentions that the children were receiving ART with non-nucleoside-reverse-transcriptase-inhibitor (NNRTI)-based regimens.",1
Human Answer,36920025,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — the reported sequences derive from in vitro cell-culture selections (NL4-3 clone and defined isogenic mutant virus pool), not from patient-derived clinical specimens.",1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes.,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1
Human Answer,36920025,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes — the paper reports in vitro viral infectivity EC50 measurements and enzymatic Ki and Km assays for wild-type and mutant proteases.,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36920025,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes — sequencing data are deposited in the NCBI SRA under BioProject PRJNA853351 and source datasets are available in the Carolina Digital Repository.,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,No,0,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36920025,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,"The accession numbers are reported in the paper, but the exact numbers are not provided in the text.",1,Not provided in the text snippet,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,MN234327 - MN235714,0,Not reported,1
Human Answer,36920025,5,How many individuals had samples obtained for HIV sequencing?,Number,0,"Not applicable / not reported — sequencing was performed on in vitro cell-culture–derived virus stocks and experimental selections, not on samples from human individuals.",1,0,1,0,1,Not reported.,1,0,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported.,1,The exact number of individuals is not provided in the text.,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,6,0,Not reported,1
Human Answer,36920025,6,From which countries were the sequenced samples obtained?,List,No,Not reported / not applicable — the study used laboratory cell lines and NL4-3–derived virus stocks; no country origins for clinical samples are provided.,1,No,1,No,1,Not Reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,The country of origin is not explicitly mentioned in the text.,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,"United States, Australia",0,Not reported,1
Human Answer,36920025,7,From what years were the sequenced samples obtained?,List,No,Not reported — the manuscript does not specify calendar years when sequencing samples were obtained (only repository deposit year citations for datasets).,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,The exact years are not provided in the text.,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,2004-2007,0,Not reported,1,Not reported,1
Human Answer,36920025,8,Were samples cloned prior to sequencing?,Boolean,No,"Yes — some PCR products were cloned and sequenced, and Primer-ID MiSeq (next-generation) libraries were also generated for deep sequencing.",0,No,1,No,1,Yes.,0,No,1,Not reported,1,No,1,Yes,0,No,1,No,1,Yes.,0,Yes,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,36920025,9,Which HIV genes were reported to have been sequenced?,List,PR,"The HIV-1 protease (PR) coding region was sequenced (by Primer-ID MiSeq and PCR/Sanger), and portions of gag encoding protease cleavage sites (NC/SP2 and SP2/p6) were also sequenced.",1,No,0,PR,1,PR.,1,PR,1,Not reported,0,Protease gene,1,Not reported,0,Protease,1,PR,1,Protease.,1,Pol,0,Pol,0,IN,0,Not reported,0,Protease,1,No,0,PR,1,Pol,0,Pol,0,"Gag, PR, RT",1,"IN, PR, RT",1
Human Answer,36920025,10,What method was used for sequencing?,List,Illumina sequencing,Both next-generation Primer-ID deep sequencing on the Illumina MiSeq platform and Sanger sequencing of PCR products (with some PCR products cloned into pT7Blue prior to sequencing) were used.,1,Illumina sequencing,1,NGS,0,NGS.,0,NGS,0,Not reported,0,Not reported,0,Next-generation sequencing (NGS),1,Illumina sequencing,1,Illumina sequencing,1,NGS.,0,Sanger sequencing,0,NGS,0,Not reported,0,Not reported,0,Illumina sequencing,1,No,0,NGS,0,NGS,0,Not reported,0,Not reported,0,"Illumina sequencing, Sanger sequencing",1
Human Answer,36920025,11,What type of samples were sequenced?,List,No,"Sequencing was performed on viral material derived from the cell-culture selections: total cellular DNA from infected cell pellets, viral RNA (extracted from 'plasma samples' as described in Primer-ID methods, likely referring to culture supernatant-derived viral RNA), and cloned protease genes for expression studies.",1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Laboratory cells (CEMx174),0,Plasma,0,Plasma,0,Cell culture,1,Plasma and infected cell pellets.,0,Plasma,0,Plasma,0,Not reported,1,Not reported,1,Viral RNA,0,No,1,Plasma,0,Plasma,0,Plasma,0,PBMC,0,"PBMC, Plasma",0
Human Answer,36920025,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — the sequences were derived from laboratory cell-culture selections of NL4-3 and defined isogenic mutant virus pools, not from patients experiencing treatment failure.",1,No,1,No,1,No.,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,36920025,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients in this study and no clinical trial; experiments were performed with laboratory cell lines and molecular clones of HIV-1.,1,No,1,No,1,Not Reported.,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported.,1,Yes,0,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer,36920025,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — sequences reported are from in vitro-selected laboratory viruses derived from NL4-3 and defined mutant pools, not from treated individuals.",1,No,1,No,1,No.,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,36920025,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable — there were no human individuals in the study; only in vitro selections with protease inhibitors (PIs) including darunavir and UMASS PI analogs were used.,1,No,1,No,1,None.,1,,1,,1,"NRTI, NNRTI",0,"INSTI, NRTI, NNRTI, CCR5 antagonist",0,No,1,No,1,Protease inhibitors (PIs).,0,The exact drug classes are not provided in the text.,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"NRTI, PI, NNRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, INSTI, CCR5 antagonist",0,"NRTI, PI",0
Human Answer,36920025,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not applicable — no individuals were sampled; the experimental viruses were exposed in vitro to protease inhibitors (darunavir and the series of UMASS protease inhibitor analogs listed).,1,No,1,No,1,None.,1,,1,,1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Raltegravir (RAL), Emtricitabine (FTC)",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Raltegravir (RAL), Maraviroc (MVC), Emtricitabine (FTC)",0,No,1,No,1,Darunavir (DRV) and UMASS-1 through -10 inhibitors.,0,The exact drugs are not provided in the text.,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"AZT, 3TC, FTC, TDF, ATV, DRV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",0,"Raltegravir, Dolutegravir, Elvitegravir, Bictegravir, Maraviroc, Lenacapavir",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0,"Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)",0
Human Answer,36931676,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36931676,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No direct in vitro susceptibility data are reported; the paper reports predicted phenotypic sensitivity.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,36931676,3,Were sequences from the paper made publicly available?,Boolean,No,"No — sequences are stored in the registry and data (including sequences) are available upon reasonable request and after ethical approval, but no public deposition is reported.",1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No.,1,No,1,No.,1,Yes,0,Yes,0,No,1,No,1,Not Reported,1,No,1,Yes,0,Yes,0,Yes,0
Human Answer,36931676,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not reported / None provided in the paper.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported.,1,KR860607 to KR861345,0,KR860607 to KR861345,0,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,MN234327 - MN235714,0
Human Answer,36931676,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Not specified in the paper.,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,13029,0,13029,0,0,1,0,1,"13,029.",0,"13,029",0,Not reported.,1,6,0,6,0,0,1,0,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,6,0
Human Answer,36931676,6,From which countries were the sequenced samples obtained?,List,Sweden,Sweden (samples originate from people with diagnosed HIV in Sweden).,1,No,0,Sweden,1,Sweden,1,Sweden,1,Sweden,1,"Sweden, Sub-Saharan Africa",1,Sweden,1,No,0,No,0,"Sweden, SSA (sub-Saharan Africa), and other countries (not specified).",1,Sweden,1,Sweden.,1,"United States, Australia",0,"United States, Australia",0,No,0,No,0,Sweden,1,Sweden,1,Sweden,1,"Sweden, SSA (sub-Saharan Africa)",1,"United States, Australia",0
Human Answer,36931676,7,From what years were the sequenced samples obtained?,List,No,Not explicitly specified; cohort data span from establishment in 2003 with retrospective data backlogged before 2008 and are current through at least 2022.,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,2003-2022,0,No,1,No,1,2003-2019.,0,2003-2022,0,2003-2022.,0,Not reported,1,Not reported,1,No,1,No,1,2003-2022,0,Not reported,1,2003-2015,0,2003 and later,0,1999-2011,0
Human Answer,36931676,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported.,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,Not reported,1,Yes,0
Human Answer,36931676,9,Which HIV genes were reported to have been sequenced?,List,RT,pol (HIV pol) sequences were reported.,1,No,0,Pol,0,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,0,No,0,Pol.,0,Not reported,1,Not reported.,1,"Gag, PR, RT",1,"Gag, PR, RT",1,No,0,PR,0,Pol,0,"Pol, PR, RT",1,Pol,0,Not reported,1,"PR, RT",1
Human Answer,36931676,10,What method was used for sequencing?,List,No,Not specified in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Sanger sequencing,0,Sanger sequencing and NGS,0,Not reported,1,"Sanger sequencing, NGS",0
Human Answer,36931676,11,What type of samples were sequenced?,List,"Plasma, CSF, PBMC","The paper does not explicitly state which sample types were sequenced, but the cohort collects blood plasma/serum, liquor (CSF), peripheral blood mononuclear cells, HIV isolates and CSF cells in biobanks.",0,No,0,"Plasma, CSF",0,"Plasma, PBMC, CSF",1,"Plasma, PBMC",0,"Plasma, CSF",0,"Plasma, Serum",0,"Plasma, Serum",0,No,0,No,0,"Plasma, CSF.",0,"Plasma, PBMC",0,"Plasma, CSF.",0,PBMC,0,PBMC,0,No,0,No,0,Plasma,0,Plasma,0,"Plasma, serum, PBMC, proviral DNA, and dried blood spots",0,"Plasma, CSF",0,PBMC,0
Human Answer,36931676,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Not explicitly stated; the registry includes treatment-experienced patients and drug-resistance data, so sequences may include individuals with virological failure but the paper does not specifically report this.",1,No,0,Yes,1,No,0,Not reported,0,No,0,Not reported,0,No,0,No,0,No,0,Yes.,1,Yes,1,Not reported.,0,No,0,No,0,No,0,No,0,Not Reported,0,No,0,Yes,1,Yes,1,Yes,1
Human Answer,36931676,13,Were the patients in the study in a clinical trial?,Boolean,No,"No, this is a prospective registry-based cohort (not a clinical trial).",1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,Yes,0
Human Answer,36931676,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes.,1,Yes,1,Not reported.,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36931676,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI","The paper mentions nucleoside reverse transcriptase inhibitor (NRTI)–related mutations, protease inhibitor regimens, and integrase inhibitor (dolutegravir)-based regimens, indicating exposure to NRTIs, protease inhibitors (PIs) and integrase strand transfer inhibitors (INSTIs).",0,No,0,"NRTI, INSTI, PI",0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,"NRTI, PI.",0,"NRTI, NNRTI, PI, INSTI",1,Not reported.,0,Not reported,0,Not reported,0,No,0,No,0,Not Reported,0,NRTI,0,"NRTI, NNRTI, PI, INSTI, CAI, and CCR5 antagonist",1,Not reported,0,"NRTI, PI, INSTI",0
Human Answer,36931676,16,Which drugs were received by individuals in the study before sample sequencing?,List,DTG,Dolutegravir is specifically mentioned; other specific drug names are not detailed in the paper excerpt (but drug classes such as NRTIs and protease inhibitors are referenced).,1,No,0,Dolutegravir,1,Not reported,0,Not reported,0,Not reported,0,Not reported,0,"Abacavir, 3TC, Ritonavir-boosted Lopinavir",0,No,0,No,0,"Dolutegravir, protease inhibitors.",1,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",1,Not reported.,0,Not reported,0,Not reported,0,No,0,No,0,Not Reported,0,"AZT, 3TC, FTC, TDF, ABC",0,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, DTG, BIC, CAB, LEN, and MVC",1,Not reported,0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF), Emtricitabine (FTC), Lopinavir (LPV), Darunavir (DRV), Dolutegravir (DTG)",1
Human Answer,36961945,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports sequencing of HIV from patient samples (blood plasma RNA by bulk genotyping and archived proviral DNA from PBMCs by NGS).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,36961945,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic drug resistance (NGS and bulk genotyping) but does not present in vitro (phenotypic) drug susceptibility assay data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer,36961945,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported. The paper does not provide or cite public sequence deposits or accession numbers.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Not reported,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,36961945,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. No GenBank accession numbers are provided in the paper content.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,MN234327 - MN235714,0,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,** MN234327 - MN235714,0,MN234327 - MN235714,0
Human Answer,36961945,5,How many individuals had samples obtained for HIV sequencing?,Number,190,190 individuals.,1,190,1,190,1,190,1,190,1,190,1,190,1,190,1,190,1,190,1,190.,1,190,1,190,1,190,1,190,1,190,1,190,1,190,1,190,1,190,1,** 190,1,103,0
Human Answer,36961945,6,From which countries were the sequenced samples obtained?,List,USA,"United States (San Diego, USA).",1,No,0,No,0,USA,1,Not Reported,0,Not reported,0,United States,1,Not reported,0,No,0,No,0,Not reported.,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,Not Reported,0,United States,1,Not reported,0,** United States,1,Not reported,0
Human Answer,36961945,7,From what years were the sequenced samples obtained?,List,2005-2020,Samples were collected from January 2005 to February 2020.,1,2005-2020,1,2005-2020,1,2005–2020,1,2005–2020,1,2005–2020,1,2005-2020,1,2005-2020,1,2005-2020,1,2005-2020,1,2005-2020.,1,2005-2020,1,2005-2020,1,2005-2020,1,2005-2020,1,2005-2020,1,No,0,2005-2020,1,2005-2020,1,2005-2020,1,** 2005-2020,1,2012-2015,0
Human Answer,36961945,8,Were samples cloned prior to sequencing?,Boolean,No,No. Samples were amplified by PCR/nested PCR and directly sequenced by NGS or bulk genotyping without cloning.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,** No,1,No,1
Human Answer,36961945,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Protease (PR) and reverse transcriptase (RT) (partial pol) were sequenced; the Methods state PR, RT and integrase (IN) were targeted by the assay, but the Discussion notes integrase (INSTI) sequencing/data were not investigated due to lack of data.",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT",0,"PR, RT, IN",1,"PR, RT",0,"PR, RT, IN",1,Pol (including RT and PR),1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN.",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease (PR), Reverse transcriptase (RT), Integrase (IN)",1,"PR, RT, IN",1,Pol,0,Pol,0,Not reported,0,** RT,0,"PR, RT",0
Human Answer,36961945,10,What method was used for sequencing?,List,Illumina sequencing,"Next-generation (deep) sequencing (modified ""deepTypeHIV"" assay) was used for proviral DNA; bulk (consensus) genotyping (GeneSeq HIV or ViroSeq) was used on plasma RNA. PCR and nested PCR were used to generate amplicons prior to sequencing.",0,Illumina sequencing,1,NGS,0,NGS,0,NGS,0,NGS,0,Deep sequencing,0,"Deep sequencing, consensus sequencing",0,Next-generation sequencing (NGS),1,Next-generation sequencing,1,Deep sequencing and consensus sequencing.,0,NGS,0,NGS,0,Next-generation sequencing (NGS),1,Not reported,0,Illumina sequencing,1,NGS,0,NGS,0,Illumina sequencing,1,Yes,0,** Deep sequencing,0,Illumina sequencing,1
Human Answer,36961945,11,What type of samples were sequenced?,List,"Plasma, PBMC",Peripheral blood mononuclear cells (PBMCs) for proviral DNA NGS and blood plasma (blood plasma RNA) for bulk (consensus) genotyping.,1,PBMC,0,"Plasma, PBMC",1,"Plasma, PBMC",1,"Plasma, PBMC",1,"PBMC, Plasma",1,"PBMC, Plasma",1,Peripheral Blood Mononuclear Cells (PBMCs),0,PBMC; Plasma,1,"PBMC, Plasma",1,Peripheral blood mononuclear cells and blood plasma.,0,"PBMCs, plasma",1,PBMC,0,PBMC,0,PBMC,0,Plasma,0,"PBMC, Plasma",1,"Peripheral blood mononuclear cells, Blood plasma",0,"Plasma, PBMC",1,NRTI,0,"** Peripheral blood mononuclear cells, Blood plasma",0,Plasma,0
Human Answer,36961945,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No. No participants experienced virologic failure after initiating ART during follow-up.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"3TC, FTC",1,** No,1,Yes,0
Human Answer,36961945,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Participants were enrolled in the San Diego Primary Infection Research Consortium (PIRC) observational cohort, not described as part of a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,** No,1,No,1
Human Answer,36961945,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The sequencing was performed on samples from antiretroviral-naïve individuals (pre-ART).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,Yes,0,No,1,** Yes,0,Yes,0
Human Answer,36961945,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None. Samples were obtained and sequenced prior to ART initiation (participants were ART-naïve).,1,NRTI,0,No,1,,1,,1,,1,Not reported,1,"NRTI, NNRTI, PI",0,NRTI,0,No,1,Not reported.,1,Not reported,1,,1,"NRTI, NNRTI, PI",0,Not reported,1,"NRTI, NNRTI",0,No,1,NRTI,0,"NRTI, NNRTI",0,No,1,"** NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0
Human Answer,36961945,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None. Participants were antiretroviral-naïve at the time of sampling and sequencing.,1,"Lamivudine (3TC), Emtricitabine (FTC)",0,No,1,,1,Not Reported,1,,1,"Lamivudine (3TC), Emtricitabine (FTC)",0,"Tenofovir (TDF), Zidovudine (AZT), Stavudine (d4T)",0,Lamivudine (3TC); Emtricitabine (FTC),0,No,1,Not reported.,1,Not reported,1,,1,"Tenofovir (TFV), Zidovudine (AZT), Stavudine (D4T)",0,Not reported,1,"Lamivudine (3TC), Emtricitabine (FTC)",0,No,1,"Lamivudine (3TC), Emtricitabine (FTC)",0,"AZT, 3TC, FTC, TDF, EFV",0,No,1,"** Tenofovir (TFV), Zidovudine (AZT), Stavudine (D4T), Nevirapine (NVP), Efavirenz (EFV), Lamivudine (3TC)",0,"3TC, NVP, EFV, D4T, AZT, LPV, ABC, ATZ, DTG, TDF",0
Human Answer,36967989,1,Does the paper report HIV sequences from patient samples?,Boolean,No,Yes. The study used genotype data (patient-derived viral isolates) from the Stanford HIV drug resistance database.,0,No,1,No,1,No,1,No,1,** Not reported.,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes.,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,36967989,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,Yes. The study used genotype-phenotype data including fold-change in drug susceptibility (IC50/fold-change) from PhenoSense assay results.,0,Yes,0,No,1,No,1,No,1,** Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes.,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,** Yes,0,No,1
Human Answer,36967989,3,Were sequences from the paper made publicly available?,Boolean,No,"Partially. The processed data and code used in the study are made available on GitHub and Zenodo, and the underlying genotype-phenotype data originate from the publicly accessible Stanford HIV drug resistance database, but the paper does not report new sequence depositions (e.g., GenBank accessions).",1,Yes,0,No,1,Yes,0,Yes,0,** Yes.,0,Yes,0,Not reported,1,Yes,0,No,1,No,1,No,1,Yes.,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,36967989,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. The paper does not provide GenBank accession numbers for isolates.,1,No,1,No,1,Not reported,1,Not reported,1,** Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451",0,"The paper reports the following GenBank accession numbers: FJ800379–FJ800386, GQ477441-GQ477451, KP170487.",0,** MN234327 - MN235714,0,FN557303 to FN557343,0
Human Answer,36967989,5,How many individuals had samples obtained for HIV sequencing?,Number,0,"The paper reports numbers of isolates analyzed per protease inhibitor: ATV 1,218; DRV 678; FPV 1,809; IDV 1,860; LPV 1,562; NFV 1,907; SQV 1,861; TPV 908. A single total unique-individual count is not provided.",1,0,1,0,1,0,1,Not reported,1,** Not reported.,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,"11,803",0,"At least 10,083 individuals had samples obtained for HIV sequencing.",0,** 6,0,6,0
Human Answer,36967989,6,From which countries were the sequenced samples obtained?,List,No,Not reported. The paper does not specify the countries of origin for the sequences/isolates.,1,No,1,No,1,Not reported,1,Not reported,1,** Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Not reported,1,"United States, Australia, Equatorial Guinea",0
Human Answer,36967989,7,From what years were the sequenced samples obtained?,List,No,Not reported. The paper does not provide sampling years or date ranges for the sequences/isolates.,1,No,1,No,1,Not reported,1,Not reported,1,** Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Not reported,1,"2008, 1983-2018",0
Human Answer,36967989,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported. The paper does not describe any cloning of samples prior to sequencing.,1,No,1,No,1,No,1,No,1,** Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** No,1,No,1
Human Answer,36967989,9,Which HIV genes were reported to have been sequenced?,List,No,Protease (PR) gene sequences (HIV-1 protease) were used.,0,No,1,No,1,Not reported,1,Not reported,1,** Not reported (but likely PR).,1,Not reported,1,Not reported,1,Protease,0,PR,0,PR,0,PR,0,Protease.,0,Not reported,1,Not reported,1,No,1,PR,0,PR,0,Pol,0,Pol,0,"** Gag, PR, RT",0,"Gag, PR, RT",0
Human Answer,36967989,10,What method was used for sequencing?,List,No,Not reported. The manuscript does not describe sequencing laboratory methods; it used genotype data retrieved from the Stanford HIV drug resistance database without specifying how those sequences were originally obtained.,1,No,1,No,1,Not reported,1,Not reported,1,** Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Sanger sequencing.,0,Not reported,1,Not reported,1,No,1,No,1,NGS,0,Sanger sequencing and NGS,0,Sanger sequencing,0,** Sanger sequencing,0,Sanger sequencing,0
Human Answer,36967989,11,What type of samples were sequenced?,List,No,Patient-derived viral isolates (population-level viral sequences) from clinical samples; genotype-fold change measurements were population-based isolates.,0,No,1,No,1,Not reported,1,Not reported,1,** Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Plasma,0,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Plasma and PBMC,0,"Plasma, serum, PBMC, proviral DNA, and dried blood spots",0,** PBMC,0,PBMC,0
Human Answer,36967989,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,Not reported. The paper does not state whether isolates came specifically from individuals with virological failure.,1,No,1,No,1,No,1,No,1,** Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes.,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,36967989,13,Were the patients in the study in a clinical trial?,Boolean,No,Not reported. The paper does not indicate that patients were enrolled in a clinical trial; data were obtained from an external database.,1,No,1,No,1,No,1,No,1,** Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Yes,0,No,1
Human Answer,36967989,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,Not explicitly reported. The paper does not provide explicit statements about prior antiretroviral treatment histories for the individuals whose isolates were in the dataset.,1,No,1,No,1,No,1,No,1,** Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes.,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,36967989,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not reported. The paper does not provide patient-level antiretroviral treatment-class histories.,1,No,1,No,1,,1,Not reported,1,** Not reported.,1,Not reported,1,Not reported,1,PI,0,No,1,PI,0,"PI, NRTI",0,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"NRTI, PI, and INSTI",0,"NRTI, NNRTI, PI, INSTI, and CAI",0,"** NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0
Human Answer,36967989,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not reported. The paper does not report individual-level prior drug names or regimens for the isolates; only the protease inhibitors analyzed in the dataset are listed.,1,No,1,No,1,,1,Not reported,1,** Not reported.,1,Not reported,1,Not reported,1,"ATV, DRV, FPV, IDV, LPV, NFV, SQV, TPV",0,No,1,"ATV, DRV, FPV, IDV, LPV, NFV, SQV, TPV",0,"ATV, DRV, FPV, IDV, LPV, NFV, SQV, TPV",0,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"AZT, 3TC, TDF, EFV, DRV, and RAL",0,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, and MVC",0,"** Etravirine, Rilpivirine",0,"Etravirine, Rilpivirine",0
Human Answer,36982978,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — this is a review article and does not report original HIV sequences from patient samples.,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Not explicitly stated,1,No,1,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,36982978,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"Yes — the review reports and summarizes in vitro susceptibility/phenotypic data from cited studies (EC50/IC50 values), but it does not present new experimental susceptibility data generated by the authors.",0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes.,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1
Human Answer,36982978,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report depositing any sequences in public databases.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1,No.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,36982978,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,"GU966535 through GU966581, HM771234 through HM771239",0,HQ694834 to HQ694845,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,"KP226396-KP226481, MW697236-MW697343, MW697344-MW697444, KP226314-KP226501, MW714050-MW714124",0,Not reported,1,No,1,No,1,ROD and EHO,0,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,"HQ694834 to HQ694845, KP226396-KP226481, MW697236-MW697343, MW697344-MW697444, KP226314-KP226501, MW714050-MW714124, GU966535 through GU966581, HM771234 through HM771239, HM771240, EF611309 to EF611333, HQ451906 to HQ451937",0,FN557303 to FN557343,0
Human Answer,36982978,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Not applicable — the review did not obtain samples for sequencing (no individuals sampled in this study).,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,45,0,138,0,0,1,0,1,Not reported.,1,Not reported,1,Not reported,1,291,0,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,"291, 45",0,7,0
Human Answer,36982978,6,From which countries were the sequenced samples obtained?,List,No,Not applicable for this paper — no original sequenced samples were obtained; the review cites studies from various countries but does not itself collect samples.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,France,0,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,France,0,Not reported,1,No,1,No,1,Portugal and Senegal,0,Portugal,0,Not reported,1,"France, Belgium, Luxembourg, Mali",0,Not reported,1
Human Answer,36982978,7,From what years were the sequenced samples obtained?,List,No,Not applicable — the review does not report original sample collection years for sequenced isolates.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Since 1994,0,1997-2008,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,1994-2019,0,Not reported,1,No,1,No,1,2014-2021,0,2017-2021,0,Not reported,1,"1994-2019, 1997-2008",0,Not reported,1
Human Answer,36982978,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — the paper does not report generating or sequencing samples and therefore does not describe cloning prior to sequencing.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Yes,0,No,1,No,1,Not reported.,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,36982978,9,Which HIV genes were reported to have been sequenced?,List,No,"The review discusses sequences and resistance mutations in multiple HIV genes from the literature, specifically reverse transcriptase (RT), protease (PR), integrase (IN), gag (capsid/CA) and env (V3/envelope) regions, but it did not itself sequence these genes.",0,No,1,"RT, IN",0,Not reported,1,Not reported,1,IN,0,"IN, PR, RT",0,"IN, PR, RT",0,No,1,No,1,"Pol, Integrase.",0,"RT, PR, IN",0,"Reverse transcriptase, protease, integrase, and capsid",0,"PR, RT, Vif, Env, LTR",0,"RT, PR, IN",0,No,1,No,1,Pol,0,"Pol, PR, RT",0,"Pol, RT, IN",0,"PR, RT, Vif, Env, LTR",0,IN,0
Human Answer,36982978,10,What method was used for sequencing?,List,No,Not reported for this paper — no sequencing methods were described because the article is a review and did not perform new sequencing.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Population-based sequencing (likely Sanger sequencing),0,Sanger sequencing,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0
Human Answer,36982978,11,What type of samples were sequenced?,List,No,"Not applicable — the review did not sequence any samples; it summarizes results from studies that used clinical viral isolates, primary isolates, and molecular clones, but did not itself sequence sample types.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Plasma,0,Plasma,0,No,1,No,1,"Plasma, PBMC.",0,"Plasma, PBMC",0,Plasma and PBMC,0,Plasma,0,Plasma,0,No,1,No,1,Plasma,0,"Plasma, PBMC",0,Plasma,0,Plasma,0,Plasma,0
Human Answer,36982978,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No sequences were obtained in this paper; however, the review discusses sequences and resistance mutations reported in the literature from individuals failing therapy (e.g., patients failing RAL-based regimens).",1,No,1,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,36982978,13,Were the patients in the study in a clinical trial?,Boolean,No,No — the paper is a review and did not enroll patients; it cites clinical trials and observational studies from the literature but did not conduct a trial itself.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Yes,0,No,1,No,1,Not reported.,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,36982978,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the review does not present original sequences from previously treated individuals, though it discusses literature reporting sequences from treatment-experienced patients.",1,No,1,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,36982978,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not applicable to this paper's own data (no original sequenced patients), but the review discusses individuals and studies involving multiple drug classes including NRTIs, NNRTIs, protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), fusion inhibitors, CCR5 antagonists, CD4-directed antibodies (e.g., ibalizumab), and capsid inhibitors.",1,No,1,"NRTI, PI, INSTI",0,Not reported,1,Not reported,1,Not reported,1,"NRTI, PI",0,"NRTI, PI, INSTI",0,"NRTI, PI, INSTI, CAI",0,No,1,"NRTIs, NNRTIs, PIs, INSTIs.",0,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI, and CAI",0,"NRTI, PI",0,"NRTI, PI, INSTI",0,No,1,No,1,NRTIs and PIs,0,,1,"NRTI, PI, INSTI",0,"NRTI, PI, INSTI",0,"NRTI, PI, INSTI",0
Human Answer,36982978,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable to original data in this paper (no patients sequenced), but the review lists many specific drugs used in the literature: NRTIs such as lamivudine (3TC), abacavir (ABC), zidovudine (AZT), stavudine (d4T), emtricitabine (FTC), didanosine (ddI), tenofovir (TDF) and tenofovir alafenamide (TAF); NNRTIs including delavirdine (DLV), nevirapine (NVP) and efavirenz (EFV) and second-generation NNRTIs (etravirine, rilpivirine, doravirine); PIs including darunavir (DRV), lopinavir (LPV), saquinavir (SQV), indinavir (IDV), nelfinavir (NFV), amprenavir (APV), fosamprenavir (FPV) and ritonavir (RTV); INSTIs raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG), bictegravir (BIC) and cabotegravir (CAB); entry/fusion agents such as enfuvirtide (T-20), maraviroc (MVC) and ibalizumab; and newer agents like lenacapavir and investigational compounds (azvudine, islatravir, festinavir, spiro-β-lactams).",1,No,1,"Lamivudine (3TC), Abacavir (ABC), Zidovudine (AZT), Stavudine (D4T), Emtricitabine (FTC), Didanosine (DDI), Tenofovir (TFV), Tenofovir alafenamide (TAF), Darunavir, Saquinavir, Lopinavir",0,Not reported,1,Not reported,1,Not reported,1,"Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)",0,"Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)",0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Raltegravir (RAL)",0,No,1,"3TC, ABC, AZT, TDF, RAL, DTG.",0,"3TC, FTC, AZT, TDF, ABC, EFV, LPV/r, DRV/r, RAL, DTG",0,"3TC, FTC, AZT, TDF, EFV, NVP, LPV/r, DRV/r, RAL, DTG, and LEN",0,Not reported,1,"Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)",0,No,1,No,1,"TDF, FTC, and RAL",0,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0,"Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)",0,"Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)",0
Human Answer,37017009,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The study performed HIV genotyping and obtained sequences from patient plasma samples (809/899 specimens were successfully sequenced).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
""""",1,Yes,1
Human Answer,37017009,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance and predicted resistance profiles from sequence data, not direct in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"No
""""",1,No,1
Human Answer,37017009,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No evidence of public deposition was provided in the paper.,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Not Reported,1,"No
""""",1,Yes,0
Human Answer,37017009,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,MK123456-MK123900,0,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not Reported,1,"Not reported
""""",1,OM176712-OM177027,0
Human Answer,37017009,5,How many individuals had samples obtained for HIV sequencing?,Number,809 or 899,899 participants had specimens included for sequencing attempts; 809 specimens were successfully sequenced.,1,899,1,809,1,809,1,899,1,899.,1,899,1,899,1,899,1,899,1,899,1,899,1,899,1,899,1,899,1,899,1,899,1,899,1,809,1,899,1,"899
""""",1,418,0
Human Answer,37017009,6,From which countries were the sequenced samples obtained?,List,South Africa,South Africa.,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa.,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,South Africa,1,"South Africa
""""",1,South Africa,1
Human Answer,37017009,7,From what years were the sequenced samples obtained?,List,2017-2019,"Samples were obtained during the study period, March 2017 to March 2019.",1,2017-2019,1,2017-2019,1,2017–2019,1,2017–2019,1,2017–2019.,1,2017-2019,1,2017-2019,1,2017-2019,1,2017-2019,1,2017-2019,1,2017-2019,1,2017-2019,1,2017-2019,1,2017-2019,1,2017-2019,1,No,0,2017-2019,1,2017-2019,1,2017-2019,1,"2017-2019
""""",1,2017-2019,1
Human Answer,37017009,8,Were samples cloned prior to sequencing?,Boolean,No,No. Samples were PCR-amplified and prepared as NGS libraries; cloning was not described.,1,No,1,No,1,Not reported,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,"No
""""",1,No,1
Human Answer,37017009,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",A 1.5 kb region of pol encompassing the protease gene and the first 250 amino acids of reverse transcriptase (partial RT) was sequenced.,1,"Protease, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT.",1,"PR, RT",1,"PR, RT",1,"Protease, Reverse transcriptase",1,"PR, RT",1,Pol (protease and reverse transcriptase regions),1,Pol,0,Pol,0,"PR, RT",1,"PR, RT",1,"Protease, RT",1,No,0,Pol,0,Pol,0,Not Reported,0,"PR, RT
""""",1,"PR, RT",1
Human Answer,37017009,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing",Next-generation sequencing using Illumina MiSeq (Nextera XT library prep) with Sanger sequencing used as a fallback for failed NGS or smaller amplicons.,1,Illumina sequencing,0,Sanger sequencing; Illumina sequencing,1,NGS,0,NGS,0,NGS.,0,Next-generation sequencing (MiSeq),0,Illumina sequencing,0,Next-generation sequencing,0,Illumina sequencing,0,NGS (MiSeq),0,NGS,0,Next-generation sequencing,0,Next-generation sequencing,0,NGS,0,Illumina sequencing,0,Next-generation sequencing,0,NGS,0,NGS,0,Yes,0,"Next-generation sequencing
""""",0,Illumina sequencing,0
Human Answer,37017009,11,What type of samples were sequenced?,List,Whole Blood,Plasma derived from whole blood (minimum 500 μL plasma) was used for nucleic acid extraction and sequencing.,1,Whole Blood,1,Plasma,0,"Plasma, Whole Blood",1,Plasma,0,Whole Blood.,1,Plasma,0,Plasma,0,Whole Blood,1,Plasma,0,Whole blood,1,Plasma,0,Plasma,0,Whole blood,1,Whole blood,1,Whole Blood,1,Plasma,0,Whole Blood,1,Whole Blood,1,"NRTI, NNRTI",0,"Plasma, whole blood
""""",1,Plasma,0
Human Answer,37017009,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Inclusion required recent evidence of virological failure (viral load ≥1000 copies/mL) in children on ART, and sequences were obtained from those participants.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not Reported,0,"Yes
""""",1,Yes,1
Human Answer,37017009,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. This was a cross-sectional facility-based observational study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not Reported,1,"No
""""",1,No,1
Human Answer,37017009,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. Participants were on ART for at least one year and prior/current regimen information (including PMTCT exposure) was collected and reported.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
""""",1,Yes,1
Human Answer,37017009,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI","Participants had received protease inhibitor (PI)-based regimens, non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens, and nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)-only regimens.",1,"PI, NNRTI",1,"NRTI, NNRTI, PI",1,"PI, NNRTI, NRTI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI.",0,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,"PI, NNRTI",1,"NRTIs, NNRTIs, PIs",1,"NRTIs, NNRTIs, PIs",1,"PI, NNRTI",1,"PI, NNRTI, NRTI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,PI,0,"NRTI, NNRTI, PI",1,"NRTI, NNRTI",0,"NRTI, NNRTI, PI
""""",1,"NRTI, NNRTI, INSTI",0
Human Answer,37017009,16,Which drugs were received by individuals in the study before sample sequencing?,List,"LPV, ATV, EFV, NVP, 3TC, ABC, AZT, FTC, D4T, TDF","Reported drugs included ritonavir-boosted lopinavir (majority of PI regimens), ritonavir-boosted atazanavir (minority), efavirenz (majority of NNRTI regimens), nevirapine (few), lamivudine, abacavir, zidovudine, emtricitabine, stavudine and tenofovir disoproxil fumarate (as components of NRTI regimens).",1,"Ritonavir-boosted lopinavir, Ritonavir-boosted atazanavir, Efavirenz",0,"Lopinavir (LPV), Atazanavir (ATV), Efavirenz (EFV), Nevirapine (NVP), Lamivudine (3TC), Abacavir (ABC), Zidovudine (AZT), Emtricitabine (FTC), Stavudine (D4T), Tenofovir (TFV)",1,"Lopinavir, Efavirenz",0,"Ritonavir-boosted lopinavir, efavirenz, lamivudine, abacavir",0,"Lopinavir/ritonavir, efavirenz.",0,"Efavirenz (EFV), Nevirapine (NVP)",0,"Efavirenz (EFV), Nevirapine (NVP), Lamivudine (3TC), Abacavir (ABC)",0,"Abacavir, Zidovudine, Lamivudine, Stavudine, Emtricitabine, Tenofovir, Nevirapine, Delavirdine, Efavirenz, Etravirine, Rilpivirine, Doravirine, Amprenavir, Lopinavir, Atazanavir, Derunavir, Raltegravir, Elvitegravir, Dolutagravir, Bictegravir, cabotagravir",1,"Abacavir (ABC), Lamivudine (3TC), Zidovudine (AZT), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Darunavir (DRV)",1,"Lopinavir, ritonavir, efavirenz",0,"Abacavir, lamivudine, efavirenz",0,"Efavirenz, nevirapine, lopinavir",0,"Ritonavir-boosted lopinavir, Ritonavir-boosted atazanavir, Efavirenz, Nevirapine",0,"Ritonavir-boosted lopinavir, Efavirenz, Nevirapine, Abacavir, Lamivudine, Tenofovir disoproxil fumarate",0,"Abacavir (ABC), Lamivudine (3TC), Efavirenz (EFV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,0,"Ritonavir-boosted lopinavir, ritonavir-boosted atazanavir",0,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, LPV/r, ATV/r, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, LEN",0,No,0,"Ritonavir-boosted lopinavir, ritonavir-boosted atazanavir, efavirenz, lamivudine, abacavir, zidovudine, tenofovir disoproxil fumarate, stavudine, didanosine, emtricitabine, doravirine, rilpivirine, etravirine, darunavir.",0,"Dolutegravir (DTG), Tenofovir disoproxil fumarate (TDF), Emtricitabine (FTC)",0
Human Answer,37029656,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer,37029656,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,"Yes
```",0,No,1
Human Answer,37029656,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No indication of public sequence deposition.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Not Reported,1,"No
```",1,No,1
Human Answer,37029656,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,KP170487,0,Not Reported,1,"Not reported
```",1,Not reported,1
Human Answer,37029656,5,How many individuals had samples obtained for HIV sequencing?,Number,1223,1223 individuals.,1,1223,1,1223,1,1223,1,1223,1,1223,1,1223,1,1223,1,1223,1,1223,1,1223,1,1223,1,1223,1,Not reported,0,Not reported,0,1223,1,1223,1,1223,1,1223,1,1223,1,"1223
```",1,1223,1
Human Answer,37029656,6,From which countries were the sequenced samples obtained?,List,Italy,Primarily Italy (patients of Italian origin); samples are from a single centre in Italy.,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,No,0,Not Reported,0,Not reported,0,Not reported,0,Not reported,0,Not Found,0,No,0,No,0,Italy,1,Italy,1,Not Reported,0,"Italy
```",1,Italy,1
Human Answer,37029656,7,From what years were the sequenced samples obtained?,List,2009-2019,2009–2019.,1,2009-2019,1,2009-2019,1,2009–2019,1,2009–2019,1,2009–2019,1,2009–2019,1,2009–2019,1,2009-2019,1,2009-2019,1,2009-2019,1,2009-2019,1,2009-2019,1,2009-2019,1,Not reported,0,2009--19,0,2009-2019,1,2009-2019,1,2009-2019,1,2009-2019,1,"2009-2019
```",1,2009-2019,1
Human Answer,37029656,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No indication that samples were cloned prior to sequencing.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,"No
```",1,No,1
Human Answer,37029656,9,Which HIV genes were reported to have been sequenced?,List,IN,Integrase (INSTI region) was sequenced; the study focuses on integrase genotypic resistance (pol/integrase region).,1,No,0,IN,1,Pol,0,Pol,0,IN,1,INSTI genes (specific mutations mentioned but not detailed),1,Not reported,0,Not specified,0,No,0,IN,1,"Pol, including integrase",1,IN,1,Not reported,0,Not reported,0,No,0,No,0,Pol,0,Pol,0,Pol,0,"PR, RT, IN
```",1,"PR, RT, IN",1
Human Answer,37029656,10,What method was used for sequencing?,List,Sanger sequencing,Sanger sequencing using an ABI PRISM 3130xl Genetic Analyzer.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,"Sanger sequencing
```",1,Sanger sequencing,1
Human Answer,37029656,11,What type of samples were sequenced?,List,Plasma,Not specified in the provided text; described only as pre-ART genotypic resistance tests from ART-naive patients.,0,No,0,Plasma,1,Plasma,1,Not Reported,0,Plasma,1,Blood samples from ART-naive individuals,0,Blood samples (plasma),1,No,0,No,0,Not Reported,0,Plasma,1,Not reported,0,Not reported,0,Not reported,0,No,0,Plasma,1,Blood,0,Plasma,1,Plasma,1,"Plasma
```",1,Plasma,1
Human Answer,37029656,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,"Yes
```",0,No,1
Human Answer,37029656,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,"No
```",1,No,1
Human Answer,37029656,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"No
```",1,No,1
Human Answer,37029656,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None (participants were ART-naive).,1,"NRTI, NNRTI, PI",0,No,1,,1,,1,,1,Not reported,1,INSTI,0,INSTI,0,No,1,,1,Not reported,1,,1,Not reported,1,Not reported,1,No,1,No,1,,1,,1,,1,"NRTI, NNRTI, PI
```",0,"NRTI, NNRTI, PI, INSTI",0
Human Answer,37029656,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None (participants were ART-naive).,1,No,1,No,1,,1,,1,,1,Not reported,1,"Etravirine, Rilpivirine",0,Not mentioned,1,No,1,,1,Not reported,1,,1,Not reported,1,Not reported,1,No,1,No,1,,1,,1,,1,"Raltegravir (RAL), Elvitegravir (EVG), Dolutegravir (DTG)",0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF), Dolutegravir (DTG)",0
Human Answer,37039023,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37039023,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37039023,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37039023,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported for study isolates.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1,Not reported,1
Human Answer,37039023,5,How many individuals had samples obtained for HIV sequencing?,Number,86,86 individuals.,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1,86,1
Human Answer,37039023,6,From which countries were the sequenced samples obtained?,List,Brazil,Brazil (cities/regions: Rio de Janeiro and Rio Grande do Sul).,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1,Brazil,1
Human Answer,37039023,7,From what years were the sequenced samples obtained?,List,2016-2018,2016–2018.,1,2016-2018,1,2016-2018,1,2016–2018,1,2016–2018,1,2016–2018,1,2016-2018,1,2016-2018,1,2016-2018,1,2016-2018,1,2016-2018,1,2016-2018,1,2016-2018,1,2016-2018,1,2016-2018,1,2016-2018,1,No,0,"2016-2018 (RJ), 2017 (RS)",1,2016-2018,1,2016-2018,1,"2016-2018 (RJ), 2017 (RS)",1,"2016-2018, 2017",1
Human Answer,37039023,8,Were samples cloned prior to sequencing?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer,37039023,9,Which HIV genes were reported to have been sequenced?,List,"NFLG, PR, RT, IN, Env","Near full-length genome (NFLG) including protease (PR), reverse transcriptase (RT), integrase (IN) and envelope (env) regions (including the V3 region); C-terminal RT subdomains (RNaseH and connection) were also analysed.",1,"Protease, RT, IN, Envelope",0,Near full length genome,1,"PR, RT, IN, Env",0,"PR, RT, IN, Env",0,Full length genome,0,"PR, RT, IN, Env",0,"PR, RT, IN, Env",0,"Protease, PR; Reverse transcriptase, RT; Integrase, IN; Near full length genome",1,"PR, RT, IN, Env",0,"Protease, reverse transcriptase, integrase, and envelope",0,"Protease, reverse transcriptase, integrase, and envelope",0,Full length genome,0,"PR, RT, IN, Env",0,"PR, RT, IN, Env",0,"Protease, Reverse transcriptase, Integrase, Envelope",0,"PR, RT, IN",0,"Pol, Env",0,"PR, RT",0,No,0,"Protease, Reverse Transcriptase, Integrase, Envelope",0,"NFLG (protease, reverse transcriptase, integrase, and envelope regions)",1
Human Answer,37039023,10,What method was used for sequencing?,List,Illumina sequencing,High-throughput sequencing using Illumina MiSeq (paired-end 2×251) with Nextera XT library preparation (ultradeep HTS).,1,Illumina sequencing,1,Illumina sequencing,1,NGS,0,NGS,0,NGS,0,Illumina sequencing,1,Illumina sequencing,1,Illumina sequencing,1,Illumina sequencing,1,Illumina MiSeq,1,NGS,0,NGS,0,Illumina sequencing,1,Illumina sequencing,1,Illumina sequencing,1,Illumina sequencing,1,NGS (Illumina MiSeq),1,NGS,0,Yes,0,Illumina sequencing,1,Illumina sequencing,1
Human Answer,37039023,11,What type of samples were sequenced?,List,PBMC,DNA extracted from peripheral blood cells (archived proviral DNA from blood cells / PBMC compartment).,1,Whole Blood,0,PBMC,1,Whole Blood,0,"Whole Blood, Plasma",0,Whole Blood,0,Whole peripheral blood,0,Whole blood,0,PBMC,1,Whole Blood,0,Peripheral blood cells,0,PBMCs,1,PBMC,1,Whole Blood,0,Whole Blood,0,Peripheral blood cells,0,PBMC,1,Whole blood,0,"Plasma, PBMC",1,"NRTI, NNRTI",0,Peripheral blood cells,0,Blood,0
Human Answer,37039023,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"TDF, 3TC, EFV",1,No,1,No,1
Human Answer,37039023,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,No,1
Human Answer,37039023,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,37039023,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI","NRTIs, NNRTIs and PIs.",1,"NRTI, NNRTI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI",1,"NRTIs, NNRTIs, PIs",1,"NRTIs, NNRTIs, and PIs",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI",1,"NRTI, NNRTI, PI",1,No,0,"NRTI, NNRTI",1,"NRTI, NNRTI",1
Human Answer,37039023,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, EFV","Predominantly tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV); some patients received PI-based regimens (examples include atazanavir/ritonavir (ATV/r)).",1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",1,"TDF, 3TC, EFV, ATV/r",1,"TDF, 3TC, EFV",1,"TDF, 3TC, EFV",1,"TDF, 3TC, EFV",1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",1,"Zidovudine (ZDV), Lamivudine (3TC), Lopinavir/ritonavir (LPV/RTV)",0,"Tenofovir (TFV), Lamivudine (3TC), Efavirenz (EFV), Atazanavir (ATV), Raltegravir (RAL), Dolutagravir (DTG)",1,"Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV)",1,"TDF, 3TC, EFV",1,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, and darunavir",1,"TDF, 3TC, EFV",1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",1,No,0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",1,"TDF, 3TC, EFV, ATV/r",1,No,0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",1
Human Answer,37042390,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports sequencing (genotypic resistance testing) of patient-derived HIV samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,37042390,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic resistance testing and interpretation but does not report in vitro phenotypic (laboratory) drug susceptibility assays.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,No,1
Human Answer,37042390,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report that sequences were deposited in public databases or provide accession numbers.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Not Reported,1,** No,1,No,1
Human Answer,37042390,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not reported. No GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not Reported,1,** Not reported,1,Not reported,1
Human Answer,37042390,5,How many individuals had samples obtained for HIV sequencing?,Number,85,"At baseline, 40 patient samples were successfully sequenced for the integrase (IN) gene and 38 samples were successfully sequenced for the protease (PR) and reverse transcriptase (RT) genes.",0,85,1,85,1,85,1,85,1,85,1,"40 for IN, 38 for PR and RT",0,85,1,87,0,40,0,87,0,87,0,85.,1,87,0,Not reported,0,87,0,85,1,87,0,85,1,85,1,** 85,1,85,1
Human Answer,37042390,6,From which countries were the sequenced samples obtained?,List,India,"India (patients were enrolled at a single centre in Varanasi, India, serving Indian states).",1,India,1,India,1,India,1,India,1,India,1,India,1,India,1,India,1,India,1,India,1,India,1,India.,1,India,1,Not reported,0,India,1,India,1,Not Reported,0,India,1,Not Reported,0,** India,1,Not reported,0
Human Answer,37042390,7,From what years were the sequenced samples obtained?,List,2016-2019,"Baseline sequencing was performed on samples from patients who started third-line ART between July 2016 and December 2019 (i.e., samples obtained in that interval).",1,2016-2019,1,2016-2019,1,2016–2019,1,2016–2019,1,2016–2019,1,2016-2019,1,2016-2019,1,2016-2019,1,2016-2019,1,2016-2019,1,2016-2019,1,2016-2019.,1,2016-2019,1,Not reported,0,2016-2019,1,2016-2019,1,2016-2019,1,2016-2019,1,2016-2019,1,** 2016-2019,1,2016-2019,1
Human Answer,37042390,8,Were samples cloned prior to sequencing?,Boolean,No,"No. The methods describe RT-PCR, nested PCR, gel purification and direct Sanger sequencing, with no mention of cloning.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported.,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,37042390,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Integrase (IN), protease (PR) and reverse transcriptase (RT) regions of the pol gene were sequenced.",1,"Integrase, IN; Reverse transcriptase, RT; Protease, PR",1,"PR, RT, IN",1,"IN, RT, PR",1,"IN, RT, PR",1,"IN, RT, PR",1,"IN, RT, PR",1,"IN, RT, PR",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"IN, RT, PR",1,"Integrase, Reverse Transcriptase, Protease",1,"Integrase, reverse transcriptase, and protease genes.",1,"IN, RT, PR",1,IN,0,"Protease, PR; Reverse transcriptase, RT",0,"PR, RT",0,"PR, RT",0,"Pol, PR, RT",0,Not Reported,0,"** PR, RT",0,"PR, RT",0
Human Answer,37042390,10,What method was used for sequencing?,List,Sanger sequencing,"Sanger (capillary) sequencing was used (Applied Biosystems 3730xl), following RT-PCR and nested PCR amplification and gel purification.",1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Not reported,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Yes,0,** Sanger sequencing,1,Sanger sequencing,1
Human Answer,37042390,11,What type of samples were sequenced?,List,Plasma,Plasma-derived viral RNA (from patient plasma separated from whole blood) was sequenced.,1,Whole Blood,0,Plasma,1,Plasma,1,"Plasma, Whole Blood",1,"Plasma, Whole Blood",1,Plasma,1,Plasma,1,Whole Blood,0,Plasma,1,"Whole blood, Plasma",1,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,Whole Blood; Plasma,1,Plasma,1,"Whole blood, Plasma",1,"Whole blood, Plasma",1,"NRTI, NNRTI",0,** Plasma,1,Plasma,1
Human Answer,37042390,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Genotyping was performed on patients who did not attain virological suppression after 12 months, and sequencing was done on samples from those failing therapy (e.g., 12 of 13 failing at 12 months were genotyped).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not Reported,0,** Yes,1,Yes,1
Human Answer,37042390,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. This was a single-centre observational study in programmatic (routine care) conditions, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,** No,1,No,1
Human Answer,37042390,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. The cohort consisted of treatment-experienced patients who had prior first-line and second-line ART before initiation of third-line therapy, and sequencing included their viruses.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,** Yes,1,Yes,1
Human Answer,37042390,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI, INSTI","Prior to sequencing the cohort had exposure to NRTIs, NNRTIs and protease inhibitors (PIs); integrase inhibitors (INSTIs) were generally not previously used (patients were largely INSTI‑naive) though INSTI mutations were detected.",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, PI",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI, INSTI, CAI",1,No,0,"INSTI, PI, NRTI",1,"NRTI, PI, INSTI",1,"INSTI, PI.",0,"INSTI, PI",0,"NRTI, NNRTI, PI, INSTI",1,"INSTI, PI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,No,0,"** NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0
Human Answer,37042390,16,Which drugs were received by individuals in the study before sample sequencing?,List,"RAL, DRV","Specific prior first- and second-line drug names are not comprehensively listed in the paper. The paper does report the initial standardized third-line regimen (raltegravir + darunavir + ritonavir) and that raltegravir was later replaced by dolutegravir in 2020, but detailed names of all prior first- and second-line drugs were not provided.",1,"Individuals in the study received an initial regimen of raltegravir (400 mg), darunavir (600 mg), and ritonavir (100 mg) before sample sequencing.",1,"Raltegravir (RAL), Darunavir (DRV), Ritonavir (RTV), Dolutegravir (DTG)",1,"Raltegravir, Darunavir, Ritonavir",1,"Raltegravir, Darunavir, Ritonavir",1,Not reported,0,"Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP), Abacavir (ABC), Lopinavir (LPV)",0,"TDF, AZT, d4T, NNRTIs, PIs",0,"Raltegravir, Darunavir, Ritonavir",1,No,0,"Raltegravir, Darunavir, Ritonavir",1,"Raltegravir, Darunavir, Ritonavir, Tenofovir",1,"Raltegravir, darunavir, ritonavir.",1,"Raltegravir, Darunavir, Ritonavir",1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",1,"Raltegravir, Darunavir",1,"Raltegravir, Darunavir, Ritonavir, Dolutegravir",1,"Raltegravir, Darunavir, Ritonavir",1,"AZT, 3TC, FTC, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",1,No,0,"** Raltegravir, Darunavir, Ritonavir, Tenofovir, Lamivudine, Efavirenz, Stavudine, Zidovudine, Nevirapine",1,"Various antiretroviral drugs, including NRTIs, NNRTIs, PIs, and INSTIs.",0
Human Answer,37052343,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,"Yes
""""",0,Yes,0
Human Answer,37052343,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility (phenotypic) data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"No
""""",1,No,1
Human Answer,37052343,3,Were sequences from the paper made publicly available?,Boolean,No,No — there were no sequences reported and thus none made publicly available.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,"Yes
""""",0,Yes,0
Human Answer,37052343,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None — no GenBank accession numbers are reported because no HIV sequences were reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,"MN234327 - MN235714
""""",0,MN234327 - MN235714,0
Human Answer,37052343,5,How many individuals had samples obtained for HIV sequencing?,Number,0,"None for sequencing; the study included 4,310 ART‑naive participants overall.",1,0,1,0,1,4310,0,Not reported,1,Not reported,1,4310,0,4310,0,0,1,0,1,4310,0,4310,0,4310,0,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,4310,0,"4310
""""",0,6,0
Human Answer,37052343,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no sequences were reported; the RESPOND cohort includes sites in Europe and Australia (multiple national cohorts).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,"Europe, Australia",0,Not reported,1,No,1,No,1,"Europe, Australia",0,"Europe, Australia",0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Europe and Australia,0,"Europe, Australia
""""",0,"Malawi, Tanzania, South Africa, Thailand, India",0
Human Answer,37052343,7,From what years were the sequenced samples obtained?,List,No,Not applicable — no sequences were reported; study ART initiation period was 2014–2020.,1,No,1,No,1,2014–2020,0,2014–2020,0,2014–2020,0,2014-2020,0,2014-2020,0,No,1,No,1,2014-2020,0,2014-2020,0,2014-2020,0,Not reported,1,Not reported,1,No,1,2014-2020,0,2014-2020,0,Not reported,1,2014-2020,0,"2014-2020
""""",0,Not reported,1
Human Answer,37052343,8,Were samples cloned prior to sequencing?,Boolean,No,No — not applicable because no sequencing was performed.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,"No
""""",1,No,1
Human Answer,37052343,9,Which HIV genes were reported to have been sequenced?,List,No,None — no HIV genes were sequenced or reported in this study.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,HIV-1 RNA,0,Pol,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,"Not reported
""""",1,Full length genome,0
Human Answer,37052343,10,What method was used for sequencing?,List,No,Not applicable — no sequencing methods were reported because no sequences were generated.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,"Not reported
""""",1,Next-generation sequencing,0
Human Answer,37052343,11,What type of samples were sequenced?,List,No,Not applicable — no samples were sequenced. The clinical data were based on plasma HIV‑1 RNA measurements (plasma).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Plasma,0,Plasma,0,Plasma,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,,1,"Plasma
""""",0,PBMC,0
Human Answer,37052343,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — no sequences were obtained; the study did report virological failure events but did not sequence samples from those individuals.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Not reported,1,No,1,No,1,No,1,No,1,,1,"No
""""",1,Yes,0
Human Answer,37052343,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — participants were from observational cohorts (RESPOND), not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,"Yes
""""",0,Yes,0
Human Answer,37052343,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the study focused on ART‑naive individuals and did not report sequences.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,"No
""""",1,Yes,0
Human Answer,37052343,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not applicable for 'before sequencing' because no sequencing was performed and participants were ART‑naive; after ART initiation, initial regimens included NRTI backbones plus a third agent from PI, NNRTI, or INSTI classes.",1,No,1,No,1,,1,,1,,1,None (ART-naive),1,Not reported,1,INSTI,0,No,1,"INSTI, NRTI",0,"NRTIs, NNRTIs, PIs, INSTIs",0,INSTI,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,"Not reported
""""",1,Not reported,1
Human Answer,37052343,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable for 'before sequencing' — participants were ART‑naive; the initial ART drugs used in the study included abacavir-lamivudine, TDF-emtricitabine, TAF-emtricitabine, darunavir (boosted), rilpivirine, elvitegravir (cobicistat‑boosted), dolutegravir, and raltegravir.",1,No,1,No,1,,1,Not reported,1,Not reported,1,None (ART-naive),1,Not reported,1,"Raltegravir, Elvitegravir, Dolutagravir, Bictegravir, cabotagravir, Lenacapavir",0,No,1,"Dolutegravir, Raltegravir",0,"Abacavir, lamivudine, tenofovir, emtricitabine, efavirenz, rilpivirine, darunavir, dolutegravir",0,Dolutegravir,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1
Human Answer,37071019,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,No,1,Yes,0,** Yes.,0,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37071019,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37071019,3,Were sequences from the paper made publicly available?,Boolean,No,No evidence of public deposition (no sequences appear to have been made publicly available).,1,No,1,No,1,No,1,No,1,** No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer,37071019,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,** Not reported.,1,Not reported,1,MZ568467-MZ568625,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,KP170487,0,Not reported in the provided text,1,Not reported,1,MZ568467-MZ568625,0
Human Answer,37071019,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero — no individual/patient samples were obtained for sequencing in this study.,1,0,1,0,1,Not reported,1,Not reported,1,** Not reported.,1,Not reported,1,22,0,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,"30,000",0,Not reported,1,1,0,1,0
Human Answer,37071019,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no patient-derived sequenced samples were obtained.,1,No,1,No,1,Not reported,1,Not reported,1,** Not reported.,1,Not reported,1,Italy,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Italy,0,Italy,0
Human Answer,37071019,7,From what years were the sequenced samples obtained?,List,No,Not applicable — no patient-derived sequenced samples were obtained.,1,No,1,No,1,Not reported,1,Not reported,1,** Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2014-2017,0,Not reported,1,Not reported,1,2018-2019,0
Human Answer,37071019,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable for patient samples; plasmid constructs were generated and amplified in bacteria prior to Sanger sequencing.,1,No,1,No,1,Not reported,1,No,1,** Not reported.,1,No,1,Yes,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer,37071019,9,Which HIV genes were reported to have been sequenced?,List,No,The integrase coding region (integrase gene) was the sequenced/validated target in the plasmid constructs.,1,No,1,IN,0,IN,0,IN,0,** Not reported.,1,IN,0,IN,0,No,1,No,1,Not reported,1,IN,0,IN,0,Full length genome,0,IN,0,No,1,IN,0,Integrase,0,"Pol, PR, RT",0,Pol,0,"RT, IN",0,IN,0
Human Answer,37071019,10,What method was used for sequencing?,List,No,Sanger sequencing.,0,No,1,Sanger sequencing,0,Not reported,1,Sanger sequencing,0,** Not reported.,1,Not reported,1,Sanger sequencing; NGS,0,No,1,No,1,Not reported,1,Sanger sequencing,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Cell-based assays,0,Sanger sequencing,0,Not reported,1,Sanger sequencing; NGS,0,Sanger sequencing; NGS,0
Human Answer,37071019,11,What type of samples were sequenced?,List,No,Engineered plasmid DNA (plasmid constructs) was sequenced/validated by Sanger sequencing.,1,No,1,No,1,Not reported,1,Not Reported,1,** Not reported.,1,Not reported,1,Plasma,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Viral stocks,0,Plasma,0,Plasma,0,Plasma,0,Plasma,0
Human Answer,37071019,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No sequences from such individuals were obtained in this study (the paper cites other studies reporting such cases).,1,No,1,No,1,Not reported,1,Yes,0,** Yes.,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37071019,13,Were the patients in the study in a clinical trial?,Boolean,No,No — this study did not include patients; it is laboratory-based. Clinical trials are only cited in the Discussion.,1,No,1,No,1,No,1,No,1,** No.,1,No,1,Yes,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,Yes,0,No,1,No,1,Not Reported,1,Yes,0,Yes,0,Yes,0
Human Answer,37071019,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report sequences from individuals previously treated with antiretrovirals; patient cases are referenced from other studies.,1,No,1,No,1,Not reported,1,Yes,0,** Yes.,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37071019,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable — no individuals in this study had samples sequenced. (The experimental work tested integrase strand transfer inhibitor drugs DTG and BIC in vitro.),1,No,1,No,1,,1,Not reported,1,** INSTI (Integrase Strand Transfer Inhibitors).,0,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0,INSTI,0,No,1,INSTI,0,INSTI,0,INSTI,0,Not reported,1,Not reported,1,"INSTI (Integrase Inhibitor), including Dolutegravir (DTG)",0,No,1,Not reported,1,"NRTI, NNRTI, INSTI",0,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0
Human Answer,37071019,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not applicable — no individuals in this study had samples sequenced. (The paper experimentally tested dolutegravir and bictegravir and discusses raltegravir and elvitegravir in the Discussion.),1,No,1,No,1,,1,Not reported,1,** Dolutegravir (DTG).,0,"Indinavir, Lamivudine (3TC), Stavudine, Ritonavir-boosted Lopinavir (r/LPV), Nevirapine, Didanosine (ddI), Tenofovir disoproxil fumarate (TDF), Emtricitabine (FTC), Dolutegravir (DTG)",0,"Indinavir, 3TC, Stavudine, Ritonavir, Lopinavir, Nevirapine, Tenofovir, Emtricitabine, Dolutegravir",0,"DTG, BIC",0,No,1,"DTG, BIC",0,"DTG, BIC",0,"DTG, BIC",0,Not reported,1,Not reported,1,Dolutegravir (DTG),0,No,1,Not reported,1,"AZT, 3TC, FTC, TDF, ABC, EFV, RPV, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, LEN",0,Not reported,1,"Abacavir (ABC), Lamivudine (3TC), Stavudine (D4T), Didanosine (DDI), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Lopinavir (LPV), Indinavir (IDV), Dolutegravir (DTG)",0,"Abacavir (ABC), Lamivudine (3TC), Stavudine (D4T), Didanosine (DDI), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Lopinavir (LPV), Indinavir (IDV), Dolutegravir (DTG)",0
Human Answer,37085698,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37085698,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No — only genotypic/in silico susceptibility interpretation was reported, not in vitro phenotypic assays.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37085698,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37085698,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,MW560010 to MW560058,MW560010 to MW560058.,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058.,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1
Human Answer,37085698,5,How many individuals had samples obtained for HIV sequencing?,Number,49,49 individuals.,1,49,1,49,1,49,1,49,1,49,1,49,1,49,1,49,1,49,1,49,1,49,1,49.,1,49,1,49,1,49,1,49,1,49,1,49,1,49,1,49,1,49,1
Human Answer,37085698,6,From which countries were the sequenced samples obtained?,List,Ethiopia,Ethiopia.,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia.,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Not reported,0
Human Answer,37085698,7,From what years were the sequenced samples obtained?,List,2018,Samples were obtained in 2018 (June to December 2018).,1,2018,1,2018,1,2018,1,2018,1,2018,1,2018,1,2018,1,2018,1,2018,1,2018,1,2018,1,2018.,1,2018,1,2018,1,2018,1,2018,1,2018,1,2018,1,2018,1,2018,1,2018,1
Human Answer,37085698,8,Were samples cloned prior to sequencing?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,37085698,9,Which HIV genes were reported to have been sequenced?,List,IN,The HIV-1 integrase (IN) gene region — the first 263 codons of integrase.,1,"Integrase, IN",1,IN,1,IN,1,IN,1,IN,1,IN (Integrase),1,IN (Integrase),1,"Integrase, IN",1,IN,1,IN,1,IN,1,Integrase.,1,IN,1,IN,1,Integrase (IN),1,IN,1,IN,1,Integrase,1,IN,1,IN,1,IN,1
Human Answer,37085698,10,What method was used for sequencing?,List,Sanger sequencing,Sanger DNA sequencing using the BigDye Terminator v3.1 kit and an ABI PRISM 3500 xL genetic analyzer.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37085698,11,What type of samples were sequenced?,List,Plasma,"Plasma-derived viral RNA (blood collected in EDTA tubes, plasma separated and viral RNA extracted).",1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Blood samples (plasma),1,Plasma,1,Plasma,1,Blood,0,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Blood,0,Blood,0
Human Answer,37085698,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not reported,1,Not reported,1
Human Answer,37085698,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37085698,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0
Human Answer,37085698,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None — participants were ART-naive and had not received any antiretroviral drug classes prior to sampling.,1,No,1,No,1,,1,,1,,1,Not applicable (none received ARV drugs),1,,1,No,1,No,1,,1,,1,None.,1,Not reported,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,No,1,,1,"NRTI, NNRTI",0,,1,Not reported,1,Not reported,1
Human Answer,37085698,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None — no individual had received antiretroviral drugs prior to sampling.,1,No,1,No,1,,1,,1,,1,Not applicable (none received ARV drugs),1,,1,No,1,No,1,Not Reported,1,,1,None.,1,Not reported,1,Not reported,1,"NRTI (Abacavir, Zidovudine, Zalcitabine, Didanosine, Lamivudine, Stavudine, Emtricitabine, Tenofovir), NNRTI (Nevirapine, Delavirdine, Efavirenz, Etravirine, Rilpivirine, Doravirine), PI (Amprenavir, Lopinavir, Atazanavir, Derunavir), INSTI (Raltegravir, Elvitegravir, Dolutegravir, Bictegravir, cabotegravir, Lenacapavir)",0,No,1,,1,Not reported,1,,1,Not reported,1,Not reported,1
Human Answer,37104815,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV sequences from patient samples generated by Sanger and ultra-deep sequencing of the HIV-1 genome (RNA at failure and DNA at baseline).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0,Yes,1
Human Answer,37104815,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance (Sanger and UDS) and pharmacological drug concentration measurements, but does not report in vitro phenotypic drug susceptibility assay data.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,,1,No,1
Human Answer,37104815,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported. The paper does not provide GenBank accession numbers or state that sequence data were deposited in public repositories.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,,1,No,1
Human Answer,37104815,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not provided in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,,1,Not reported,1
Human Answer,37104815,5,How many individuals had samples obtained for HIV sequencing?,Number,121 or 10,Sequencing was reported both for the substudy cohort (first 121 participants had ultrasensitive analyses) and specifically for resistance sequencing in 10 participants with virological failure (6 in 4/7 arm and 4 in 7/7 arm).,1,121,1,121,1,121,1,121,1,121,1,121,1,Not reported,0,121,1,121,1,121,1,121,1,121,1,121,1,121,1,0,0,121,1,121,1,121,1,121,1,,0,121,1
Human Answer,37104815,6,From which countries were the sequenced samples obtained?,List,France,"Samples were obtained in France (multicentre French trial); participants included people of diverse origins, with 10% reported as from sub-Saharan Africa.",1,No,0,France,1,Not reported,0,France,1,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,Not Reported,0,Not reported,0,Not reported,0,,0,France,1
Human Answer,37104815,7,From what years were the sequenced samples obtained?,List,2017-2019,Samples were collected from 2017 through 2019 (participants screened 7 September 2017 to 22 January 2018; W48 analyses included data up to 4 April 2019).,1,No,0,2017-2019,1,2017–2019,1,2017–2019,1,2017–2018,0,2017-2019,1,2017-2018,0,No,0,2017-2019,1,2017-2018,0,2017-2019,1,2017-2019,1,2017-2018,0,2017-2018,0,No,0,No,0,2017-2019,1,Not reported,0,2017-2019,1,,0,2017-2019,1
Human Answer,37104815,8,Were samples cloned prior to sequencing?,Boolean,No,No. The methods describe Sanger sequencing and ultra-deep (Illumina) sequencing without mention of cloning of samples prior to sequencing.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,,1,No,1
Human Answer,37104815,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Reverse transcriptase (RT), protease (PR), and integrase (INT) regions were sequenced.",1,"PR, RT, IN",1,"PR, RT, IN",1,"RT, PR, IN",1,"RT, PR, IN",1,Pol,0,"RT, PR, INT",1,"RT, PR, INT",1,"Reverse transcriptase, RT; Protease, PR; Integrase, IN",1,"PR, RT, IN",1,"RT, PR, INT",1,"RT, PR, INT",1,Pol,0,"RT, PR, IN",1,"RT, PR, INT",1,"Protease, RT; Reverse transcriptase, RT; Integrase, IN",1,"RT, PR, IN",1,"RT, PR, INT",1,Pol,0,Yes,0,,0,"RT, PR, IN",1
Human Answer,37104815,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing",Sanger sequencing and ultra-deep sequencing (UDS) using Illumina technology were used.,1,"Sanger sequencing, Illumina sequencing",1,Sanger sequencing; Illumina sequencing,1,Sanger and ultra-deep sequencing (UDS),0,Sanger sequencing and ultra-deep sequencing (UDS),0,Sanger sequencing and NGS,0,"Sanger sequencing, Illumina sequencing",1,Sanger and ultra-deep sequencing,0,Illumina sequencing,0,Sanger sequencing; Illumina sequencing,1,Sanger sequencing and ultra-deep sequencing (UDS) using Illumina technology,1,NGS,0,Sanger sequencing and Illumina technology,1,"Sanger sequencing, Illumina sequencing",1,"Sanger sequencing, Illumina sequencing",1,Illumina sequencing,0,Illumina sequencing,0,Sanger and ultra-deep sequencing (UDS),0,NGS,0,Yes,0,,0,"Sanger sequencing, Illumina sequencing",1
Human Answer,37104815,11,What type of samples were sequenced?,List,"Whole Blood, Semen",Plasma RNA samples at failure and cellular HIV total DNA samples at baseline (D0) were sequenced; the study also measured plasma and seminal viral loads but sequencing is reported for RNA and DNA samples.,0,"Whole Blood, Other",0,Plasma; PBMC,0,Blood plasma and semen,0,"Plasma, Semen",0,"Plasma, Semen",0,Plasma,0,Blood and semen,0,Plasma; Semen,0,Plasma; PBMC; Semen,0,Blood plasma and total HIV-1 DNA,0,"Plasma, PBMC",0,Plasma and PBMC,0,Plasma,0,"Plasma, Semen",0,Plasma,0,"Plasma, Semen",0,Blood and semen,0,Plasma,0,"NRTIs, NNRTIs, PIs",0,,0,Plasma,0
Human Answer,37104815,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes. Resistance sequencing (RNA at failure) was performed for the 10 participants who experienced virological failure (6 in the 4/7 arm and 4 in the 7/7 arm).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Tenofovir/emtricitabine, rilpivirine, darunavir/ritonavir",0,,0,Yes,1
Human Answer,37104815,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes. Participants were enrolled in the ANRS 170 QUATUOR open-label, randomized, multicentre, non-inferiority Phase III clinical trial (registered NCT03256422).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,,0,Yes,1
Human Answer,37104815,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. All participants were on continuous combination ART with sustained virological suppression (>12 months) at enrollment, and sequencing was performed on their RNA/DNA samples.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,,0,Yes,1
Human Answer,37104815,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI","Participants received integrase strand transfer inhibitors (INSTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) backbones.",1,"INSTI, NNRTI, PI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, INSTI, PI",1,"INSTI, NNRTI, PI",1,"NRTI, INSTI, NNRTI, PI",1,"INSTI, NNRTI, PI",1,INSTI; NNRTI; PI,1,"NRTI, NNRTI, PI, INSTI",1,"INSTIs, NNRTIs, PIs",1,"NRTIs, NNRTIs, PIs, INSTIs",1,"NRTIs, NNRTIs, and PIs",0,"INSTI, NNRTI, PI",1,"INSTI, NNRTI, PI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"INSTIs, NNRTIs, PIs",1,"NRTIs, NNRTIs, PIs",0,No,0,,0,"NRTI, NNRTI, INSTI",0
Human Answer,37104815,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, FTC, ABC, 3TC","Reported drugs included NRTI backbones tenofovir/emtricitabine (TDF/FTC) or tenofovir alafenamide/emtricitabine (TAF/FTC) and abacavir/lamivudine; third agents mentioned include rilpivirine, raltegravir, elvitegravir/cobicistat, dolutegravir, and efavirenz among others.",1,"Tenofovir/emtricitabine, Tenofovir alafenamide/emtricitabine, Abacavir/lamivudine",1,"Tenofovir (TFV), Emtricitabine (FTC), Abacavir (ABC), Lamivudine (3TC), Rilpivirine (RPV), Raltegravir (RAL), Dolutegravir (DTG), Lopinavir (LPV)",1,"Tenofovir, Emtricitabine, Abacavir, Lamivudine",1,"Tenofovir, Emtricitabine",0,"Tenofovir/emtricitabine, Tenofovir alafenamide/emtricitabine",0,"Tenofovir, Emtricitabine, Abacavir, Lamivudine, Raltegravir, Efavirenz, Darunavir",1,"Tenofovir, Emtricitabine, Abacavir, Lamivudine",1,Tenofovir/emtricitabine; Rilpivirine,0,"Abacavir (ABC), Lamivudine (3TC), Tenofovir (TFV), Tenofovir alafenamide (TAF), Emtricitabine (FTC)",1,"Tenofovir, emtricitabine, rilpivirine, abacavir, lamivudine, raltegravir",1,"Tenofovir, emtricitabine, rilpivirine",0,"Tenofovir, emtricitabine, and rilpivirine",0,"Tenofovir, Emtricitabine, Tenofovir alafenamide, Abacavir, Lamivudine",1,"Tenofovir, Emtricitabine, Tenofovir alafenamide, Abacavir, Lamivudine",1,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",1,"Abacavir, Lamivudine, Tenofovir, Tenofovir alafenamide, Emtricitabine, Rilpivirine, Dolutegravir, Elvitegravir, Cobicistat, Raltegravir",1,"INSTIs, NNRTIs, PIs",0,"Tenofovir, Lamivudine, Efavirenz, Raltegravir",0,No,0,,0,"Tenofovir (TFV), Emtricitabine (FTC), Abacavir (ABC), Lamivudine (3TC)",1
Human Answer,37112971,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The study reports HIV sequences obtained from patient samples (4481 PR-RT and 844 INT sequences).,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37112971,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic resistance interpretation derived from sequence data but does not report in vitro phenotypic (laboratory) drug susceptibility assays.,1,No,1,No,1,No,1,No,1,** No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37112971,3,Were sequences from the paper made publicly available?,Boolean,No,No. The sequence data are not publicly available; they are available on request from the corresponding author due to the RuHIV database privacy policy.,1,No,1,No,1,No,1,No,1,** No,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,Yes.,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer,37112971,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,No GenBank accession numbers for the study sequences are reported.,1,No,1,No,1,Not reported,1,K03455,0,** Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported.,1,"MH062016- MH062024, MH062026- MH062029, MH062125- MH062138, MK931539- MK931547, MK931784, MK931789- MK931801, MK931912- MK931931, MK931933, MK931934, MK931937, MK931939, MK931940, MK931942, MK931943, MK931945, MK931947- MK931964, MK931996, MK931997, MK931999- MK932016, and MW483846- MW484805.",0,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,37112971,5,How many individuals had samples obtained for HIV sequencing?,Number,4481,"4481 treatment-naïve individuals had PR-RT sequences; among them, 844 also had integrase (INT) sequences.",1,4481,1,4481,1,4481,1,4481,1,** 4481,1,4481,1,4481,1,4481,1,4481,1,4481.,1,4481,1,4481.,1,1071,0,4481,1,4481,1,4481,1,4481,1,4481,1,4481,1,4481,1,4481,1
Human Answer,37112971,6,From which countries were the sequenced samples obtained?,List,Russia,All sequenced samples were obtained from Russia (from all Russian federal districts).,1,No,0,Russia,1,Russia,1,Russia,1,** Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia.,1,Russia,1,Russia.,1,"Armenia, Azerbaijan, Belarus, Russia, Tajikistan, Uzbekistan",1,Russia,1,No,0,Russia,1,Russia,1,Not reported,0,Russia,1,"Armenia, Azerbaijan, Belarus, Russia, Tajikistan, Uzbekistan",1,Not reported,0
Human Answer,37112971,7,From what years were the sequenced samples obtained?,List,2006-2022,Blood sampling (sequenced sample) years ranged from 2006 to 2022.,1,2006-2022,1,2006-2022,1,2006–2022,1,2006–2022,1,** 2006–2022,1,2006-2022,1,2006-2022,1,2006-2022,1,2006-2022,1,2006-2022.,1,2006-2022,1,2006-2022.,1,2017-2019,0,2006-2022,1,1997-2022,0,2006-2022,1,2006-2022,1,2006-2022,1,2006-2022,1,2017-2019,0,1997-2022,0
Human Answer,37112971,8,Were samples cloned prior to sequencing?,Boolean,No,No. The methods describe direct genotyping (commercial kits and in-house methods) with Sanger or NGS sequencing and do not report any cloning prior to sequencing.,1,No,1,No,1,No,1,No,1,** No,1,No,1,No,1,No,1,No,1,Not reported.,1,Not reported,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1
Human Answer,37112971,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Regions of the HIV-1 pol gene were sequenced: protease (PR), part of reverse transcriptase (RT), and integrase (INT) for a subset of samples.",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"** PR, RT, IN",1,"PR, RT, INT",1,"PR, RT, INT",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, INT.",1,"Pol, INT",0,"PR, RT, INT.",1,"PR, RT",0,"PR, RT, INT",1,"Protease (PR), Reverse transcriptase (RT), Integrase (IN)",1,"PR, RT, IN",1,"PR, RT, INT",1,Pol,0,Not reported,0,"PR, RT, INT",1,"PR, RT, INT",1
Human Answer,37112971,10,What method was used for sequencing?,List,"Sanger sequencing, NGS","Sanger-based sequencing and next-generation sequencing (NGS) (with a 20% detection threshold) were used, employing commercial genotyping kits (AmpliSens HIV-Resist-Seq, ViroSeq) and in-house methods.",1,Sanger sequencing,0,Sanger sequencing; NGS,1,"Sanger sequencing, NGS",1,Sanger sequencing and NGS,1,"** Sanger sequencing, NGS",1,Sanger-based or NGS-based sequencing,1,Sanger-based and NGS-based sequencing,1,Sanger sequencing; Next-generation sequencing (NGS),1,"Sanger sequencing, NGS",1,Sanger sequencing and NGS.,1,Sanger-based or NGS-based,1,Sanger-based or NGS-based sequencing.,1,Not reported,0,Sanger sequencing or NGS,1,Sanger sequencing,0,No,0,Sanger-based or NGS-based sequencing,1,Sanger sequencing,0,No,0,Sanger sequencing,0,Sanger sequencing,0
Human Answer,37112971,11,What type of samples were sequenced?,List,Plasma,Blood plasma samples (plasma) were sequenced.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,** Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma.,1,"Plasma, PBMC",1,Plasma.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,"Plasma, PBMC",1,,0,Plasma,1,Plasma,1
Human Answer,37112971,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. The study population consisted of treatment-naïve patients, so sequences were not from individuals with virological failure on ART.",1,No,1,No,1,No,1,No,1,** No,1,No,1,Yes,0,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,,1,No,1,No,1
Human Answer,37112971,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Patients were not described as participants in a clinical trial; sequences originated from routine HIV DR testing, research and clinical projects, and outbreak investigations uploaded to the national database.",1,No,1,No,1,No,1,No,1,** No,1,No,1,No,1,No,1,No,1,Not reported.,1,Not reported,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37112971,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No. The study explicitly analyzed sequences from treatment-naïve individuals, so subjects had not previously received antiretroviral drugs prior to sampling.",1,No,1,No,1,No,1,No,1,** No,1,Yes,0,Yes,0,No,1,No,1,No.,1,No,1,No.,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0
Human Answer,37112971,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None. Individuals were treatment-naïve and had not received antiretroviral drug classes prior to sequencing.,1,No,1,No,1,,1,,1,** None,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,None.,1,Not reported,1,Not reported,1,No,1,No,1,,1,"NRTI, NNRTI",0,No,1,Not reported,1,Not reported,1
Human Answer,37112971,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None. The study enrolled treatment-naïve individuals who had not received any antiretroviral drugs prior to sequencing.,1,No,1,No,1,,1,,1,** None,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,None.,1,Not reported,1,Not reported,1,No,1,No,1,,1,"AZT, 3TC, FTC, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0,No,1,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF), Emtricitabine (FTC), Lopinavir (LPV), Darunavir (DRV), Dolutegravir (DTG)",0,Not reported,1
Human Answer,37147875,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,37147875,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,Yes,1,No,0,Yes,1,No,0,No,0,Yes,1,No,0,No,0,No,0,No,0,** Yes,1,Yes,1
Human Answer,37147875,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not Reported,1,** No,1,No,1
Human Answer,37147875,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,MT244321-MT244324,0,Not reported,1,Not Reported,1,** Not reported,1,Not reported,1
Human Answer,37147875,5,How many individuals had samples obtained for HIV sequencing?,Number,1,One individual,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,** 1,1,1,1
Human Answer,37147875,6,From which countries were the sequenced samples obtained?,List,France,France,1,No,0,France,1,France,1,France,1,France,1,Not reported,0,France,1,France,1,France,1,France,1,France,1,France,1,Not Found,0,Not Found,0,No,0,France,1,Not Reported,0,Not reported,0,Not Reported,0,** Not Found,0,Not reported,0
Human Answer,37147875,7,From what years were the sequenced samples obtained?,List,2022,2022,1,No,0,2022,1,2022,1,2022,1,2022,1,2022,1,2022,1,2022,1,No,0,2022,1,2022,1,2022,1,Not reported,0,Not reported,0,No,0,2022,1,2022,1,2022,1,2022,1,** 2022,1,2022,1
Human Answer,37147875,8,Were samples cloned prior to sequencing?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,Not Reported,1,** No,1,No,1
Human Answer,37147875,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Reverse transcriptase (RT), protease, and integrase",1,"Integrase, RT, PR",1,"PR, RT, IN",1,"RT, PR, IN",1,"RT, PR, IN",1,"RT, IN",0,"RT, PR, IN",1,"PR, RT, IN",1,"Reverse transcriptase, RT; Protease, PR; Integrase, IN",1,"PR, RT, IN",1,"RT, protease, integrase",1,"RT, PR, IN",1,"RT, Protease, Integrase",1,"PR, RT, IN",1,"RT, PR, IN",1,"Protease, RT, IN",1,"RT, PR, IN",1,Integrase,0,"RT, PR, IN",1,Not Reported,0,"** RT, PR, IN",1,"RT, PR, IN",1
Human Answer,37147875,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing",Sanger-based sequencing (SBS) and next-generation sequencing (Illumina MiSeq) with PASeq analysis,1,Illumina sequencing,0,Sanger sequencing; NGS,0,"Sanger sequencing, NGS",0,Sanger sequencing,0,NGS,0,Sanger sequencing; NGS,0,"Sanger sequencing, NGS",0,Sanger sequencing; Next-generation sequencing,1,"Sanger sequencing, Illumina sequencing",1,"Sanger sequencing, NGS",0,NGS,0,"Sanger sequencing, NGS",0,Sanger sequencing; NGS,0,"Sanger sequencing, NGS",0,Illumina sequencing,0,"SBS, NGS",0,NGS,0,Sanger sequencing,0,Not Reported,0,** NGS,0,Sanger sequencing,0
Human Answer,37147875,11,What type of samples were sequenced?,List,Plasma,Baseline clinical sample (patient blood/plasma) from the newly infected patient (pre-treatment); the paper does not explicitly state 'plasma' but gives viral load and CD4 consistent with blood/plasma sample.,1,No,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Blood,0,Plasma,1,Plasma,1,Plasma,1,Not reported,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Not Reported,0,** Blood,0,Plasma,1
Human Answer,37147875,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,Not reported,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,37147875,13,Were the patients in the study in a clinical trial?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,Not Reported,1,** No,1,No,1
Human Answer,37147875,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,37147875,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None (the sequenced patient was ART-naive prior to sequencing),1,"NRTI, NNRTI",0,No,1,,1,"NRTI, NNRTI",0,,1,"NRTI, INSTI",0,"NRTI, PI",0,INSTI; NRTI,0,No,1,"INSTI, NRTI",0,,1,"INSTI, NRTI",0,"NRTI, NNRTI, PI, INSTI",0,Not reported,1,INSTI,0,INSTI,0,"Integrase inhibitors, NRTIs",0,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, INSTI",0,"** NRTI, INSTI, NNRTI",0,"NRTI, INSTI",0
Human Answer,37147875,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"None received by the sequenced individual prior to sequencing; the patient started DTG + FTC + TDF 7 days after diagnosis (i.e., after baseline sequencing).",1,"Doravirine, TDF, FTC",0,No,1,"DTG, FTC, TDF",0,"Doravirine, TDF, FTC",0,,1,"Doravirine, TDF, FTC",0,"Tenofovir disoproxil fumarate (TDF), Emtricitabine (FTC), Efavirenz (EFV)",0,Dolutegravir (DTG); Emtricitabine (FTC); Tenofovir disoproxil fumarate (TDF),0,No,1,"DTG, FTC, TDF",0,,1,"DTG, FTC, TDF",0,"Dolutegravir (DTG), Emtricitabine (FTC), Tenofovir disoproxil fumarate (TDF), Doravirine, Lamivudine (3TC), Abacavir (ABC)",0,Not reported,1,"DTG, FTC, TDF",0,"DTG, CAB, BIC, FTC, TDF",0,"Dolutegravir, Emtricitabine, Tenofovir disoproxil fumarate",0,"DTG, FTC, TDF",0,"Doravirine, TDF, FTC, DTG",0,"** DTG, FTC, TDF",0,"Dolutegravir (DTG), Emtricitabine (FTC), Tenofovir disoproxil fumarate (TDF)",0
Human Answer,37272233,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37272233,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer,37272233,3,Were sequences from the paper made publicly available?,Boolean,No,No (no public deposition reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37272233,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not Reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,37272233,5,How many individuals had samples obtained for HIV sequencing?,Number,248,248 individuals.,1,0,0,248,1,248,1,248,1,248,1,248,1,248,1,0,0,248,1,248.,1,248,1,248,1,248,1,6,0,248,1,0,0,248,1,248,1,248,1,248,1,248,1
Human Answer,37272233,6,From which countries were the sequenced samples obtained?,List,South Korea,Republic of Korea (Korea).,1,No,0,Korea,1,Korea,1,Korea,1,Korea,1,South Korea,1,South Korea,1,No,0,Korea,1,Korea.,1,Not Reported,0,No,0,Korea,1,"United States, Australia",0,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,Korea,1
Human Answer,37272233,7,From what years were the sequenced samples obtained?,List,2012-2020 or 2010-2020,"Patients diagnosed between January 2010 and December 2020 (sequencing/results analyzed within that period); INSTI resistance testing began May 30, 2018.",0,No,0,2010-2020,0,2010–2020,0,2010–2020,0,2010–2020,0,2010-2020,0,2010 - 2020,0,No,0,2010-2020,0,2010-2020.,0,2012-2020,1,2012-2020,1,2010-2020,0,Not reported,0,2010-2020,0,No,0,2010-2020,0,2010-2020,0,2010-2020,0,2010-2020,0,2010-2020,0
Human Answer,37272233,8,Were samples cloned prior to sequencing?,Boolean,No,No evidence of cloning; cloning is not reported.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not Reported,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer,37272233,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Regions corresponding to genes targeted by ARV classes: reverse transcriptase (for NRTI and NNRTI), protease (for PI), and integrase (for INSTI).",1,No,0,"PR, RT, IN",1,Pol,0,Pol,0,Not reported,0,"PR, RT, IN",1,Not reported,0,No,0,No,0,"Pol (protease, reverse transcriptase, and integrase).",1,"Pol, IN",0,Pol,0,"NRTI, NNRTI, PI, INSTI",0,"PR, RT, IN",1,"Protease, Reverse transcriptase, and Integrase",1,No,0,"Pol, RT, PR, IN",1,Pol,0,Not reported,0,"NRTI, NNRTI, PI, INSTI",0,Not reported,0
Human Answer,37272233,10,What method was used for sequencing?,List,Sanger sequencing,"PCR-based sequencing using an ABI 3500xL Dx genetic analyzer (Applied Biosystems) — i.e., Sanger sequencing of PCR products.",1,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,PCR sequencing,0,PCR,0,No,0,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Not Reported,0,PCR,0,Not reported,0,No,0,No,0,Sanger sequencing,1,Sanger sequencing,1,Yes,0,Not reported,0,PCR,0
Human Answer,37272233,11,What type of samples were sequenced?,List,Plasma,"Not explicitly stated; sequencing was performed on patient-derived clinical specimens (implied viral RNA from patient samples), but the manuscript does not specify the biological specimen type (e.g., plasma).",1,No,0,Plasma,1,Not Reported,0,Not Reported,0,Not reported,0,Clinical samples,0,Blood/Plasma,1,No,0,No,0,Plasma.,1,"Plasma, PBMC",1,Plasma,1,Not reported,0,PBMC,0,Plasma,1,No,0,Plasma,1,"Plasma, PBMC",1,"NRTIs, NNRTIs, PIs, and INSTIs",0,Plasma,1,Not reported,0
Human Answer,37272233,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not explicitly reported as sequences from virological failure cases; however, some detected mutations (e.g., T215 revertants) are related to virological failure and some patients had prior ART exposure shortly before testing.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,"Zidovudine, lamivudine, emtricitabine, tenofovir, abacavir, efavirenz, nevirapine, lopinavir, atazanavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, and cabotegravir",1,Yes,0,Yes,0
Human Answer,37272233,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37272233,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,Yes — some individuals had prior ART exposure before sequencing.,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0
Human Answer,37272233,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not specified in detail by drug class prior to sequencing.,1,No,1,No,1,Not reported,1,"NRTI, NNRTI",0,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0,No,1,"NRTI, NNRTI, PI, and INSTI.",0,"NRTI, NNRTI, PI, INSTI",0,"NRTIs, NNRTIs, PIs, INSTIs",0,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0,No,1,"NRTI, NNRTI, PI",0,Not reported,1,No,1,"NRTI, NNRTI, PI, INSTI",0,Not reported,1
Human Answer,37272233,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not reported (specific drugs or regimens prior to sequencing are not detailed).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN), GS-CA1, Lenacapavir (GS-6207)",0,No,1,"Zidovudine, lamivudine, efavirenz, raltegravir, and others.",0,"zidovudine, lamivudine, efavirenz, raltegravir",0,"Zidovudine, lamivudine, efavirenz, raltegravir",0,Not reported,1,Not reported,1,"Abacavir (ABC), Zidovudine (AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir (EVG), Dolutegravir (DTG), Bictegravir (BIC), cabotegravir (CAB), Lenacapavir (LEN)",0,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1
Human Answer,37279764,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV sequences obtained from patient samples (partial HIV-1 pol sequences).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37279764,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro (phenotypic) drug susceptibility assays; drug sensitivity changes were inferred from genotypic interpretation.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37279764,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes — sequences were deposited in GenBank and accession numbers are provided.,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,No,0
Human Answer,37279764,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,"MW947591–MW957968, OP058117–OP058658",GenBank accession ranges listed are MW947591–MW957968 and OP058117–OP058658.,1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,MW947591–MW957968 and OP058117–OP058658,1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,No,0,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,Not reported,0,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1
Human Answer,37279764,5,How many individuals had samples obtained for HIV sequencing?,Number,12320,"12,320 individuals.",1,12320,1,12320,1,12320,1,12320,1,12320,1,12320,1,"12,320",1,12320,1,12320,1,"12,320",1,"12,320",1,"12,320",1,"12,320",1,"12,320",1,12320,1,12320,1,"12,320",1,"12,320",1,"12,320",1,"12,320",1,"12,320",1
Human Answer,37279764,6,From which countries were the sequenced samples obtained?,List,China,"China (samples were collected in Shenzhen, China).",1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,Not Reported,0,China,1,China,1,China,1,China,1,China,1,China,1,Not Reported,0,China,1,China,1,China,1,Not reported,0
Human Answer,37279764,7,From what years were the sequenced samples obtained?,List,2011-2019,From 2011 to 2019 (January 2011 to December 2019).,1,2011 to 2019,1,2011-2019,1,2011–2019,1,2011–2019,1,2011–2019,1,2011 to 2019,1,2011–2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1
Human Answer,37279764,8,Were samples cloned prior to sequencing?,Boolean,No,No cloning prior to sequencing is reported.,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1
Human Answer,37279764,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol",A partial region of the HIV-1 pol gene (HXB2 positions 2252–3255).,0,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",0,Pol,0,Pol,0,Pol,0,Pol,0,pol gene (including segments for PR and RT),1,Pol,0,"Protease, Reverse transcriptase, Integrase",0,"PR, RT",0,Pol,0,Pol,0,Pol,0,"PR, RT",0,Pol,0,"Protease, Reverse transcriptase, Integrase",0,Pol,0,Pol,0,Pol,0,Pol,0,Pol,0,"PR, RT",0
Human Answer,37279764,10,What method was used for sequencing?,List,No,"The paper reports nucleic acid extraction, PCR amplification and sequencing as described previously but does not specify the sequencing platform or detailed method.",0,No,1,No,1,Not Reported,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,Sanger sequencing,0,Sanger sequencing,0,Not Reported,1,Not Reported,1,Sanger sequencing,0,Not reported,1,Not reported,1
Human Answer,37279764,11,What type of samples were sequenced?,List,Whole Blood,Blood samples collected from newly diagnosed patients.,0,Whole Blood,1,Plasma,0,Blood samples,0,Not Reported,0,Plasma,0,Blood samples,0,Blood samples,0,Plasma,0,Whole Blood,1,Not Reported,0,Plasma,0,Not Reported,0,Plasma,0,Blood,0,Blood samples,0,Plasma or whole blood,1,Whole Blood,1,Plasma,0,Blood samples,0,Blood,0,Plasma,0
Human Answer,37279764,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — all individuals were treatment naive at enrolment, so sequences were not from persons with virological failure on treatment.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,No,1,No,1
Human Answer,37279764,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the study involved newly diagnosed patients enrolled for surveillance/analysis, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1
Human Answer,37279764,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — sequences were from individuals who were treatment naive and had not previously received ARV drugs.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,No,1,No,1
Human Answer,37279764,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"None — individuals were treatment naive, so no antiretroviral drug classes had been received prior to sampling.",1,No,1,No,1,,1,,1,,1,,1,Not reported,1,No,1,No,1,Not Reported,1,Not Reported,1,Not Reported,1,,1,,1,NNRTI,0,No,1,,1,Not Reported,1,"NRTIs, NNRTIs, PIs",0,,1,Not reported,1
Human Answer,37279764,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None — participants were treatment naive and had not received antiretroviral drugs prior to sampling.,1,No,1,No,1,,1,,1,,1,,1,Not reported,1,No,1,No,1,Not Reported,1,Not Reported,1,Not Reported,1,,1,,1,"Nevirapine, Efavirenz",0,No,1,,1,Not Reported,1,"AZT, 3TC, EFV, NVP, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC, IBA",0,,1,Not reported,1
Human Answer,37327289,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37327289,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37327289,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37327289,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,LC723952-LC724015,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,LC723952–LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,"LC723952-LC724015 (Note: These are DDBJ accession numbers, not GenBank accession numbers)",1,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,Not reported,0,LC723952-LC724015,1
Human Answer,37327289,5,How many individuals had samples obtained for HIV sequencing?,Number,157,64 individuals had samples sequenced (64 sequences analyzed).,0,157,1,64,0,64,0,157,1,157,1,64,0,64,0,64,0,64,0,157,1,64,0,64,0,64,0,64,0,64,0,64,0,64,0,157,1,157,1,157,1,157,1
Human Answer,37327289,6,From which countries were the sequenced samples obtained?,List,Kenya,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,No,0,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1
Human Answer,37327289,7,From what years were the sequenced samples obtained?,List,2020-2021,Samples were obtained between November 2020 and April 2021.,1,2020-2021,1,2020-2021,1,2020–2021,1,2020–2021,1,2020–2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1
Human Answer,37327289,8,Were samples cloned prior to sequencing?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer,37327289,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol",pol gene (primary) and the env V3 region (for tropism determination) in many samples.,0,Full genome,0,Pol,0,Pol,0,Pol,0,Pol,0,*pol* gene,0,*pol*,0,"Protease, Reverse transcriptase, Integrase",0,"PR, RT",0,Pol,0,Pol,0,Pol,0,pol,0,Pol,0,"Reverse transcriptase, RT",0,"PR, RT, IN",0,Pol,0,Pol,0,No,0,Pol,0,Pol,0
Human Answer,37327289,10,What method was used for sequencing?,List,Sanger sequencing,Sanger sequencing (Thermo Fisher HIV Genotyping kit on an Applied Biosystems 3500xL DX analyzer with BigDye chemistry).,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37327289,11,What type of samples were sequenced?,List,Plasma,Plasma samples (viral RNA extracted from plasma).,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,,0,Plasma,1,Plasma,1
Human Answer,37327289,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,,1,No,1,No,1
Human Answer,37327289,13,Were the patients in the study in a clinical trial?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37327289,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No (all participants were treatment-naive), although one sequence showed a pattern suggesting possible prior ARV exposure.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37327289,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None — participants were treatment-naive (no ARV classes received prior to sequencing).,1,No,1,No,1,,1,,1,,1,Not reported,1,Not applicable,1,No,1,No,1,Not Reported,1,,1,,1,Not reported,1,Not reported,1,"NRTI, NNRTI",0,No,1,,1,,1,No,1,Not reported,1,Not reported,1
Human Answer,37327289,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None — participants were treatment-naive and had not received antiretroviral drugs before sequencing.,1,No,1,No,1,,1,,1,,1,Not reported,1,Not applicable,1,No,1,No,1,Not Reported,1,,1,,1,Not reported,1,Not reported,1,"Abacavir (ABC), Zidovudine'(AZT), Nevirapine (NVP), Efavirenz (EFV)",0,No,1,,1,,1,No,1,Not reported,1,Not reported,1
Human Answer,37340869,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The paper reports genotypic (sequence-based) analyses from participant samples, including identification of resistance-associated mutations and HIV-1 subtypes.",1,No,0,No,0,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,,0
Human Answer,37340869,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No—direct in vitro drug susceptibility (phenotypic) results are not presented in the main text (phenotypic analyses are only referenced as published elsewhere/supplementary).,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,,1
Human Answer,37340869,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported. The manuscript does not provide GenBank accession numbers or state that sequence data were deposited in a public repository.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,,1
Human Answer,37340869,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not reported. No GenBank accession numbers are provided in the manuscript text.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451",0,Not reported in the provided text,1,Not reported,1,,1
Human Answer,37340869,5,How many individuals had samples obtained for HIV sequencing?,Number,1651,"Not explicitly reported. The manuscript gives counts of participants included in analytic datasets (e.g., 1651 total participants; BFAs included 1363 and 1431 participants with complete records) but does not explicitly state the number of individuals from whom sequences were obtained.",1,1651,1,0,0,1651,1,Not reported,0,1651,1,1651,1,1651,1,0,0,0,0,1651,1,1651,1,1651,1,3,0,1651,1,0,0,1651,1,1651,1,1651,1,1651,1,1651,1,,0
Human Answer,37340869,6,From which countries were the sequenced samples obtained?,List,No,"Not fully reported. The manuscript reports regional analyses and notes that 11 participants with CVF were from Russia, but it does not provide a complete list of countries from which sequenced samples were obtained in the main text.",0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Russia,0,"North America, Europe",0,No,1,No,1,"North America, Europe, and other regions",0,Not reported,1,Not reported,1,Russia,0,Russia,0,No,1,No,1,"North America, Europe, and other regions",0,"United States, Europe, and ""other"" regions",0,Not reported,1,Russia,0,,1
Human Answer,37340869,7,From what years were the sequenced samples obtained?,List,No,Not reported. The manuscript provides follow-up cutoffs (weeks of study) but does not provide calendar years for sample collection or sequencing in the main text.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported (specific years not mentioned),1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,2015-2020,0,2004-2017,0,Not reported in the provided text,1,2015-2019,0,,1
Human Answer,37340869,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported. The main text does not describe cloning of samples prior to sequencing.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,,1
Human Answer,37340869,9,Which HIV genes were reported to have been sequenced?,List,RT,"The paper reports sequence-based findings implicating integrase (L74I) and NNRTI-associated regions (RPV RAMs), indicating sequencing/analysis of the integrase and reverse transcriptase/RT-associated (pol) regions.",1,No,0,No,0,Not reported,1,Not reported,1,Not reported,1,"RT, IN",1,Integrase (IN),0,No,0,No,0,Not reported,1,Pol,0,"Pol, specifically the integrase region",0,"PR, RT, IN",1,"PR, RT, IN",1,No,0,No,0,Pol,0,"Pol, including protease and reverse transcriptase",1,Yes,0,"IN, RT",1,,0
Human Answer,37340869,10,What method was used for sequencing?,List,No,Not reported in the main text. Sequencing methodology is referred to as described in the Supplementary materials/previous publications but specific sequencing method details are not provided in the manuscript body.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing,0,Yes,0,Not reported,1,,1
Human Answer,37340869,11,What type of samples were sequenced?,List,No,Proviral DNA (retrospective proviral DNA analysis) is explicitly mentioned; historical plasma genotypic evidence is also referenced but archived resistance testing was not prospectively performed.,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Plasma,0,Not reported,1,No,1,No,1,Plasma and proviral DNA,0,Plasma,0,Plasma,0,Plasma,0,Plasma,0,No,1,No,1,Plasma,0,Plasma,0,Not reported in the provided text,1,Plasma,0,,1
Human Answer,37340869,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Yes. Some sequence-derived findings relate to participants who experienced confirmed virologic failure (CVF); 23 participants had CVF and the analyses relate baseline sequence findings (e.g., preexisting RPV RAMs) to later CVF.",0,No,1,No,1,Not reported,1,Not reported,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Not reported,1,Yes,0,,1
Human Answer,37340869,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes. Participants were enrolled in randomized, multicenter, open-label phase 3/3b clinical trials (FLAIR, ATLAS, and ATLAS-2M).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,,0
Human Answer,37340869,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. Participants were virologically suppressed on antiretroviral therapy at randomization and had prior ARV exposure; the paper discusses historical genotypic evidence and retrospective proviral DNA analyses to detect archived resistance related to prior ARV use.,1,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,,0
Human Answer,37340869,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,The manuscript explicitly references INSTI (integrase strand transfer inhibitor) and NNRTI (non-nucleoside reverse-transcriptase inhibitor) classes in eligibility and resistance analyses; participants were on prior daily oral antiretroviral regimens (which could include these classes).,0,NNRTI,0,No,1,Not reported,1,Not reported,1,Not reported,1,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, INSTI",0,"INSTI, NNRTI",0,No,1,INSTI and NNRTI,0,"INSTIs, NNRTIs",0,"INSTI, NNRTI",0,"NRTI, NNRTI, INSTI",0,NNRTI,0,No,1,No,1,"NRTIs, NNRTIs, and INSTIs",0,"NRTIs, NNRTIs, and PIs",0,No,1,"NRTI, NNRTI, PI, INSTI, CCR5 antagonist",0,,1
Human Answer,37340869,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not specifically reported. The manuscript indicates participants continued daily oral therapy before randomization or switched from oral therapy to CAB + RPV LA, but it does not list specific prior antiretroviral drugs for participants in the provided text.",0,Rilpivirine (RPV),0,No,1,Not reported,1,Not reported,1,Not reported,1,"Cabotegravir (CAB), Rilpivirine (RPV), Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC), Tenofovir (TAF), Emtricitabine (FTC)",0,"Cabotegravir, Rilpivirine, Lamivudine, Tenofovir",0,"Cabotegravir, Rilpivirine",0,No,1,Cabotegravir and rilpivirine,0,"Cabotegravir, rilpivirine",0,"Cabotegravir, Rilpivirine",0,"Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC), Cabotegravir (CAB), Rilpivirine (RPV)",0,"Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC), Cabotegravir (CAB), Rilpivirine (RPV)",0,No,1,No,1,CAB and RPV,0,"AZT, 3TC, FTC, TDF, ABC, EFV, RPV, and DRV",0,No,1,"Tenofovir (TFV), Emtricitabine (FTC), Darunavir (DRV), Dolutegravir (DTG), Doravirine (DOR), Ibalizumab (IBA), Lenacapavir (LEN)",0,,1
Human Answer,37358226,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** Yes,0,No,1
Human Answer,37358226,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,No,1
Human Answer,37358226,3,Were sequences from the paper made publicly available?,Boolean,No,No — no sequences were reported or made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer,37358226,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1
Human Answer,37358226,5,How many individuals had samples obtained for HIV sequencing?,Number,0,None — the study did not obtain samples for HIV sequencing.,1,0,1,0,1,14242,0,Not reported,1,14242,0,"14,242",0,Not reported,1,0,1,0,1,Not reported,1,"14,242",0,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not Reported,1,Not reported,1,"14,242",0,** Not reported,1,14 242,0
Human Answer,37358226,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no sequences were reported; the study population was from Lesotho.,1,No,1,No,1,Lesotho,0,Lesotho,0,Lesotho,0,Lesotho,0,Lesotho,0,Lesotho,0,No,1,Lesotho,0,Lesotho,0,Lesotho,0,Not reported,1,Not reported,1,No,1,Lesotho,0,Lesotho,0,Not reported,1,Lesotho,0,** Lesotho,0,Lesotho,0
Human Answer,37358226,7,From what years were the sequenced samples obtained?,List,No,Not applicable — no sequences were reported. Cohort data include transitions to DTG before 30 October 2021 and data closure 1 May 2023.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Up to 2021,0,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,2021-2023,0,Not reported,1,2021-2023,0,** Not reported,1,2021,0
Human Answer,37358226,8,Were samples cloned prior to sequencing?,Boolean,No,"Not applicable — no sequencing was performed, so no cloning was reported.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,** No,1,No,1
Human Answer,37358226,9,Which HIV genes were reported to have been sequenced?,List,No,Not applicable — no HIV genes were sequenced or reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1
Human Answer,37358226,10,What method was used for sequencing?,List,No,Not applicable — no sequencing methods are reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1
Human Answer,37358226,11,What type of samples were sequenced?,List,No,Not applicable — no samples were sequenced. The study involved routine viral load testing among participants in Lesotho.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Viral load samples (not explicitly sequenced),0,Not reported,1,No,1,No,1,Not reported,1,Plasma,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Plasma,0,** Plasma,0,Viral load (VL) testing data,0
Human Answer,37358226,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not applicable — no sequences were obtained; however, the cohort included individuals with virologic failure (e.g., pretransition VL >999 copies/mL).",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,Yes,0,** Yes,0,Yes,0
Human Answer,37358226,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the patients were part of a prospective open cohort receiving routine care (programmatic transitioning), not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer,37358226,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report any HIV sequences. The study population consists of individuals who previously received ARV drugs (NNRTI- and NRTI-containing regimens) and transitioned to DTG.,1,No,1,No,1,Yes,0,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,** Yes,0,Yes,0
Human Answer,37358226,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable for sequencing; participants had received NNRTIs and NRTIs prior to transition.,1,"NRTI, NNRTI",0,No,1,"NRTI, NNRTI",0,"NRTI, NNRTI",0,Not reported,1,"NRTI, NNRTI",0,Not reported,1,"NRTI, NNRTI, INSTI",0,No,1,NNRTI,0,"NNRTIs, INSTIs",0,NNRTI,0,Not reported,1,Not reported,1,No,1,No,1,"NRTI, NNRTI",0,Not reported,1,"NRTIs, NNRTIs",0,"** NRTI, NNRTI, PI",0,NNRTI,0
Human Answer,37358226,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable for sequencing; participants had received efavirenz or nevirapine (NNRTIs) and NRTIs including abacavir (ABC), zidovudine (ZDV), tenofovir disoproxil fumarate (TDF) together with lamivudine (3TC).",1,"Efavirenz, Nevirapine, Abacavir, Zidovudine, Tenofovir, Lamivudine",0,No,1,"Efavirenz, Nevirapine, Abacavir, Zidovudine, TDF, 3TC",0,"Efavirenz, Nevirapine, Abacavir, Zidovudine",0,Not reported,1,"Abacavir, Zidovudine, Tenofovir, Efavirenz, Nevirapine",0,"Efavirenz (EFV), Nevirapine (NVP)",0,"Abacavir (ABC), Zidovudine'(AZT), Lamivudine (3TC), Tenofovir (TFV), Nevirapine (NVP), Efavirenz (EFV), Dolutagravir (DTG)",0,No,1,"Efavirenz, nevirapine",0,"Efavirenz, nevirapine, dolutegravir",0,Efavirenz or nevirapine,0,Not reported,1,Not reported,1,No,1,No,1,"Efavirenz, nevirapine, abacavir, zidovudine, TDF, 3TC",0,Not reported,1,"Efavirenz, Nevirapine",0,"** Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF), Efavirenz (EFV)",0,Efavirenz,0
Human Answer,37376649,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports proviral DNA genotyping (NGS) performed on baseline whole blood samples from participants.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0,Yes,1
Human Answer,37376649,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not report any in vitro phenotypic drug susceptibility assays; it reports proviral DNA genotypic resistance (NGS) data only.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,,1,No,1
Human Answer,37376649,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report deposition of sequences in public repositories or provide GenBank accession numbers; data availability refers to requesting anonymized participant data through a data request portal.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Not Reported,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,,1,No,1
Human Answer,37376649,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. The paper does not provide any GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,,1,Not reported,1
Human Answer,37376649,5,How many individuals had samples obtained for HIV sequencing?,Number,734,"Retrospective proviral DNA testing was performed on baseline samples from 734 participants; genotypic results were reported for 330 and 324 participants in the two treatment groups (total 654), with 80 assay failures.",1,734,1,734,1,734,1,734,1,734,1,734,1,464,0,734,1,734,1,Not reported,0,Not Reported,0,734,1,734,1,734,1,543,0,734,1,734,1,320 and 318,0,734,1,,0,734,1
Human Answer,37376649,6,From which countries were the sequenced samples obtained?,List,No,Not specified in the paper content provided. The manuscript does not list the countries of origin for the sequenced samples.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,,1,Not reported,1
Human Answer,37376649,7,From what years were the sequenced samples obtained?,List,No,Not specified in the paper content provided. The manuscript does not report the years when baseline samples were collected.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2004-2007,0,Not reported,1,,1,2018-2020,0
Human Answer,37376649,8,Were samples cloned prior to sequencing?,Boolean,No,No evidence of cloning is reported; sequencing was performed by the GenoSure Archive NGS assay on proviral DNA from whole blood without mention of cloning.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,,1,No,1
Human Answer,37376649,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","The HIV-1 polymerase (pol) region was sequenced, enabling analysis of protease, reverse transcriptase, and integrase resistance-associated mutations.",1,"RT, IN",0,"PR, RT, IN",1,Pol,0,"RT, IN",0,Not reported,0,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, IN",0,"Reverse transcriptase, RT; Protease, PR; Integrase, IN",1,"PR, RT, IN",1,Pol,0,Pol,0,Pol,0,"PR, RT, IN",1,"PR, RT, IN",1,No,0,No,0,Pol,0,Pol,0,Pol,0,,0,Polymerase,0
Human Answer,37376649,10,What method was used for sequencing?,List,Illumina sequencing,Next-generation sequencing (NGS) using the GenoSure Archive assay (Monogram Biosciences) on proviral DNA.,1,Illumina sequencing,1,NGS,0,NGS,0,NGS,0,NGS,0,Next-generation sequencing (NGS),1,Next-generation sequencing (NGS),1,Next-generation sequencing (NGS),1,NGS,0,NGS,0,NGS,0,NGS,0,NGS,0,NGS,0,Illumina sequencing,1,No,0,NGS,0,NGS,0,NGS,0,,0,Next-generation sequencing (NGS),1
Human Answer,37376649,11,What type of samples were sequenced?,List,Whole Blood,Baseline whole blood samples (proviral DNA) were used for genotyping/sequencing.,1,Whole Blood,1,Whole Blood,1,Whole Blood,1,Proviral DNA,0,Whole Blood,1,Whole blood,1,Whole blood samples,1,Whole Blood,1,PBMC,0,Whole Blood,1,Whole Blood,1,Whole Blood,1,Proviral DNA,0,Whole blood,1,Whole Blood,1,No,0,Whole blood,1,Whole Blood,1,Whole blood,1,,0,Proviral DNA,0
Human Answer,37376649,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. Participants with recent virologic failure or a prior regimen switch for virologic failure were excluded, and baseline samples came from virologically suppressed participants.",1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,,1,No,1
Human Answer,37376649,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes. The data come from the randomized TANGO clinical trial (ClinicalTrials.gov NCT03446573).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0,Yes,1
Human Answer,37376649,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. Participants were on antiretroviral therapy prior to the switch and had prior ART histories; proviral DNA from these individuals was genotyped to detect archived resistance.,1,No,0,Yes,1,No,0,Yes,1,No,0,Yes,1,Yes,1,No,0,No,0,Not reported,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0,Yes,1
Human Answer,37376649,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, INSTI","NRTIs, NNRTIs, PIs, and INSTIs (as referenced by analysis of NRTI, NNRTI, PI and INSTI resistance-associated mutations and by baseline third-agent classes).",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, INSTI",1,,0,Not reported,0,,0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,INSTI,0,No,0,Not reported,0,"NRTI, INSTI",1,,0,Not reported,0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, INSTI",1,No,0,"NRTI, INSTI",1,NRTI,0,"NRTIs, NNRTIs, and/or PIs",0,,0,"NRTI, INSTI",1
Human Answer,37376649,16,Which drugs were received by individuals in the study before sample sequencing?,List,"Lamivudine (3TC), Tenofovir (TAF), Dolutegravir (DTG)",The study participants were on or switching from regimens including dolutegravir/lamivudine (DTG/3TC) or tenofovir alafenamide (TAF)-based regimens; specific other individual drugs are not comprehensively listed in the provided manuscript content.,1,"Lamivudine (3TC), Tenofovir (TAF), Dolutegravir (DTG)",1,"DTG, 3TC, TAF",1,Not reported,0,Not reported,0,,0,"Efavirenz (EFV), Tenofovir (TFV), Emtricitabine (FTC), Lamivudine (3TC), Nevirapine (NVP), Zidovudine (AZT)",0,"Efavirenz, Tenofovir disoproxil fumarate, Emtricitabine, Lamivudine, Nevirapine, Zidovudine",0,"Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,0,Not reported,0,Not Reported,0,,0,Not reported,0,"Tenofovir (TFV), Emtricitabine (FTC), Darunavir (DRV), Dolutegravir (DTG), Doravirine (DOR), Ibalizumab (IBA)",0,No,0,No,0,"Tenofovir, Lamivudine, Dolutegravir",0,TDF and 3TC,0,Not reported,0,,0,"Dolutegravir (DTG), Lamivudine (3TC), Tenofovir (TFV), Emtricitabine (FTC), Nevirapine (NVP), Zidovudine (AZT)",0
Human Answer,37381002,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — HIV sequences from patient samples were reported (pol gene sequences from 398 patients and ten near full-length genomes).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37381002,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper did not report in vitro phenotypic susceptibility assays; resistance was inferred from sequence analysis using the Stanford HIVdb.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37381002,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported — the paper does not provide GenBank accession numbers or state that sequences were deposited in a public database.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1
Human Answer,37381002,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not provided — no GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1
Human Answer,37381002,5,How many individuals had samples obtained for HIV sequencing?,Number,398,398 individuals (398 viral pol gene sequences were successfully obtained).,1,398,1,398,1,398,1,398,1,398,1,398,1,398,1,398,1,398,1,398,1,398,1,398,1,398,1,398,1,450,0,398,1,398,1,398,1,398,1,398,1,398,1
Human Answer,37381002,6,From which countries were the sequenced samples obtained?,List,China,"China (specifically Suzhou City, China).",1,No,0,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,Not reported,0,Not reported,0,China,1,China,1,China,1
Human Answer,37381002,7,From what years were the sequenced samples obtained?,List,2017-2020,Samples were obtained from 2017 to 2020.,1,2017-2020,1,2017-2020,1,2017–2020,1,2017–2020,1,2017–2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1
Human Answer,37381002,8,Were samples cloned prior to sequencing?,Boolean,No,No — there is no indication that samples were cloned; PCR products were sequenced directly (Sanger) or pooled and sequenced by NGS.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1
Human Answer,37381002,9,Which HIV genes were reported to have been sequenced?,List,"NFLG, PR, RT, IN, Pol","pol gene (full protease and first 300 amino acids of reverse transcriptase) for 398 samples, and near full-length genomes (gag to nef) for ten samples.",0,"Protease, PR; Reverse transcriptase, RT",0,"Near full length genome, PR, RT",1,"PR, RT",0,Pol,0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"Protease, PR; Reverse transcriptase, RT",0,"PR, RT, Near full length genome",1,Pol,0,Pol,0,"Pol (PR, RT)",0,"PR, RT",0,"PR, RT",0,Near full-length genome,1,"PR, RT",0,Pol,0,Pol,0,No,0,"Pol, PR, RT",0,Pol,0
Human Answer,37381002,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing","Sanger sequencing was used for the pol gene fragments; Illumina next-generation sequencing (Nextera library prep, iSeq platform) was used for near full-length genomes.",1,Illumina sequencing,0,Sanger sequencing; NGS,0,Sanger sequencing,0,NGS,0,NGS,0,Sanger sequencing,0,Sanger sequencing,0,Next-generation sequencing (NGS),0,Sanger sequencing; Illumina sequencing,1,Sanger sequencing,0,Sanger sequencing,0,Next generation sequencing and Sanger sequencing,1,Sanger sequencing,0,Sanger sequencing,0,Illumina sequencing,0,Sanger sequencing,0,PCR and NGS,0,Sanger sequencing,0,Yes,0,Sanger sequencing,0,Sanger sequencing,0
Human Answer,37381002,11,What type of samples were sequenced?,List,Plasma,Plasma from EDTA-anticoagulated blood samples (200 µl plasma used for RNA extraction).,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Blood,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,"NRTIs, NNRTIs, PIs",0,Plasma,1,Plasma,1
Human Answer,37381002,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — sequences were obtained from individuals with ART failure (virological failure; viral load ≥ 1000 copies/ml).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,"AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",0,Yes,1,Yes,1
Human Answer,37381002,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the study was retrospective and observational, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1
Human Answer,37381002,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — all sequenced individuals were people who had received antiretroviral therapy and experienced treatment failure.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,37381002,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Primarily nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs); protease inhibitors (PIs) are also discussed (resistance detected), suggesting exposure or relevance to PIs.",0,"NRTI, NNRTI, PI",0,No,1,"NRTI, NNRTI",0,NRTI,0,NRTIs,0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,NRTIs and NNRTIs,0,Not reported,1,No,1,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",0
Human Answer,37381002,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"The paper does not list individual treatment histories, but states the common first-line regimen (TDF or AZT + 3TC + EFV or NVP) and reports resistance analyses for many drugs (e.g., ABC, AZT, D4T, DDI, FTC, 3TC, TDF, DOR, EFV, NVP, ETR, RPV and several PIs such as ATV, FPV, IDV, LPV, NFV, SQV, TPV).",0,"Abacavir (ABC), Zidovudine (AZT), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TDF)",0,No,1,Not reported,1,Not reported,1,Not reported,1,"ABC, AZT, D4T, DDI, FTC, 3TC, TDF",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), others",0,"ABC, AZT, EFV",0,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,"TDF, AZT, 3TC, EFV, NVP",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,1,"TDF, AZT, 3TC, and EFV/NVP",0,Not reported,1,No,1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Nevirapine (NVP), Zidovudine (AZT)",0,"TDF, AZT, D4T, DDI, FTC, 3TC, NVP",0
Human Answer,37439411,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The study reports HIV-1 RNA protease/reverse transcriptase sequences (genotypes) retrieved from patient samples in the ARCA database; these include 5,982 treatment-naïve individuals and 28,505 genotypes from 9,387 treatment-experienced PLWH.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,37439411,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not report in vitro phenotypic susceptibility assays; it reports genotypic resistance interpreted via the Stanford HIVdb (genotypic susceptibility scoring).,1,Yes,0,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,** No,1,No,1
Human Answer,37439411,3,Were sequences from the paper made publicly available?,Boolean,No,"Partially: sequences were obtained from the public ARCA observational database, but the paper does not report deposition of sequence data to public repositories such as GenBank or provide accession numbers.",1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,** No,1,No,1
Human Answer,37439411,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1
Human Answer,37439411,5,How many individuals had samples obtained for HIV sequencing?,Number,9387,"5,982 treatment-naïve individuals and 9,387 treatment-experienced individuals (total 15,369 individuals); the dataset included 28,505 genotypes from the treatment-experienced group.",1,9387,1,9387,1,9387,1,9387,1,9387,1,9387,1,9387,1,5982 naïve individuals and 9387 treatment-experienced individuals,1,14969,0,15369,0,5982 naïve individuals and 9387 treatment-experienced individuals,1,5982 naïve individuals and 9387 treatment-experienced PLWH,1,5982 naïve individuals and 9387 treatment-experienced individuals,1,5982 naïves and 9387 treatment-experienced PLWH,1,0,0,9387,1,5982 naïves and 9387 treatment-experienced individuals,1,5982 naïves and 9387 treatment-experienced PLWH,1,"9,387",1,** 5982,0,"5982 naïves, 28 505 genotypes from 9387 treatment-experienced PLWH",1
Human Answer,37439411,6,From which countries were the sequenced samples obtained?,List,Italy,"Primarily Italy (data drawn from >100 Italian centres); some patients were born outside Italy (e.g., sub-Saharan Africa) but samples were from Italian centres.",1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Not reported,0,"** Italy, sub-Saharan Africa",1,Not reported,0
Human Answer,37439411,7,From what years were the sequenced samples obtained?,List,2000-2020,From 2000 to 2020.,1,2000-2020,1,2000-2020,1,2000–2020,1,2000–2020,1,2000–2020,1,2000-2020,1,2000–2020,1,2000-2020,1,2000-2020,1,2000-2020,1,2000-2020,1,2000-2020,1,2000-2020,1,2000-2020,1,2000-2020,1,2000-2020,1,2000-2020,1,2000-2020,1,2000-2020,1,** 2000-2020,1,2000-2020,1
Human Answer,37439411,8,Were samples cloned prior to sequencing?,Boolean,No,No indication of cloning; the paper does not report that samples were cloned prior to sequencing.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,** No,1,No,1
Human Answer,37439411,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",Protease and reverse transcriptase (HIV-1 RNA protease/reverse transcriptase sequences).,1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"Protease, Reverse transcriptase",1,"PR, RT",1,"Protease, Reverse Transcriptase",1,Protease and reverse transcriptase,1,Protease and reverse transcriptase,1,"PR, RT",1,"PR, RT",1,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,Protease and reverse transcriptase,1,Pol,0,No,0,"** Protease, Reverse Transcriptase",1,"PR, RT",1
Human Answer,37439411,10,What method was used for sequencing?,List,No,"Not specified. The paper reports retrieval of HIV-1 PR/RT genotypes from the ARCA database (genotypic sequencing on RNA) but does not specify the sequencing platform or laboratory method (e.g., Sanger vs. next-generation sequencing).",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Yes,0,** Not reported,1,Not reported,1
Human Answer,37439411,11,What type of samples were sequenced?,List,Plasma,HIV-1 RNA (plasma viral RNA) genotypes were sequenced (genotyping on RNA in cases of detectable viraemia).,1,No,0,Plasma,1,Plasma,1,Not reported,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,RNA,0,Plasma,1,Plasma,1,RNA,0,Plasma,1,"NRTIs, NNRTIs, PIs, and INSTIs",0,** Plasma,1,Plasma,1
Human Answer,37439411,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Genotyping on RNA was performed in cases of virological failure with detectable viraemia, and the dataset includes many treatment-experienced individuals for whom genotypes were retrieved.",1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,** Yes,1,Yes,1
Human Answer,37439411,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Patients were drawn from a public observational cohort (ARCA); the study is observational and real-life, not a clinical trial.",1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,No,1
Human Answer,37439411,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. The paper includes 28,505 genotypes from 9,387 treatment-experienced PLWH and defines PDR based on genotypes of experienced individuals with previous ARV exposure.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,** Yes,1,Yes,1
Human Answer,37439411,15,Which drug classes were received by individuals in the study before sample sequencing?,List,NNRTI,"The paper specifically reports prior exposure to NNRTIs as a predictor of resistance; it also references other ARV classes introduced over time such as integrase strand transfer inhibitors (INSTIs), but does not provide a comprehensive class-by-class breakdown of prior exposures.",1,NNRTI,1,No,0,NNRTI,1,Not reported,0,NNRTI,1,NNRTI,1,"NRTI, NNRTI",1,NNRTI,1,"NRTI, NNRTI, PI, INSTI",1,NNRTIs,1,"NNRTIs, NRTIs, and PIs",1,"NNRTIs, NRTIs, and PIs",1,NNRTI,1,NNRTI,1,No,0,"NNRTI, INSTI",1,"NRTIs, NNRTIs, and possibly other classes",1,"NRTI, NNRTI",1,No,0,"** NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI, INSTI",1
Human Answer,37439411,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"The paper does not provide individual-level drug histories listing which specific drugs each person received. It discusses NNRTI agents in the context of susceptibility (e.g., rilpivirine [RPV], etravirine [ETR], nevirapine [NVP], efavirenz [EFV], doravirine [DOR]) and notes prior exposure to NNRTIs generally, but does not report per-patient drug lists or counts.",0,"Nevirapine (NVP), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR)",0,No,1,Not reported,1,Not reported,1,Not reported,1,"NVP, EFV, RPV, DOR",0,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC.",0,"Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), and Doravirine (DOR)",0,No,1,"EFV, RPV, ETR, DOR",0,"Efavirenz, nevirapine, and rilpivirine",0,"Efavirenz (EFV), nevirapine (NVP), etravirine (ETR), rilpivirine (RPV), doravirine (DOR), and other ARV drugs",0,Not reported,1,NNRTI,0,No,1,"NVP, EFV, RPV, DOR, RAL, DTG, BIC, CAB, LEN",0,Not reported,1,Not reported,1,No,1,"** NRTI, NNRTI, PI, INSTI",0,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c",0
Human Answer,37495103,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37495103,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37495103,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No accession numbers provided.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not Reported,1,No,1,No,1
Human Answer,37495103,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,No GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1
Human Answer,37495103,5,How many individuals had samples obtained for HIV sequencing?,Number,271,Sequencing was performed on the study cohort of 271 patients (sequencing attempted); 237 patients had sequences reported for variant analysis.,1,271,1,271,1,271,1,271,1,271,1,271,1,271,1,271,1,271,1,271.,1,271,1,271,1,271,1,271,1,271,1,271,1,271,1,271,1,271,1,271,1,271,1
Human Answer,37495103,6,From which countries were the sequenced samples obtained?,List,Russia,Russia (Novosibirsk region).,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia.,1,Russia,1,Russia,1,Russia,1,Russia,1,No,0,Russia,1,Not Reported,0,Russia,1,Not Reported,0,Russia,1,Not reported,0
Human Answer,37495103,7,From what years were the sequenced samples obtained?,List,2018-2022,March 2018 to August 2022.,1,2018-2022,1,2018-2022,1,2018–2022,1,2018–2022,1,2018–2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022.,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1
Human Answer,37495103,8,Were samples cloned prior to sequencing?,Boolean,No,No (no cloning was reported).,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,No,1
Human Answer,37495103,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT","The pol gene, specifically the protease (PR) and reverse transcriptase (RT) regions (PR-RT fragment).",1,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,Pol,0,Pol,0,Pol,0,"PR, RT",1,"PR, RT",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT",1,"PR, RT.",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,Protease and Reverse transcriptase,1,"PR, RT",1,"PR, RT",1,"PR, RT",1,Not Reported,0,"PR, RT",1,"PR, RT",1
Human Answer,37495103,10,What method was used for sequencing?,List,Sanger sequencing,Sanger (capillary) DNA sequencing using an ABI PRISM 3130xl DNA Analyser.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,ABI PRISM 3130xl DNA Analyser,0,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Yes,0,DNA sequencing,0,Sanger sequencing,1
Human Answer,37495103,11,What type of samples were sequenced?,List,Plasma,Plasma samples (HIV-1 RNA isolated from plasma).,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,"NRTIs, NNRTIs",0,Plasma,1,Plasma,1
Human Answer,37495103,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not Reported,0,Yes,1,Yes,1
Human Answer,37495103,13,Were the patients in the study in a clinical trial?,Boolean,No,No (they were clinic patients in a real-world setting).,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not Reported,1,No,1,No,1
Human Answer,37495103,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37495103,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI","NRTIs (nucleoside/nucleotide reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), PIs (protease inhibitors), and INSTIs (integrase strand transfer inhibitors).",1,"NRTI, NNRTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI",0,"NRTI, PI (specifically TDF, 3TC, EFV, DTG, and others)",0,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI",0,"NRTIs, NNRTIs.",0,"NRTIs, NNRTIs, PIs",0,"NRTIs, INSTIs",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, INSTI, PI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,"NRTIs, NNRTIs",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1
Human Answer,37495103,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, FTC, EFV, ABC, 3TC, DTG, LPV, Elsulfavirine, RAL, DRV, AZT","Drugs mentioned as received in regimens include tenofovir (TDF), lamivudine (3TC), efavirenz (EFV), abacavir (ABC), dolutegravir (DTG), ritonavir-boosted lopinavir (LPV/r), elsulfavirine (ESV), raltegravir (RAL), darunavir/ritonavir (DRV/r), and PhAZT (phosphoside) in combination regimens.",0,"Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV), Abacavir (ABC)",0,"Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV), Abacavir (ABC), Dolutegravir (DTG), Lopinavir (LPV), Raltegravir (RAL), Darunavir (DRV), Elsulfavirine (ESV)",0,"TDF, 3TC, ABC, EFV, DTG",0,"TDF, 3TC, EFV, DTG",0,"TDF, 3TC, EFV",0,"Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV)",0,"TDF, 3TC, EFV, ABC, LPV/r",0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TFV), Nevirapine (NVP), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG)",0,"TDF, 3TC, EFV, ABC, DTG, LPV/r, ETR",0,"TDF, 3TC, EFV.",0,"TDF, 3TC, EFV, LPV/r, DTG",0,"TDF, 3TC, DTG",0,"TDF, 3TC, EFV, DTG, LPV/r, ABC",0,"Tenofovir (TDF), Lamivudine (3TC), Abacavir (ABC), Efavirenz (EFV), Dolutegravir (DTG), Lopinavir (LPV)",0,"Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV), Abacavir (ABC), Ritonavir-boosted Lopinavir (LPV/r), Dolutegravir (DTG)",0,"ABC, 3TC, TDF, EFV, LPV/r, DTG, RAL, DOR, ETR, RPV",0,"TDF, 3TC, EFV, ABC, LPV/r",0,"TDF, 3TC, EFV, ABC, LPV/r",0,Not Reported,0,"TDF, 3TC, EFV, ABC, LPV/r, DTG",0,"TDF, 3TC, EFV, ABC, LPV/r, RAL, DRV/r, ESV, DTG",0
Human Answer,37498738,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports near full-length HIV-1 proviral sequences obtained from participant PBMCs using PCR and next-generation sequencing.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37498738,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not report in vitro phenotypic drug susceptibility assays; it reports genotypic/resistance mutation analysis from sequencing only.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37498738,3,Were sequences from the paper made publicly available?,Boolean,No,Not explicitly in the main text. Data availability is referenced but specific public sequence accession details are not provided in the main text and are said to be described in Supplementary Appendix 6.,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,Not reported,1,Yes,0
Human Answer,37498738,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not reported in the main text provided. No GenBank accession numbers are listed; the paper refers to Supplementary Appendix 6 for data availability.,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,MN...,0,Not reported in the provided text,1,Not reported,1,Not reported,1
Human Answer,37498738,5,How many individuals had samples obtained for HIV sequencing?,Number,43 or 101,"Samples were obtained from 101 individuals in the ESS; sequencing produced 297 NGS sequences overall, and detailed longitudinal consensus analyses were performed for 43 individuals with three successful time-point consensus sequences.",1,43,1,43,1,101,1,101,1,43,1,101,1,101,1,43,1,101,1,101,1,101,1,43,1,Not reported,0,Not reported,0,101,1,101,1,101,1,101,1,101,1,101,1,101,1
Human Answer,37498738,6,From which countries were the sequenced samples obtained?,List,Switzerland,Switzerland.,1,No,0,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,No,0,Switzerland,1,Not reported,0,Switzerland,1,Not reported,0,Not reported,0,Not reported,0,No,0,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1
Human Answer,37498738,7,From what years were the sequenced samples obtained?,List,No,"Calendar years are not specified in the provided text; samples are described relative to treatment time points (ART start, 1 year after ART start, ESS week 0, ESS week 48) spanning 48 weeks but no calendar years are given.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,2004-2007,0,Not reported,1,Not reported,1,Not reported,1
Human Answer,37498738,8,Were samples cloned prior to sequencing?,Boolean,No,"No. Samples were not cloned; single-genome dilution and whole-genome amplification were used for single-provirus analysis and PCR amplicons were sequenced, but no cloning into vectors is described.",1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,No,1
Human Answer,37498738,9,Which HIV genes were reported to have been sequenced?,List,NFLG,"Near full-length proviral genomes were sequenced, and analyses specifically report gag, pol (including protease, reverse transcriptase, integrase), and env regions.",0,"Gag, Pol, Env",0,Near full length genome,1,"Gag, Pol, Env",0,"Gag, Pol, Env",0,"Gag, Pol, Env",0,"Gag, Pol, Env",0,"Gag, Pol, Env",0,"Protease, PR; Reverse transcriptase, RT; Integrase, IN; Envelope",0,Near full length genome,1,Full length genome,0,Full length genome,0,Full length genome,0,Near full length genome,1,Near full length genome,1,"gag, pol, and env",0,Near full-length genome,1,Pol,0,"Pol, PR, RT",0,Yes,0,"gag, pol, env",0,"gag, pol, env",0
Human Answer,37498738,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing",Next-generation sequencing (NGS) of near full-length HIV-1 proviral PCR amplicons (bulk NGS) and single-genome amplification followed by sequencing; consensus assembly used SmaltAlign.,0,Illumina sequencing,0,NGS,0,NGS,0,Next-generation sequencing (NGS),0,NGS,0,Near full-length PCR and next-generation sequencing (NGS),0,Next-generation sequencing (NGS),0,Next-generation sequencing (NGS),0,Next-generation sequencing (NGS),0,NGS,0,NGS,0,NGS,0,Next-generation sequencing,0,Next-generation sequencing,0,Illumina sequencing,0,Illumina sequencing,0,NGS,0,NGS,0,Yes,0,Next-generation sequencing,0,Next-generation sequencing,0
Human Answer,37498738,11,What type of samples were sequenced?,List,PBMC,Peripheral blood mononuclear cells (PBMCs) (DNA and RNA) and co-culture virus from PBMCs were used; proviral DNA from PBMCs was the primary material sequenced.,1,PBMC,1,PBMC,1,PBMC,1,PBMC,1,PBMC,1,PBMCs,1,Peripheral blood mononuclear cells (PBMCs),1,PBMC,1,PBMC,1,PBMC,1,PBMC,1,PBMC,1,PBMC,1,PBMC,1,PBMC,1,PBMC,1,PBMC,1,PBMC,1,"NRTIs, NNRTIs, PIs",0,PBMCs,1,PBMCs,1
Human Answer,37498738,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No. Participants showed sustained virological suppression over 48 weeks and the paper reports no viral failure during the study; one individual with a detected mutation did not show viral failure over an additional 3 years.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"Dolutegravir, tenofovir, emtricitabine, lamivudine",1,Yes,0,No,1
Human Answer,37498738,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes. Participants were enrolled in the Early Simplified Study (ESS), a randomized clinical trial (NCT00537966) comparing switch to dolutegravir monotherapy versus continuation of cART.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,37498738,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. The participants were early-treated individuals who had initiated combination ART prior to randomization and some sequences (e.g., transmitted DRMs) were from initial plasma before undergoing cART.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,37498738,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, INSTI","The paper explicitly documents use of an integrase inhibitor (dolutegravir) for the monotherapy group and combination antiretroviral therapy (cART) for others; specific cART components are not enumerated in the main text, but analyses and DRMs concern reverse transcriptase, protease, and integrase regions, implying prior exposure to regimens including nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and/or other classes commonly used in cART.",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI",0,"NRTI, NNRTI, INSTI",1,Not reported,0,"NRTI (Thymidine analogues, Lamivudine, Didanosine)",0,"NRTI, PI",0,"NRTI, NNRTI, PI, INST",0,No,0,Not reported,0,"INSTI, NRTI",1,"INSTI, NRTI",1,Not reported,0,Not reported,0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI",0,No,0,"NRTI, PI",0,"NRTI, NNRTI, INSTI",1
Human Answer,37498738,16,Which drugs were received by individuals in the study before sample sequencing?,List,DTG,Dolutegravir is explicitly reported (participants were switched to dolutegravir monotherapy); specific other individual drugs in the prior cART regimens are not listed in the provided main text and are not specified here.,1,No,0,DTG,1,Not reported,0,Not Reported,0,Not reported,0,"Zidovudine, Lamivudine, Didanosine",0,"Zidovudine (AZT), Abacavir (ABC), Lamivudine (3TC), Ritonavir-boosted Lopinavir (LPVr)",0,Dolutegravir (DTG),1,No,0,Not reported,0,"Dolutegravir, other ARV drugs",1,"DTG, NRTIs",1,Not reported,0,Not reported,0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",1,No,0,"Dolutegravir, Tenofovir, Lamivudine, Efavirenz, Ritonavir, Lopinavir, Atazanavir, Darunavir, Raltegravir, Elvitegravir, Bictegravir, Cabotegravir",1,"TDF, FTC",0,No,0,"Didanosine, Lamivudine, PI",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0
Human Answer,37515095,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV sequences obtained from patient samples (968 partial HIV-1 pol sequences from people living with HIV in Kazakhstan).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37515095,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance profiling using sequence-based analysis and Stanford HIVdb scoring, but does not report in vitro (phenotypic) drug susceptibility assays.",1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37515095,3,Were sequences from the paper made publicly available?,Boolean,No,No. The study states that study data are unavailable to protect patient confidentiality.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37515095,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. The paper does not provide GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported (the paper does not provide specific accession numbers),1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1
Human Answer,37515095,5,How many individuals had samples obtained for HIV sequencing?,Number,968 or 1004,"968 individuals (i.e., 968 sequences in the final dataset).",1,1004,1,968,1,968,1,1004,1,968,1,968,1,968,1,0,0,968,1,1004,1,968,1,968,1,968,1,968,1,1004,1,1004,1,Not reported,0,968,1,968,1,1004,1,968,1
Human Answer,37515095,6,From which countries were the sequenced samples obtained?,List,Kazakhstan,Kazakhstan.,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,No,0,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1
Human Answer,37515095,7,From what years were the sequenced samples obtained?,List,2017-2020,Samples were obtained between 2017 and 2020.,1,2017-2020,1,2017-2020,1,2017–2020,1,2017–2020,1,2017–2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1
Human Answer,37515095,8,Were samples cloned prior to sequencing?,Boolean,No,"No. The methods describe RT-PCR and direct sequencing using AmpliSens HIV-Resist-Seq and an Applied Biosystems Genetic Analyzer, with no cloning step reported.",1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37515095,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol",Partial pol gene: protease and the 5′-end of reverse transcriptase (positions 2253 to 3337 on HXB2).,0,"Protease, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"Pol (Protease, RT)",0,"Protease, Reverse Transcriptase",0,"Reverse transcriptase, RT",0,"PR, RT",0,Pol,0,"Pol (PR, RT)",0,Pol,0,Pol,0,Pol,0,Protease and Reverse transcriptase,0,No,0,Pol,0,Pol,0,Protease and Reverse Transcriptase,0,"PR, RT",0,"Protease, Reverse Transcriptase",0
Human Answer,37515095,10,What method was used for sequencing?,List,Sanger sequencing,RT-PCR followed by Sanger sequencing using AmpliSens HIV-Resist-Seq and an Applied Biosystems Genetic Analyzer 3130.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,RT-PCR and Sanger sequencing,1,AmpliSens® HIV-Resist-Seq and Applied Biosystems® Genetic Analyzer 3130,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Not reported,0,Illumina sequencing,0,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37515095,11,What type of samples were sequenced?,List,Whole Blood,mRNA purified from blood samples (patient blood-derived RNA).,0,Whole Blood,1,Plasma,0,Blood samples,0,Plasma,0,Blood,0,Blood samples,0,Blood samples,0,Plasma,0,Whole Blood,1,Blood,0,Plasma,0,Plasma,0,Not reported,0,Blood,0,Whole Blood,1,Plasma,0,Blood,0,Plasma,0,"Plasma, Serum, PBMC, Proviral DNA, Dried Blood Spots",0,Blood,0,Blood,0
Human Answer,37515095,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not explicitly labeled as 'virological failure' in the paper; however, most sequences were from ART-experienced individuals and many sequences showed resistance to drugs on patients' regimens (consistent with treatment failure).",1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Yes,0,Not reported,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Yes,0
Human Answer,37515095,13,Were the patients in the study in a clinical trial?,Boolean,No,No. Participants were registered at a national clinical center and provided informed consent for blood sampling; there is no indication they were enrolled in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,968,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37515095,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. The majority of sequenced participants were ART-experienced and had received antiretroviral drugs prior to sequencing.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37515095,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI","Nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs) were received by individuals in the study.",1,"NRTI, NNRTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI",1,"NRTIs, NNRTIs",1,Not reported,0,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTIs, NNRTIs",1,"NRTI, NNRTI",1,"NRTIs, NNRTIs, PIs",1,"NRTI, NNRTI, PI",1,Not reported,0,"NRTI, NNRTI, PI",1,No,0,"NRTI, NNRTI, PI",1,NRTIs,0,"NRTIs, NNRTIs, PIs, INSTIs",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1
Human Answer,37515095,16,Which drugs were received by individuals in the study before sample sequencing?,List,"3TC, ABC, AZT, D4T, DDI, FTC, TDF, ETR, EFV, NVP, RPV","Drugs received included NRTIs: zidovudine (AZT), didanosine (DDI), stavudine (D4T), lamivudine (3TC), abacavir (ABC), tenofovir (TDF), emtricitabine (FTC); NNRTIs: nevirapine (NVP), efavirenz (EFV), etravirine (ETR), rilpivirine (RPV); PIs: darunavir/ritonavir (DRV/r), darunavir/cobicistat (DRV/c), lopinavir/ritonavir (LPV/r); and INSTI: dolutegravir (DTG). The most common regimen reported was FTC + TDF + EFV.",1,"FTC, TDF, EFV",0,"Zidovudine (AZT), Didanosine (DDI), Stavudine (D4T), Lamivudine (3TC), Abacavir (ABC), Tenofovir (TDF), Emtricitabine (FTC), Nevirapine (NVP), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Darunavir (DRV), Lopinavir (LPV)",1,"FTC, TDF, EFV",0,"FTC, TDF, EFV",0,Not reported,0,"FTC, TDF, EFV",0,"Zidovudine (AZT), Nevirapine (NVP), Combination ART with NNRTIs and PIs",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR)",1,"Emtricitabine (FTC), Tenofovir (TDF), Efavirenz (EFV)",0,"FTC, TDF, EFV",0,"FTC, TDF, EFV",0,"AZT, 3TC, FTC, ABC, D4T, ddI, TDF, EFV, NVP, ETR, RPV, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC, IBA",1,"FTC, TDF, EFV",0,Not reported,0,"NRTI (Nucleoside Reverse Transcriptase Inhibitor), including Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV); NNRTI (Non-Nucleosid Reverse Transcriptase Inhibitor), including Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR); PI (Protease Inhibitor), including Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV)",1,No,0,"FTC, TDF, EFV",0,"AZT, 3TC, FTC, TDF, ABC, D4T, ddI",0,"AZT, 3TC, FTC, TDF, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",0,"Zidovudine (AZT), Nevirapine (NVP)",0,"FTC, TDF, EFV",0
Human Answer,37515146,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV-1 sequences obtained from patient samples (379 sequences).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37515146,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance interpretation and predictive efficacy from HIVdb, not in vitro (phenotypic) susceptibility assays.",1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37515146,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. Sequence data were deposited in GenBank and made publicly available.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37515146,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457","GenBank MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457.",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457.",1,"MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457",1,"GenBank MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457",1
Human Answer,37515146,5,How many individuals had samples obtained for HIV sequencing?,Number,379,379 individuals had successful sequencing (379 sequences obtained).,1,379,1,379,1,379,1,379,1,379,1,379,1,379,1,379,1,379,1,379.,1,379,1,379,1,379,1,379,1,379,1,379,1,379,1,379,1,379,1,379,1,379,1
Human Answer,37515146,6,From which countries were the sequenced samples obtained?,List,Cameroon,All sequenced samples were obtained in Cameroon (from eight regions of Cameroon).,1,No,0,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon.,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Not Reported,0,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1
Human Answer,37515146,7,From what years were the sequenced samples obtained?,List,2014-2019,Samples were obtained between December 2014 and June 2019 (2014–2019).,1,2014-2019,1,2014-2019,1,2014–2019,1,2014–2019,1,2014–2019,1,2014-2019,1,2014-2019,1,2014-2019,1,2014-2019,1,2014-2019.,1,2014-2019,1,2014-2019,1,2014-2019,1,2014-2019,1,2014-2019,1,2014-2019,1,2014-2019,1,2014-2019,1,2014-2019,1,2014-2019,1,2014-2019,1
Human Answer,37515146,8,Were samples cloned prior to sequencing?,Boolean,No,No. Samples were amplified by RT-PCR and semi-nested PCR and directly sequenced; no cloning step is reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported.,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,No,1
Human Answer,37515146,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol",The pol gene regions: protease and reverse transcriptase were sequenced.,0,"Protease, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"RT, PR",0,"RT, PR",0,"Protease, Reverse transcriptase",0,"PR, RT",0,Protease and reverse transcriptase.,0,Pol (reverse transcriptase and protease regions),0,Pol,0,"PR, RT",0,"PR, RT",0,"Protease, Reverse transcriptase, and Integrase",0,"PR, RT",0,"PR, RT",0,Pol,0,No,0,Reverse transcriptase and protease,0,"PR, RT",0
Human Answer,37515146,10,What method was used for sequencing?,List,Sanger sequencing,RT-PCR followed by semi-nested PCR and Sanger sequencing on an ABI 3500 genetic analyzer (direct sequencing of PCR products).,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Yes,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37515146,11,What type of samples were sequenced?,List,Plasma,Plasma samples (derived from venous blood collected in EDTA tubes) were sequenced.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,"NRTI, NNRTI, PI",0,Plasma,1,Plasma,1
Human Answer,37515146,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. All sequenced individuals were ART-naïve (initiating ART) and had no prior history of ART, so sequences are not from people with virological failure on treatment.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,"AZT, 3TC, EFV, NVP, TDF, FTC, ATV, RTV, RAL, DTG, BIC, CAB, MVC, LEN",1,No,1,No,1
Human Answer,37515146,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. The study was a cross-sectional sentinel surveillance/analytical study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1
Human Answer,37515146,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No. The study excluded individuals with prior ART exposure, so reported sequences are from individuals without previous ARV treatment.",1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37515146,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None—participants were ART-naïve and had no prior antiretroviral drug exposure per inclusion criteria.,1,No,1,No,1,,1,,1,,1,"NNRTI, NRTI",0,"NRTI, NNRTI",0,No,1,No,1,Not Reported.,1,Not Reported,1,"NNRTIs, NRTIs, PIs",0,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,NRTI,0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, INSTI",0
Human Answer,37515146,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None—no specific antiretroviral drugs were received prior to sequencing (participants were ART-naïve).,1,"Individuals in the study did not receive any antiretroviral drugs before sample sequencing, as they were ART-naive participants.",0,No,1,,1,,1,,1,"Efavirenz, Nevirapine",0,"AZT, 3TC, NVP, EFV",0,No,1,No,1,Not Reported.,1,Not Reported,1,"EFV, NVP, 3TC, TDF, ATV",0,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"AZT, 3TC, FTC, TDF, and EFV",0,"AZT, 3TC, EFV, NVP, TDF, FTC, ATV, RTV, RAL, DTG, BIC, CAB, MVC, LEN",0,"AZT, 3TC, NVP, EFV, DTG",0,"AZT, 3TC, NVP, EFV, DTG",0
Human Answer,37520425,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37520425,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37520425,3,Were sequences from the paper made publicly available?,Boolean,Yes,"Yes, some sequences were deposited in GenBank.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37520425,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,OQ627458-OQ627474,OQ627458–OQ627474.,1,OQ627458-OQ627474,1,OQ627458-OQ627474,1,OQ627458-OQ627474,1,OQ627458-OQ627474,1,OQ627458-OQ627474,1,OQ627458-OQ627474,1,OQ627458-OQ627474,1,OQ627458-OQ627474,1,OQ627458-OQ627474,1,OQ627458-OQ627474.,1,OQ627458-OQ627474,1,Not reported,0,OQ627458-OQ627474,1,Not reported,0,OQ627458-OQ627474,1,OQ627458-OQ627474,1,OQ627458-OQ627474,1,OQ627458-OQ627474,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,OQ627458-OQ627474,1,OQ627458-OQ627474,1
Human Answer,37520425,5,How many individuals had samples obtained for HIV sequencing?,Number,25 or 30,Pre-treatment samples were available for 25 of 30 viremic DTG patients (14 of those were successfully sequenced); plasma samples at viremia were available for 13 of 30 patients (2 of those were successfully sequenced); in total sequencing was successful for 14 + 2 = 16 individuals.,1,25,1,30,1,25,1,14,0,30,1,30,1,25,1,30,1,16,0,At least 25 individuals had samples obtained for HIV sequencing.,1,902,0,902,0,25,1,6,0,25,1,0,0,195 (DTG cohort) and 211 (NNRTI cohort),0,436 and 466,0,436 and 466,0,195 (DTG cohort) and 211 (NNRTI cohort),0,195 (DTG cohort) and 211 (NNRTI cohort),0
Human Answer,37520425,6,From which countries were the sequenced samples obtained?,List,Tanzania,Tanzania.,1,No,0,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania.,1,Tanzania,1,Tanzania,1,Tanzania,1,"United States, Australia",0,No,0,No,0,Not reported,0,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania,1
Human Answer,37520425,7,From what years were the sequenced samples obtained?,List,"2016-2017, 2019-2020","Samples were obtained from participants initiating NNRTI-based ART between 16 December 2016 and 15 December 2017, and DTG-based ART between 16 March 2019 and 15 September 2020; sequencing was performed on biobanked samples from those cohorts.",1,No,0,"2016-2017, 2019-2020",1,2016-2020,0,2016–2020,0,2016–2020,0,2016 to 2020,0,2016-2020,0,No,0,2016-2020,0,2016-2020.,0,2016-2020,0,2016-2020,0,2016-2020,0,Not reported,0,2005-2020,0,No,0,2016-2020,0,2016-2020,0,2016-2020,0,2016-2020,0,2016-2017 and 2019-2020,1
Human Answer,37520425,8,Were samples cloned prior to sequencing?,Boolean,No,No — direct (population) sequencing was used rather than cloning.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1
Human Answer,37520425,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Protease and reverse transcriptase sequences were reported (the protocol targeted protease, reverse transcriptase, and integrase/INSTI regions).",1,"Protease, RT",0,"PR, RT, IN",1,"PR, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT, IN",1,"PR, RT, IN",1,"Reverse transcriptase, Protease, INSTI",1,"PR, RT",0,Reverse transcriptase and protease.,0,Pol (including protease and reverse transcriptase),1,Pol,0,"RT, PR, IN",1,"Gag, PR, RT",0,"Protease, RT",0,"PR, RT, IN",1,"Reverse transcriptase, protease, and INSTI",1,"Pol, PR, RT",0,Pol,0,"Reverse transcriptase, protease, and integrase",1,"Reverse transcriptase, protease, and integrase",1
Human Answer,37520425,10,What method was used for sequencing?,List,Sanger sequencing,RT-PCR amplification followed by direct Sanger sequencing (population sequencing using 6 overlapping primers) and assembly with BioEdit.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,PCR-based sequencing,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Not reported,0,Sanger sequencing,1,Not reported,0,Sanger sequencing,1,Sanger sequencing,1,PCR,0,Sanger sequencing and Illumina sequencing,1,Sanger sequencing,1,PCR sequencing,0,PCR and Sanger sequencing,1
Human Answer,37520425,11,What type of samples were sequenced?,List,Plasma,Cryopreserved blood plasma samples (150 µL plasma) from a biobank.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Blood plasma,1,Plasma,1,Plasma,1,Blood plasma.,1,Plasma,1,Plasma,1,Plasma,1,PBMC,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma samples,1,Biobanked plasma samples,1
Human Answer,37520425,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Sequencing was performed on samples from viremic individuals (VL ≥50 copies/mL), and some of those individuals had VL ≥1000 copies/mL, but it is not explicitly stated whether the successfully sequenced samples came from individuals meeting the virological failure definition (≥1000 copies/mL on two measurements).",1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37520425,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was an observational cohort study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37520425,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"No — treatment-experienced individuals were excluded; the report focuses on treatment-naive participants, so sequences were from those who had not previously received ART.",0,No,0,Yes,1,No,0,No,0,No,0,No,0,Yes,1,Yes,1,No,0,No.,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37520425,15,Which drug classes were received by individuals in the study before sample sequencing?,List,INSTI,None — participants included for sequencing were treatment-naive and had not previously received ARV drugs.,0,NNRTI,0,"NRTI, NNRTI, INSTI",1,,0,,0,,0,"NRTI, NNRTI",0,"NRTI, NNRTI, PI, INSTI",1,INSTI,1,No,0,None.,0,"NRTIs, NNRTIs, PIs",0,"NRTIs, NNRTIs, INSTIs",1,,0,Not reported,0,INSTI,1,No,0,,0,"NRTI, NNRTI, PI",0,"NRTIs, NNRTIs, and PIs",0,NNRTI-based ART,0,NNRTI,0
Human Answer,37520425,16,Which drugs were received by individuals in the study before sample sequencing?,List,DTG,None — the individuals were treatment-naive and had not received antiretroviral drugs prior to sequencing.,0,No,0,"DTG, NRTI, NNRTI",1,,0,,0,,0,Not reported,0,"Stavudine, Lamivudine, Nevirapine, Abacavir, Lopinavir, Ritonavir, Tenofovir, Emtricitabine, Dolutegravir",1,Dolutegravir (DTG),1,No,0,None.,0,"Dolutegravir, efavirenz, tenofovir",1,"DTG, EFV, TDF",1,,0,Not reported,0,Dolutegravir (DTG),1,No,0,Not reported,0,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, DRV",0,"AZT, 3TC, EFV, NVP, LPV/r, ATV/r, and DTG",1,DTG and NNRTI-based ART,1,"Lamivudine (3TC), Nevirapine (NVP), Efavirenz (EFV)",0
Human Answer,37537871,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV sequences derived from patient plasma samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37537871,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report phenotypic (in vitro) drug susceptibility assays; it reports genotypic resistance profiling inferred from sequence data.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37537871,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report deposition of patient-derived HIV sequences in public sequence repositories.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No.,1,No,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1
Human Answer,37537871,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported — no GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,No,1,Not reported,1,KR860607 to KR861345,0,No,1,No,1,Not reported,1,KP170487,0,Not reported in the provided text,1,Not reported,1,Not reported,1
Human Answer,37537871,5,How many individuals had samples obtained for HIV sequencing?,Number,77,77 individuals (77 plasma samples) had samples obtained for sequencing.,1,77,1,77,1,77,1,77,1,77,1,77,1,77,1,77,1,77,1,77.,1,77,1,77,1,27,0,649,0,77,1,77,1,77,1,77,1,77,1,77,1,77,1
Human Answer,37537871,6,From which countries were the sequenced samples obtained?,List,Hong Kong,"Hong Kong (samples were collected at Queen Mary Hospital, Hong Kong).",1,Hong Kong,1,Hong Kong,1,Hong Kong,1,Hong Kong,1,Hong Kong,1,Hong Kong,1,Hong Kong,1,Hong Kong,1,Hong Kong,1,Hong Kong.,1,Hong Kong,1,Not reported,0,"Spain, Switzerland, USA",0,Botswana,0,Hong Kong,1,Hong Kong,1,Hong Kong,1,Hong Kong,1,Hong Kong,1,Hong Kong,1,Hong Kong,1
Human Answer,37537871,7,From what years were the sequenced samples obtained?,List,2002-2014,Samples were obtained between 2002 and 2014.,1,2002-2014,1,2002-2014,1,2002–2014,1,2002–2014,1,2002–2014,1,2002-2014,1,2002-2014,1,2002-2014,1,2002-2014,1,2002-2014.,1,2002-2014,1,2002-2014,1,Not reported,0,2013-2014,0,2002-2014,1,2002-2014,1,2002-2014,1,2002-2014,1,2002-2014,1,2002-2014,1,2002-2014,1
Human Answer,37537871,8,Were samples cloned prior to sequencing?,Boolean,No,No — samples were not cloned; viral RNA was reverse-transcribed and long-region PCR amplicons were directly sequenced.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37537871,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Protease, reverse transcriptase (RT), and integrase regions were sequenced (long amplicon covering regions associated with these ARV-targeted genes).",1,"Protease, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT",0,"PR, RT",0,Integrase,0,"Protease, Reverse Transcriptase, Integrase",1,"Protease, Reverse transcriptase, Integrase",1,"PR, RT, IN",1,"Multiple HIV genes, including protease, reverse transcriptase, and integrase.",1,Protease and reverse transcriptase,0,Protease and reverse transcriptase,0,Full length genome,0,Full length genome,0,No,0,Full genome,0,"Pol, RT, and IN",0,"Pol, PR, RT",0,Pol,0,"Protease, Reverse Transcriptase",0,"Protease, Reverse Transcriptase",0
Human Answer,37537871,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing, Oxford nanopore",Long-read Oxford Nanopore Technologies (ONT) sequencing (GridION) was the primary method; Sanger sequencing and Illumina MiSeq short-read sequencing were also used for comparison/validation.,1,Oxford Nanopore sequencing,0,Oxford Nanopore sequencing,0,ONT and Sanger sequencing,0,"ONT sequencing, Sanger sequencing, Illumina sequencing",0,Oxford Nanopore Technologies (ONT) sequencing and Sanger sequencing,0,Oxford Nanopore Technologies (ONT) and Sanger sequencing,0,"ONT sequencing, Sanger sequencing, Illumina sequencing",0,Oxford Nanopore sequencing,0,Oxford Nanopore sequencing,0,Long-read sequencing using Oxford Nanopore Technologies (ONT).,0,ONT sequencing,0,ONT sequencing,0,Illumina sequencing,0,Illumina sequencing,0,Oxford Nanopore sequencing,0,Oxford Nanopore sequencing,0,NGS,0,NGS,0,ONT and Illumina sequencing,0,Nanopore sequencing,0,ONT sequencing,0
Human Answer,37537871,11,What type of samples were sequenced?,List,Plasma,Plasma samples — viral RNA (vRNA) extracted from patient plasma was sequenced.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,PBMC,0,PBMC,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37537871,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Not reported / unclear — the paper does not explicitly state whether sampled individuals were experiencing virological failure while on treatment.,1,Yes,1,No,0,Not reported,0,No,0,No,0,Yes,1,Yes,1,No,0,No,0,No.,0,Yes,1,Yes,1,No,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37537871,13,Were the patients in the study in a clinical trial?,Boolean,No,No — the patients were clinical samples obtained from a hospital; there is no indication they were enrolled in a clinical trial.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37537871,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Not reported / unclear — the paper does not provide explicit antiretroviral treatment histories for the sampled individuals.,0,No,0,No,0,Not reported,0,No,0,Not reported,0,Yes,1,Yes,1,No,0,No,0,No.,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37537871,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not reported — the paper does not provide patients' ARV treatment histories or list which drug classes individuals had received prior to sequencing.,1,No,1,No,1,,1,,1,Not reported,1,"NRTI, NNRTI, CCR5 antagonist, INSTI",0,"NRTI, NNRTI, INSTI, CCR5 antagonist",0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,"NRTI, NNRTI, INSTI, CCR5 antagonist",0,"NRTI, NNRTI, PI, INSTI",0,No,1,"NRTI, NNRTI, and PI",0,"NRTI, NNRTI",0,"NRTIs, NNRTIs, and/or PIs",0,Antiretroviral therapy (ART),0,"NRTI, NNRTI, PI, INSTI",0
Human Answer,37537871,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not reported — the paper does not list specific antiretroviral drugs received by study participants prior to sequencing.,1,No,1,No,1,Not reported,1,,1,Not reported,1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,1,Not reported,1,"AZT, 3TC, FTC, TDF, EFV",0,Not reported in the provided text,1,Not reported,1,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.",0
Human Answer,37540331,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** No,1,Yes,0
Human Answer,37540331,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer,37540331,3,Were sequences from the paper made publicly available?,Boolean,No,No (no sequences reported and no public sequence deposition referenced).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,37540331,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,KP170487,0,Not reported,1,** Not reported,1,Not reported,1
Human Answer,37540331,5,How many individuals had samples obtained for HIV sequencing?,Number,0,None — the paper does not report any HIV sequencing of samples.,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,85,0,Not reported,1,0,1,0,1,Not reported,1,85,0,85,0,85,0,Not reported,1,0,1,0,1,85,0,85,0,85,0,** 85,0,85,0
Human Answer,37540331,6,From which countries were the sequenced samples obtained?,List,No,Not applicable (no sequences). Participants were recruited in Iran.,1,No,1,No,1,Not reported,1,Not reported,1,Iran,0,Iran,0,Iran,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Iran,0,** Not reported,1,Not reported,1
Human Answer,37540331,7,From what years were the sequenced samples obtained?,List,No,Not applicable (no sequences reported).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,2019,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,2019,0,** 2019-2020,0,Not reported,1
Human Answer,37540331,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — no sequencing or cloning reported.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,** No,1,No,1
Human Answer,37540331,9,Which HIV genes were reported to have been sequenced?,List,No,Not applicable — no HIV genes were sequenced in this study.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"Pol, IN",0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Pol,0,Pol,0,** Not reported,1,Not reported,1
Human Answer,37540331,10,What method was used for sequencing?,List,No,Not applicable — no sequencing was performed; viral load was measured by PCR.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,PCR,0,Sanger sequencing and Illumina sequencing,0,NGS,0,** Not reported,1,Not reported,1
Human Answer,37540331,11,What type of samples were sequenced?,List,No,Not applicable — no sequencing; the study performed viral load testing (presumably plasma) but the paper does not specify sample type for sequencing.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Plasma,0,"Plasma, PBMC",0,Not reported,1,Not reported,1,No,1,No,1,Plasma,0,Plasma,0,Plasma,0,** Not reported,1,Plasma,0
Human Answer,37540331,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — there were no sequences reported, and no virological failures occurred during the study.",1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not reported,1,Yes,0,No,1,No,1,Yes,0,Yes,0,** No,1,Yes,0
Human Answer,37540331,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes — participants were enrolled in a registered randomized open-label non-inferiority clinical trial.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,37540331,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report any HIV sequences; participants were treatment-experienced and on ART prior to enrollment.,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,37540331,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not applicable for sequencing (no sequencing), but participants' baseline regimens mainly included two NRTIs plus one NNRTI; the study also involved NRTI (TAF) and INSTI (dolutegravir) during the trial.",1,"NRTI, NNRTI",0,No,1,"NRTI, NNRTI",0,"NRTI, NNRTI",0,Not reported,1,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NRTI, NNRTI",0,No,1,Not reported,1,"NRTI, INSTI",0,"NRTI, NNRTI, INSTI, PI",0,"NRTI, NNRTI, PI, INSTI",0,Not reported,1,No,1,No,1,"NRTI, NNRTI",0,"NRTI, NNRTI, and INSTI",0,"NRTIs, NNRTIs, PIs, and INSTIs",0,"** NRTI, NNRTI",0,"NRTI, NNRTI",0
Human Answer,37540331,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not applicable for sequencing (no sequences). The paper reports classes (two NRTIs plus one NNRTI) but does not provide a comprehensive list of specific prior drugs for the cohort; the intervention drugs included TAF and dolutegravir.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,"Tenofovir alafenamide (TAF), Dolutegravir (DTG)",0,Not reported,1,"NRTI, NNRTI",0,No,1,Not reported,1,"TAF, DTG",0,"TAF, DTG, EFV, LPV/r, ATV/r",0,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.",0,Not reported,1,No,1,No,1,"Tenofovir, Lamivudine, Efavirenz",0,"TAF, DTG, and FTC",0,"AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, and LEN",0,"** Tenofovir, Lamivudine, Efavirenz",0,"NRTIs (Tenofovir, Lamivudine, Abacavir), NNRTIs (Efavirenz, Nevirapine)",0
Human Answer,37541705,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,No — the paper does not report patient-derived HIV sequences.,0,No,0,No,0,No.,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,Yes,1,Yes,1,No,0,No,0,No,0,No,0,,0,Yes,1,Yes,1,** No,0,No,0
Human Answer,37541705,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report any in vitro drug susceptibility data.,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,,1,No,1,Yes,0,** No,1,No,1
Human Answer,37541705,3,Were sequences from the paper made publicly available?,Boolean,No,No — sequence or participant-level data were not made publicly available.,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,,1,No,1,Yes,0,** No,1,No,1
Human Answer,37541705,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,None.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,,1,Not reported,1,Not reported in the provided text,1,** Not reported,1,Not reported,1
Human Answer,37541705,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Not reported (no count of sequenced samples provided).,1,0,1,0,1,Not reported.,1,Not reported,1,Not reported,1,57,0,Not reported,1,0,1,0,1,Not reported,1,57,0,57,0,Not reported,1,57,0,0,1,0,1,,1,57,0,57,0,** 57,0,57,0
Human Answer,37541705,6,From which countries were the sequenced samples obtained?,List,"Botswana, South Africa, Thailand, and the U.S.","Samples were obtained from participants recruited in Botswana, South Africa, Thailand, and the United States.",0,No,0,No,0,"Botswana, South Africa, Thailand, USA.",0,"Botswana, South Africa, Thailand, USA",0,"Botswana, South Africa, Thailand, USA",0,"Botswana, South Africa, Thailand, USA",0,"Botswana, South Africa, Thailand, USA",0,No,0,No,0,Not reported,0,"Botswana, South Africa, Thailand, U.S.",0,"Botswana, South Africa, Thailand, U.S.",0,Not reported,0,Not reported,0,"Botswana, South Africa, Thailand, and the U.S.",1,No,0,,0,"Botswana, South Africa, Thailand, and the U.S.",1,"Botswana, South Africa, Thailand, and the U.S.",1,"** Botswana, South Africa, Thailand, USA",0,"Botswana, South Africa, Thailand, U.S.",0
Human Answer,37541705,7,From what years were the sequenced samples obtained?,List,2020-2021,"Samples were collected during study enrollment and follow-up from September 9, 2020 through at least December 14, 2021 (last Week 24 visit).",1,No,0,No,0,Not reported.,0,Not reported,0,Not reported,0,2020-2021,1,2020-2021,1,No,0,No,0,Not reported,0,2020-2021,1,2020-2021,1,Not reported,0,2020-2021,1,2020-2021,1,No,0,,0,2020-2021,1,2020-2021,1,** 2020-2021,1,2020-2021,1
Human Answer,37541705,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No information provided.,1,No,1,No,1,Not reported.,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,,1,No,1,No,1,** Not reported,1,No,1
Human Answer,37541705,9,Which HIV genes were reported to have been sequenced?,List,RT,Not reported (no genes explicitly stated).,1,No,0,No,0,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,0,No,0,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,0,No,0,,0,"Pol, PR, RT",1,Yes,0,** Not reported,1,Not reported,1
Human Answer,37541705,10,What method was used for sequencing?,List,No,Not reported.,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,,1,Sanger sequencing,0,Yes,0,** Not reported,1,Not reported,1
Human Answer,37541705,11,What type of samples were sequenced?,List,No,"Not reported; clinical virologic monitoring used plasma HIV-1 RNA, so any genotypic testing would likely have used plasma, but the paper does not explicitly state the sample type for sequencing.",1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Plasma,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,,1,Plasma,0,NRTIs,0,** Pharmacokinetic samples,0,Pharmacokinetic samples,0
Human Answer,37541705,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not reported. The paper notes one ART-naïve participant met the protocol definition of virologic failure, but it does not report sequences obtained from that or other failing participants.",1,No,1,No,1,No.,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,,1,Yes,0,Not reported in the provided text,1,** No,1,Yes,0
Human Answer,37541705,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes — participants were enrolled in an international phase I/II clinical trial (IMPAACT 2019, NCT03760458).",1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,,0,Yes,1,No,0,** Yes,1,Yes,1
Human Answer,37541705,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"No — the paper does not report sequences, but most participants were treatment-experienced (previously received ARV drugs).",0,No,0,Yes,1,No.,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Not reported,0,Yes,1,Yes,1,Not reported,0,Not reported,0,Yes,1,No,0,,0,Yes,1,No,0,** Yes,1,Yes,1
Human Answer,37541705,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"PI, INSTI","Participants had prior exposure to protease inhibitors (e.g., lopinavir/ritonavir) and integrase strand transfer inhibitors (e.g., dolutegravir, raltegravir); NRTI backbones would also have been present but are not enumerated in detail.",0,"PI, INSTI",1,"PI, INSTI",1,Not reported.,0,"NRTI, PI",0,Not reported,0,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,No,0,Not reported,0,"NRTI, INSTI",0,Not reported,0,Not reported,0,Not reported,0,NNRTI,0,No,0,,0,"NRTI, PI, INSTI",1,No,0,"** NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI, INSTI",1
Human Answer,37541705,16,Which drugs were received by individuals in the study before sample sequencing?,List,"LPV, DTG, RAL, ABC, 3TC","Reported prior anchor drugs included lopinavir/ritonavir, dolutegravir, and raltegravir; additionally, some participants had known M184V mutations (implying prior lamivudine/emtricitabine exposure).",0,"Lopinavir/ritonavir, Dolutegravir, Raltegravir",0,"Lopinavir (LPV), Dolutegravir (DTG), Raltegravir (RAL)",0,Not reported.,0,Lopinavir/ritonavir,0,Not reported,0,"Dolutegravir, Lopinavir/Ritonavir, Raltegravir",0,"Efavirenz, Tenofovir, Emtricitabine, Lamivudine, Nevirapine",0,"Dolutegravir, Abacavir, Lamivudine",0,No,0,Not reported,0,"Abacavir, dolutegravir, lamivudine",0,Not reported,0,Not reported,0,Not reported,0,"NRTI (Abacavir, Lamivudine), NNRTI (Nevirapine, Efavirenz), PI (Lopinavir), INSTI (Raltegravir)",0,No,0,,0,"AZT, 3TC, FTC, TDF, ABC, ATV/r, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, LEN",0,No,0,"** Lopinavir/ritonavir, Dolutegravir, Raltegravir",0,"Lopinavir, Ritonavir, Dolutegravir, Raltegravir",0
Human Answer,37546367,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. Partial HIV-1 pol sequences were obtained from patient plasma samples (2074 sequences from 3274 collected samples).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37546367,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The study reports genotypic resistance inferred from sequence data using the Stanford HIVdb, not direct in vitro phenotypic susceptibility assays.",1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37546367,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. The partial pol nucleotide sequences were submitted to GenBank.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37546367,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,OQ886077 - OQ888150,OQ886077 - OQ888150.,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1
Human Answer,37546367,5,How many individuals had samples obtained for HIV sequencing?,Number,2074,"3274 plasma samples were collected from patients, and partial pol sequences were successfully obtained from 2074 individuals (i.e., 2074 sequences).",1,2074,1,2074,1,2074,1,2074,1,2074,1,2074,1,2074,1,2074,1,3274,0,2074,1,2074,1,3274,0,2074,1,2074,1,2074,1,2074,1,2074,1,2074,1,2074,1,2074,1,1071,0
Human Answer,37546367,6,From which countries were the sequenced samples obtained?,List,China,"China (patients living in Guangdong Province, China).",1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,Not reported,0,"Armenia, Azerbaijan, Belarus, Russia, Tajikistan, Uzbekistan",0
Human Answer,37546367,7,From what years were the sequenced samples obtained?,List,2011-2022,"Between 2011 and 2022 (specifically Nov 1, 2011 to Dec 31, 2022).",1,2011-2022,1,2011-2022,1,2011–2022,1,2011–2022,1,2011–2022,1,2011-2022,1,2011-2022,1,2011-2022,1,2011-2022,1,2011-2022,1,2011-2022,1,2011-2022,1,2011-2022,1,2011-2022,1,2011-2022,1,2011-2022,1,2011-2022,1,2011-2022,1,2011-2022,1,2011-2022,1,2017-2019,0
Human Answer,37546367,8,Were samples cloned prior to sequencing?,Boolean,No,No. Samples were amplified by one-step RT-PCR and nested PCR and the PCR products were purified and Sanger-sequenced; no cloning step was reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37546367,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol","Partial pol gene (HIV-1 pol, HXB2 nt 2253--3252).",0,"PR, RT",0,"PR, RT",0,Pol,0,Pol,0,Pol,0,pol gene,0,*pol* gene,0,"Protease, Reverse transcriptase, Integrase",0,"PR, RT, IN",0,Pol,0,Pol,0,Pol,0,pol,0,pol,0,Pol,0,Pol,0,Pol,0,Pol,0,No,0,Pol,0,Pol-gene,0
Human Answer,37546367,10,What method was used for sequencing?,List,Sanger sequencing,"Sanger sequencing of PCR-amplified products (one-step RT-PCR followed by nested PCR, products purified and Sanger-sequenced).",1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not Reported,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not Reported,0,Sanger sequencing,1,Yes,0,Sanger sequencing,1,Not reported,0
Human Answer,37546367,11,What type of samples were sequenced?,List,Plasma,Plasma derived from EDTA whole blood (0.5 mL plasma concentrated by ultracentrifugation prior to RNA extraction).,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,"NRTI, NNRTI, PI",0,Plasma,1,Plasma,1
Human Answer,37546367,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Not explicitly stated. Sequences were obtained from ART-experienced individuals with low-level viremia (viral load 200–1000 copies/mL) after at least 6 months of ART; the paper does not explicitly classify these individuals as virological failure cases.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,Yes,1,Not Reported,0,Yes,1,Not Reported,0,Yes,1,Yes,1
Human Answer,37546367,13,Were the patients in the study in a clinical trial?,Boolean,No,No. This was a retrospective observational study using samples and data from routine care (National Free Antiretroviral Treatment Database).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37546367,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. Inclusion criteria required individuals to have received ART for at least 6 months prior to sampling; sequences therefore derive from ART-experienced individuals.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,37546367,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI","Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs) (e.g., regimens described as 2NRTI+NNRTI or 2NRTI+PI).",1,"NRTI, NNRTI, PI",1,No,0,"NRTI, NNRTI",0,NRTIs,0,"NRTI, NNRTI",0,"NRTI, PI, NNRTI",1,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",1,No,0,Not reported,0,Not Reported,0,Not reported,0,"NRTI, PI, NNRTI",1,"NRTI, PI, NNRTI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,Not Reported,0,"NRTIs, NNRTIs, and PIs",1,No,0,"NRTI, NNRTI, PI",1,Not reported,0
Human Answer,37546367,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"The manuscript references first-line and analyzed drugs including NRTIs (e.g., AZT, ABC, FTC, 3TC, TDF, D4T, DDI), NNRTIs (e.g., NVP, EFV, ETR, RPV, DOR) and PIs (e.g., NFV/r, DRV/r); first-line regimens mentioned include FTC, 3TC, EFV and NVP.",0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Efavirenz (EFV)",0,No,1,"FTC, 3TC, EFV, NVP",0,Not Reported,1,Not reported,1,"AZT, ABC, FTC, 3TC, TDF, D4T",0,"TDF, AZT, 3TC, EFV, NNRTI, PI",0,"ABC, AZT, 3TC, FTC, EFV",0,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,See above,0,"NRTI, NNRTI, PI",0,Not Reported,1,"AZT, 3TC, FTC, TDF, and EFV",0,No,1,"AZT, D4T, 3TC, FTC, EFV, NVP, and others.",0,Not reported,1
Human Answer,37554471,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0,Yes,0,No.,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,,1
Human Answer,37554471,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"The paper reports in vitro susceptibility testing for Mycobacterium avium-intracellulare and reports HBV resistance testing, but it does not report HIV in vitro drug susceptibility data.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,,1
Human Answer,37554471,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report making any sequences publicly available.,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,,1
Human Answer,37554471,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not reported — no GenBank accession numbers are provided.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,,1
Human Answer,37554471,5,How many individuals had samples obtained for HIV sequencing?,Number,1,"One patient was described in the report; however, no HIV sequencing is reported.",1,0,0,0,0,1,1,1,1,Not reported.,0,1,1,1,1,0,0,0,0,1,1,1,1,1,1,Not reported,0,Not reported,0,0,0,0,0,1,1,1,1,1,1,1,1,,0
Human Answer,37554471,6,From which countries were the sequenced samples obtained?,List,No,Not specified — the paper does not state a country of origin for sequenced samples (and no HIV sequences are reported).,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,,1
Human Answer,37554471,7,From what years were the sequenced samples obtained?,List,No,Not reported — no HIV sequencing or sequence dates are provided.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,2021-2022,0,Not reported,1,Not reported,1,Not reported,1,,1
Human Answer,37554471,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported — no information about cloning prior to sequencing is provided.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1,,1
Human Answer,37554471,9,Which HIV genes were reported to have been sequenced?,List,RT,Not reported — the paper does not specify any HIV genes sequenced.,1,No,0,No,0,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,"RT, IN",1,No,0,No,0,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,0,No,0,Not Reported,1,Not reported,1,Not reported,1,"PR, RT, IN",1,,0
Human Answer,37554471,10,What method was used for sequencing?,List,No,Not reported — no sequencing methods are described.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,,1
Human Answer,37554471,11,What type of samples were sequenced?,List,No,Not reported — the paper does not describe any samples being sequenced for HIV.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Plasma,0,Plasma,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Blood,0,Not reported,1,Not reported,1,Plasma,0,,1
Human Answer,37554471,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No HIV sequences were reported; the single patient did have virologic failure (high viral load) prior to CAB/RPV but no sequences were obtained or presented.,1,No,1,No,1,Yes,0,Yes,0,No.,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,,1
Human Answer,37554471,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the patient was treated clinically (a case report), not as part of a described clinical trial.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,,1
Human Answer,37554471,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No HIV sequences are reported; however, the patient described had extensive prior ARV exposure.",1,No,1,No,1,Yes,0,Yes,0,Yes.,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,,1
Human Answer,37554471,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"The patient had received drugs from multiple classes: non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitor (INSTI), protease inhibitor (PI), and nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs).",0,"NNRTI, INSTI, PI",0,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI",0,"NNRTI, INSTI, PI",0,"NNRTI, PI.",0,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,No,1,"INSTI, PI, NNRTI",0,"NNRTI, INSTI, PI",0,"NNRTI, INSTI, PI",0,Not reported,1,Not reported,1,"NRTI, NNRTI",0,No,1,"NRTI, NNRTI, PI",0,Not reported,1,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI, INSTI",0,,1
Human Answer,37554471,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Drugs mentioned in the patient's history include etravirine, dolutegravir, darunavir, ritonavir, tenofovir, lamivudine, emtricitabine, abacavir, and efavirenz; the patient later received cabotegravir/rilpivirine (long-acting) and was started on emtricitabine/tenofovir alafenamide for HBV.",0,"Etravirine, Dolutegravir, Darunavir, Ritonavir",0,"Etravirine (ETR), Dolutegravir (DTG), Darunavir (DRV), Ritonavir (RTV), Tenofovir (TFV), Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Efavirenz (EFV)",0,"Etravirine, Dolutegravir, Darunavir, Ritonavir",0,"Etravirine, Dolutegravir, Darunavir, Ritonavir",0,"Etravirine, Dolutegravir, Darunavir, Ritonavir.",0,"Etravirine, Dolutegravir, Darunavir, Ritonavir",0,"Abacavir (ABC), Lamivudine (3TC), Lopinavir (LPV), Ritonavir (RTV)",0,"Etravirine, Dolutegravir, Darunavir, Ritonavir",0,No,1,"etravirine, dolutegravir, darunavir, ritonavir",0,"Etravirine, dolutegravir, darunavir, ritonavir",0,"Etravirine, dolutegravir, darunavir, ritonavir",0,Not reported,1,Not reported,1,"Etravirine, dolutegravir, darunavir, lamivudine, emtricitabine, abacavir, efavirenz, tenofovir",0,No,1,"Etravirine, dolutegravir, darunavir, ritonavir",0,Not reported,1,"AZT, 3TC, EFV, ATV/r, DRV/r",0,"Etravirine, Dolutegravir, Darunavir, Ritonavir",0,,1
Human Answer,37573167,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37573167,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,Yes,0,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37573167,3,Were sequences from the paper made publicly available?,Boolean,No,No (not reported).,1,No,1,No,1,No.,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,No,1
Human Answer,37573167,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported in the provided text,1,Not reported,1,Not reported,1
Human Answer,37573167,5,How many individuals had samples obtained for HIV sequencing?,Number,1126,1126 individuals.,1,1126,1,1126,1,1126.,1,1126,1,1126,1,1126,1,1126,1,1126,1,1126,1,1126,1,1126,1,1126,1,1126,1,1126,1,1126,1,1126,1,1126,1,1126,1,1126,1,1126,1,1126,1
Human Answer,37573167,6,From which countries were the sequenced samples obtained?,List,Italy,Italy.,1,Italy,1,Italy,1,Italy.,1,Italy,1,Italy,1,Italy,1,Italy,1,No,0,Italy,1,Italy,1,Italy,1,Italy,1,Italy,1,Not reported,0,Italy,1,No,0,Not Reported,0,Not reported,0,Italy,1,Not reported,0,Not reported,0
Human Answer,37573167,7,From what years were the sequenced samples obtained?,List,2010-2021,2010–2021.,1,2010-2021,1,2010-2021,1,2010–2021.,1,2010–2021,1,2010–2021,1,2010-2021,1,2010-2021,1,2010-2021,1,2010-2021,1,2010-2021,1,2010-2021,1,2010-2021,1,2010-2021,1,2010-2021,1,2010-2021,1,2010-2021,1,2010-2021,1,2010-2021,1,2010-2021,1,2010-2021,1,2010-2021,1
Human Answer,37573167,8,Were samples cloned prior to sequencing?,Boolean,No,No — cloning is not reported.,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37573167,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Protease (PR), reverse transcriptase (RT) — combined as PR/RT — and integrase.",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,Pol.,0,"PR, RT",0,Pol,0,Not reported,0,"PR, RT, IN",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,Pol,0,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,No,0,"PR/RT, Integrase",1,Pol,0,"PR/RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1
Human Answer,37573167,10,What method was used for sequencing?,List,Sanger sequencing,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37573167,11,What type of samples were sequenced?,List,PBMC,HIV-1 DNA extracted from whole blood or lymphomonocytic cells (PBMCs).,1,PBMC,1,PBMC,1,"Whole blood, PBMC.",1,"Whole Blood, PBMC",1,"Whole Blood, PBMC",1,"Whole blood, lymphomonocytic cells",0,Whole blood; PBMC,1,PBMC,1,PBMC,1,"Whole blood, PBMC",1,"Whole blood, PBMC",1,PBMC,1,PBMC,1,"Whole Blood, PBMC",1,Whole Blood; PBMC,1,Plasma,0,"Whole-blood, Lymphomonocytic cells",0,"Whole-blood, PBMCs",1,"Whole-blood, lymphomonocytic cells",0,PBMC,1,"Whole-blood, Lymphomonocytic cells",0
Human Answer,37573167,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — sequences were from virologically suppressed individuals.,1,No,1,No,1,No.,1,Yes,0,No,1,No,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37573167,13,Were the patients in the study in a clinical trial?,Boolean,No,No — samples were from routine clinical practice (retrospective study).,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1,No,1
Human Answer,37573167,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37573167,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI","NRTIs, NNRTIs, PIs, and INSTIs.",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI.",1,NRTI,0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,Not reported,0,Not reported,0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"PI, NNRTI, INSTI, NRTI",1,NRTI,0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1
Human Answer,37573167,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Specific ARV drug names are not reported; only drug classes and regimen types are described.,1,No,1,No,1,Not reported.,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,"3TC, NVP, EFV, D4T, AZT, LPV, ABC, ATZ, DTG, TDF",0,Not reported,1,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,"NRTI, NNRTI, PI, INSTI",0,"PI, NNRTI, INSTI, NRTI (specifically, TDF, FTC, ABC, 3TC, EFV, NVP, RAL, DTG)",0,Not reported,1,Not reported in the provided text,1,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.",0,"PI, NNRTI, INSTI, NRTI",0
Human Answer,37574435,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes — the paper reports and uses archived HIV genotypic resistance data (resistance-associated mutations) from patient samples, but it does not present raw sequence data or newly generated sequencing reads in the manuscript.",1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,37574435,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro phenotypic drug susceptibility testing results.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,** No,1,No,1
Human Answer,37574435,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not indicate that HIV sequences or accessioned sequence data were made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Not Reported,1,** No,1,No,1
Human Answer,37574435,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,KP170487,0,Not Reported,1,** Not reported,1,Not reported,1
Human Answer,37574435,5,How many individuals had samples obtained for HIV sequencing?,Number,70 or 79,70 individuals had available genotypic resistance data prior to switch (out of 79 included participants).,1,0,0,0,0,79,1,79,1,79,1,79,1,79,1,0,0,0,0,79,1,79,1,79,1,79,1,79,1,0,0,0,0,79,1,79,1,79,1,** 79,1,79,1
Human Answer,37574435,6,From which countries were the sequenced samples obtained?,List,Taiwan,Taiwan.,1,No,0,Taiwan,1,Taiwan,1,Taiwan,1,Taiwan,1,Taiwan,1,Taiwan,1,No,0,Taiwan,1,Taiwan,1,Taiwan,1,Taiwan,1,Not reported,0,Taiwan,1,No,0,No,0,Taiwan,1,Taiwan,1,Not Reported,0,** Not reported,0,Not reported,0
Human Answer,37574435,7,From what years were the sequenced samples obtained?,List,2016-2022,Patient care and data used in the study cover 1 January 2016 through 30 March 2022; archived genotypic resistance data were those available prior to switches occurring within that timeframe.,1,No,0,2016-2022,1,2016–2022,1,2016–2022,1,2016–2022,1,2016-2022,1,2016-2022,1,No,0,2016-2022,1,2016-2022,1,2016-2022,1,2016-2022,1,Not reported,0,2016-2022,1,No,0,No,0,2016-2022,1,2016-2022,1,2016-2022,1,** 2016-2022,1,2016-2022,1
Human Answer,37574435,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No indication that samples were cloned prior to sequencing.,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,37574435,9,Which HIV genes were reported to have been sequenced?,List,RT,Regions corresponding to reverse transcriptase (NRTI-related RAMs) and integrase (INSTI-related RAMs) were reported; specific protease sequencing is not described.,1,No,0,No,0,Pol,0,Not reported,1,Pol,0,"NRTI, INSTI",1,"NRTI, INSTI",1,No,0,"PR, RT, IN",1,Not reported,1,"Pol, IN",0,Pol,0,Not reported,1,Not reported,1,No,0,No,0,Not Reported,1,"PR, RT",1,Not Reported,1,"** PR, RT, IN",1,Not reported,1
Human Answer,37574435,10,What method was used for sequencing?,List,No,Not reported — the paper does not describe the sequencing methodology used in the genotypic resistance reports.,1,No,1,No,1,Not Reported,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Sanger sequencing,0,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Sanger sequencing,0,Yes,0,** Not reported,1,"Sanger sequencing, Illumina sequencing",0
Human Answer,37574435,11,What type of samples were sequenced?,List,Plasma,"Not explicitly reported; the paper refers to genotypic resistance reports and plasma HIV RNA load, so sequencing likely derived from plasma, but sample type is not specified.",1,No,0,Plasma,1,Not Reported,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,No,0,Plasma,1,Plasma,1,"Plasma, PBMC",1,Plasma,1,Plasma,1,Plasma,1,No,0,No,0,Plasma,1,Plasma,1,Not Reported,0,** Plasma,1,Plasma,1
Human Answer,37574435,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — genotypic resistance data were collected for patients who experienced viral rebound (virologic failure) while on treatment prior to switching regimens.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Not Reported,0,** Yes,1,Yes,1
Human Answer,37574435,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a single-center, retrospective cohort study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer,37574435,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — the study population consisted of antiretroviral-experienced people with HIV who had been receiving ART prior to the observed viral rebound and genotypic resistance data were from these treatment-experienced individuals.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,** Yes,1,Yes,1
Human Answer,37574435,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, INSTI","Reported prior drug classes include nucleos(t)ide reverse-transcriptase inhibitors (NRTIs), non-nucleoside reverse-transcriptase inhibitors (NNRTIs), and first-generation integrase strand-transfer inhibitors (INSTIs); some individuals may have had exposure to protease inhibitors (PIs) though PI exposure is not emphasized.",1,"NRTI, INSTI",1,"NRTI, NNRTI, INSTI",1,"NRTI, potentially others",0,"NRTI, NNRTI",0,"NRTI, INSTI",1,"NRTI, INSTI",1,"NRTI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTIs, INSTIs, NNRTIs",1,"NRTI, PI, INSTI",1,"NRTIs, NNRTIs, INSTIs",1,"NRTI, INSTI",1,"NNRTI, INSTI, NRTI",1,No,0,No,0,"NRTIs, NNRTIs, PIs",0,"NRTI, NNRTI, PI, INSTI",1,No,0,"** NRTI, NNRTI, PI, INSTI",1,Not reported,0
Human Answer,37574435,16,Which drugs were received by individuals in the study before sample sequencing?,List,"DTG, BIC, FTC, TAF","Specific drugs mentioned or implied include NRTIs such as tenofovir (resistance mutation K65R referenced) and lamivudine/emtricitabine (M184V/I associated), and first-generation INSTIs such as raltegravir and elvitegravir are referenced as prior exposures leading to INSTI RAMs; NNRTIs are mentioned as prior regimen class but specific NNRTI agents are not listed.",0,No,0,"DTG, FTC, TAF, BIC, NRTI, NNRTI",1,Not Reported,0,Not reported,0,Not reported,0,"Abacavir (ABC), Lamivudine (3TC), Efavirenz (EFV), Tenofovir disoproxil (TDF), Dolutegravir (DTG)",0,"Abacavir (ABC), Lamivudine (3TC), Efavirenz (EFV), Tenofovir (TDF), Dolutegravir (DTG)",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,0,"BIC/FTC/TAF, DTG, NNRTI-based ART",1,"Bictegravir, Dolutegravir, Emtricitabine",0,"TDF, FTC, DTG",0,Dolutegravir (DTG),0,"DTG, BIC, FTC, TAF",1,No,0,No,0,Not Reported,0,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, DTG, BIC, CAB, LEN, MVC",0,No,0,"** Tenofovir (TFV), Emtricitabine (FTC), Darunavir (DRV), Dolutegravir (DTG), Doravirine (DOR), Ibalizumab (IBA), Lenacapavir (LEN)",0,Not reported,0
Human Answer,37585352,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV-1 proviral sequences obtained from participant samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37585352,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,No — the paper does not report in vitro (phenotypic) drug susceptibility assays; it reports genotypic analysis and in silico resistance predictions.,0,Yes,1,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No.,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,Yes,1,No,0,No,0
Human Answer,37585352,3,Were sequences from the paper made publicly available?,Boolean,No,Partially — sequences are not deposited in a public repository within the paper but are available on request through the PANGEA consortium.,1,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37585352,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,,1,The paper reports that sequences were submitted to GenBank and provides accession numbers for sequences generated in this study.,0,Not reported,1,Not reported,1
Human Answer,37585352,5,How many individuals had samples obtained for HIV sequencing?,Number,5805,5805 individuals (one consensus sequence per participant).,1,5805,1,5805,1,5805,1,5805,1,5805,1,5805,1,5805,1,5805,1,5805,1,5805.,1,5805,1,5805,1,5805,1,5805,1,5805,1,0,0,5805,1,No,0,5805,1,5805,1,5805,1
Human Answer,37585352,6,From which countries were the sequenced samples obtained?,List,Botswana,Botswana.,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana.,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,No,0,Botswana,1,No,0,Botswana,1,Botswana,1,Botswana,1
Human Answer,37585352,7,From what years were the sequenced samples obtained?,List,2013-2018,Samples were from the 2013–2018 period.,1,2013-2018,1,2013-2018,1,2013–2018,1,2013-2018,1,2013–2018,1,2013--2018,1,2013-2018,1,2013-2018,1,2013-2018,1,2013-2018.,1,2013-2018,1,2013-2018,1,2013-2018,1,2013-2018,1,2013-2018,1,No,0,2013-2018,1,No,0,2013-2018,1,2013-2018,1,2013-2018,1
Human Answer,37585352,8,Were samples cloned prior to sequencing?,Boolean,No,No — samples were not described as cloned; sequencing was performed on PCR amplicons by NGS and a single consensus was generated per participant.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37585352,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol",Near full-length HIV-1 pol gene sequences were generated and analysed.,0,Near full length genome,0,Near full length genome,0,Pol,0,Pol,0,Pol,0,pol gene,0,"Regions of the HIV-1 genome, primarily the pol region.",0,"Reverse transcriptase, RT; Integrase, IN",0,"PR, RT, IN",0,Pol.,0,Pol,0,Pol,0,pol,0,Pol,0,"Protease, Reverse transcriptase, and Integrase",0,Pol,0,Pol,0,No,0,Pol,0,Pol,0,Pol,0
Human Answer,37585352,10,What method was used for sequencing?,List,Illumina sequencing,Next-generation sequencing (Illumina platforms — MiSeq and HiSeq) of long-range PCR amplicons.,1,Illumina sequencing,1,NGS,0,NGS,0,NGS,0,NGS,0,Illumina sequencing,1,Illumina sequencing,1,Illumina sequencing,1,NGS,0,NGS.,0,NGS,0,NGS,0,NGS,0,Next-generation sequencing (NGS),1,Illumina sequencing,1,Illumina sequencing,1,NGS,0,No,0,NGS,0,NGS,0,Illumina sequencing,1
Human Answer,37585352,11,What type of samples were sequenced?,List,PBMC,Proviral DNA from participant samples (proviral DNA extracted from participants).,0,Other,0,No,0,Proviral DNA,0,Proviral DNA,0,Proviral DNA,0,Proviral DNA,0,Proviral DNA from blood samples,0,PBMC,1,PBMC,1,Proviral DNA.,0,Proviral DNA,0,"Plasma, PBMC",1,Proviral DNA,0,Proviral DNA,0,Proviral DNA,0,Proviral DNA,0,Proviral DNA,0,No,0,Plasma,0,Proviral DNA,0,Proviral DNA,0
Human Answer,37585352,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — sequences from individuals experiencing virological failure were not included.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer,37585352,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes — participants were recruited from the Botswana Combination Prevention Project (BCPP), a registered trial (ClinicalTrials.gov NCT01965470).",1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,Yes,1,Yes.,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1
Human Answer,37585352,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — the dataset includes 4524 sequences from ART-experienced (virally suppressed) individuals in addition to 1281 from treatment-naive individuals.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1
Human Answer,37585352,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI",Primarily nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs); very few participants had received integrase strand transfer inhibitors (INSTIs).,1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTIs, NNRTIs",1,"NRTI, NNRTI",1,"NNRTI (efavirenz, nevirapine), NRTI (tenofovir, emtricitabine, lamivudine, zidovudine)",1,"NNRTI, NRTI",1,NNRTI,1,"NRTI, NNRTI.",1,"NNRTI, NRTI",1,"NRTIs, NNRTIs, PIs",1,"NNRTI, NRTI",1,"NNRTI, NRTI",1,"NRTI (Nucleoside Reverse Transcriptase Inhibitor), NNRTI (Non-Nucleosid Reverse Transcriptase Inhibitor), PI (Protease Inhibitor)",1,No,0,"NRTI, NNRTI",1,No,0,"NRTIs, NNRTIs, and/or PIs",1,"NRTI, NNRTI, INSTI",1,"NRTI, NNRTI, PI",1
Human Answer,37585352,16,Which drugs were received by individuals in the study before sample sequencing?,List,"EFV, FTC, TDF, 3TC, NVP, AZT","Common drugs included efavirenz (EFV), emtricitabine (FTC), tenofovir (TDF), lamivudine (3TC), nevirapine (NVP) and zidovudine (ZDV); very few participants had exposure to INSTI drugs.",1,"Efavirenz, Emtricitabine, Tenofovir, Lamivudine, Nevirapine, Zidovudine",1,"Efavirenz (EFV), Emtricitabine (FTC), Tenofovir (TFV), Lamivudine (3TC), Nevirapine (NVP), Zidovudine (ZDV)",1,"Efavirenz, Emtricitabine, Tenofovir, Lamivudine, Nevirapine, Zidovudine",1,"Efavirenz, Emtricitabine, Tenofovir, Lamivudine, Zidovudine",0,"Efavirenz, Emtricitabine, Tenofovir",0,"Efavirenz (EFV), Emtricitabine (FTC), Tenofovir (TDF), Lamivudine (3TC), Nevirapine (NVP), Zidovudine (ZDV)",1,"Efavirenz, Emtricitabine, Tenofovir, Lamivudine, Nevirapine, Zidovudine",1,"Nevirapine (NVP), Efavirenz (EFV), Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV)",1,"Efavirenz (EFV), Nevirapine (NVP), Rilpivirine (RPV)",0,"Efavirenz, emtricitabine, tenofovir, lamivudine, nevirapine, zidovudine.",1,"Efavirenz, emtricitabine, tenofovir",0,"Efavirenz, nevirapine, tenofovir",0,"Efavirenz, emtricitabine, lamivudine, nevirapine, tenofovir, zidovudine",1,"Efavirenz, emtricitabine, lamivudine, nevirapine, tenofovir, zidovudine",1,"NRTI, NNRTI, PI",0,No,0,"EFV, FTC, TDF, 3TC, NVP, ZDV",0,No,0,"TDF, FTC, EFV, NVP, and/or ATV",0,"Efavirenz, Emtricitabine, Tenofovir, Lamivudine, Nevirapine, Zidovudine, Raltegravir",1,"Efavirenz, Emtricitabine, Tenofovir, Lamivudine, Nevirapine, Zidovudine",1
Human Answer,37593123,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV-1 pol gene sequences obtained from patient samples (ART-naïve HIV-positive individuals).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37593123,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper did not report in vitro (phenotypic) drug susceptibility data; it used genotypic prediction via the Stanford HIVdb.,1,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,No,1,Yes,0
Human Answer,37593123,3,Were sequences from the paper made publicly available?,Boolean,No,"Partly — the study used sequences that were publicly available in databases (China CDC holdings, Los Alamos, and GenBank annotations), but the paper does not present new accession numbers or explicitly state deposition of new sequences.",1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,Not reported,1
Human Answer,37593123,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not reported — the paper does not provide specific GenBank accession numbers for the sequences.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,37593123,5,How many individuals had samples obtained for HIV sequencing?,Number,57902,"57,902 individuals (final dataset).",1,57902,1,57902,1,57902,1,"57,902",1,"57,902",1,"57,902",1,"57,902",1,57902,1,57802,0,"57,902",1,"57,902",1,"57,902",1,"57,902",1,"57,902",1,57902,1,67739,0,"57,902",1,"57,902",1,"57,902",1,"57,902",1,"57,902",1
Human Answer,37593123,6,From which countries were the sequenced samples obtained?,List,China,China.,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,No,0,China,1,China,1,China,1,China,1,China,1,China,1
Human Answer,37593123,7,From what years were the sequenced samples obtained?,List,2004-2022,From 2004 through 2022.,1,2004-2022,1,2004-2022,1,2004-2022,1,2004–2022,1,2004–2022,1,2004--2022,1,2004-2022,1,2004-2022,1,2004-2022,1,2004-2022,1,2004-2022,1,2004-2022,1,2004--2022,1,2004-2022,1,2004-2022,1,2004-2022,1,2004-2022,1,2004-2022,1,2004-2022,1,2004-2022,1,2004-2022,1
Human Answer,37593123,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported; there is no indication that samples were cloned prior to sequencing.,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,No,1,No,1
Human Answer,37593123,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol","The HIV-1 pol gene region was sequenced, specifically protease and at least the initial 238 amino acids of reverse transcriptase.",1,"Protease, RT",0,"PR, RT",0,Pol,0,Pol,0,Pol,0,Pol,0,"pol (protease, reverse transcriptase)",0,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",0,"PR, RT",0,Pol,0,Pol,0,Pol,0,Pol,0,Pol,0,Reverse transcriptase (RT),0,"PR, RT",0,Pol,0,Pol,0,Pol,0,Pol,0,Pol,0
Human Answer,37593123,10,What method was used for sequencing?,List,No,"Not reported — the paper does not specify the laboratory sequencing method or platform (e.g., Sanger or next-generation sequencing).",1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,NGS,0,Not reported,1,Not reported,1
Human Answer,37593123,11,What type of samples were sequenced?,List,Plasma,"Not specified — the paper states sequences came from ART-naïve HIV-infected individuals but does not specify biological sample type (e.g., plasma, serum, or PBMC).",1,No,0,No,0,Not reported,0,Not Reported,0,Not reported,0,Blood,0,Plasma,1,No,0,No,0,Not reported,0,Plasma,1,Plasma,1,Plasma,1,Blood,0,Plasma,1,"Plasma, Whole Blood",1,Blood samples,0,Plasma,1,Not reported,0,Plasma,1,Blood samples,0
Human Answer,37593123,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — sequences were from ART-naïve individuals, so none were from persons with virological failure on treatment.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37593123,13,Were the patients in the study in a clinical trial?,Boolean,No,No — the study compiled surveillance/repository sequences from ART-naïve individuals and does not describe enrollment in any clinical trial.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,No,1,No,1
Human Answer,37593123,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the study explicitly focused on ART-naïve individuals and did not include sequences from persons with prior ARV exposure.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37593123,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None — study participants were ART-naïve and had not received antiretroviral drug classes prior to sequencing.,1,NNRTI,0,No,1,,1,,1,,1,Not reported,1,,1,No,1,No,1,Not reported,1,,1,Not reported,1,Not reported,1,Not reported,1,"NRTI, NNRTI, PI",0,No,1,,1,,1,,1,,1,Not reported,1
Human Answer,37593123,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None — participants were ART-naïve and had not received antiretroviral drugs prior to sequencing.,1,"Efavirenz, Nevirapine",0,No,1,,1,,1,,1,Not reported,1,,1,No,1,No,1,Not reported,1,,1,Not reported,1,Not reported,1,Not reported,1,"NRTI, NNRTI, PI",0,No,1,,1,Not reported,1,Not reported,1,,1,Not reported,1
Human Answer,37626789,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV-1 genotyping and sequencing of the pol gene from children with virologic failure.,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,37626789,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance (sequence-based inference) using the Stanford HIVDB algorithm, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,Yes,0,** No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,37626789,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report public deposition of sequences; raw data are available from the corresponding author on request.,1,No,1,No,1,No,1,** No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,37626789,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,** Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,** Not reported,1,Not reported,1
Human Answer,37626789,5,How many individuals had samples obtained for HIV sequencing?,Number,551,Not reported (no explicit count provided for sequenced individuals).,0,551,1,0,0,551,1,** 551,1,554,0,554,0,551,1,551,1,551,1,551,1,551,1,551.,1,551,1,551,1,551,1,551,1,554,0,551,1,551,1,** Not reported,0,551,1
Human Answer,37626789,6,From which countries were the sequenced samples obtained?,List,Ethiopia,Ethiopia.,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,** Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Not reported.,0,Ethiopia,1,Ethiopia,1,No,0,Ethiopia,1,Not Reported,0,Ethiopia,1,Ethiopia,1,** Ethiopia,1,Ethiopia,1
Human Answer,37626789,7,From what years were the sequenced samples obtained?,List,2007-2019,"Sequencing was performed during the study period (2017–2019), with viral load testing between March and September 2019; the samples used for genotyping thus derive from the 2017–2019 study window (likely 2019 samples).",0,2007-2019,1,2007-2019,1,2007–2019,1,** 2007–2019,1,2017–2019,0,2017-2019,0,2017-2019,0,2017-2019,0,2017-2019,0,2017-2019,0,2017-2019,0,2017-2019.,0,2007-2019,1,2017-2019,0,2007--2019,1,2007-2019,1,2017-2019,0,2007-2019,1,2007-2019,1,** 2017-2019,0,2007-2019,1
Human Answer,37626789,8,Were samples cloned prior to sequencing?,Boolean,No,No indication of cloning; the manuscript does not report cloning prior to sequencing.,1,No,1,No,1,No,1,** No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No.,1,No,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,37626789,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol",The pol gene region of HIV-1 was sequenced.,0,"Reverse transcriptase, RT; Protease, PR",0,Pol,0,Pol,0,** Pol,0,Pol,0,pol,0,RT,0,"Reverse transcriptase, RT; Protease, PR; Integrase, IN",0,"PR, RT, IN",0,Pol,0,Pol,0,Pol.,0,pol,0,Pol,0,"Protease, RT, IN",0,"PR, RT",0,Pol,0,"Pol, PR, RT",0,No,0,** Pol gene,0,Pol,0
Human Answer,37626789,10,What method was used for sequencing?,List,Sanger sequencing,Sanger capillary sequencing using an ABI-3730 DNA genetic analyzer with an in-house PCR/sequencing assay validated by the Chinese CDC (sequences edited with ReCall).,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,** Sanger sequencing,1,Not reported,0,ABI-3730 DNA genetic analyzer,0,In-house assay,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,In-house assay,0,In-house assay,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Yes,0,** Sanger sequencing,1,In-house sequencing,0
Human Answer,37626789,11,What type of samples were sequenced?,List,Plasma,Plasma derived from EDTA whole blood samples.,1,Whole Blood,0,Plasma,1,"Plasma, Whole Blood",1,** Plasma,1,Whole Blood,0,Whole blood and plasma,1,Plasma,1,Whole Blood,0,Plasma,1,Whole blood and plasma,1,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Whole blood,0,Plasma,1,NRTIs and NNRTIs,0,** Plasma,1,Plasma,1
Human Answer,37626789,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes. Sequencing/genotyping was performed specifically for children with virologic failure (two consecutive plasma viral loads ≥1000 copies/mL).,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"AZT, 3TC, TDF, FTC, EFV, and NVP",0,** Yes,1,Yes,1
Human Answer,37626789,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. The study was a longitudinal observational cohort (part of a national cohort study), not a clinical trial.",1,No,1,No,1,No,1,** No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer,37626789,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. All sequenced individuals were children already on first-line ART for at least six months, so they had prior ARV exposure.",1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,** Yes,1,Yes,1
Human Answer,37626789,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI",Primarily NRTIs and NNRTIs (first-line regimens); protease inhibitors (PIs) were infrequently used (mainly second-line) and thus occasionally present.,1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"** NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, PI",0,"NRTI, NNRTI",1,"NRTI, NNRTI",1,NRTIs and NNRTIs,1,"NRTIs, NNRTIs, PIs",1,"NRTIs, NNRTIs, PIs.",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI",1,NRTI,0,No,0,"** NRTI, NNRTI, PI",1,"NRTI, NNRTI",1
Human Answer,37626789,16,Which drugs were received by individuals in the study before sample sequencing?,List,"AZT, 3TC, NVP, D4T, EFV, ABC, EFV, TDF","Participants received drugs including Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (d4T), Efavirenz (EFV), Abacavir (ABC), Tenofovir (TDF), ddI (didanosine), and, rarely, protease inhibitors such as lopinavir/ritonavir (LPV/r), saquinavir/ritonavir (SQV/r), nelfinavir (NFV) or indinavir/ritonavir (IND/r).",1,"Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), Efavirenz (EFV)",0,"Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), Efavirenz (EFV)",0,"Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Tenofovir (TDF)",0,"** AZT, 3TC, NVP, D4T, EFV",0,"Zidovudine, Lamivudine, Nevirapine",0,"Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP)",0,"Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP)",0,"Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), Efavirenz (EFV)",0,"Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), Efavirenz (EFV)",0,"AZT, 3TC, D4T, NVP, and EFV",0,"AZT, 3TC, ABC, D4T, EFV, NVP, LPV/r",0,"AZT, 3TC, FTC, ABC, D4T, EFV, NVP, LPV/r.",0,"Zidovudine (AZT), Lamivudine (3TC), Stavudine (D4T), Nevirapine (NVP), Efavirenz (EFV)",0,"Zidovudine, Stavudine, Lamivudine, Nevirapine, Efavirenz",0,"NRTI, NNRTI, PI",0,"AZT, 3TC, NVP, D4T, EFV, LPV/r, NFV, TDF, ABC, DOR, ETR, RPV, DOR, CAB, DTG, BIC, RAL, EVG, LEN",1,"AZT, 3TC, NVP, D4T, EFV",0,"AZT, 3TC, FTC, TDF, ABC, EFV",0,No,0,"** Zidovudine (AZT), Lamivudine (3TC), Stavudine (D4T), Nevirapine (NVP), Efavirenz (EFV)",0,"Zidovudine (AZT), Lamivudine(3TC), Stavudine(D4T), Nevirapine (NVP)",0
Human Answer,37632026,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37632026,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper reports genotypic interpretation (predicted susceptibility) rather than in vitro phenotypic susceptibility assays.,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,No,1
Human Answer,37632026,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37632026,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; OQ985493-OQ985958,MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; OQ985493-OQ985958.,1,MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; OQ985493-OQ985958,1,MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; OQ985493-OQ985958,1,"MK580543-MK580618, JF273935-JF273965, JQ796152-JQ796169, MK867721-MK867755, OQ985493-OQ985958",1,"MK580543-MK580618, JF273935-JF273965, JQ796152-JQ796169, MK867721-MK867755, OQ985493-OQ985958",1,"MK580543–MK580618, JF273935–JF273965, JQ796152–JQ796169, MK867721–MK867755, OQ985493–OQ985958",1,MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; OQ985493-OQ985958,1,MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; OQ985493-OQ985958,1,"MK580543-MK580618 ; JF273935-JF273965 ; JQ796152-JQ796169, MK867721-MK867755 ; and OQ985493-OQ985958",1,"MK580543-MK580618, JF273935-JF273965, JQ796152-JQ796169, MK867721-MK867755, OQ985493-OQ985958",1,"MK580543-MK580618, JF273935-JF273965, JQ796152-JQ796169, MK867721-MK867755, OQ985493-OQ985958",1,"MK580543-MK580618, JF273935-JF273965, JQ796152-JQ796169, MK867721-MK867755, and OQ985493-OQ985958",1,No,0,"MK580543-MK580618 ; JF273935-JF273965 ; JQ796152-JQ796169, MK867721-MK867755 ; and OQ985493-OQ985958",1,"MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169, MK867721-MK867755; and OQ985493-OQ985958",1,"MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169, MK867721-MK867755; and OQ985493-OQ985958",1,No,0,"MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169, MK867721-MK867755; and OQ985493-OQ985958",1,"MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169, MK867721-MK867755; and OQ985493-OQ985958",1,"MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169, MK867721-MK867755; and OQ985493-OQ985958",1,"MK580543-MK580618, JF273935-JF273965, JQ796152-JQ796169, MK867721-MK867755, and OQ985493-OQ985958",1,"MK580543-MK580618, JF273935-JF273965, JQ796152-JQ796169, MK867721-MK867755, OQ985493-OQ985958",1
Human Answer,37632026,5,How many individuals had samples obtained for HIV sequencing?,Number,759,759 participants.,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1,759,1
Human Answer,37632026,6,From which countries were the sequenced samples obtained?,List,Cameroon,Cameroon.,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,No,0,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1
Human Answer,37632026,7,From what years were the sequenced samples obtained?,List,2011-2019,November 2011 to August 2019.,1,2011-2019,1,2011-2019,1,2011-2019,1,2011–2019,1,2011–2019,1,2011 to 2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1,2011-2019,1
Human Answer,37632026,8,Were samples cloned prior to sequencing?,Boolean,No,No — samples were PCR-amplified and directly sequenced; no cloning step is described.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37632026,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol","The HIV-1 pol gene, specifically the protease and reverse-transcriptase regions.",0,"Protease, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,Protease and reverse-transcriptase regions (pol-gene),0,"Protease (PR), Reverse Transcriptase (RT)",0,"Protease, Reverse transcriptase",0,"PR, RT",0,Pol,0,Pol,0,Pol,0,pol,0,"PR, RT",0,"Protease, RT, IN",0,No,0,Pol,0,Pol,0,No,0,Protease and Reverse Transcriptase,0,"Protease, Reverse Transcriptase",0
Human Answer,37632026,10,What method was used for sequencing?,List,Sanger sequencing,PCR amplification (RT-PCR and nested PCR) followed by Sanger sequencing on an Applied Biosystems 3500 genetic analyzer.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not Reported,0,Applied Biosystems 3500 genetic analyzer,0,Applied Biosystems 3500 genetic analyzer,0,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1,Yes,0,Sanger Sequencing,1,Sanger sequencing,1
Human Answer,37632026,11,What type of samples were sequenced?,List,Plasma,Plasma samples (viral RNA extracted from patient plasma).,1,Whole Blood,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,No,0,Plasma,1,"Plasma, PBMC",1,"NRTIs, NNRTIs, PIs",0,Plasma,1,Plasma,1
Human Answer,37632026,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — all participants were experiencing virological failure on first- or second-line ART.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN, MVC",0,Yes,1,Yes,1
Human Answer,37632026,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a laboratory-based cross-sectional and analytical study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37632026,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — participants were previously treated and failing first- or second-line ART regimens.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37632026,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI","Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and boosted protease inhibitors (PI/r). Integrase inhibitors were not used/exposed in this population.",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,"NRTIs, NNRTIs, PIs",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI/r",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI/r",1,"NRTIs, NNRTIs, PIs",1,"NRTIs, NNRTIs, PIs",1,"NNRTI, PI/r",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,No,0,"NRTI, NNRTI, PI/r",1,"NRTI, PI, INSTI",0,"NRTIs, NNRTIs, PIs",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI",1
Human Answer,37632026,16,Which drugs were received by individuals in the study before sample sequencing?,List,"AZT, D4T, XTC, TDF, ATV, LPV, DRV","Common drugs mentioned include NRTIs: tenofovir (TDF), zidovudine (AZT, and older d4T), abacavir (ABC), lamivudine/emtricitabine (3TC/FTC); NNRTIs: efavirenz (EFV), nevirapine (NVP); PIs: atazanavir/ritonavir (ATV/r), lopinavir/ritonavir (LPV/r), darunavir/ritonavir (DRV/r); and older PIs such as nelfinavir (NFV) and indinavir (IDV).",1,No,0,"NRTI (Nucleoside Reverse Transcriptase Inhibitor), including Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Emtricitabine (FTC), Tenofovir (TFV); NNRTI (Non-Nucleosid Reverse Transcriptase Inhibitor), including Nevirapine (NVP), Efavirenz (EFV); PI (Protease Inhibitor), including Lopinavir (LPV), Atazanavir (ATV), Darunavir (DRV)",0,Not reported,0,Not Reported,0,Not Reported,0,"AZT, TDF, ABC, 3TC, EFV, NVP, ATV, LPV, DRV.",0,"Tenofovir (TFV), Zidovudine (AZT), Efavirenz (EFV), Nevirapine (NVP), Atazanavir (ATV), Lopinavir (LPV)",0,"TDF, AZT, ABC, EFV, ATV, LPV, DRV",0,"AZT, 3TC, TDF, EFV, NVP, LPV/r, ATV/r",0,Not Reported,0,"AZT, 3TC, FTC, ABC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r",0,"AZT, 3TC, TDF",0,"EFV, NVP, AZT, 3TC, TDF",0,"AZT, TDF, 3TC, ABC, EFV, NVP, ATV/r, LPV/r, DRV/r",0,"Abacavir (ABC), Zidovudine (AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Raltegravir (RAL), Elvitegravir (EVG), Dolutegravir (DTG), Bictegravir (BIC), cabotegravir (CAB), Lenacapavir (LEN)",1,No,0,"AZT, TDF, ABC, EFV, NVP, ATV/r, LPV/r, DRV/r",0,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN, MVC",0,"AZT, D4T, 3TC, FTC, TDF, EFV, NVP, ATV, LPV, DRV, DTG",1,"AZT, TDF, 3TC, ABC, EFV, NVP, ATV/r, LPV/r, DRV/r",0
Human Answer,37632071,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes.,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37632071,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37632071,3,Were sequences from the paper made publicly available?,Boolean,No,No — no sequences were reported or made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37632071,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1,Not reported,1
Human Answer,37632071,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero — no samples were obtained for HIV sequencing.,1,0,1,0,1,Not reported,1,0,1,Not reported,1,197,0,197,0,0,1,0,1,197,0,197,0,197.,0,Not reported,1,197,0,0,1,0,1,Not Reported,1,197,0,329,0,197,0,197,0
Human Answer,37632071,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no sequenced samples; the study cohort was from Italy.,1,No,1,No,1,Italy,0,Italy,0,Italy,0,Italy,0,Italy,0,No,1,No,1,Italy,0,Italy,0,Not reported.,1,Not reported,1,Italy,0,No,1,No,1,Not Reported,1,Italy,0,Italy,0,Italy,0,Not reported,1
Human Answer,37632071,7,From what years were the sequenced samples obtained?,List,No,Not applicable — no sequencing; study samples were collected in 2019--2022.,1,No,1,No,1,2019–2022,0,2019–2022,0,2019–2022,0,2019-2022,0,2019-2022,0,No,1,No,1,2019-2022,0,2019-2022,0,2019-2022.,0,Not reported,1,2019-2022,0,No,1,No,1,2019-2022,0,2019-2022,0,2019-2022,0,2019-2022,0,2019-2022,0
Human Answer,37632071,8,Were samples cloned prior to sequencing?,Boolean,No,No — not applicable; no sequencing or cloning was reported.,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No.,1,Not reported,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,No,1,No,1
Human Answer,37632071,9,Which HIV genes were reported to have been sequenced?,List,No,None — the paper does not report sequencing of any HIV genes.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"Pol, PR, RT",0,No,1,Not reported,1,"PR, RT, IN",0
Human Answer,37632071,10,What method was used for sequencing?,List,No,Not applicable — no sequencing method is reported.,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"Sanger sequencing, Illumina sequencing",0,Yes,0,Not reported,1,"Sanger sequencing, Illumina sequencing",0
Human Answer,37632071,11,What type of samples were sequenced?,List,No,Not applicable — no sequencing was performed; the study used plasma samples for HIV RNA (viral load) testing.,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Blood samples,0,Plasma,0,No,1,No,1,Plasma,0,Plasma,0,Plasma.,0,Not reported,1,Plasma,0,No,1,No,1,Plasma,0,Plasma,0,"NRTI, NNRTI, PI, INSTI",0,Plasma,0,Plasma,0
Human Answer,37632071,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — no sequences were obtained. Some participants had prior detectable viremia (≥50 copies/mL) in the year before switch, but no sequencing was performed.",1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes.,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,"AZT, 3TC, FTC, TDF, EFV, NVP, RAL, DTG, BIC, CAB",1,Yes,0,Yes,0
Human Answer,37632071,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a retrospective cohort study of routine clinical practice, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1
Human Answer,37632071,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the paper does not report sequences. However, the participants were treatment-experienced and had received ARV drugs prior to switching.",1,No,1,No,1,Not reported,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes.,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0
Human Answer,37632071,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not applicable for sequencing, but the participants had received NRTIs, INSTIs, NNRTIs, and PIs prior to the switch.",1,INSTI,0,No,1,Not reported,1,"NRTI, INSTI",0,Not reported,1,"NRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0,No,1,No,1,"INSTI, NNRTI, PI",0,INSTI,0,"NRTIs, NNRTIs, INSTIs.",0,Not reported,1,INSTI,0,No,1,No,1,INSTI,0,NRTI,0,No,1,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0
Human Answer,37632071,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"The paper does not list specific prior drugs for most participants; it reports regimen classes (e.g., 2NRTI+INSTI, 2NRTI+NNRTI, 2NRTI+PI). The switch regimen was bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and lamivudine is mentioned in discussion as an example in other contexts.",0,"INSTI (Bictegravir, etc.)",0,No,1,Not reported,1,Not Reported,1,Not reported,1,"BIC, TAF, FTC, ABC",0,"Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC), Tenofovir (TDF), Efavirenz (EFV), Lopinavir (LPV)",0,No,1,No,1,"Bictegravir, emtricitabine, tenofovir alafenamide, and other ARV drugs.",0,Not reported,1,"Emtricitabine, tenofovir, bictegravir.",0,Not reported,1,INSTI-based regimen,0,No,1,No,1,BIC/FTC/TAF,0,"TDF, FTC",0,No,1,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c",0,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c",0
Human Answer,37649807,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the study analyzed retrospective viral load (VL) program data and did not report HIV sequence data from patient samples.,1,No,1,No,1,Yes,0,No,1,Yes.,0,No,1,** No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37649807,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report any in vitro drug susceptibility assays or results.,1,No,1,No,1,No,1,No,1,No.,1,No,1,** No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37649807,3,Were sequences from the paper made publicly available?,Boolean,No,No — no sequences were reported or deposited; the study used existing VL program data and data are owned by the Kenyan Ministry of Health.,1,No,1,No,1,No,1,No,1,No.,1,No,1,** No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37649807,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,"None — no HIV sequences were generated or deposited, so there are no GenBank accession numbers.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,** Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported in the provided text,1,Not reported,1,Not reported,1
Human Answer,37649807,5,How many individuals had samples obtained for HIV sequencing?,Number,0,"Zero — the study did not perform HIV sequencing. The analysis included 793,902 VL records from patients, but these were viral load records, not sequencing samples.",1,0,1,0,1,"793,902",0,Not reported,1,Not reported.,1,Not reported,1,** Not reported,1,0,1,0,1,Not reported,1,"793,902",0,"793,902",0,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,"793,902",0,"793,902",0,"793,902",0,"793,902",0
Human Answer,37649807,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no sequencing was performed; the program data analyzed are from Kenya.,1,No,1,No,1,Kenya,0,Kenya,0,Kenya.,0,Kenya,0,** Kenya,0,Kenya,0,No,1,Not reported,1,Kenya,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Kenya,0,Not reported,1,Not reported,1,Not reported,1,Kenya,0
Human Answer,37649807,7,From what years were the sequenced samples obtained?,List,No,Not applicable — no sequencing was performed; the VL data analyzed cover 2015–2021.,1,No,1,No,1,2015–2021,0,2015-2021,0,2015–2021.,0,2015-2021,0,** 2015-2021,0,2015-2021,0,No,1,Not reported,1,2015-2021,0,2015–2021,0,Not reported,1,Not reported,1,No,1,No,1,2015-2021,0,2015-2021,0,2015-2021,0,2015-2021,0,2015-2021,0
Human Answer,37649807,8,Were samples cloned prior to sequencing?,Boolean,No,"No — there was no sequencing performed, and therefore no cloning prior to sequencing.",1,No,1,No,1,Not Reported,1,Not Reported,1,Not reported.,1,Not reported,1,** Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1
Human Answer,37649807,9,Which HIV genes were reported to have been sequenced?,List,No,None — the paper does not report sequencing of any HIV genes.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,** Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Pol,0,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,37649807,10,What method was used for sequencing?,List,No,"Not applicable — no sequencing was performed, so no sequencing method was used.",1,No,1,No,1,Not Reported,1,Not Reported,1,Not reported.,1,Not reported,1,** Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing and Illumina sequencing,0,Yes,0,Not reported,1,Not reported,1
Human Answer,37649807,11,What type of samples were sequenced?,List,No,Not applicable — no sequencing was performed; the viral load testing used plasma samples.,1,No,1,No,1,Plasma,0,Plasma,0,Not reported.,1,Plasma,0,** Plasma,0,Plasma,0,No,1,Not reported,1,Plasma,0,Plasma,0,Not reported,1,Not reported,1,No,1,No,1,Plasma,0,Plasma,0,"NRTIs, NNRTIs, PIs, and/or INSTIs",0,Plasma,0,Plasma,0
Human Answer,37649807,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the study did not generate sequences. The cohort did include individuals with virologic non-suppression and virologic failure based on VL data.,1,No,1,No,1,Yes,0,No,1,Not reported.,1,No,1,** Not reported,1,Yes,0,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,"TDF, FTC, EFV, NVP, LPV/r, ATV/r, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, and LEN",1,Yes,0,Yes,0
Human Answer,37649807,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the study analyzed retrospective routine programmatic VL data from the national database, not a clinical trial.",1,No,1,No,1,No,1,No,1,No.,1,No,1,** No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37649807,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the paper does not report any HIV sequences. However, the analyzed cohort comprised people with prior ARV exposure.",1,No,1,No,1,Yes,0,No,1,Yes.,0,Yes,0,** Not reported,1,Yes,0,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0
Human Answer,37649807,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not applicable for sequencing (no sequencing performed). The cohort had prior exposure to NRTIs, NNRTIs, INSTIs, and PIs.",1,"NRTI, NNRTI, INSTI",0,No,1,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI.",0,"NRTI, NNRTI, INSTI",0,"** NRTI, NNRTI, INSTI, PI",0,"INSTI, NRTI, NNRTI, PI",0,No,1,Not reported,1,"NRTIs, NNRTIs, INSTIs",0,"NRTIs, NNRTIs, PIs, INSTIs",0,Not reported,1,Not reported,1,No,1,No,1,NRTI,0,"NRTI, NNRTI, PI, INSTI",0,No,1,"NRTI, NNRTI, PI",0,"NRTI, INSTI",0
Human Answer,37649807,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable for sequencing. Reported drugs in the cohort include tenofovir disoproxil fumarate (TDF), lamivudine (3TC) or emtricitabine (FTC), dolutegravir (DTG), NNRTIs (unspecified), and protease inhibitors (unspecified).",1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Emtricitabine (FTC), NNRTIs, Dolutegravir (DTG), Protease Inhibitors (PI)",0,No,1,"TDF, 3TC, FTC, NNRTIs, DTG, PIs",0,"TDF, 3TC, FTC",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Emtricitabine (FTC).",0,"Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV), Dolutegravir (DTG)",0,"** Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Emtricitabine (FTC), Dolutegravir (DTG), Protease Inhibitors (PI)",0,"Dolutegravir (DTG), Tenofovir (TFV), Lamivudine (3TC), Emtricitabine (FTC)",0,No,1,Not reported,1,"TDF, 3TC, FTC, EFV, DTG",0,"TDF, 3TC, FTC, ABC, EFV, NVP, ETR, RPV, DRV, DTG",0,Not reported,1,Not reported,1,No,1,No,1,"TDF, 3TC, FTC",0,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, DTG, CAB, LEN",0,No,1,"TDF, 3TC, FTC, NNRTIs, DTG, PIs",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Emtricitabine (FTC), INSTI",0
Human Answer,37662576,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples; it uses protein structures from the PDB and molecular dynamics simulations.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37662576,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not present in vitro drug susceptibility assays; it reports computational molecular dynamics analyses of protease structures and cites resistance levels from the literature.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37662576,3,Were sequences from the paper made publicly available?,Boolean,No,"No — the paper does not report depositing sequences (e.g., GenBank accessions); it references PDB entries and provides a GitHub link for code.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer,37662576,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None — the paper does not report any GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"6DGX, 2PC0",0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported (no specific accession numbers mentioned in the paper),1,Not reported,1,Not reported,1,"MN234327 - MN235714, GQ848100-GQ848156, GU301078-GU301088, MF499156-MF502416, MF957336-MF957707, HQ694834 to HQ694845",0
Human Answer,37662576,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Not applicable — no individuals or patient-derived samples were sequenced in this study.,1,0,1,0,1,0,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not Reported,1,Not reported (no specific number mentioned in the paper),1,Not reported,1,600,0,600,0
Human Answer,37662576,6,From which countries were the sequenced samples obtained?,List,No,"Not applicable — no patient or sequencing samples were obtained, so no countries are reported.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported (no specific country mentioned in the paper),1,Not reported,1,Japan,0,"Spain, Switzerland, USA",0
Human Answer,37662576,7,From what years were the sequenced samples obtained?,List,No,Not applicable — the study does not report sequencing of samples and therefore provides no sampling years.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported (no specific year range mentioned in the paper),1,Not reported,1,2007-2008,0,2007-2008,0
Human Answer,37662576,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — no sequencing was performed and therefore no cloning for sequencing was performed.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37662576,9,Which HIV genes were reported to have been sequenced?,List,No,None — the paper did not perform sequencing; it studies the HIV-1 protease protein (the protease region of pol) using PDB structures.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,Protease,0,No,1,Not reported,1,"Pol, PR",0,Protease,0,Not reported,1,Not reported,1,No,1,No,1,Pol,0,"Pol, PR, RT",0,Pol,0,IN,0,IN,0
Human Answer,37662576,10,What method was used for sequencing?,List,No,Not applicable — no sequencing was performed; the primary methods used were structural data retrieval from the PDB and molecular dynamics (MD) simulations (accelerated MD with Amber20).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Sanger sequencing,0,Sanger sequencing,0,Illumina sequencing,0,Illumina sequencing,0
Human Answer,37662576,11,What type of samples were sequenced?,List,No,Not applicable — no biological samples were sequenced; the study used protein structures from the PDB (protease crystal structures) as inputs to computational simulations.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"Plasma, PBMC",0,"Plasma, serum, PBMCs, proviral DNA, and dried blood spots",0,PBMC,0,PBMC,0
Human Answer,37662576,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — the paper does not report sequences from individuals, including those with virological failure; it analyzes PDB structures and known resistance variants computationally.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37662576,13,Were the patients in the study in a clinical trial?,Boolean,No,Not applicable — there were no patients in this study; it is a computational/structural analysis using PDB data.,1,No,1,No,1,Not reported,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported (no specific information mentioned in the paper),1,Not reported,1,No,1,Yes,0
Human Answer,37662576,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report sequences from individuals with prior ARV exposure; it analyzes structural protease variants from PDB and discusses clinical drugs in the literature context.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37662576,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable — there were no individuals or sequencing in the study; therefore no drug class exposure of sampled individuals is reported.,1,No,1,No,1,,1,Not reported,1,None.,1,Not reported,1,Not reported,1,PI,0,No,1,Not reported,1,PI,0,PI,0,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported (no specific information mentioned in the paper),1,"NRTIs, NNRTIs, and PIs",0,"NRTI, NNRTI, INSTI, CCR5 antagonist",0,"NRTI, NNRTI, PI",0
Human Answer,37662576,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable — no individuals were sampled or sequenced in this study; therefore no drugs received by individuals are reported. The study does discuss and model binding of specific drugs (darunavir, lopinavir, ritonavir boosting, and pepstatin) in structural/MD analyses.",1,No,1,No,1,,1,Not reported,1,None.,1,Not reported,1,Not reported,1,"Darunavir, Lopinavir",0,No,1,Not reported,1,"Darunavir, Lopinavir",0,Darunavir,0,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported (no specific information mentioned in the paper),1,"Darunavir, lopinavir, and other ARVs",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0,"Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL), Zidovudine (AZT), Lamivudine (3TC), Didanosine (DDI), Efavirenz (EFV), Raltegravir (RAL), Maraviroc, Darunavir (DRV)",0
Human Answer,37674678,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The paper reports HIV-1 pol gene sequences obtained from patient plasma samples and analyzes 1,161 successfully sequenced samples.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37674678,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance analysis using sequence-based interpretation algorithms, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer,37674678,3,Were sequences from the paper made publicly available?,Boolean,Yes,"No accession numbers are reported in the manuscript, and the Data availability statement indicates data must be deposited prior to publication but does not show deposited sequence identifiers.",0,Yes,1,No,0,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,Yes.,1,No,0,No,0,Yes,1,No,0,Yes,1,No,0,Yes,1,Yes,1,Not reported,0
Human Answer,37674678,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,No GenBank accession numbers are reported in the manuscript.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"The GenBank accession numbers for sequenced HIV isolates are not explicitly provided in the paper, but the paper reports that sequences were submitted to GenBank and provides accession numbers for sequences generated in this study.",0,Not reported,1,Not reported,1
Human Answer,37674678,5,How many individuals had samples obtained for HIV sequencing?,Number,1161 or 1393,"1,161 samples were successfully sequenced (from 1,393 ART-naïve individuals enrolled).",1,1393,1,1161,1,1393,1,"1,161",1,"1,393",1,1393,1,1393,1,1161,1,1161,1,"1,393",1,"1,393",1,"1,161.",1,1393,1,"1,393",1,1393,1,1393,1,1393,1,"1,161",1,"1,393",1,1053,0,1393,1
Human Answer,37674678,6,From which countries were the sequenced samples obtained?,List,China,"China (samples collected in Nanjing, China).",1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China.,1,China,1,China,1,China,1,No,0,Not reported,0,Not reported,0,China,1,Bulgaria,0,Not reported,0
Human Answer,37674678,7,From what years were the sequenced samples obtained?,List,2019 to 2021,Samples were obtained during 2019–2021 (enrollment between January 2019 and late 2021).,1,2019 to 2021,1,2019-2021,1,2019-2021,1,2019–2021,1,2019–2021,1,2019-2021,1,2019-2021,1,2019-2021,1,2019-2021,1,2019-2021,1,2019-2021,1,2019-2021.,1,2019-2021,1,2019-2021,1,2019-2021,1,2019-2021,1,2019-2021,1,2019-2021,1,2019-2021,1,2012--2020,0,2019-2021,1
Human Answer,37674678,8,Were samples cloned prior to sequencing?,Boolean,No,No. PCR products were directly sequenced after nested PCR; no cloning step is described.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1
Human Answer,37674678,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol","A fragment of the pol gene was sequenced (HXB2 coordinates 2253–3312), covering protease and reverse transcriptase regions used for PI, NRTI and NNRTI resistance analysis.",1,"Protease, PR; Reverse transcriptase, RT",0,"PR, RT",0,Pol,0,Pol,0,Pol,0,Pol,0,Pol,0,"Reverse transcriptase, RT; Protease, PR",0,Pol,0,Pol,0,Pol,0,Pol.,0,Pol,0,Pol,0,Pol gene,0,Pol,0,Pol,0,Pol,0,No,0,Pol,0,Pol,0
Human Answer,37674678,10,What method was used for sequencing?,List,Sanger sequencing,Nested RT-PCR amplification followed by Sanger (automated) sequencing on an ABI 3730XL instrument.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,ABI 3730XL sequencing,0,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,NGS,0,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37674678,11,What type of samples were sequenced?,List,Plasma,Plasma samples (viral RNA extracted from 200 μl plasma).,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,,0,Plasma,1,Plasma,1
Human Answer,37674678,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. All participants were ART-naïve with no history of antiretroviral therapy, so sequences were not from individuals with virological failure on treatment.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,,1,No,1,No,1
Human Answer,37674678,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Patients were recruited from voluntary counseling and testing clinics and the study was an observational surveillance study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1
Human Answer,37674678,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The study specifically enrolled ART-naïve individuals with no history of antiretroviral therapy.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1
Human Answer,37674678,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None — participants were ART-naïve and had not received any antiretroviral drug classes prior to sampling.,1,No,1,No,1,,1,,1,,1,Nan,0,,1,"NRTI, NNRTI, PI",0,No,1,Not reported,1,Not reported,1,None.,1,,1,Not reported,1,No,1,No,1,Not reported,1,"NRTI, NNRTI",0,No,1,"NRTI, NNRTI, INSTI, CCR5 antagonist",0,Not reported,1
Human Answer,37674678,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None — study participants had not received any specific antiretroviral drugs prior to sample collection.,1,No,1,No,1,,1,,1,,1,Nan,0,,1,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV)",0,No,1,Not reported,1,Not reported,1,None.,1,,1,Not reported,1,No,1,No,1,Not reported,1,"AZT, 3TC, FTC, TDF, ABC, d4T, ddI, EFV, NVP, RPV, DOR, LPV/r, ATV/r, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, LEN",0,No,1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0,Not reported,1
Human Answer,37701387,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports baseline genotypic data (viral mutations) from patient samples (Rainbow study participants).,1,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,No,0,Yes,1,No,0,No,0,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37701387,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro phenotypic drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37701387,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report that sequences were deposited in public repositories.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37701387,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1
Human Answer,37701387,5,How many individuals had samples obtained for HIV sequencing?,Number,0,30 individuals (Rainbow study).,0,0,1,0,1,Not reported,1,30,0,30,0,"1,349 (OPERA Cohort), 30 (Rainbow Study)",0,Not reported,1,0,1,0,1,Not reported,1,30,0,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,30,0,Not reported,1,"1,349",0,30,0,"1349, 30",0
Human Answer,37701387,6,From which countries were the sequenced samples obtained?,List,No,"Italy (Rainbow study, single-center in a tertiary-care Italian hospital).",0,No,1,No,1,Italy,0,Italy,0,Italy,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Italy,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Italy,0,Not reported,1,Not Reported,1,Not reported,1,Not reported,1
Human Answer,37701387,7,From what years were the sequenced samples obtained?,List,No,From 2020 to 2021 (Rainbow study: 1 May 2020 to 31 December 2021).,0,No,1,No,1,2020-2021,0,2020–2021,0,2020–2021,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2020-2021,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,2020-2021,0,Not reported,1,2010-2017,0,2020-2021,0,2020-2021,0
Human Answer,37701387,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No information provided.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Yes,0,No,1,No,1
Human Answer,37701387,9,Which HIV genes were reported to have been sequenced?,List,No,"Regions associated with NRTI and INSTI resistance — i.e., reverse transcriptase (RT) and integrase sequences were assessed.",0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,IN,0,Not reported,1,Not reported,1,No,1,No,1,Full length genome,0,Pol,0,Pol,0,Not reported,1,Not reported,1
Human Answer,37701387,10,What method was used for sequencing?,List,No,Not reported / sequencing methodology not specified in the text.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Sanger sequencing,0,Not reported,1,Not reported,1
Human Answer,37701387,11,What type of samples were sequenced?,List,Whole Blood,Clinical blood samples (plasma/blood) from study participants; the paper refers to baseline HIV RNA and blood sampling.,0,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,Plasma samples (indirectly indicated),0,Not reported,0,No,0,No,0,Not reported,0,Plasma,0,Plasma,0,Not reported,0,Not reported,0,No,0,No,0,Plasma,0,Plasma,0,Plasma,0,Blood samples,0,Plasma,0
Human Answer,37701387,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — sequences described were from ART‑naive individuals at baseline, not from persons with virological failure on treatment.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0
Human Answer,37701387,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes — the Rainbow study was a prospective phase IV clinical trial (single-arm) and the LAPTOP study is described as an ongoing randomized controlled trial.,1,Yes,1,Yes,1,Not reported,0,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Not reported,0,No,0,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1
Human Answer,37701387,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,No — the sequences described (baseline genotypes) come from ART‑naive individuals.,0,No,0,No,0,No,0,No,0,No,0,Yes,1,No,0,No,0,No,0,No,0,No,0,No,0,Not reported,0,Not reported,0,No,0,No,0,No,0,Yes,1,Yes,1,No,0,Yes,1
Human Answer,37701387,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI, INSTI",None — participants were ART‑naive and had not received antiretroviral drug classes prior to baseline sequencing.,0,No,0,No,0,,0,,0,,0,"NRTI, NNRTI, PI, INSTI",1,Not reported,0,"INSTI, PI",0,No,0,"INSTI, NRTI, PI",1,Not reported,0,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,,0,Not reported,0,"NRTIs, NNRTIs, PIs",0,Not reported,0,"NRTI, NNRTI, PI, INSTI",1
Human Answer,37701387,16,Which drugs were received by individuals in the study before sample sequencing?,List,"BIC, FTC, TAF, DRV",None — no antiretroviral drugs were received prior to baseline sequencing (participants were ART‑naive).,0,No,0,No,0,,0,,0,,0,"Abacavir (ABC), Lamivudine (3TC), Tenofovir (TDF), Efavirenz (EFV), among others.",0,Not reported,0,"Bictegravir (BIC), Emtricitabine (FTC), Tenofovir (TFV), Darunavir (DRV)",0,No,0,"Bictegravir, emtricitabine, tenofovir alafenamide, darunavir, cobicistat",1,Not reported,0,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,,0,Not reported,0,"AZT, 3TC, EFV, ATV/r, DRV/r",0,Not reported,0,"Bictegravir, Emtricitabine, Tenofovir, Darunavir, Cobicistat, Elvitegravir, Ritonavir, Lamivudine, Tenofovir disoproxil fumarate, Efavirenz",0
Human Answer,37716367,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — this paper is a reporting guideline and does not present primary HIV sequence data from patient samples.,1,Yes,0,No,1,No,1,Yes,0,Not reported,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer,37716367,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37716367,3,Were sequences from the paper made publicly available?,Boolean,No,"No — there are no sequences reported in this paper, so none were made publicly available.",1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1
Human Answer,37716367,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported — this paper does not list any GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,SRP075904,0,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"SRP075904, KX247148",0,"The paper reports the following GenBank accession numbers: FJ800379–FJ800386, GQ477441-GQ477451, KP170487.",0,Not reported,1,Not reported,1
Human Answer,37716367,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Not applicable / none — the paper is a guideline and does not report participants or sequencing from individuals.,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,0,1,Not reported,1,0,1,0,1,1138,0,1138,0,1138,0,Not reported,1,0,1
Human Answer,37716367,6,From which countries were the sequenced samples obtained?,List,No,Not applicable / none — the paper does not present sequenced samples from any country.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Cuba,0,Not reported,1,No,1,No,1,"Spain, Suriname, Uganda",0,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Taiwan,0,Taiwan,0,"South Africa, Taiwan, Uganda",0,Not reported,1,South Africa,0
Human Answer,37716367,7,From what years were the sequenced samples obtained?,List,No,Not applicable / none — the paper does not report sequenced samples or collection years.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,1983-2018,0,Not reported,1,No,1,No,1,2007-2012,0,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,2012-2016,0,2012-2016,0,2012-2016,0,Not reported,1,Not reported,1
Human Answer,37716367,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / not applicable — the paper does not present laboratory methods applied to original samples and does not state that samples were cloned.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37716367,9,Which HIV genes were reported to have been sequenced?,List,No,Not applicable / none reported — the paper does not report sequencing of particular HIV genes.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,"Pol, Integrase",0,Not reported,1,"Pol, IN",0,Not reported,1,Not reported,1,No,1,No,1,Pol,0,Pol,0,Pol,0,Not reported,1,Not reported,1
Human Answer,37716367,10,What method was used for sequencing?,List,No,Not applicable / not reported — the paper does not apply or report a sequencing method for primary data.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing,0,Sanger sequencing,0,Not reported,1,Not reported,1
Human Answer,37716367,11,What type of samples were sequenced?,List,No,Not applicable / not reported — the paper does not present sequencing of samples.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,"Plasma, DBS",0,Not reported,1,"Plasma, PBMC",0,Not reported,1,Not reported,1,No,1,No,1,Plasma,0,"Plasma, PBMC",0,"Plasma, serum, PBMC, proviral DNA, dried blood spots",0,Not reported,1,Not reported,1
Human Answer,37716367,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,Not applicable / no — the paper does not present sequence data from individuals on treatment or with virological failure.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Not reported,1,Yes,0,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,No,1
Human Answer,37716367,13,Were the patients in the study in a clinical trial?,Boolean,No,No — this paper is a guideline and not a clinical trial report.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37716367,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report sequences from treated individuals.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Not reported,1,Yes,0,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,No,1
Human Answer,37716367,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable / not reported — the paper does not contain a study cohort and so lists no drug classes received by study participants.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,"NRTI, NNRTI, PI",0,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,Not reported,1,Not reported,1,No,1,No,1,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NRTIs, NNRTIs, PIs",0,Not reported,1,Not reported,1
Human Answer,37716367,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not applicable / not reported — the paper does not report individual-level drug exposures or specific drugs received.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,"Efavirenz, Nevirapine, Lopinavir",0,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,"AZT, 3TC, EFV, NVP, RPV",0,"AZT, 3TC",0,"AZT, 3TC, EFV, NVP, LPV/r",0,Not reported,1,Not reported,1
Human Answer,37755428,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the study reports HIV sequences generated from patient samples (dried blood spots) and successful quality-assured genotypes for PR/RT and integrase were obtained.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0,Yes,1
Human Answer,37755428,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No — the paper reports genotypic resistance predictions using the Stanford HIVdb algorithm, not phenotypic in vitro drug susceptibility testing.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,,1,No,1
Human Answer,37755428,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported — the paper does not state GenBank or other public accession deposition.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Not Reported,1,,1,No,1
Human Answer,37755428,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not provided — the paper does not list any GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,KP170487,0,Not Reported,1,,1,Not reported,1
Human Answer,37755428,5,How many individuals had samples obtained for HIV sequencing?,Number,143,"143 infants had remnant specimens available for HIVDR testing; of these, 121 yielded quality-assured PR/RT genotypes and 105 yielded quality-assured integrase genotypes.",1,143,1,143,1,143,1,143,1,Not reported,0,143,1,143,1,143,1,143,1,143,1,143,1,143,1,143,1,143,1,276,0,143,1,143,1,143,1,143,1,,0,143,1
Human Answer,37755428,6,From which countries were the sequenced samples obtained?,List,Haiti,Haiti.,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Haiti,1,Not Reported,0,,0,Haiti,1
Human Answer,37755428,7,From what years were the sequenced samples obtained?,List,2020-2021,"Samples were obtained between April 2020 and March 2021 (i.e., 2020–2021).",1,2020-2021,1,2020-2021,1,2020–2021,1,2020–2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,2020-2021,1,,0,2020-2021,1
Human Answer,37755428,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported — there is no mention of cloning; sequencing was performed by a Sanger-based method on extracted nucleic acids.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,,1,No,1
Human Answer,37755428,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",Protease/reverse transcriptase (PR/RT) and integrase regions.,1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,No,0,"PR/RT, Integrase",1,IN,0,IN,0,"PR, RT, IN",1,"PR/RT, integrase",1,No,0,No,0,"PR/RT, Integrase",1,"PR/RT, IN",1,"PR/RT, IN",1,,0,"PR/RT, IN",1
Human Answer,37755428,10,What method was used for sequencing?,List,Sanger sequencing,Sanger-based sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,,0,Sanger sequencing,1
Human Answer,37755428,11,What type of samples were sequenced?,List,DBS,Remnant dried blood spot (DBS) specimens collected at the time of HIV diagnosis.,1,Other,0,DBS,1,DBS,1,Dried blood spots,0,DBS,1,Dried blood spots (DBS),1,Dried blood spots,0,DBS,1,DBS,1,Dried blood spots,0,DBS,1,DBS,1,DBS,1,Dried blood spots,0,DBS,1,DBS,1,Dried blood spot,0,DBS,1,DBS,1,,0,DBS,1
Human Answer,37755428,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — sequences were from ART-naive infants; the mother's virus was not sequenced despite her having detectable viral load before delivery.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Yes,0,Not reported,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,,1,Yes,0
Human Answer,37755428,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the data derive from a national survey of HIV drug resistance, not a clinical trial.",1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,,1,No,1
Human Answer,37755428,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"Yes — although infants were ART-naive, the majority had prior exposure to antiretroviral drugs for PMTCT and some infants received prophylaxis (e.g., ZDV-based PNP); mothers had received ART including DTG-based regimens.",0,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,,1,Yes,0
Human Answer,37755428,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Reported exposures include nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) — e.g., zidovudine (ZDV), tenofovir, lamivudine — and integrase strand transfer inhibitor (INSTI) exposure via maternal dolutegravir. The paper also discusses prior use/exposure to NNRTIs in the context of PNP historically.",0,INSTI,0,"NRTI, INSTI",0,,1,NRTI,0,"NRTI, INSTI",0,"NRTI, NNRTI",0,"NRTI, INSTI",0,"NRTI, INSTI",0,"NRTI, INSTI",0,"NRTIs, INSTIs",0,"NRTI, INSTI",0,"NRTI, INSTI",0,INSTI,0,INSTI,0,INSTI,0,INSTI,0,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, INSTI",0,,1,"NRTI, NNRTI, INSTI",0
Human Answer,37755428,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Specifically reported drugs include maternal tenofovir/lamivudine/dolutegravir (TDF/3TC/DTG) and infant ZDV-based postnatal prophylaxis; the paper also notes widespread DTG-based ART among mothers and PMTCT exposures generally.,0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG)",0,,1,Zidovudine,0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, Lamivudine (3TC), Dolutegravir (DTG)",0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, lamivudine, dolutegravir",0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, lamivudine, dolutegravir",0,Dolutegravir (DTG),0,DTG,0,"DTG, tenofovir, and lamivudine",0,DTG,0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, Lamivudine, Dolutegravir",0,,1,"DTG, ABC, 3TC, TDF, EFV, NVP",0
Human Answer,37775947,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37775947,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37775947,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No accession information provided.,1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,Not reported,1,No,1
Human Answer,37775947,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not Reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences, but the specific accession numbers are not provided in the text.",1,Not reported,1,Not reported,1
Human Answer,37775947,5,How many individuals had samples obtained for HIV sequencing?,Number,1380 or 1819,Baseline NGS data were available for 1380 participants included in the analysis (1819 participants had NGS data at ≥200 read depth overall).,1,1380,1,1380,1,1380,1,1380,1,1380,1,1380,1,1380,1,1380,1,1380,1,1380.,1,1380,1,1380,1,1380,1,1380,1,1380,1,1380,1,1380,1,1380,1,1380,1,1380,1,1380,1
Human Answer,37775947,6,From which countries were the sequenced samples obtained?,List,"South America, Africa, USA, Asia, Australia, Europe","Specific countries are not listed; samples were obtained from multiple regions including South America, Africa, the USA, Europe and other START study regions.",0,"South America, Africa, USA",0,No,0,Not reported,0,"Africa, USA",0,"South America, Africa, USA",0,"USA, Africa, South America",0,Not reported,0,"South America, Africa, USA",0,No,0,"South America, Africa, Europe, USA.",0,Not Reported,0,Not Reported,0,"Africa, USA",0,Multiple countries,0,No,0,No,0,Not Reported,0,"South America, Europe, USA, Africa",0,"South America, Africa, and the USA",0,Not reported,0,"South America, Europe, USA",0
Human Answer,37775947,7,From what years were the sequenced samples obtained?,List,2009-2013,Samples were obtained from participants enrolled between April 2009 and December 2013 (baseline samples taken within 60 days before enrolment).,1,2009-2013,1,2009-2013,1,2009–2013,1,2009–2013,1,2009–2013,1,2009-2013,1,2009-2013,1,2009-2013,1,2009-2013,1,2009-2013.,1,2009-2013,1,2009-2013,1,2009-2013,1,2009-2013,1,2009-2013,1,2009-2013,1,2009-2013,1,2009-2013,1,2009-2013,1,2009-2013,1,2009-2013,1
Human Answer,37775947,8,Were samples cloned prior to sequencing?,Boolean,No,No — cloning is not reported; samples were amplified and sequenced by NGS without mention of cloning.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37775947,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol","The pol gene was sequenced (positions 1–935 covering protease positions 1–99, reverse transcriptase positions 100–659, and partial integrase positions 660–935).",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"Pol (including PR, RT)",1,"PR, RT, IN",0,"Protease, Reverse transcriptase, Integrase",0,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",0,"PR, RT, IN",0,"Pol (protease, reverse transcriptase, integrase).",1,Pol (protease and reverse transcriptase regions),0,Pol,0,"PR, RT, IN",0,Pol,0,"Protease, Reverse transcriptase, and Integrase",0,"PR, RT, IN",0,Pol,0,"Pol, PR, RT",0,Yes,0,Pol,0,Pol,0
Human Answer,37775947,10,What method was used for sequencing?,List,Illumina sequencing,"Next-generation sequencing using Illumina MiSeq, with variant calling by VirVarSeq.",1,Illumina sequencing,1,Illumina sequencing,1,NGS,0,NGS,0,NGS,0,Illumina NGS,1,"Next Generation Sequencing (NGS, Illumina MiSeq)",1,Next-generation sequencing (NGS),1,Illumina sequencing,1,NGS (Illumina MiSeq).,1,NGS (Illumina MiSeq),1,NGS,0,Illumina sequencing,1,NGS,0,Illumina sequencing,1,Illumina sequencing,1,NGS,0,Sanger sequencing,0,Yes,0,NGS,0,NGS,0
Human Answer,37775947,11,What type of samples were sequenced?,List,Plasma,Stored plasma samples.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,"NRTIs, NNRTIs, and PIs",0,Plasma,1,Plasma,1
Human Answer,37775947,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — sequences were from ART-naïve participants at baseline; they were not sampled while failing therapy.,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Yes.,0,Not Reported,1,Yes,0,Yes,0,Not reported,1,No,1,No,1,Yes,0,Yes,0,"Tenofovir, lamivudine, efavirenz, and lopinavir/ritonavir",1,Yes,0,Yes,0
Human Answer,37775947,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes — participants were enrolled in the START randomized clinical trial.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,37775947,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the participants were antiretroviral therapy (ART)-naïve at enrollment.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer,37775947,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"None prior to sequencing (participants were ART-naïve). After sequencing, first-line regimens initiated included NRTIs (tenofovir + emtricitabine or 3TC) plus either an NNRTI, a boosted protease inhibitor, or an integrase strand transfer inhibitor.",1,"NRTI, NNRTI",0,No,1,,1,,1,,1,"NNRTI, PI, INSTI",0,"NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0,No,1,Not reported.,1,Not Reported,1,"NNRTI, PI, INSTI",0,"NNRTI, PI, INSTI",0,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,No,1,,1,"NRTI, NNRTI, PI, INSTI",0,No,1,Not reported,1,"NRTI, NNRTI",0
Human Answer,37775947,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"None prior to sequencing. After baseline, commonly initiated drugs/regimens included tenofovir and emtricitabine (FTC) or lamivudine (3TC) as NRTI backbone, and efavirenz (NNRTI) was commonly used; other drugs mentioned include rilpivirine, raltegravir, elvitegravir and boosted protease inhibitors.",1,"Individuals in the study received a first-line antiretroviral therapy (ART) that included a non-nucleoside reverse transcriptase inhibitor (NNRTI), a boosted protease inhibitor, or an integrase strand transfer inhibitor, with the majority receiving a regimen that included tenofovir/emtricitabine (FTC) combined with efavirenz.",0,No,1,,1,,1,,1,"Tenofovir disoproxil fumarate (TDF), Emtricitabine (FTC), Efavirenz (EFV)",0,Not explicitly reported,0,"Efavirenz, Tenofovir, Emtricitabine",0,No,1,Not reported.,1,Not Reported,1,"NNRTI, PI, INSTI",0,Not reported,1,Not reported,1,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,1,,1,"Tenofovir, Lamivudine, Efavirenz, Raltegravir",0,No,1,Not reported,1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0
Human Answer,37817087,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The paper reports HIV sequences obtained from patient samples (protease and reverse-transcriptase sequences from 4559 cases and protease, reverse-transcriptase and integrase sequences from 3097 cases) collected as plasma, serum or dried spots.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37817087,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance (sequence-based) interpreted with the Stanford HIVdb algorithm, not in vitro phenotypic drug susceptibility assays.",1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37817087,3,Were sequences from the paper made publicly available?,Boolean,No,No — sequences were not deposited in a public repository in the paper; the datasets including sequences are available from the corresponding author upon reasonable request.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37817087,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. No GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1
Human Answer,37817087,5,How many individuals had samples obtained for HIV sequencing?,Number,4559 and 3097,PR/RT sequences were obtained from 4559 individuals; PR/RT/IN sequences were obtained from 3097 individuals.,1,4559,1,4559,1,4559,1,4559,1,4559,1,4559,1,4559,1,4559,1,4559,1,"4559 (PR and RT), 3097 (PR, RT, and IN)",1,"4559 (PR and RT), 3097 (PR, RT, and IN)",1,4559,1,4559,1,4559,1,4559; 3097,1,"4559, 3097",1,4559,1,4559,1,4559,1,4559,1,4559,1
Human Answer,37817087,6,From which countries were the sequenced samples obtained?,List,Germany,Germany (national surveillance of new HIV diagnoses reported to the Robert Koch Institute); cases include persons of German and non-German origin but samples were submitted within Germany.,1,No,0,Germany,1,Germany,1,Germany,1,Germany,1,Germany,1,Not reported,0,Germany,1,Germany,1,Germany (implied),1,Germany,1,Germany,1,Germany,1,Germany,1,No,0,Germany,1,Germany and non-German countries,1,Germany,1,Germany,1,Germany,1,Not reported,0
Human Answer,37817087,7,From what years were the sequenced samples obtained?,List,2017-2020,From 2017 to 2020.,1,2017-2020,1,2017-2020,1,2017–2020,1,2017–2020,1,2017–2020,1,2017-2020,1,2017–2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1,2017-2020,1
Human Answer,37817087,8,Were samples cloned prior to sequencing?,Boolean,No,No. The methods describe PCR amplification of target regions and direct Illumina NGS (MiSeq) sequencing of amplicons; no cloning step is reported.,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1
Human Answer,37817087,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Protease (PR), reverse transcriptase (RT) and integrase (IN).",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, and IN",1,"PR, RT, IN",1,"Pol, Integrase",0,"PR, RT, IN",1,"PR, RT, IN",1
Human Answer,37817087,10,What method was used for sequencing?,List,Illumina sequencing,Illumina next-generation sequencing (MiSeq) of PCR amplicons.,1,Illumina sequencing,1,Illumina sequencing,1,NGS,0,NGS,0,NGS,0,Illumina NGS (MiSeq),1,Illumina sequencing,1,Illumina sequencing,1,Illumina sequencing,1,Illumina NGS (MiSeq),1,NGS,0,NGS,0,Illumina sequencing,1,Illumina sequencing,1,Illumina sequencing,1,Illumina sequencing,1,NGS (Illumina MiSeq),1,NGS,0,"Illumina NGS method (MiSeq), Sanger sequencing",1,Illumina sequencing,1,Illumina sequencing,1
Human Answer,37817087,11,What type of samples were sequenced?,List,"Serum, Plasma, DBS",Patient plasma or serum and dried serum/plasma spots (Whatman 903) eluted from filter paper.,0,Serum,0,Plasma; Serum; DBS,1,"Plasma, Serum",0,"Plasma, Serum",0,DBS,0,Serum; Plasma,0,"Serum, Plasma, Dried spots",0,Plasma; Serum,0,Plasma; Serum,0,"Serum, plasma, dried serum/plasma spots",0,"Plasma, serum",0,"Plasma, Serum",0,Plasma; Serum,0,Plasma; Serum,0,Plasma; Serum,0,"Plasma, Serum",0,Plasma or serum,0,"Plasma, serum, spot elution",0,"Plasma, Serum, PBMC, Proviral DNA",0,Plasma; Serum,0,"Serum, Plasma, Spot elution",0
Human Answer,37817087,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not specifically reported; the study analyzed new HIV diagnoses (primary/transmitted resistance), not persons selected for virological failure on treatment, although the authors note some treated cases abroad could be misclassified.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0
Human Answer,37817087,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Samples were collected as part of national surveillance reporting to the Robert Koch Institute, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1
Human Answer,37817087,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the study focuses on new diagnoses (primary/transmitted resistance). The authors note they cannot completely exclude that some cases previously treated abroad were misclassified as new diagnoses, but sequences from previously treated individuals are not specifically reported.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37817087,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not reported. The paper does not provide information on antiretroviral drug classes received prior to sequencing by the sampled individuals (the analysis concerns transmitted resistance prevalence across NRTI, NNRTI, PI and INI classes but not prior exposures).",1,No,1,No,1,,1,,1,,1,Not reported,1,Not reported,1,"NRTI, NNRTI, PI, INST",0,No,1,Not reported,1,,1,Not reported,1,"NRTI, NNRTI, PI, INI",0,"NRTI, NNRTI, PI, INSTI",0,No,1,No,1,Not reported,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INI",0,"NRTI, NNRTI, PI",0
Human Answer,37817087,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not reported. The manuscript does not list specific antiretroviral drugs received by participants prior to sequencing.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,1,Not reported,1,,1,Not reported,1,"Tenofovir disoproxil fumarate (TDF), Emtricitabine (FTC), Lamivudine (3TC), Abacavir (ABC)",0,"Tenofovir disoproxil fumarate (TDF), Emtricitabine (FTC), Efavirenz (EFV), and others",0,No,1,No,1,Not reported,1,Not reported,1,"Tenofovir, Lamivudine, Efavirenz, Raltegravir",0,"TDF, FTC, 3TC, ABC, EFV, NVP, AZT, d4T",0,"NRTIs, NNRTIs, PIs",0
Human Answer,37823653,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37823653,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37823653,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No evidence of public deposition in the paper.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1,Not Reported,1,No,1,Not Reported.,1,No,1,No,1,No,1,No,1,Not Reported,1,"Yes, but accession numbers are not provided",0,Yes,0,Not reported,1,Yes,0
Human Answer,37823653,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None provided / Not reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not Reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,"The paper reports that sequences were submitted to GenBank and provides accession numbers, but the specific accession numbers are not provided in the text.",1,Not reported,1,MN234327 - MN235714,0
Human Answer,37823653,5,How many individuals had samples obtained for HIV sequencing?,Number,6078 or 6030,"6,078 individuals (sequences) were generated; analysis focused on subsets (e.g., 1,495 for the FTR analysis).",1,6078,1,6078,1,"6,030",1,"1,495",0,6078,1,6030,1,"6,078",1,6078,1,6030,1,"6,078",1,"6,078",1,"6,078 - 48 = 6,030.",1,"6,078",1,"6,078",1,6078,1,6078,1,Not Reported,0,"6,030",1,"6,078",1,"6,078",1,"6,078",1
Human Answer,37823653,6,From which countries were the sequenced samples obtained?,List,Botswana,Botswana.,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana.,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1
Human Answer,37823653,7,From what years were the sequenced samples obtained?,List,2013-2018,Enrolled between 2013 and 2018.,1,2013-2018,1,2013-2018,1,2013–2018,1,2013–2018,1,2013–2018,1,2013-2018,1,2013-2018,1,2013-2018,1,2013-2018,1,2013-2018,1,2013-2018,1,Not Reported.,0,2013-2018,1,2013-2018,1,2013-2018,1,2013-2018,1,2013-2018,1,2013-2018,1,2013-2018,1,2013-2018,1,2013-2018,1
Human Answer,37823653,8,Were samples cloned prior to sequencing?,Boolean,No,No evidence of cloning; samples were amplified from proviral DNA and sequenced by NGS to produce a consensus.,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not Reported.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1
Human Answer,37823653,9,Which HIV genes were reported to have been sequenced?,List,"NFLG, gp120","Near full-length HIV-1 sequences were generated, and the gp120 region of the envelope (env) gene was specifically extracted and analyzed.",0,Near full length genome,1,Near full length genome,1,Env (gp120),0,Not reported,0,Env,0,gp120,0,gp120,0,Envelope,0,Envelope,0,gp120,0,Not reported,0,Env.,0,gp120,0,gp120,0,Envelope,0,No,0,Full-length genome,0,Env,0,Env,0,gp120,0,Envelope gene,0
Human Answer,37823653,10,What method was used for sequencing?,List,Illumina sequencing,Long-range PCR genotyping followed by next-generation sequencing (NGS) on Illumina MiSeq and HiSeq platforms.,1,Illumina sequencing,1,Illumina sequencing,1,NGS (Next-Generation Sequencing),1,NGS,0,NGS,0,Illumina sequencing,1,Illumina sequencing,1,Illumina sequencing,1,Illumina sequencing,1,NGS,0,NGS (Illumina platform),1,NGS.,0,Illumina sequencing,1,Illumina sequencing,1,Illumina sequencing,1,No,0,NGS,0,NGS,0,NGS,0,Next-generation sequencing (NGS),1,Next-generation sequencing,1
Human Answer,37823653,11,What type of samples were sequenced?,List,PBMC,Proviral DNA templates (from participants) were amplified and sequenced.,0,No,0,PBMC,1,Proviral DNA,0,Not reported,0,Proviral DNA,0,Plasma,0,Blood samples,0,PBMC,1,PBMC,1,Proviral DNA,0,PBMCs,1,Not Reported.,0,Plasma,0,Proviral DNA,0,Proviral DNA templates,0,Proviral DNA,0,PBMC,1,Plasma,0,Proviral DNA,0,Plasma,0,Proviral DNA,0
Human Answer,37823653,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — sequences from individuals experiencing virologic failure (VL >400 copies/mL) were included; 213 such individuals were analyzed.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37823653,13,Were the patients in the study in a clinical trial?,Boolean,No,"Yes — participants were enrolled in the Botswana Combination Prevention Project (BCPP), which is registered on ClinicalTrials.gov (NCT01965470).",0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Not Reported.,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer,37823653,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes — sequences from ART-experienced individuals were included (4,748 ART-experienced participants overall).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37823653,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI","Primarily non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens (efavirenz or nevirapine); dolutegravir (an integrase strand transfer inhibitor, INSTI) was introduced as first-line later (after June 2016).",1,NNRTI,1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,NNRTI,1,NNRTI,1,NNRTI,1,"NNRTI, PI",1,"NNRTI, INSTI",1,"NNRTI, NRTI",1,NNRTI,1,Not Reported.,0,Not reported,0,NNRTI,1,NNRTI,1,No,0,"NRTI, NNRTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTIs, NNRTIs, and PIs",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1
Human Answer,37823653,16,Which drugs were received by individuals in the study before sample sequencing?,List,"EFV, NVP",Efavirenz and nevirapine were the main drugs reported; dolutegravir-based regimens were implemented after June 2016 (and thus some participants may have had dolutegravir exposure depending on timing).,1,Individuals in the study before sample sequencing primarily received efavirenz (EFV) or nevirapine (NVP) as part of their antiretroviral therapy (ART).,1,"Efavirenz (EFV), Nevirapine (NVP)",1,"Efavirenz, Nevirapine",1,"Efavirenz, Nevirapine",1,"Efavirenz, Nevirapine",1,"Efavirenz, Nevirapine",1,"Efavirenz, Nevirapine",1,"Efavirenz, Nevirapine",1,"Efavirenz (EFV), Nevirapine (NVP), Dolutegravir (DTG)",1,"Efavirenz, Nevirapine, Dolutegravir",1,"Efavirenz, nevirapine",1,Not Reported.,0,Not reported,0,"Efavirenz, Nevirapine",1,"Efavirenz, Nevirapine",1,No,0,"Efavirenz, Nevirapine, Other ARVs",1,"AZT, 3TC, FTC, TDF, EFV, NVP, RAL, DTG, CAB, LEN",1,"Efavirenz, nevirapine, and lopinavir/ritonavir",1,"Efavirenz, Nevirapine, Dolutegravir",1,"Efavirenz, Nevirapine, Dolutegravir",1
Human Answer,37872202,1,Does the paper report HIV sequences from patient samples?,Boolean,No,Yes. The study uses HIV env sequences derived from previously reported patient-derived isolates (including a transmitted/founder CRF01_AE T/F100 from participant 40100 of the RV217 cohort) and engineered env constructs.,0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes.,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37872202,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes. The paper reports in vitro neutralization/drug susceptibility data for temsavir using single-round luciferase-expressing pseudovirus neutralization assays and reports IC50 values.,1,Yes,1,No,0,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0
Human Answer,37872202,3,Were sequences from the paper made publicly available?,Boolean,No,"Partially. Structural data (atomic models and EM maps) were deposited in PDB and EMDB, but no GenBank accession numbers for nucleotide sequences are reported in the Data availability statement.",1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,Yes.,0,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer,37872202,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,No GenBank accession numbers are provided in this paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported (specific accession numbers are not listed in the paper provided),1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,"8DOK, 8G6U, 8CZZ, and 8TTW",0,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1,MN234327 - MN235714,0
Human Answer,37872202,5,How many individuals had samples obtained for HIV sequencing?,Number,0,"The paper does not report new patient sampling numbers for sequencing; it uses previously reported env sequences (e.g., T/F100 from participant 40100 and previously described env plasmids) rather than describing the number of individuals newly sequenced in this study.",0,0,1,0,1,1,0,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported.,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,6,0,5,0
Human Answer,37872202,6,From which countries were the sequenced samples obtained?,List,No,"The transmitted/founder CRF01_AE T/F100 Env was derived from a participant in Thailand; origins of other referenced env constructs (e.g., 92TH023, CM244) are noted as previously reported but specific countries for those constructs are not specified in this paper.",1,No,1,No,1,Thailand,0,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Thailand,0,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Thailand,0,Not reported,1,"United States, Australia",0,"United States, Australia",0
Human Answer,37872202,7,From what years were the sequenced samples obtained?,List,No,The paper does not report the years when the original patient-derived sequences were obtained.,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2004–2007,0,Not reported,1,Not reported,1,2007-2008,0
Human Answer,37872202,8,Were samples cloned prior to sequencing?,Boolean,No,Yes—env sequences used in the study were present in cloned expression plasmids and mutations were introduced by site-directed mutagenesis with confirmation by automated DNA sequencing.,0,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported.,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37872202,9,Which HIV genes were reported to have been sequenced?,List,No,env gene products were the focus: gp120/gp41 regions and stabilized gp140 (SOSIP.664) trimers were used and analyzed (Env/gp120/gp41/gp140).,0,No,1,No,1,Env,0,Env,0,Not reported,1,Env,0,gp120,0,No,1,No,1,"Pol, Env.",0,"Pol, Env",0,Pol,0,IN,0,Not reported,1,No,1,No,1,Env,0,Pol,0,Pol,0,IN,0,"Gag, PR, RT",0
Human Answer,37872202,10,What method was used for sequencing?,List,No,"Automated DNA sequencing was used to confirm the presence of introduced mutations in the env expression plasmids; the manuscript does not specify the platform (e.g., Sanger vs. NGS).",1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Cryo-electron microscopy (Cryo-EM),0,Illumina sequencing,0,No,1,No,1,Not reported.,1,"Sanger sequencing, Illumina MiSeq",0,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Sanger sequencing and NGS,0,Sanger sequencing,0,Sanger sequencing and NGS,0,Illumina sequencing,0,Sanger sequencing,0
Human Answer,37872202,11,What type of samples were sequenced?,List,No,Cloned env expression plasmids and engineered protein constructs were sequenced/validated; experimental assays used recombinant luciferase-expressing pseudoviruses produced from transfected HEK293T cells and purified SOSIP.664 gp140 proteins from Expi293F cells.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Engineered viral samples,1,Engineered viruses,1,No,1,No,1,Not reported.,1,"Plasma, PBMC",0,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,"Plasma, serum, and PBMC",0,"Plasma, PBMC",0,"Plasma, serum, PBMC, proviral DNA, and dried blood spots",0,PBMC,0,PBMC,0
Human Answer,37872202,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No. The manuscript does not report sequences from individuals characterized as experiencing virological failure on antiretroviral therapy.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,No,1,Not reported.,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37872202,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The manuscript does not describe enrolling patients in a clinical trial; it uses previously collected cohort-derived material (RV217 Early Capture HIV Cohort) and previously reported env constructs.,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer,37872202,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The paper does not report treatment histories or indicate that the source individuals had previously received antiretroviral drugs.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1,Not reported.,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37872202,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not reported. The manuscript does not provide antiretroviral treatment histories or list drug classes received by source individuals.,1,No,1,No,1,,1,Not reported,1,Not reported,1,"NRTI (Tenofovir disoproxil fumarate), NNRTI (Lamivudine, Efavirenz), CCR5 Antagonist (Maraviroc), INSTI (Raltegravir)",0,"NRTI, NNRTI, INSTI, CCR5 antagonist",0,No,1,No,1,Not reported.,1,"NRTI, NNRTI, PI, INSTI",0,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,"NRTIs, NNRTIs, and PIs",0,"NRTI, PI, NRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI, CAI",0,"NRTI, NNRTI, INSTI, CCR5 antagonist",0,"NRTI, NNRTI, INSTI, CCR5 antagonist",0
Human Answer,37872202,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not reported. The manuscript does not state any specific antiretroviral drugs received by the individuals who provided the source env sequences.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL)",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL)",0,No,1,No,1,Not reported.,1,"Zidovudine, Lamivudine, Efavirenz, Raltegravir",0,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Temsavir,0,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0,"Raltegravir, dolutegravir, elvitegravir, bictegravir, maraviroc, lenacapavir",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0
Human Answer,37878637,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer,37878637,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"No
```",1,No,1
Human Answer,37878637,3,Were sequences from the paper made publicly available?,Boolean,No,"Partially — underlying study data are available on figshare, but the paper does not report GenBank accession numbers for the sequences.",1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,"Yes
```",0,Yes,0
Human Answer,37878637,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"Not reported
```",1,Not reported,1
Human Answer,37878637,5,How many individuals had samples obtained for HIV sequencing?,Number,141,141 participants had samples successfully sequenced and were included in the analysis.,1,141,1,141,1,141,1,141,1,141,1,141,1,141,1,141,1,141,1,141,1,141,1,141,1,29,0,29,0,141,1,141,1,141,1,141,1,141,1,"141
```",1,141,1
Human Answer,37878637,6,From which countries were the sequenced samples obtained?,List,Cameroon,Cameroon.,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Uganda,0,Cameroon,1,No,0,Cameroon,1,Cameroon,1,Cameroon,1,"Cameroon
```",1,Cameroon,1
Human Answer,37878637,7,From what years were the sequenced samples obtained?,List,2018-2020,Samples were obtained during 2018–2020.,1,2018-2020,1,2018-2020,1,2018–2020,1,2018–2020,1,2018–2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2006-2011,0,2018-2020,1,No,0,2018-2020,1,2018-2020,1,2018-2020,1,"2018-2020
```",1,2018-2020,1
Human Answer,37878637,8,Were samples cloned prior to sequencing?,Boolean,No,No; PCR products were directly sequenced (no cloning step reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,"No
```",1,No,1
Human Answer,37878637,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT","Protease and reverse transcriptase regions of the pol gene (approximately 1,600 bp).",1,"Protease, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"Protease, Reverse Transcriptase",1,"PR, RT",1,"Protease, Reverse transcriptase",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,Protease and reverse transcriptase,1,"PR, RT",1,"PR, RT, Env",1,"Protease, Reverse transcriptase",1,"PR, RT",1,Pol,0,"PR, RT",1,No,0,"Protease, Reverse Transcriptase
```",1,"PR, RT",1
Human Answer,37878637,10,What method was used for sequencing?,List,Sanger sequencing,Sanger (capillary) sequencing of PCR products using an Applied Biosystems 3500 genetic analyzer (in-house PCR and primer set).,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Next-generation sequencing,0,Not reported,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Yes,0,"PCR sequencing
```",0,Sanger sequencing,1
Human Answer,37878637,11,What type of samples were sequenced?,List,Plasma,Plasma samples (viral RNA extracted from plasma obtained from whole blood).,1,Whole Blood,0,Plasma,1,"Whole blood, Plasma",1,"Plasma, Whole Blood",1,Whole Blood,0,Plasma,1,Plasma,1,Whole Blood,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Whole Blood,0,Whole Blood,0,Whole blood,0,Plasma,1,"NRTIs, NNRTIs",0,"Plasma
```",1,Whole blood,0
Human Answer,37878637,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — sequences were obtained from participants experiencing virological failure (PVL ≥ 1000 RNA copies/mL) while on ART.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,"TDF, 3TC, EFV, ATV/r, DRV/r",0,"Yes
```",1,Yes,1
Human Answer,37878637,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the study was a cohort study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"No
```",1,No,1
Human Answer,37878637,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — participants were on ART (first- or second-line regimens) and some had prior exposure to PMTCT; sequences were obtained from these treated individuals.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,Yes,1,Yes,1,No,0,"Yes
```",1,Yes,1
Human Answer,37878637,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI","Nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).",1,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",1,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NRTI, PI",0,"NRTIs, PIs",0,"NRTI, PI, NNRTI",1,"NRTI, NNRTI",0,No,0,"NRTI, PI",0,"NRTIs, NNRTIs, PIs",1,Not reported,0,"NRTI, NNRTI",0,Not reported,0,"NRTI, NNRTI, PI",1,No,0,NRTIs,0,"NRTIs, NNRTIs",0,No,0,"NRTI, PI
```",0,NRTI,0
Human Answer,37878637,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, EFV","Commonly reported regimens included TDF (tenofovir), 3TC (lamivudine), and EFV (efavirenz) as the predominant first-line combination; some participants were switched to ritonavir-boosted protease inhibitor-based second-line regimens.",1,"Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV)",1,"Tenofovir (TFV), Lamivudine (3TC), Efavirenz (EFV), Lopinavir (LPV), Atazanavir (ATV), Darunavir (DRV)",1,"TDF, 3TC, EFV",1,"TDF, 3TC, EFV",1,"TDF, 3TC, EFV",1,"Stavudine (d4T), Lamivudine (3TC), Lopinavir (LPV/r)",0,"Stavudine (d4T), Lamivudine (3TC), Abacavir (ABC), Didanosine (ddI), Zidovudine (AZT)",0,"Tenofovir (TFV), Lamivudine (3TC), Efavirenz (EFV)",1,No,0,"TDF, 3TC, EFV",1,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, and lenacapavir",1,Not reported,0,"Lamivudine, Stavudine, Nevirapine, Zidovudine, Efavirenz",0,Not reported,0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV)",1,No,0,TDF + 3TC + EFV,1,"TDF, 3TC, EFV",1,No,0,"Lamivudine (3TC), Stavudine (d4T), Lopinavir (LPV/r), Ritonavir (RTV)
```",0,"Tenofovir (TDF), Emtricitabine (3TC), Efavirenz (EFV)",1
Human Answer,37880705,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports patient-derived HIV-1 pol sequences (1070 sequences) from ART-naïve Ethiopian individuals.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37880705,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper reports genotypic (sequence-based) resistance analysis but does not report in vitro phenotypic drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37880705,3,Were sequences from the paper made publicly available?,Boolean,No,Yes — many sequences were publicly available via GenBank and sequences not found online were requested from study authors; the paper states sequences were downloaded from GenBank or obtained from authors.,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37880705,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not listed in the provided text — GenBank accession numbers are not specified in the main manuscript text shown (likely provided in the supplementary files or in the original source studies).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1,Not reported,1
Human Answer,37880705,5,How many individuals had samples obtained for HIV sequencing?,Number,1070,1070 individuals (corresponding to 1070 HIV-1 pol sequences) were included in the pooled analysis.,1,1070,1,1070,1,Not reported,0,1070,1,1070,1,1070,1,1070,1,1070,1,1070,1,1070,1,1070,1,1070,1,1070,1,1070,1,1070,1,1070,1,1070,1,1070,1,1070,1,1070,1,1070,1
Human Answer,37880705,6,From which countries were the sequenced samples obtained?,List,Ethiopia,Ethiopia.,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1
Human Answer,37880705,7,From what years were the sequenced samples obtained?,List,2003-2018,From 2003 to 2018.,1,2003-2018,1,2003-2018,1,2003–2018,1,2003–2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1,2003-2018,1
Human Answer,37880705,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported — the paper does not state that samples were cloned prior to sequencing.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1
Human Answer,37880705,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",HIV-1 pol gene encompassing full protease (PR) and partial reverse transcriptase (RT) (the first ~230 codons of RT) were sequenced/analyzed.,1,"PR, RT",1,"PR, RT",1,Pol,0,Pol,0,"PR, RT",1,"PR, RT",1,Pol,0,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,Pol,0,Pol,0,Pol,0,Pol,0,Pol,0,No,0,"PR, RT",1,Pol,0,Pol,0,Not reported,0,Pol,0,Pol,0
Human Answer,37880705,10,What method was used for sequencing?,List,No,"Not specified in the provided text — the paper does not describe the laboratory sequencing method (e.g., Sanger or NGS); sequences were retrieved from GenBank or authors and analyzed bioinformatically.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing,0,No,1,Not reported,1,Not reported,1
Human Answer,37880705,11,What type of samples were sequenced?,List,No,"Not specified in the provided text — the manuscript does not state the biological specimen type (e.g., plasma RNA, proviral DNA) used for sequencing in the included studies.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Plasma,0,Plasma,0,Whole Blood,0,Not reported,1,No,1,"Plasma, Whole Blood, Serum",0,Not reported,1,Plasma,0,,1,Plasma,0,Blood,0
Human Answer,37880705,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — sequences were from ART-naïve individuals and studies among ART-experienced individuals were excluded.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,,1,No,1,No,1
Human Answer,37880705,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the paper is a pooled sequence analysis of observational studies/surveillance among ART-naïve individuals, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1
Human Answer,37880705,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the sequences analyzed come from ART-naïve individuals (i.e., individuals who had not previously received ARV drugs).",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1
Human Answer,37880705,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None — individuals were ART-naïve and had not received ARV drug classes prior to sequencing.,1,NNRTI,0,No,1,,1,,1,,1,NRTI,0,NRTIs,0,No,1,No,1,,1,Not reported,1,"NRTIs, NNRTIs, PIs",0,Not reported,1,Not reported,1,No,1,No,1,,1,"NRTI, NNRTI",0,No,1,"NRTI, NNRTI",0,Not reported,1
Human Answer,37880705,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None — the participants were ART-naïve and had not received antiretroviral drugs before sequencing.,1,"Efavirenz, Nevirapine",0,No,1,,1,,1,,1,Atazanavir,0,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,,1,"AZT, 3TC, FTC, TDF, ABC, d4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC.",0,No,1,"Zidovudine (AZT), Lamivudine (3TC), Didanosine (DDI)",0,Not reported,1
Human Answer,37896785,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV-1 nucleotide sequences obtained from patient plasma samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37896785,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic resistance (sequence-based) analyses but does not report phenotypic (in vitro) drug susceptibility assays.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37896785,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. The nucleotide sequences were deposited in GenBank.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37896785,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,OQ215322-OQ215382,OQ215322–OQ215382.,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382.,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,No,0,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1
Human Answer,37896785,5,How many individuals had samples obtained for HIV sequencing?,Number,61,61 individuals (pregnant women).,1,61,1,61,1,61,1,61,1,61.,1,61,1,61,1,61,1,61,1,61,1,61,1,61,1,61,1,61,1,61,1,61,1,61,1,61,1,61,1,61,1,61,1
Human Answer,37896785,6,From which countries were the sequenced samples obtained?,List,Vietnam,"Vietnam (Ho Chi Minh City, Vietnam).",1,Vietnam,1,Vietnam,1,Vietnam,1,Vietnam,1,Vietnam.,1,Vietnam,1,Vietnam,1,Vietnam,1,Vietnam,1,Vietnam,1,Vietnam,1,Vietnam,1,Vietnam,1,Vietnam,1,Vietnam,1,No,0,Vietnam,1,Vietnam,1,Vietnam,1,Vietnam,1,Vietnam,1
Human Answer,37896785,7,From what years were the sequenced samples obtained?,List,2021,Samples were collected in 2021.,1,2021,1,2021,1,2021,1,2021,1,2021.,1,2021,1,2021,1,2021,1,2021,1,2021,1,2021,1,2021,1,2021,1,2021,1,2021,1,No,0,2021,1,2021,1,2021,1,2021,1,2021,1
Human Answer,37896785,8,Were samples cloned prior to sequencing?,Boolean,No,No. The samples underwent RT‑PCR and direct Sanger sequencing; no cloning step is described.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37896785,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",A fragment of the pol gene: the protease (PR) region and part of reverse transcriptase (RT).,1,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,"PR, RT",1,Pol,0,"Pol (PR, RT).",1,"PR, RT",1,"Protease (PR), Reverse Transcriptase (RT)",1,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,Pol (PR and RT),1,Pol,0,Pol,0,"PR, RT",1,Pol,0,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,Pol,0,Pol,0,No,0,"PR, RT",1,"PR, RT",1
Human Answer,37896785,10,What method was used for sequencing?,List,Sanger sequencing,Sanger sequencing of RT‑PCR amplicons using the AmpliSens HIVResist-Seq kit and analysis on an ABI Prism 3500 genetic analyzer.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1,Yes,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37896785,11,What type of samples were sequenced?,List,Plasma,Blood plasma samples (viral RNA from plasma).,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma.,1,Plasma,1,Blood plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,"NRTIs, NNRTIs",0,Plasma,1,Plasma,1
Human Answer,37896785,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. 31 of the 61 women showed virological failure of ART, and their samples were included among the sequenced isolates.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not Reported,0,Yes,1,Yes,1
Human Answer,37896785,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The paper describes an observational study of plasma samples from pregnant women seeking PMTCT; there is no indication that patients were enrolled in a clinical trial.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1
Human Answer,37896785,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. Sequences include samples from 31 women with virological failure of ART (i.e., previously treated individuals).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,37896785,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"The study indicates prior exposure and/or resistance to NRTIs, NNRTIs, and protease inhibitors (PIs); first-line regimens in Vietnam described are NRTI + NRTI + NNRTI, and PIs are used in later lines.",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,Not reported,1,Not reported,1,NRTI.,0,"NRTI, NNRTI, PI",0,"NRTI, PI",0,"NRTI, NNRTI, PI",0,No,1,Not Reported,1,Not Reported,1,"NRTIs, NNRTIs, PIs",0,"NRTI, NNRTI",0,"NRTI, PI",0,"NRTI, NNRTI, PI",0,No,1,"NRTIs, NNRTIs, PIs",0,Not Reported,1,No,1,"NRTI, PI",0,"NRTI, PI, NNRTI",0
Human Answer,37896785,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Individual-level ARV histories are not fully reported due to limited anamnesis and anonymity; however the paper cites common drugs/regimens used in Vietnam and drugs implicated by the detected resistance mutations, including stavudine (d4T), lamivudine (3TC), zidovudine (AZT), nevirapine (NVP), efavirenz (EFV), lamivudine/emtricitabine (3TC/FTC), and PIs such as lopinavir (LPV), darunavir (DRV), and others mentioned (e.g., fosamprenavir (FPV), indinavir, tipranavir, ritonavir).",0,"Stavudine (d4T), Lamivudine (3TC), Zidovudine (AZT), Nevirapine (NVP), Efavirenz (EFV)",0,"Lamivudine (3TC), Emtricitabine (FTC), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Darunavir (DRV), Lopinavir (LPV), Atazanavir (ATV)",0,Not reported,1,Not reported,1,Not reported.,1,"Zidovudine (AZT), Lamivudine (3TC), Stavudine (d4T), Nevirapine (NVP), Efavirenz (EFV)",0,"Zidovudine (ZDV), Lamivudine (3TC), Lopinavir/Ritonavir (LPV/RTV)",0,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,"Stavudine (d4T), Lamivudine (3TC), Zidovudine (AZT), Nevirapine (NVP), Efavirenz (EFV)",0,"Zidovudine (ZDV), Lamivudine (3TC), Lopinavir/ritonavir (LPV/RTV)",0,"Lamivudine (3TC), Stavudine (D4T), Zidovudine (AZT), Nevirapine (NVP), Efavirenz (EFV)",0,No,1,Not reported,1,Not Reported,1,No,1,"Zidovudine (ZDV), Lamivudine (3TC), Lopinavir/ritonavir (LPV/RTV)",0,"Zidovudine (ZDV), Lamivudine (3TC), Lopinavir/ritonavir (LPV/RTV)",0
Human Answer,37896860,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37896860,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37896860,3,Were sequences from the paper made publicly available?,Boolean,No,No — sequences/data are not publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer,37896860,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,"OM329944-48, OM366233-37, OM489471, OM418561, OM700184-199, OM801891-93",0
Human Answer,37896860,5,How many individuals had samples obtained for HIV sequencing?,Number,704,106 individuals had at least one DRT result.,0,704,1,106,0,106,0,106,0,106,0,106,0,106,0,704,1,0,0,106,0,106,0,704,1,Not reported,0,Not reported,0,704,1,0,0,106,0,106,0,106,0,704,1,32,0
Human Answer,37896860,6,From which countries were the sequenced samples obtained?,List,Kenya,Kenya.,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,No,0,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,No,0,Kenya,1,Kenya,1,Kenya,1,Kenya,1,South Africa,0
Human Answer,37896860,7,From what years were the sequenced samples obtained?,List,2019-2020,"Samples were obtained during the study enrollment and 12-month follow-up period (enrollment March 2019–December 2020 with 12-month follow-up), i.e., approximately 2019–2021.",1,2019-2020,1,2019-2020,1,2019–2020,1,2019–2020,1,2019–2020,1,2019 to 2020,1,2019-2020,1,2019-2020,1,No,0,2019-2020,1,2019-2020,1,2019-2020,1,2019-2020,1,2019-2020,1,2019-2020,1,No,0,2019-2020,1,2019-2020,1,2019-2020,1,2019-2020,1,2008-2012,0
Human Answer,37896860,8,Were samples cloned prior to sequencing?,Boolean,No,No evidence of cloning; sequencing was performed directly by Sanger methods.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37896860,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Reverse transcriptase (RT) and protease (PI) regions (i.e., RT and protease portions of pol); integrase was not routinely evaluated.",1,No,0,"PR, RT",0,Not reported,0,Not reported,0,Pol,0,"RT, PR",0,Not explicitly stated,0,No,0,No,0,Pol,0,"Pol, PR, RT",0,Pol,0,"RT, PR",0,Not reported,0,No,0,No,0,Pol,0,"Pol, PR, RT",0,Yes,0,HIV genome,0,"PR, RT",0
Human Answer,37896860,10,What method was used for sequencing?,List,Sanger sequencing,Sanger sequencing (Applied Biosystems 3130xl and 3730xl instruments) with genotypic interpretation via the Stanford HIVdb algorithm.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1,Yes,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37896860,11,What type of samples were sequenced?,List,Plasma,Plasma samples (separated from whole blood).,1,Whole Blood,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Whole Blood,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,No,0,Plasma,1,Whole blood,0,"NRTIs, PIs",0,Plasma,1,Plasma,1
Human Answer,37896860,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes — DRT was targeted to individuals with virologic failure (VL ≥ 1000 copies/mL), and the DRT results reported are from those with VF.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,"Abacavir, Zidovudine, Lopinavir/Ritonavir",0,Yes,1,Yes,1
Human Answer,37896860,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes — participants were enrolled in the Opt4Kids randomized controlled trial.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,37896860,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — participants were on ART (on or initiating ART) and many had prior ARV exposure at time of sequencing.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,37896860,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI, NNRTI, INSTI","NRTIs, NNRTIs, protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs) were received by participants (with NRTI-containing backbones and NNRTI, PI, and INSTI regimens noted).",1,"NRTI, PI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, PI",0,"NRTI, NNRTI, PI",0,PI,0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,"NRTIs, NNRTIs, PIs",0,"NRTIs, NNRTIs, PIs",0,"NRTIs, NNRTIs, PIs",0,"NRTI, PI, NNRTI",0,"NNRTI, PI",0,"NRTI, NNRTI, and PI",0,No,0,"NRTIs, NNRTIs, and PIs",0,"NRTI, NNRTI, PI",0,No,0,"NRTI, PI, NNRTI",0,"NRTI, NNRTI, PI",0
Human Answer,37896860,16,Which drugs were received by individuals in the study before sample sequencing?,List,"3TC, ABC, AZT, LPV, EFV, DTG","Participants received specific drugs including lamivudine, abacavir, zidovudine, lopinavir/ritonavir, efavirenz, dolutegravir, and others; resistance was reported to abacavir, emtricitabine, lamivudine, efavirenz, nevirapine, zidovudine, tenofovir, and rilpivirine among others.",1,"Lamivudine, Abacavir, Zidovudine, Lopinavir/Ritonavir",0,"Lamivudine (3TC), Abacavir (ABC), Zidovudine (AZT), Lopinavir (LPV), Efavirenz (EFV)",0,"Lamivudine, abacavir, zidovudine, lopinavir/ritonavir",0,"Lamivudine, Abacavir, Zidovudine, Lopinavir/Ritonavir",0,"Lamivudine, Abacavir, Zidovudine",0,"Lamivudine, Abacavir, Zidovudine, Lopinavir/Ritonavir",0,Not specifically listed,0,"Abacavir, Zidovudine, Lamivudine, Nevirapine, Efavirenz, Lopinavir",0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Lopinavir (LPV), Efavirenz (EFV), Dolutegravir (DTG)",1,"Lamivudine, abacavir, zidovudine, lopinavir/ritonavir, efavirenz",0,"Lamivudine, abacavir, zidovudine, lopinavir/ritonavir, efavirenz",0,"Lamivudine, abacavir, zidovudine, lopinavir/ritonavir, efavirenz",0,"Abacavir, Zidovudine, Lamivudine, Lopinavir/ritonavir, Efavirenz",0,"Lamivudine, Abacavir, Lopinavir/ritonavir, Efavirenz",0,See above list of drugs,0,No,0,"Abacavir, lamivudine, zidovudine, lopinavir, and efavirenz",0,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN",1,No,0,"Lamivudine, Abacavir, Zidovudine, Lopinavir/Ritonavir, Efavirenz, Dolutegravir",1,"Stavudine (D4T), Lamivudine (3TC), Lopinavir (LPV/r), Ritonavir (RTV), Abacavir (ABC), Didanosine (DDI), Zidovudine (AZT), Efavirenz (EFV)",0
Human Answer,37910452,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper is a systematic review/meta-analysis of ART adherence and does not report HIV sequences from patient samples.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,Yes,0
Human Answer,37910452,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer,37910452,3,Were sequences from the paper made publicly available?,Boolean,No,No — no HIV sequences are reported or made publicly available by this paper. The paper's shared data are adherence study data deposited to figshare and Dryad.,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,** No,1,Yes,0
Human Answer,37910452,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None — the paper does not report any GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported (the paper does not provide the specific accession numbers),1,** Not reported,1,"GQ848100-GQ848156, GU301078-GU301088",0
Human Answer,37910452,5,How many individuals had samples obtained for HIV sequencing?,Number,0,"Zero — the paper does not report any HIV sequencing; therefore no individuals had samples obtained for sequencing. The review included 4,436 HIV-positive patients across the 14 adherence studies.",1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,"4,436",0,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,4436,0,** 4436,0,3,0
Human Answer,37910452,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no sequencing was performed; the included studies were conducted in Ghana.,1,No,1,No,1,Ghana,0,Ghana,0,Ghana,0,Ghana,0,Ghana,0,Ghana,0,No,1,Not reported,1,Not reported,1,Ghana,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Not reported,1,Switzerland,0
Human Answer,37910452,7,From what years were the sequenced samples obtained?,List,No,Not applicable — no sequencing was performed; the included studies were conducted between 2013 and 2022.,1,No,1,No,1,2013–2022,0,Not reported,1,Not reported,1,2013-2022,0,2013-2022,0,2013-2022,0,No,1,Not reported,1,Not reported,1,2013-2022,0,Not reported,1,Not reported,1,No,1,No,1,2013-2022,0,Not reported,1,2013-2022,0,** Not reported,1,2008-2012,0
Human Answer,37910452,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — no sequencing or cloning was reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** No,1,No,1
Human Answer,37910452,9,Which HIV genes were reported to have been sequenced?,List,No,None — the paper does not report sequencing of any HIV genes.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Pol,0,** Not reported,1,"PR, RT",0
Human Answer,37910452,10,What method was used for sequencing?,List,No,Not applicable — no sequencing methods were reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Sanger sequencing,0,** Not reported,1,Sanger sequencing,0
Human Answer,37910452,11,What type of samples were sequenced?,List,No,Not applicable — the paper does not report sequencing and thus no sample types were sequenced.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"Plasma, serum, PBMC, proviral DNA, and dried blood spots",0,** Not reported,1,Plasma,0
Human Answer,37910452,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the paper does not report any sequences; it discusses risk of treatment failure due to sub-optimal adherence but provides no virological failure sequencing data.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,** No,1,Yes,0
Human Answer,37910452,13,Were the patients in the study in a clinical trial?,Boolean,No,"Some included studies were randomized controlled trials, but the review as a whole is a meta-analysis of diverse study designs; no sequencing was associated with trial participants.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Not reported,1,** No,1,Yes,0
Human Answer,37910452,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report any HIV sequences from individuals (regardless of prior ARV exposure). It discusses individuals on ART in general but provides no sequence data.,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,** No,1,Yes,0
Human Answer,37910452,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable — no sequencing was performed and the paper does not detail specific antiretroviral drug classes; it refers generically to antiretroviral therapy (ART).,1,No,1,No,1,,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"NRTI, NNRTI, and PI",0,** Not reported,1,"NRTI, NNRTI, PI",0
Human Answer,37910452,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,Not reported — the paper does not specify individual antiretroviral drugs received by participants; it only refers to ART in general and no sequencing was performed.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, and MVC",0,** Not reported,1,"Zidovudine (AZT), Lamivudine (3TC), Efavirenz (EFV), Stavudine (D4T), Nelfinavir (NFV), Nevirapine (NVP), Indinavir (IDV)",0
Human Answer,37914679,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV sequences (pre-existing low-frequency drug resistance mutations) detected from patient plasma samples using second-generation sequencing.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37914679,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility (phenotypic) assay data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37914679,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report that sequences were deposited in public databases or provide accession numbers.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not Reported,1,No,1,No,1
Human Answer,37914679,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported — no GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1
Human Answer,37914679,5,How many individuals had samples obtained for HIV sequencing?,Number,76,76 individuals had samples obtained and sequenced.,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1,76,1
Human Answer,37914679,6,From which countries were the sequenced samples obtained?,List,China,China.,1,No,0,China,1,China,1,China,1,China,1,China,1,China,1,Not specified,0,China,1,Not reported,0,China,1,China,1,Not Found,0,Not Found,0,No,0,No,0,Not reported,0,China,1,Not Reported,0,Not Found,0,Not Found,0
Human Answer,37914679,7,From what years were the sequenced samples obtained?,List,2018 to 2020,"Samples were obtained between January 1, 2018 and December 31, 2020.",1,2018 to 2020,1,2018-2020,1,2018-2020,1,2018–2020,1,2018–2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,No,0,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1
Human Answer,37914679,8,Were samples cloned prior to sequencing?,Boolean,No,No indication of cloning prior to sequencing is given; samples were amplified and directly analyzed by MiSeq.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1
Human Answer,37914679,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","The paper does not explicitly name gene regions, but reported mutations map to reverse transcriptase (RT) and indicate assessment of pol-associated regions (RT and also PI and INSTI regions — implying protease and integrase were assessed).",1,RT,0,"PR, RT, IN",1,Not reported,0,Pol,0,RT,0,Not specifically stated,0,"NRTI, NNRTI",0,Not specified,0,"PR, RT, IN",1,Not reported,0,Pol (including PR and RT),1,Not reported,0,"PR, RT",0,Not reported,0,"Not specified, but likely the gag, pol, and env genes, as these are the typical genes targeted by HIV sequencing assays.",0,No,0,Not reported,0,"Pol, PR, RT",0,No,0,Not reported,0,"PR, RT",0
Human Answer,37914679,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing",MiSeq second-generation (Illumina) sequencing platform was used.,0,Illumina sequencing,0,Illumina sequencing,0,NGS,0,NGS,0,NGS,0,MiSeq second-generation sequencing,0,MiSeq sequencer,0,Illumina sequencing,0,Illumina sequencing,0,NGS,0,NGS (MiSeq),0,NGS,0,Illumina sequencing,0,MiSeq second-generation sequencing,0,Illumina sequencing,0,Illumina sequencing,0,NGS,0,NGS,0,Yes,0,MiSeq second-generation sequencing,0,Illumina sequencing,0
Human Answer,37914679,11,What type of samples were sequenced?,List,Plasma,Baseline plasma samples (plasma viral RNA) were sequenced.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Not reported,0,Plasma,1,No,0,Plasma,1,Plasma,1,"NRTI, NNRTI",0,Plasma,1,Plasma,1
Human Answer,37914679,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,Yes — sequences were obtained from both patients who later experienced virological failure and from those with successful virological response.,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,"AZT, 3TC, EFV, RPV",1,Yes,0,Yes,0
Human Answer,37914679,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a retrospective single-center observational study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,No,1
Human Answer,37914679,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the study enrolled ART-naïve patients, so sequences were from individuals who had not previously received antiretroviral drugs.",1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,No,1,Yes,0,Yes,0
Human Answer,37914679,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None — individuals were ART-naïve before baseline sequencing.,1,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, INSTI",0,,1,,1,,1,"NRTI, NNRTI",0,"NRTI, NNRTI, INSTI",0,NNRTI,0,No,1,Not reported,1,"NRTI, NNRTI",0,NNRTI,0,Not reported,1,"NRTI, NNRTI",0,NNRTI,0,"NRTI, NNRTI, INSTI",0,,1,NRTI,0,No,1,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI",0
Human Answer,37914679,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None — no specific antiretroviral drugs were received prior to baseline sequencing because participants were ART-naïve.,1,No,1,No,1,,1,,1,,1,Not specifically stated,0,"Stavudine, Lamivudine, Nevirapine, Efavirenz",0,Not specified,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,"NRTI (Abacavir (ABC), Zidovudine (AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV)), NNRTI (Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR)), PI (Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Derunavir (DRV)), INSTI (Raltegravir (RAL), Elvitegravir (EVG), Dolutegravir (DTG), Bictegravir (BIC), cabotegravir (CAB), Lenacapavir (LEN))",0,No,1,,1,"Tenofovir, Lamivudine (3TC), Dolutegravir",0,No,1,"2NRTI + NNRTI, INSTI-based antiviral regimens",0,2NRTI + NNRTI,0
Human Answer,37920909,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports sequencing of HIV-1 integrase genes from patient samples (601 successful sequences).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,37920909,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The study reports genotypic resistance interpretation but does not report in vitro (phenotypic) drug susceptibility assays.,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer,37920909,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported. The paper does not provide GenBank accession numbers or state that sequences were deposited in a public database.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,37920909,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not provided. The paper does not list any GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,KP170487,0,"Not reported in the provided text, but the paper states that sequences were submitted to GenBank.",1,** Not reported,1,Not reported,1
Human Answer,37920909,5,How many individuals had samples obtained for HIV sequencing?,Number,601 or 629,629 individuals were recruited and blood samples were obtained; integrase genes were successfully sequenced for 601 individuals.,1,629,1,601,1,601,1,601,1,601,1,601,1,629,1,629,1,629,1,629,1,601,1,629,1,601,1,601,1,601,1,629,1,601,1,601,1,629,1,** 601,1,601,1
Human Answer,37920909,6,From which countries were the sequenced samples obtained?,List,China,"China (specifically Tianjin, China).",1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,Not reported,0,China,1,No,0,China,1,China,1,China,1,China,1,** Not reported,0,China,1
Human Answer,37920909,7,From what years were the sequenced samples obtained?,List,2020-2023,"Samples were obtained between January 1, 2020 and April 1, 2023.",1,2020-2023,1,2020-2023,1,2020–2023,1,2020–2023,1,2020–2023,1,2020–2023,1,2020-2023,1,2020-2023,1,2020-2023,1,2020-2023,1,2020-2023,1,2020-2023,1,2020-2023,1,2020-2023,1,2020-2023,1,2020-2023,1,2020-2023,1,2020-2023,1,2020-2023,1,** 2020-2023,1,2020-2023,1
Human Answer,37920909,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported; no mention of cloning prior to sequencing is made.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,** No,1,No,1
Human Answer,37920909,9,Which HIV genes were reported to have been sequenced?,List,IN,The HIV-1 integrase gene was sequenced.,1,"Integrase, IN",1,IN,1,IN,1,IN,1,IN,1,Integrase (IN),1,IN (Integrase),1,"Integrase, IN",1,IN,1,IN,1,IN,1,IN,1,IN,1,IN,1,Integrase gene,1,IN,1,Integrase,1,Integrase,1,Integrase,1,** IN,1,IN,1
Human Answer,37920909,10,What method was used for sequencing?,List,Sanger sequencing,An in-house genotyping method and standard Sanger sequencing were used.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,** Sanger sequencing,1,Sanger sequencing,1
Human Answer,37920909,11,What type of samples were sequenced?,List,Whole Blood,Blood-derived specimens were collected (5 mL of blood) and RNA was extracted for sequencing.,0,Whole Blood,1,Plasma,0,Plasma,0,Plasma,0,Plasma,0,Blood,0,Blood,0,Plasma,0,Whole Blood,1,Blood,0,Not reported,0,Not reported,0,Blood,0,Blood,0,Whole Blood,1,Plasma,0,Blood,0,Plasma,0,Blood,0,** Plasma; Whole Blood,1,Blood,0
Human Answer,37920909,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. All participants were ART-naïve with no prior antiviral treatment, so sequences were not from individuals with virological failure on treatment.",1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,** Yes,0,No,1
Human Answer,37920909,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The patients were recruited as outpatients and there is no indication they were enrolled in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,Yes,0,** No,1,No,1
Human Answer,37920909,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The study exclusively involved ART-naïve individuals with no prior antiviral treatment.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,** No,1,No,1
Human Answer,37920909,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None. Participants were ART-naïve and had not received antiretroviral drugs prior to sequencing.,1,No,1,No,1,,1,,1,,1,,1,None (ART-naïve),1,INSTI,0,No,1,,1,Not reported,1,,1,Not reported,1,Not reported,1,No,1,No,1,,1,"NRTI, NNRTI, PI, INSTI",0,,1,** Not reported,1,Not reported,1
Human Answer,37920909,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None. No individuals had received antiretroviral drugs prior to sample sequencing.,1,No,1,No,1,,1,,1,,1,,1,None (ART-naïve),1,"RAL, EVG, DTG, BIC",0,No,1,Not reported,1,Not reported,1,,1,Not reported,1,Not reported,1,No,1,No,1,,1,Not Reported,1,,1,** Not reported,1,Not reported,1
Human Answer,37938856,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV drug resistance mutation testing by sequencing on patient samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37938856,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper reports genotypic DRM testing (Sanger sequencing) but does not report in vitro phenotypic drug susceptibility assays.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37938856,3,Were sequences from the paper made publicly available?,Boolean,No,No evidence of public deposition of sequences is provided in the paper.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37938856,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1
Human Answer,37938856,5,How many individuals had samples obtained for HIV sequencing?,Number,820,Sequencing (successful DRM tests) was obtained from 46 samples (46 tests successfully conducted).,0,820,1,46,0,820,1,820,1,48,0,820,1,820,1,0,0,0,0,Not reported,0,820,1,820,1,Not reported,0,820,1,0,0,0,0,820,1,820,1,820,1,820,1,820,1
Human Answer,37938856,6,From which countries were the sequenced samples obtained?,List,Kenya,Kenya.,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,No,0,No,0,Kenya,1,Kenya,1,Kenya,1,Not reported,0,Kenya,1,No,0,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1
Human Answer,37938856,7,From what years were the sequenced samples obtained?,List,2019-2022,Sequenced samples were obtained during the study's intervention period (approximately 2019–2021).,0,2019-2022,1,2019-2022,1,2019–2022,1,2019–2022,1,2019–2021,0,2019-2022,1,2019 to 2022,1,No,0,No,0,2019-2022,1,2019-2022,1,2019-2022,1,Not reported,0,2019-2022,1,No,0,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1
Human Answer,37938856,8,Were samples cloned prior to sequencing?,Boolean,No,No — there is no indication that samples were cloned prior to sequencing; Sanger sequencing is reported without mention of cloning.,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0
Human Answer,37938856,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","The paper does not explicitly state the gene region(s) sequenced; however, reported mutations (K103N, M184V) indicate sequencing of the reverse transcriptase (RT) region.",0,No,0,RT,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,"RT, PR, IN",1,No,0,No,0,Not reported,0,Pol,0,Pol,0,Not reported,0,Not reported,0,No,0,No,0,Pol,0,"Pol, PR, RT",0,"Pol, PR, RT",0,"RT, IN",0,"PR, RT, IN",1
Human Answer,37938856,10,What method was used for sequencing?,List,Sanger sequencing,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Not reported,0,No,0,No,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37938856,11,What type of samples were sequenced?,List,No,"Clinical blood-derived samples (samples associated with viral load testing from blood draws), presumably plasma/viral RNA, though the paper does not explicitly state 'plasma'.",0,No,1,No,1,Not reported,1,Not Reported,1,Plasma,0,Blood (plasma) samples,0,Plasma,0,No,1,No,1,Plasma,0,Plasma,0,Plasma,0,Not reported,1,Plasma,0,No,1,No,1,Plasma,0,Plasma,0,"Plasma, serum, PBMC, proviral DNA",0,Plasma,0,Plasma,0
Human Answer,37938856,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes — DRM sequencing was performed on participants with viral load >1000 copies/ml (viraemia), i.e., virological failure while on ART.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37938856,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the study was a pre/post-intervention prospective cohort study, not a randomized clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37938856,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — most participants were on ART at enrolment and DRM testing was performed on viraemic individuals who had prior ART exposure.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37938856,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI","Nucleos(t)ide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs).",1,"NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,No,0,"NNRTI, PI, integrase inhibitors",0,"NRTIs, NNRTIs, PIs",0,"NRTIs, NNRTIs, INSTIs",0,Not reported,0,"NRTI, NNRTI, PI, INSTI",1,No,0,No,0,NRTI,0,"NRTI, NNRTI, INSTI",0,"NRTIs, NNRTIs, PIs",0,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1
Human Answer,37938856,16,Which drugs were received by individuals in the study before sample sequencing?,List,"3TC, TDF, EFV, DTG, ATV","Specific drugs mentioned include lamivudine and tenofovir (NRTIs), efavirenz (NNRTI), dolutegravir (INSTI), and atazanavir/ritonavir (PI).",1,"Lamivudine, Tenofovir, Efavirenz, Dolutegravir",1,"Lamivudine (3TC), Tenofovir (TFV), Efavirenz (EFV), Dolutegravir (DTG), Atazanavir (ATV), Ritonavir (RTV)",1,"Lamivudine, Tenofovir, Efavirenz, Dolutegravir, Atazanavir/Ritonavir",1,"Lamivudine, Tenofovir, Efavirenz, Dolutegravir",1,Not reported,0,"Lamivudine (3TC), Tenofovir (TDF), Efavirenz (EFV)",0,"Lamivudine, Tenofovir, Efavirenz, Dolutegravir",1,"Lamivudine, tenofovir, efavirenz, dolutegravir",1,No,0,"Efavirenz, lamivudine, tenofovir, dolutegravir, atazanavir, ritonavir",1,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",1,"Tenofovir, lamivudine, dolutegravir",0,Not reported,0,"Dolutegravir, Emtricitabine, Tenofovir alafenamide, Efavirenz, Lamivudine, and others",1,No,0,No,0,Lamivudine and tenofovir,0,"AZT, 3TC, FTC, TDF, ATV/r, DRV/r, MVC, RAL",0,"Tenofovir, lamivudine, efavirenz, lopinavir/ritonavir",0,"Lamivudine, Tenofovir, Efavirenz, Dolutegravir",1,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF), Dolutegravir (DTG)",0
Human Answer,37941373,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The study reports sequencing of the HIV-1 integrase (IN) gene from patient plasma samples, generating integrase sequence data for 1,032 patients.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37941373,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance analysis using sequencing and Stanford HIVdb interpretation, not in vitro phenotypic susceptibility assays.",1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37941373,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report public deposition; data are available from the first author on reasonable request.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1
Human Answer,37941373,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,37941373,5,How many individuals had samples obtained for HIV sequencing?,Number,1080 or 1032,"Samples were collected from 1,080 patients and successful IN gene amplification/sequencing was achieved for 1,032 samples.",1,1080,1,1032,1,1032,1,1032,1,1032,1,1032,1,1032,1,1032,1,1032,1,1032,1,1032,1,1032,1,1032,1,1032,1,1032,1,1032,1,1080,1,1032,1,1080,1,1032,1,1032,1
Human Answer,37941373,6,From which countries were the sequenced samples obtained?,List,China,"China (Chongqing, China).",1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1
Human Answer,37941373,7,From what years were the sequenced samples obtained?,List,2019-2022,Between July 2019 and August 2022.,1,2019-2022,1,2019-2022,1,2019–2022,1,2019–2022,1,2019–2022,1,2019–2022,1,2019–2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1
Human Answer,37941373,8,Were samples cloned prior to sequencing?,Boolean,No,No. Samples were amplified by nested PCR and sequenced by Sanger dideoxy sequencing; no cloning step is described.,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1
Human Answer,37941373,9,Which HIV genes were reported to have been sequenced?,List,IN,The integrase (IN) region of the pol gene was sequenced (partial pol encoding integrase).,1,"Integrase, IN",1,IN,1,IN,1,IN,1,IN,1,IN,1,IN,1,"Integrase, IN",1,IN,1,IN,1,IN,1,IN,1,IN,1,IN,1,Pol,0,IN,1,Integrase,1,Pol,0,No,0,IN,1,Pol,0
Human Answer,37941373,10,What method was used for sequencing?,List,Sanger sequencing,Nested RT-PCR amplification of the IN gene followed by Sanger (dideoxy) sequencing using an in-house validated method.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,In-house method; standard sequencing techniques,0,Nested PCR; sequencing method not specified,0,No,0,Sanger sequencing,1,Not reported,0,Sanger sequencing,1,Not Reported,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Yes,0,PCR,0,Sanger sequencing,1
Human Answer,37941373,11,What type of samples were sequenced?,List,Plasma,"Plasma samples (viral RNA extracted from plasma) from patients with HIV-1 viral load >1,000 copies/ml were sequenced.",1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,NRTIs and/or NNRTIs,0,Plasma,1,Plasma,1
Human Answer,37941373,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Sequences include samples from ART-treated individuals, including ART-ineffective patients (virological failure) and INSTI-treated patients with resistance.",1,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1
Human Answer,37941373,13,Were the patients in the study in a clinical trial?,Boolean,No,No. Patients were inpatients and outpatients at Chongqing Public Health Medical Center and not enrolled in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37941373,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. The study sequenced samples from 465 ART-treated individuals (and 102 INSTI-treated patients among them).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37941373,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, INSTI","Integrase strand transfer inhibitors (INSTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs).",1,"NRTI, NNRTI, INSTI",1,"NRTI, NNRTI, INSTI",1,"NRTI, NNRTI, INSTI",1,"NRTI, NNRTI, INSTI",1,"NRTI, NNRTI, INSTI",1,"INSTI, NNRTI, NRTI",1,"NRTI, NNRTI, INSTI",1,"INSTI, NRTI, NNRTI",1,INSTI,0,"INSTIs, NNRTIs, NRTIs",1,"NRTIs, NNRTIs, INSTIs",1,"NRTIs, NNRTIs, INSTIs",1,"NNRTI, NRTI",0,"INSTI, NNRTI, NRTI",1,INSTI,0,INSTI,0,"NRTIs, NNRTIs",0,NRTI,0,NRTIs and/or NNRTIs,0,INSTI,0,"INSTI, NRTI, NNRTI, PI",1
Human Answer,37941373,16,Which drugs were received by individuals in the study before sample sequencing?,List,"DTG, RPV, 3TC, TDF, EFV","Reported drugs include dolutegravir (DTG), rilpivirine (RPV), lamivudine (3TC), tenofovir (TDF or related), crizaline (as listed), efavirenz (EFV) and historically referenced INSTIs such as raltegravir (RAL) and elvitegravir (EVG); other INSTIs referenced include cabotegravir (CAB) and bictegravir (BIC) in resistance analyses.",1,"Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Crizaline, Efavirenz",1,"Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Efavirenz",1,"Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Crizaline, Efavirenz",1,"Dolutegravir, rilpivirine, lamivudine, tenofovir, efavirenz",1,"Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Crizaline, Efavirenz",1,"Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Crizaline, Efavirenz",1,"Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Crizaline, Efavirenz",1,"Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Crizaline, Efavirenz",1,"Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Crizaline, Efavirenz",1,"Dolutegravir, rilpivirine, lamivudine, tenofovir, crizaline, efavirenz",1,"Dolutegravir, rilpivirine, lamivudine, tenofovir",0,"Dolutegravir, rilpivirine, lamivudine, tenofovir, efavirenz",1,"RAL, EVG, DTG",0,"Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Crizaline, Efavirenz",1,"Raltegravir (RAL), Elvitegravir(EVG), Dolutegravir (DTG), Bictegravir (BIC), cabotegravir (CAB), Lenacapavir (LEN)",0,"DTG, RAL, EVG, BIC, CAB",0,Various ART drugs,0,Not reported,0,Not reported,0,"RAL, EVG, CAB, DTG, BIC",0,"RAL, EVG, DTG, BIC, TDF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c",0
Human Answer,37946329,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The study amplified, sequenced, and analyzed partial pol and complete integrase gene-coding sequences from patient plasma samples; pol sequences were successfully obtained from 921 patients and integrase sequences from 751 patients.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0
Human Answer,37946329,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic resistance testing and predicted resistance via the Stanford HIVdb rather than in vitro phenotypic (cell-based) susceptibility assays.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,,1
Human Answer,37946329,3,Were sequences from the paper made publicly available?,Boolean,No,"Not explicitly reported. The paper states sequences were submitted to the Stanford HIVdb for analysis, but it does not state that raw sequences were deposited in public sequence repositories (e.g., GenBank) or provide accession numbers.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,,1
Human Answer,37946329,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,MN...,0,Not reported,1,Not reported,1,Not reported,1,,1
Human Answer,37946329,5,How many individuals had samples obtained for HIV sequencing?,Number,921,1078 ART-failing patients were included in the cohort; partial pol sequences were successfully amplified from 921 individuals and integrase sequences from 751 individuals.,1,921,1,921,1,921,1,921,1,921,1,921,1,921,1,921,1,1078,0,921,1,921,1,921,1,921,1,921,1,921,1,921,1,1078,0,1078,0,1078,0,921,1,,0
Human Answer,37946329,6,From which countries were the sequenced samples obtained?,List,China,"China (patients were from Henan Province, China).",1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,No,0,China,1,China,1,China,1,China,1,China,1,,0
Human Answer,37946329,7,From what years were the sequenced samples obtained?,List,2018-2022,Samples were collected from June 2018 to April 2022 (2018–2022).,1,2018-2022,1,2018-2022,1,2018–2022,1,2018-2022,1,2018–2022,1,2018–2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,2018-2022,1,,0
Human Answer,37946329,8,Were samples cloned prior to sequencing?,Boolean,No,No indication that samples were cloned prior to sequencing; the paper describes amplification and sequencing but does not mention cloning.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,,1
Human Answer,37946329,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",Partial polymerase (pol) gene (which includes protease and reverse transcriptase regions) and the complete integrase (INT) gene were sequenced.,1,"Protease, RT, IN",1,"Pol, IN",0,"Pol, IN",0,"Pol, IN",0,"Pol, IN",0,"Pol, Integrase (INT)",0,"Pol, Integrase (INT)",0,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"Pol, Integrase",0,"Pol, INT",0,"Pol, Integrase",0,"Pol, Integrase",0,"Pol, Integrase",0,Pol and integrase,0,"Pol, IN",0,"Pol, Integrase",0,"Pol, Integrase",0,Pol,0,"Pol, INT",0,,0
Human Answer,37946329,10,What method was used for sequencing?,List,No,"The specific sequencing platform or method is not described in the manuscript; genotypic drug resistance testing was performed as described in prior references, but no explicit sequencing technique (e.g., Sanger or NGS) is stated.",1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,PCR-based sequencing,0,Not reported,1,Sanger sequencing,0,Not reported,1,,1
Human Answer,37946329,11,What type of samples were sequenced?,List,Plasma,Plasma samples derived from people living with HIV (blood-derived plasma) were used for sequencing.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,,0
Human Answer,37946329,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. The study specifically targeted people living with HIV who were refractory to ART (viral load >200 copies/mL) and patients who failed ART; sequences derive from these virologically failing, treatment-experienced individuals.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,,0
Human Answer,37946329,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The study appears observational/clinical-service–based and does not report enrollment in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,,1
Human Answer,37946329,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. The study focused on ART-experienced patients who failed therapy, and analysis stratifies DRMs by ART regimen types and durations.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"NRTI, NNRTI, PI",0,Yes,1,,0
Human Answer,37946329,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI","Patients had received nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs).",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI",0,Not reported,0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NNRTI, PI, INSTI",1,NNRTIs,0,"NRTIs, NNRTIs, PIs, INSTIs",1,"NRTIs, NNRTIs, PIs, INSTIs",1,NNRTI,0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTIs, NNRTIs, PIs",0,Not reported,0,Not reported,0,"NRTI, NNRTI, PI, INSTI",1,,0
Human Answer,37946329,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Specific drugs mentioned include lamivudine (3TC), abacavir (ABC), tenofovir (TDF), efavirenz (EFV), nevirapine (NVP), etravirine (ETR), bictegravir (BIC), cabotegravir (CAB), dolutegravir (DTG), elvitegravir (EVG), raltegravir (RAL), atazanavir/r (ATV/r), lopinavir/r (LPV/r), fosamprenavir/r (FPV/r), saquinavir/r (SQV/r), and others referenced in the resistance predictions and figure legend.",0,"3TC, NVP, ETR, ABC, DTG",0,"NVP, ETR, ABC, 3TC, DTG, ATV, LPV, RAL, SQV",0,Not Reported,1,"NVP, ETR, ABC",0,Not reported,1,"NVP, ETR, ABC",0,"Abacavir (ABC), Tenofovir (TDF), Efavirenz (EFV), Lamivudine (3TC), Nevirapine (NVP)",0,"Abacavir (ABC), Nevirapine (NVP), Efavirenz (EFV), Raltegravir (RAL)",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,"3TC, DTG",0,Not reported,1,"NVP, ETR, ABC, ETR",0,"3TC, NVP, EFV, D4T, AZT, LPV, ABC, ATZ, DTG, TDF",0,Not reported,1,"NVP, ETR, ABC, DTG, BIC, CAB, RAL, EVG, LPV, ATV, APV, DOR, RPV, DLV, AZT, D4T, FTC, TFV",0,"NRTI, NNRTI, PI, INSTI",0,"3TC, EFV, ATV/r",0,Not reported,1,Yes,0,"3TC, NVP, EFV, D4T, AZT, LPV, ABC, ATZ, DTG, TDF",0,,1
Human Answer,37957382,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The study reports single-genome near-full-length proviral sequences and plasma HIV-1 RNA sequences from participants.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37957382,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance scoring and viral outgrowth assays, but it does not report classical in vitro phenotypic drug susceptibility assays.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37957382,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. Sequence data were submitted to GenBank under BioProject PRJNA973660.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0
Human Answer,37957382,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,The paper provides a GenBank BioProject identifier (PRJNA973660) but does not list individual GenBank accession numbers in the provided text.,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"The paper does not provide specific accession numbers, but it mentions that sequences were submitted to GenBank.",0,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,MK169416 to MK170053,0,MN234327 - MN235714,0
Human Answer,37957382,5,How many individuals had samples obtained for HIV sequencing?,Number,8,Eight participants with non-suppressible viremia had samples sequenced.,1,8,1,8,1,8,1,8,1,8,1,8,1,8,1,8,1,8,1,8,1,8,1,8,1,8,1,5,0,8,1,8,1,8,1,8,1,8,1,27 (elite controllers) and 41 (participants on ART),0,27,0
Human Answer,37957382,6,From which countries were the sequenced samples obtained?,List,No,Not explicitly stated in the provided text (country not specified).,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,United States,0,"Spain, Switzerland, USA",0,"Spain, Switzerland, USA",0
Human Answer,37957382,7,From what years were the sequenced samples obtained?,List,No,The calendar years of sample collection are not specified in the provided text.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2015-2018,0,2004-2007,0,2016 to 2017,0,2016 to 2017,0
Human Answer,37957382,8,Were samples cloned prior to sequencing?,Boolean,Yes,No. The study used limiting-dilution single-genome PCR (endpoint dilution) for near-full-length sequencing rather than cloning.,0,No,0,No,0,No,0,No,0,Not reported,0,No,0,No,0,No,0,No,0,Not reported,0,Not Reported,0,Not reported,0,No,0,No,0,No,0,No,0,No,0,Yes,1,Yes,1,No,0,Yes,1
Human Answer,37957382,9,Which HIV genes were reported to have been sequenced?,List,"Full genome, NFLG","Near-full-length proviral genomes were sequenced and plasma sequencing targeted a 6.7 kb pol–env region; analyses referenced genes including pol, env, gag and nef (and whole genome regions).",0,Full genome; Near full length genome,1,Near full length genome,0,"Pol, Env",0,Not reported,0,"Pol, Env",0,"*pol*, *env*",0,"pol, env",0,"Protease, Reverse transcriptase, Integrase",0,"Pol, Env",0,"Pol, Env",0,Pol,0,Pol,0,Near full length genome,0,Env,0,*pol-env*,0,"pol, env",0,Pol-env,0,"Pol, PR, RT",0,"Pol, PR, RT",0,"Gag, Pol, RT, Env",0,Full length genome,0
Human Answer,37957382,10,What method was used for sequencing?,List,Illumina sequencing,Single-genome near-full-length PCR (NFL-seq) with Illumina MiSeq library construction and assembly; MIP-seq was used to link proviral sequences to integration sites.,1,Illumina sequencing,1,Illumina sequencing,1,NGS,0,Not Reported,0,Not reported,0,MIP-seq,0,Next-generation sequencing,1,Illumina sequencing,1,Illumina sequencing,1,Not reported,0,Sanger sequencing,0,Not reported,0,Illumina sequencing,1,Not reported,0,Illumina sequencing,1,No,0,NGS,0,NGS,0,Sanger sequencing,0,"Illumina sequencing, Sanger sequencing, Single-genome sequencing",1,Illumina sequencing,1
Human Answer,37957382,11,What type of samples were sequenced?,List,"Plasma, PBMC",Plasma HIV-1 RNA (plasma samples) and proviral DNA from PBMCs/CD4+ T cells (peripheral blood mononuclear cells) were sequenced; CD4+ cells were also used for RNA-seq and MIP-seq integration-site analyses.,1,Plasma,0,Plasma,0,Plasma,0,Plasma,0,"Plasma, PBMC",1,Plasma,0,Plasma,0,Plasma,0,"Plasma, PBMC",1,"Plasma, PBMCs",1,Plasma,0,Plasma,0,"PBMC, LNMC",0,"Plasma, PBMC, LNMC",1,Plasma,0,"Plasma, PBMC",1,Plasma,0,Plasma,0,"Plasma, PBMC",1,"PBMC, LNMC, Plasma",1,PBMC,0
Human Answer,37957382,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Sequences were obtained from individuals with persistent low-level viremia while on ART (non-suppressible viremia), i.e., viremia despite being on antiretroviral therapy.",1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,No,0,Not reported,0,Yes,1,Yes,1,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1
Human Answer,37957382,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. The participants were enrolled in an observational study (with some comparators from cohort sources), not a clinical trial.",1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Yes,0,Yes,0,Yes,0
Human Answer,37957382,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. All participants were ART-treated with a median ART duration of 10 years and were receiving at least two active antiretroviral drugs during NSV episodes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37957382,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI, INSTI","Participants received drugs from multiple classes including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs).",1,No,0,"NRTI, INSTI",0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,"NRTI, NNRTI, PI, INSTI, CCR5 antagonist",1,"NRTI, NNRTI, PI, INSTI",1,No,0,Not reported,0,Not Reported,0,"NRTI, NNRTI, PI, INSTI",1,Not reported,0,Not reported,0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI",0,"NRTI, NNRTI, PI, INSTI",1,Not reported,0,"NRTI, NNRTI, PI, INSTI, CCR5 antagonist",1
Human Answer,37957382,16,Which drugs were received by individuals in the study before sample sequencing?,List,"DTG, DRV, TFV, FTC ","Drugs mentioned in the paper include dolutegravir (DTG), darunavir (DRV/r), darunavir/ritonavir, atazanavir/ritonavir (ATV/r), rilpivirine (RPV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and emtricitabine (FTC).",1,No,0,"Dolutegravir, Darunavir, Tenofovir, Emtricitabine",1,Not reported,0,Not reported,0,Not reported,0,Not reported,0,"Lamivudine (3TC), Abacavir (ABC), Atazanavir (ATV), Zidovudine (AZT), Darunavir (DRV), Entecavir (ECV), Efavirenz (EFV), Etravirine (ETR), Fosamprenavir (FPB), Emtricitabine (FTC), Maraviroc (MVC), Nevirapine (NVP), Raltegravir (RGV), Ritonavir (RTV), Tenofovir (TDF).",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",1,No,0,Not reported,0,Not Reported,0,"TDF, FTC, EFV, DTG",1,Not reported,0,Not reported,0,"Abacavir (ABC), Zidovudine (AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir (EVG), Dolutegravir (DTG), Bictegravir (BIC), cabotegravir (CAB), Lenacapavir (LEN)",1,No,0,Not reported,0,"Tenofovir, Lamivudine, Efavirenz",0,"AZT, 3TC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN, TDF, FTC, ABC, D4T, ddI",1,Not reported,0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0
Human Answer,37966701,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Not reported,1,No,1
Human Answer,37966701,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report any in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,No,1
Human Answer,37966701,3,Were sequences from the paper made publicly available?,Boolean,No,"No — no sequences were reported, and the study datasets are not publicly available.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,Not reported,1
Human Answer,37966701,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported — no GenBank accession numbers are provided.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1
Human Answer,37966701,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero — no samples were obtained for HIV sequencing as part of this study.,1,0,1,0,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,321,0,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,321,0,Not reported,1,321,0,** 321,0,Not reported,1
Human Answer,37966701,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no sequenced samples. The study population was from the United States (18 US states and territories).,1,No,1,No,1,United States,0,USA,0,Not reported.,1,Not reported,1,United States,0,No,1,No,1,Not reported,1,USA,0,USA,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** United States,0,Not reported,1
Human Answer,37966701,7,From what years were the sequenced samples obtained?,List,No,"Not applicable — no sequencing was performed. The study period for injections was January 21, 2021 to March 15, 2022 (first injection window through continuation injections).",1,No,1,No,1,2021–2022,0,Not reported,1,Not reported.,1,2021-2022,0,2021-2022,0,No,1,No,1,Not reported,1,2021-2022,0,2021-2022,0,Not reported,1,Not reported,1,No,1,No,1,2021-2022,0,Not reported,1,2021-2022,0,** Not reported,1,Not reported,1
Human Answer,37966701,8,Were samples cloned prior to sequencing?,Boolean,No,"Not applicable — no sequencing was performed, therefore no cloning was reported.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Yes,0,** No,1,Not reported,1
Human Answer,37966701,9,Which HIV genes were reported to have been sequenced?,List,No,None — the paper does not report any sequenced HIV genes.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,** Not reported,1,Not reported,1
Human Answer,37966701,10,What method was used for sequencing?,List,No,Not applicable — no sequencing methods are reported because sequencing was not performed.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Yes,0,** Not reported,1,Not reported,1
Human Answer,37966701,11,What type of samples were sequenced?,List,No,Not applicable — no biological samples were sequenced. The study used electronic health record data from routine clinical care.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Plasma,0,Not reported,1,Not reported,1,** Electronic health records,0,Not reported,1
Human Answer,37966701,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — although four confirmed virologic failures occurred, resistance data/sequences were not available or reported.",1,No,1,No,1,Not reported,1,Not reported,1,No.,1,Not reported,1,Yes,0,No,1,No,1,Not reported,1,Yes,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,** Yes,0,No,1
Human Answer,37966701,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — patients were part of an observational cohort (routine clinical care, OPERA), not a clinical trial.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"NRTI, NNRTI",1,** No,1,No,1
Human Answer,37966701,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the paper does not report any HIV sequences, including from individuals with prior ARV exposure.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,Not reported,1,** Yes,0,No,1
Human Answer,37966701,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not applicable for sequencing. The regimen studied was cabotegravir + rilpivirine long-acting (ART), but the paper does not report sequencing nor provide a breakdown of prior drug classes received before sequencing.",1,No,1,No,1,,1,Not reported,1,Not reported.,1,Not reported,1,"NRTI, INSTI",0,INSTI,0,No,1,Not reported,1,"INSTI, NNRTI",0,"INSTI, NNRTI",0,Not reported,1,Not reported,1,No,1,No,1,"NRTI, NNRTI",0,Not reported,1,No,1,** Antiretroviral therapy (ART),0,Not reported,1
Human Answer,37966701,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable for sequencing. The study reports participants received cabotegravir and rilpivirine long-acting injections, but no sequencing was performed and prior specific drugs (pre-sequencing) are not detailed.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,"Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC)",0,"Cabotegravir, Rilpivirine",0,No,1,Not reported,1,"Cabotegravir, Rilpivirine",0,"Cabotegravir, Rilpivirine",0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,** Not reported,1,Not reported,1
Human Answer,37973713,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV-1 protease and reverse transcriptase coding region sequences obtained from patients using Sanger sequencing.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37973713,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic resistance data but does not present in vitro (phenotypic) susceptibility testing results.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37973713,3,Were sequences from the paper made publicly available?,Boolean,No,"Partially. Sequences were submitted to the Stanford University HIV Drug Resistance Database, but no public GenBank accession numbers are reported.",1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,Yes.,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Not reported,1
Human Answer,37973713,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. The paper does not provide any GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1
Human Answer,37973713,5,How many individuals had samples obtained for HIV sequencing?,Number,117,"83 individuals had genotyping results (117 recruited, 34 excluded for lack of genotyping results).",1,117,1,117,1,117,1,117,1,83,0,117,1,117,1,117,1,0,0,117,1,117,1,117.,1,117,1,Not reported,0,117,1,117,1,117,1,117,1,117,1,117,1,117,1
Human Answer,37973713,6,From which countries were the sequenced samples obtained?,List,"Ukraine, Poland","Poland, Ukraine, and a small number from Belarus, Georgia, and Kazakhstan.",1,"Ukraine, Poland",1,"Poland, Ukraine, Belarus, Georgia, Kazakhstan",1,"Poland, Ukraine",1,"Poland, Ukraine",1,"Ukraine, Poland, Belarus, Georgia, Kazakhstan",1,"Ukraine, Belarus, Georgia, Kazakhstan",0,"Ukraine, Belarus, Georgia, Kazakhstan",0,"Ukraine, Poland",1,"Poland, Ukraine",1,"Ukraine, Belarus, Georgia, Kazakhstan, Poland",1,"Poland, Ukraine",1,"Poland, Ukraine.",1,"Ukraine, Poland",1,"Ukraine, Poland",1,"Poland, Ukraine",1,"Poland, Ukraine",1,"Poland, Ukraine, Belarus, Georgia, and Kazakhstan",1,Poland,0,"Poland, Ukraine",1,"Ukraine, Belarus, Georgia, Kazakhstan",0,Poland,0
Human Answer,37973713,7,From what years were the sequenced samples obtained?,List,2020-2022,Samples were obtained during 2020–2022.,1,2020-2022,1,2020-2022,1,2020–2022,1,2020–2022,1,2020–2022,1,2020-2022,1,2020–2022,1,2020-2022,1,2020-2022,1,2020-2022,1,2020-2022,1,2020-2022.,1,2020-2022,1,2020-2022,1,2020-2022,1,2020-2022,1,2020-2022,1,2020-2022,1,2020-2022,1,2020-2022,1,2020-2022,1
Human Answer,37973713,8,Were samples cloned prior to sequencing?,Boolean,No,No. There is no indication that samples were cloned prior to sequencing; Sanger sequencing with ViroSeq was used.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer,37973713,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",Protease (PR) and reverse transcriptase (RT) coding regions (partial pol region).,1,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,"RT, PR",1,Pol,0,"PR, RT",1,"PR, RT",1,"PR, RT",1,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT.",1,"PR, RT",1,"PR, RT",1,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,Pol,0,"PR, RT",1,"PR, RT",1
Human Answer,37973713,10,What method was used for sequencing?,List,Sanger sequencing,Sanger sequencing using the ViroSeq HIV-1 Genotyping System (Abbott Molecular).,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37973713,11,What type of samples were sequenced?,List,Plasma,Viral RNA from peripheral blood (plasma) was sequenced (implied by HIV-RNA viral load measurements and use of standard genotyping workflows).,1,No,0,Plasma,1,Not Reported,0,Not Reported,0,Not reported,0,Plasma,1,Blood samples (plasma),1,Plasma,1,No,0,Not reported,0,Plasma,1,Plasma.,1,Plasma,1,Not reported,0,Plasma; PBMC; DBS; Whole Blood; Serum; Semen; CSF; Other; Unknown,1,No,0,Not reported,0,Plasma,1,"Plasma, PBMC",1,Plasma,1,Plasma,1
Human Answer,37973713,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. All sequenced individuals were antiretroviral treatment–naïve at sampling, so sequences were not from cases of virological failure on therapy.",1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer,37973713,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes. The study was registered as a clinical trial (NCT04636736) and received bioethics approval.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Not Reported,0,No.,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37973713,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The paper reports sequences from individuals with no prior history of antiretroviral therapy.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes.,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0
Human Answer,37973713,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None. Individuals were ART-naïve and had not received any antiretroviral drug classes prior to sequencing.,1,No,1,No,1,,1,,1,,1,,1,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,No,1,,1,Not Reported,1,"NRTIs, NNRTIs, PIs.",0,Not reported,1,NRTI,0,No,1,"NRTI, NNRTI, PI",0,,1,,1,"NRTI, NNRTI, PI, INSTI",0,Not reported,1,NRTI,0
Human Answer,37973713,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None. No individual had received antiretroviral drugs prior to sequencing.,1,No,1,No,1,,1,,1,,1,Not reported,1,"3TC, d4T, NVP",0,No,1,No,1,,1,Not Reported,1,Not reported.,1,Not reported,1,"Zidovudine (AZT), Lamivudine (3TC), Didanosine (DDI)",0,No,1,No,1,,1,Not reported,1,"AZT, 3TC, FTC, TDF, EFV, NVP, RAL, DTG, BIC, CAB, LEN",0,Not reported,1,atazanavir,0
Human Answer,37976080,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The study reports HIV sequences obtained from patient plasma samples and generated sequence data for the PR/RT regions (pol gene).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,37976080,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The study reports genotypic resistance analysis (sequence-based interpretation) rather than in vitro phenotypic drug susceptibility assays.,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer,37976080,3,Were sequences from the paper made publicly available?,Boolean,No,"No specific sequence deposit (e.g., GenBank accession numbers) is reported; only web-accessible molecular network results are referenced.",1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** Yes,0,No,1
Human Answer,37976080,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"** MH062016- MH062024, MH062026- MH062029, MH062125- MH062138, MK931539- MK931547, MK931784, MK931789- MK931801, MK931912- MK931931, MK931933, MK931934, MK931937, MK931939, MK931940, MK931942, MK931943, MK931945, MK931947- MK931964, MK931996, MK931997, MK931999- MK932016, and MW483846- MW484805.",0,Not reported,1
Human Answer,37976080,5,How many individuals had samples obtained for HIV sequencing?,Number,2568,2568 participants had valid PDR sequence results; after quality filtering 2555 sequences were used for molecular network analysis.,1,2568,1,2568,1,2568,1,2568,1,2568,1,2568,1,2568,1,2568,1,2568,1,2568.,1,2568,1,2568,1,2568,1,2568,1,2568,1,2568,1,2568,1,2568,1,2568,1,** 1071,0,Not reported,0
Human Answer,37976080,6,From which countries were the sequenced samples obtained?,List,China,All sequenced samples were obtained from China (multiple provincial-level administrative divisions).,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China.,1,China,1,China,1,China,1,China,1,China,1,China,1,Not Reported,0,China,1,China,1,"** Armenia, Azerbaijan, Belarus, Russia, Tajikistan, Uzbekistan",0,China,1
Human Answer,37976080,7,From what years were the sequenced samples obtained?,List,2022,Samples were collected in 2022 (participants started or restarted ART between January and June 2022).,1,2022,1,2022,1,2022,1,2022,1,2022,1,2022,1,2022,1,2022,1,2022,1,2022.,1,2022,1,2022,1,2022,1,2022,1,2022,1,2022,1,2022,1,2022,1,2022,1,** 2017-2019,0,2022,1
Human Answer,37976080,8,Were samples cloned prior to sequencing?,Boolean,No,No. The paper describes PCR amplification followed by direct Sanger sequencing and does not report cloning prior to sequencing.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,** No,1,No,1
Human Answer,37976080,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT","The pol gene was sequenced, specifically the protease (PR) region and the partial reverse transcriptase (RT) region.",1,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"PR, RT",1,"Protease, Reverse transcriptase",1,"PR, RT",1,"PR, RT.",1,"PR, RT",1,Pol,0,Pol,0,"PR, RT",1,PR and RT regions,1,"PR, RT",1,Pol,0,Pol,0,"PR, RT",1,"** PR, RT",1,Not reported,0
Human Answer,37976080,10,What method was used for sequencing?,List,Sanger sequencing,Sanger sequencing of PCR-amplified products.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Not reported,0,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,** Sanger sequencing,1,Sanger sequencing,1
Human Answer,37976080,11,What type of samples were sequenced?,List,Plasma,Plasma samples (viral RNA extracted from 200 µL plasma) were sequenced.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,** Plasma,1,Plasma,1
Human Answer,37976080,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. The study targeted pretreatment individuals starting or restarting first-line ART; it was not a virological failure cohort, although 3.2% reported prior ARV exposure.",1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer,37976080,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. This was a multicenter observational cross-sectional surveillance study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer,37976080,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. The study included participants with prior ARV exposure (3.2% of participants), and their sequences were part of the dataset used for PDR analysis.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,37976080,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"The paper does not report which specific antiretroviral drug classes were received by the individuals with prior ARV exposure; it only reports that 3.2% had prior ARV exposure and reports class-level resistance results (NNRTI, NRTI, PI) from sequence interpretation.",0,"NRTI, NNRTI, PI",0,No,1,"NRTI, NNRTI",0,Not reported,1,Not reported,1,Not reported,1,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,Not reported.,1,Not reported,1,"NRTIs, NNRTIs, PIs",0,Not reported,1,Not reported,1,"NRTI, NNRTI, and PI",0,No,1,"NRTI, NNRTI",0,NRTI,0,"NRTIs, NNRTIs, PIs",0,** NRTI,0,Not reported,1
Human Answer,37976080,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,The paper does not provide details of the specific drugs received by individuals prior to sequencing. It lists the 12 WHO-recommended drugs monitored for resistance in the analysis but does not state which drugs individual participants had received.,0,"Efavirenz (EFV), Nevirapine (NVP)",0,No,1,Not reported,1,Not reported,1,Not reported,1,"Abacavir, Zidovudine, Tenofovir",0,"Abacavir, Tenofovir (TDF), Efavirenz (EFV), Nevirapine (NVP)",0,"Abacavir, Zidovudine, Lamivudine, and others",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV)",0,Not reported.,1,Not reported,1,"Efavirenz, nevirapine, lopinavir",0,Not reported,1,Not reported,1,"Abacavir (ABC), Zidovudine (AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir (EVG), Dolutegravir (DTG), Bictegravir (BIC), cabotegravir (CAB), Lenacapavir (LEN)",0,No,1,"Abacavir, Zidovudine, Lamivudine, Tenofovir, Efavirenz, Nevirapine",0,"AZT, 3TC, FTC, TDF, ABC, d4T, ddI",0,"TDF, FTC, EFV, NVP, LPV/r",0,** Tenofovir (TDF),0,Not reported,1
Human Answer,37976185,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,37976185,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer,37976185,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No indication in the paper that sequences were made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,** Yes,0,Yes,0
Human Answer,37976185,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None provided / Not reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,"Not reported in the provided text, but the paper likely reports the accession numbers in the text.",1,** OP539111–OP539272,0,"OP539111–OP539272, MN234327 -- MN235714, MK228137-MK228585",0
Human Answer,37976185,5,How many individuals had samples obtained for HIV sequencing?,Number,4246,4246 individuals had an available genotype obtained within 30 days of diagnosis.,1,4246,1,4246,1,4246,1,4246,1,4246,1,4246,1,4246,1,4246,1,4246,1,4246,1,4246,1,4246,1,6,0,Not reported,0,4246,1,4246,1,4246,1,4246,1,4246,1,** 4246,1,"39, 42",0
Human Answer,37976185,6,From which countries were the sequenced samples obtained?,List,USA,United States (New York City).,1,No,0,United States,1,Not reported,0,USA,1,USA,1,United States (New York City),1,Not reported,0,United States,1,United States,1,United States,1,Not reported,0,United States,1,"United States, Australia",1,Not reported,0,No,0,No,0,Not Reported,0,Not reported,0,Not reported,0,** United States,1,"Botswana, Brazil, India, South Africa, Tanzania, Thailand, Uganda, USA, Zimbabwe, Kenya",1
Human Answer,37976185,7,From what years were the sequenced samples obtained?,List,2015-2022,2015–2022.,1,2015-2022,1,2015-2022,1,2015–2022,1,2015–2022,1,2015–2022,1,2015-2022,1,2015-2022,1,2015-2022,1,2015-2022,1,2015-2022,1,2015-2022,1,2015-2022,1,Not reported,0,Not reported,0,2015-2022,1,2015-2022,1,2015-2022,1,2015-2022,1,2015-2022,1,** 2015-2022,1,"2015-2022, 2012",1
Human Answer,37976185,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No indication that samples were cloned prior to sequencing.,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,** No,1,No,1
Human Answer,37976185,9,Which HIV genes were reported to have been sequenced?,List,RT,Reverse transcriptase (RT) region of pol (inferred from reported mutations M184I/V and K65R).,1,"Reverse transcriptase, RT",1,No,0,Pol,0,Not reported,1,Not Reported,1,RT (M184I/V mutations),1,Not reported,1,Not specified,0,RT,1,Not reported,1,"Pol, IN",0,Reverse transcriptase,1,"Gag, PR, RT",1,Not reported,1,No,0,No,0,Full length genome,0,Not reported,1,Pol,0,** IN,0,"Gag, PR, RT, IN",1
Human Answer,37976185,10,What method was used for sequencing?,List,"Sanger sequencing, NGS",Sanger sequencing and consensus sequences derived from next-generation sequencing (NGS).,1,No,0,Sanger sequencing; NGS,1,Sanger sequencing,0,Sanger sequencing and NGS,1,Not Reported,0,Sanger and next-generation sequencing,1,Not reported,0,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,Sanger sequencing,0,Sanger sequencing and Illumina MiSeq sequencing,0,Sanger sequencing,0,** Sanger sequencing,0,"Next-generation sequencing, Sanger sequencing",1
Human Answer,37976185,11,What type of samples were sequenced?,List,Plasma,Not explicitly stated; inferred to be plasma viral RNA (blood plasma) used for genotypic resistance testing.,1,No,0,No,0,Not Reported,0,Not Reported,0,Plasma,1,Patient samples (HIV-positive individuals),0,Blood samples (plasma),1,Plasma,1,No,0,Not reported,0,Plasma,1,Not reported,0,PBMC,0,Not reported,0,No,0,No,0,Plasma,1,Plasma and blood donors,1,Plasma,1,** Plasma,1,"Plasma, DBS",1
Human Answer,37976185,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — sequences were baseline genotypes from newly diagnosed individuals, not from people with virological failure on ART.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,37976185,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,** No,1,Yes,0
Human Answer,37976185,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — sequences include individuals with prior PrEP exposure (antiretroviral drugs tenofovir and emtricitabine).,1,No,0,Yes,1,No,0,No,0,No,0,Yes,1,Not reported,0,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,37976185,15,Which drug classes were received by individuals in the study before sample sequencing?,List,NRTI,Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) — specifically tenofovir (TDF or TAF) and emtricitabine (FTC) as part of PrEP.,1,No,0,NRTI,1,,0,,0,,0,NRTI (Tenofovir/Emtricitabine),1,Not reported,0,NRTI,1,NRTI,1,"NRTI, NNRTI",1,"NRTI, INSTI",1,NRTIs,1,Not reported,0,Not reported,0,No,0,No,0,NRTI,1,Not reported,0,"NRTIs, NNRTIs, and PIs",1,"** NRTI, NNRTI, INSTI",1,"NRTI, INSTI",1
Human Answer,37976185,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, FTC",Tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) with emtricitabine (FTC).,1,No,0,"Tenofovir disoproxil fumarate, Tenofovir alafenamide, Emtricitabine",1,"TDF, FTC",1,,0,,0,Emtricitabine (FTC),0,"Tenofovir, Emtricitabine",1,"Emtricitabine (FTC), Tenofovir (TFV)",1,"Tenofovir disoproxil fumarate, tenofivir alafenamide fumarate, emtricitabine",1,"TDF/TAF, FTC",1,"Tenofovir disoproxil fumarate, tenofivir alafenamide fumarate, emtricitabine",1,"TDF, FTC",1,Not reported,0,Not reported,0,No,0,No,0,TDF/TAF and FTC,1,Not reported,0,"AZT, 3TC, EFV, ATV/r, and DTG",0,"** Dolutegravir, Tenofovir alafenamide, Tenofovir disoproxil fumarate, Efavirenz",0,"Cabotegravir (CAB), Tenofovir (TFV), Emtricitabine (FTC), Dolutegravir (DTG), Emtricitabine (FTC), Tenofovir alafenamide (TAF), Tenofovir disoproxil fumarate (TDF), Efavirenz (EFV), Nevirapine (NVP), Lamivudine (3TC)",1
Human Answer,37993493,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37993493,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No — the paper reports genotypic-inferred drug susceptibility, not direct in vitro phenotypic susceptibility assays.",1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1
Human Answer,37993493,3,Were sequences from the paper made publicly available?,Boolean,No,No — sequences were not deposited in a public repository; data are available on request from the corresponding author/DUCS database.,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes.,0,No,1,No,1,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG), Raltegravir (RAL), Elvitegravir(EVG), Bictegravir (BIC), cabotegravir (CAB), Lenacapavir (LEN)",1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer,37993493,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1,Not reported,1
Human Answer,37993493,5,How many individuals had samples obtained for HIV sequencing?,Number,33,"33 individuals had samples eligible for genotyping (VL ≥1000 copies/mL); 31 were successfully genotyped in at least one region — 23 had successful protease/RT genotypes, 30 had successful integrase genotypes, and 22 were genotyped in all three regions.",1,600,0,600,0,Not reported,0,33,1,Not reported,0,600,0,600,0,600,0,0,0,600,0,600,0,600.,0,600,0,Not reported,0,600,0,598,0,Not reported,0,600,0,600,0,600,0,600,0
Human Answer,37993493,6,From which countries were the sequenced samples obtained?,List,Tanzania,Tanzania (Dar es Salaam).,1,No,0,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania,1,Tanzania.,1,Tanzania,1,Tanzania,1,No,0,Tanzania,1,Not reported,0,Tanzania,1,Tanzania,1,Not reported,0,Not reported,0
Human Answer,37993493,7,From what years were the sequenced samples obtained?,List,2023,Samples were obtained in 2023 (between February and May 2023).,1,No,0,2023,1,2023,1,2023,1,2023,1,2023,1,2023,1,2023,1,2023,1,2023,1,2023,1,2023.,1,2023,1,Not reported,0,No,0,2023,1,2023,1,2019-2023,1,2023,1,2023,1,2023,1
Human Answer,37993493,8,Were samples cloned prior to sequencing?,Boolean,No,No — samples were not cloned; direct plasma-derived PCR products were Sanger-sequenced.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer,37993493,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN","Protease, reverse transcriptase (RT), and integrase.",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT",0,"Protease, Reverse Transcriptase, Integrase",1,"PR, RT, IN",1,"Protease, Reverse transcriptase, Integrase",1,"PR, RT, IN",1,"Protease, reverse transcriptase, and integrase",1,"Protease, reverse transcriptase, and integrase",1,"Protease, reverse transcriptase, and integrase.",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease, Reverse transcriptase, and Integrase",1,"PR, RT, IN",1,"PR, RT",0,Pol,0,No,0,"PR, RT, IN",1,"Protease, Reverse Transcriptase, Integrase",1
Human Answer,37993493,10,What method was used for sequencing?,List,Sanger sequencing,"Sanger-style (capillary) sequencing using an Applied Biosystems 3500xL genetic analyser, with sequence assembly/editing via RECall and interpretation via Stanford HIVDR database.",1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Yes,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37993493,11,What type of samples were sequenced?,List,Plasma,Plasma derived from venous blood (EDTA tubes).,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,NRTIs and INSTIs,0,Plasma,1,Plasma,1
Human Answer,37993493,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — sequences were obtained from individuals with virological failure (defined as VL ≥1000 copies/mL) who were on ART.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Tenofovir, lamivudine, and dolutegravir",0,Yes,1,Yes,1
Human Answer,37993493,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a cross-sectional survey of routine care patients, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1
Human Answer,37993493,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes — the study reports sequences from treatment-experienced individuals who had been on ART (at least one year), mostly on DTG-based regimens and some with prior ART exposures.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,37993493,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI, INSTI","Nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), and protease inhibitors (PIs).",1,"NRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, INSTI",0,"NRTI, INSTI",0,"NRTI, INSTI",0,"NRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, INSTI",0,"NRTIs, NNRTIs, and INSTIs",0,"NRTIs, NNRTIs, and INSTIs",0,"NRTIs, NNRTIs, and INSTIs.",0,"NRTI, INSTI",0,"NRTI, PI, INSTI",1,No,0,INSTI,0,"NRTI, NNRTI",0,"NRTI, NNRTI",0,No,0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, INSTI",0
Human Answer,37993493,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, DTG, ABC, LPV, ATV, EFV","Specifically reported drugs include tenofovir (TDF), lamivudine (3TC), dolutegravir (DTG) as the predominant TLD regimen; abacavir (ABC); lopinavir/ritonavir (LPV/r); atazanavir/ritonavir (ATV/r); efavirenz (EFV) is mentioned as part of prior first-line regimens that may have failed.",1,"Tenofovir, Lamivudine, Dolutegravir, Abacavir, Lopinavir",0,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG), Abacavir (ABC), Lopinavir (LPV), Atazanavir (ATV), Efavirenz (EFV)",1,"Tenofovir, lamivudine, dolutegravir",0,"TDF, 3TC, DTG",0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir (TDF), Lamivudine (3TC), Dolutegravir (DTG)",0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF)",0,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG)",0,Dolutegravir,0,"Tenofovir, lamivudine, and dolutegravir",0,"Tenofovir, lamivudine, and dolutegravir",0,"Tenofovir, lamivudine, and dolutegravir.",0,"Tenofovir, Lamivudine, Dolutegravir",0,"TDF, 3TC, ABC, LPV, ATV, DTG",0,"NRTI, NNRTI, PI, INSTI",0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, Lamivudine, Dolutegravir",0,"TDF, 3TC, DTG",0,No,0,"DTG, TDF, 3TC, LPV/r, ATV/r, EFV, EVG, BIC, DRV/r, RPV, TAF, FTC",0,"Tenofovir, Lamivudine, Dolutegravir",0
Human Answer,38005921,1,Does the paper report HIV sequences from patient samples?,Boolean,No,Yes. The paper uses amino acid sequences of HIV enzymes derived from clinical samples (from the Stanford HIV Drug Resistance Database) to build and evaluate prediction models.,0,Yes,0,Yes,0,Yes,0,Yes,0,** Yes,0,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes.,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer,38005921,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"Yes. The study used phenotype (in vitro) resistance data from the Stanford database, with experimental resistance levels determined by the PhenoSense™ test system.",0,Yes,0,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes.,0,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,** Yes,0,Yes,0
Human Answer,38005921,3,Were sequences from the paper made publicly available?,Boolean,Yes,"Partially yes. The datasets used to build the models are provided in the Supplementary Materials and the web service is publicly available, but no separate GenBank depositions are specified in the paper.",0,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1,No,0,Yes,1,No,0,Yes,1,** Yes,1,Yes,1
Human Answer,38005921,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,Not reported. The paper does not list any GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported in the provided text,1,** Not reported,1,"ON989213-ON989341, OK584018, OK283056-OK283059, FN557303 to FN557343, KY580473-KY580727, MN791130-MN792579, KR860607-KR861345",0
Human Answer,38005921,5,How many individuals had samples obtained for HIV sequencing?,Number,0,"Not reported as number of individuals. The paper reports sample counts by drug-class datasets: 1958 protease inhibitor samples, 1707 NRTI samples, and 1819 NNRTI samples.",1,0,1,0,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1,Not reported,1,0,1,0,1,5484,0,Not reported,1,At least 5474 (1958 + 1707 + 1819).,0,Not reported,1,Not reported,1,0,1,0,1,5474 (1958 + 1707 + 1819),0,Not reported,1,1958 (PI) + 1707 (NRTI) + 1819 (NNRTI) = 5474,0,** Not reported,1,"134, 649, 51, 22",0
Human Answer,38005921,6,From which countries were the sequenced samples obtained?,List,No,Not reported. The paper does not specify countries of origin for the sequences.,1,No,1,No,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Not reported,1,"Cyprus, Botswana, Iran, Italy",0
Human Answer,38005921,7,From what years were the sequenced samples obtained?,List,No,"Not explicitly reported. The authors used sequences from studies published before and after 2018 for training/test splits (training: studies published no later than 2018; test: studies published after 2018), but explicit sample collection years are not provided.",1,No,1,No,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported (but mentioned that the studies were published no later than 2018),1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Not reported,1,"2013-2014, 2015, 2017-2019",0
Human Answer,38005921,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported. The paper does not describe any cloning of samples prior to sequencing.,1,No,1,No,1,No,1,Not reported,1,** Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Yes,0,** No,1,Yes,0
Human Answer,38005921,9,Which HIV genes were reported to have been sequenced?,List,No,"Protease and reverse transcriptase (HIV-1 protease and reverse transcriptase). The datasets also referenced resistance to integrase inhibitors, but the presented models and web service are based on protease and reverse transcriptase sequences.",0,"Reverse transcriptase, RT; Protease, PR",0,"PR, RT",0,"RT, PR",0,"RT, PR",0,** Not reported,1,Not reported,1,"Reverse transcriptase, Protease",0,"Reverse transcriptase, RT; Protease, PR",0,"PR, RT",0,Reverse transcriptase and protease,0,"Protease, reverse transcriptase, and integrase",0,Reverse transcriptase and protease.,0,Not reported,1,IN,0,"Protease, Reverse transcriptase",0,No,1,"Reverse transcriptase, Protease",0,Pol,0,Not reported,1,"** Protease, Reverse Transcriptase, and Integrase",0,"Pol, gag, vif, vpr, tat, rev, vpu, env, PR, RT",0
Human Answer,38005921,10,What method was used for sequencing?,List,No,"Not reported. The paper uses pre-existing amino acid sequence data from the Stanford HIV Drug Resistance Database but does not describe the sequencing methods (e.g., Sanger or NGS) used to generate those sequences.",1,No,1,No,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1,Not reported,1,No,1,No,1,K-mer frequency,0,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Yes,0,** Not reported,1,Sanger sequencing,0
Human Answer,38005921,11,What type of samples were sequenced?,List,No,Viral sequences — specifically amino acid sequences of HIV-1 protease and reverse transcriptase derived from clinical (patient) samples/isolates.,0,No,1,No,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1,Viral samples from patients,0,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,"Plasma, PBMC, DBS, Whole Blood, Serum, Semen, CSF",0,No,1,Clinical samples,0,Plasma,0,"NRTI, NNRTI, PI, INSTI, CAI",0,** Plasma samples,0,"Plasma, PBMC",0
Human Answer,38005921,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,Not reported. The paper does not state whether sequences correspond specifically to individuals who experienced virological failure on treatment.,1,No,1,No,1,No,1,No,1,** Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes.,0,Not reported,1,No,1,No,1,No,1,Yes,0,Not reported,1,"AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",1,** Not reported,1,Yes,0
Human Answer,38005921,13,Were the patients in the study in a clinical trial?,Boolean,No,"Not reported. The sequences were obtained from public genotype–phenotype databases and published studies, but the paper does not state that patients were enrolled in a clinical trial.",1,No,1,No,1,No,1,No,1,** Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,** No,1,Yes,0
Human Answer,38005921,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"Not explicitly reported. The paper uses datasets that include resistant and susceptible variants and models resistance to drugs, but it does not explicitly state patients' prior antiretroviral treatment histories.",1,No,1,No,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes.,0,Not reported,1,Not reported,1,Yes,0,No,1,Yes,0,Not reported,1,No,1,** Yes,0,Yes,0
Human Answer,38005921,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not reported for individual histories. The datasets and models focus on drug classes: protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), and non-nucleoside reverse transcriptase inhibitors (NNRTI).",1,No,1,No,1,Not reported,1,,1,** Not reported,1,Not reported,1,Not reported,1,No,1,No,1,"PI, NRTI, and NNRTI",0,"Protease inhibitors, nucleoside reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors",0,"Protease inhibitors, nucleoside reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors.",0,Not reported,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,No,1,"NRTI, NNRTI, PI",0,Not reported,1,No,1,** Not reported,1,"NRTI, NNRTI, PI",0
Human Answer,38005921,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not reported for individuals. The paper does not provide per-patient drug histories; however, the models and results discuss specific drugs used in modeling, including (examples) nelfinavir, tipranavir, fosamprenavir, lamivudine, stavudine, abacavir, zidovudine, didanosine, tenofovir, etravirine, rilpivirine, nevirapine, and efavirenz.",1,No,1,No,1,Not reported,1,,1,** Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,"NRTI (Abacavir, Zidovudine, Zalcitabine, Didanosine, Lamivudine, Stavudine, Emtricitabine, Tenofovir); NNRTI (Nevirapine, Delavirdine, Efavirenz, Etravirine, Rilpivirine, Doravirine); PI (Amprenavir, Lopinavir, Atazanavir, Derunavir); INSTI (Raltegravir, Elvitegravir, Dolutegravir, Bictegravir, cabotegravir, Lenacapavir)",0,No,1,"Zidovudine, Lamivudine, Stavudine, Abacavir, Didanosine, Tenofovir, Efavirenz, Nevirapine, Rilpivirine, Etravirine, Nelfinavir, Tipranavir, Fosamprenavir, Darunavir, Raltegravir, Elvitegravir, Dolutegravir, Bictegravir, Cabotegravir",0,Not reported,1,No,1,** Not reported,1,"Etravirine, Rilpivirine",0
Human Answer,38020274,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,38020274,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No, not direct in vitro susceptibility assays; only predicted drug efficacy from genotypic data.",1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,** No,1,No,1
Human Answer,38020274,3,Were sequences from the paper made publicly available?,Boolean,No,No evidence in the paper that sequences were made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,Yes,0
Human Answer,38020274,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,** Not reported,1,KU900868-KU900902,0
Human Answer,38020274,5,How many individuals had samples obtained for HIV sequencing?,Number,311,"Sequencing was performed on samples from approximately 55 individuals at T1, 96 at T2, and 60 at T3 (i.e., 55, 96, and 60 sequences reported at T1–T3).",0,311,1,311,1,311,1,311,1,311,1,311,1,311,1,311,1,311,1,311,1,311,1,311,1,311,1,311,1,311,1,311,1,311,1,311,1,311,1,** 311,1,311,1
Human Answer,38020274,6,From which countries were the sequenced samples obtained?,List,Cameroon,Cameroon.,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,No,0,Cameroon,1,Not Reported,0,Cameroon,1,Cameroon,1,** Cameroon,1,Cameroon,1
Human Answer,38020274,7,From what years were the sequenced samples obtained?,List,2018-2020,2018–2020.,1,2018-2020,1,2018-2020,1,2018–2020,1,2018–2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,2018-2020,1,** 2018-2020,1,2018-2020,1
Human Answer,38020274,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / no evidence of cloning prior to sequencing.,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,** No,1,No,1
Human Answer,38020274,9,Which HIV genes were reported to have been sequenced?,List,No,HIV-1 polymerase and reverse transcriptase gene regions (pol/RT).,0,No,1,"PR, RT",0,Not reported,1,Not Reported,1,Not reported,1,RT (Reverse Transcriptase),0,Not reported,1,"Protease, PR; Reverse transcriptase, RT",0,"PR, RT",0,Pol,0,Pol,0,Pol,0,"Polymerase, Reverse Transcriptase",0,Not reported,1,No,1,"PR, RT",0,"Pol, RT",0,Pol,0,No,1,** Polymerase and Reverse Transcriptase,0,HIV-1 polymerase and reverse transcriptase gene regions,0
Human Answer,38020274,10,What method was used for sequencing?,List,No,An in-house genotypic resistance testing protocol was used; sequences were assembled and edited with Recall (CDC) software and analyzed with Stanford HIVdb and MEGA v10 for subtyping. No specific sequencing platform is reported.,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,Sanger sequencing,0,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Sanger sequencing and Illumina sequencing,0,Yes,0,** Not reported,1,Not reported,1
Human Answer,38020274,11,What type of samples were sequenced?,List,Plasma,"Blood samples (stored at -80°C); genotyping was performed on samples from participants with elevated plasma viral load (PVL ≥1,000 copies/ml), implying plasma-derived viral RNA was used.",1,Plasma,1,Plasma,1,Not reported,0,Plasma,1,Plasma,1,Blood samples,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Blood,0,Blood,0,Plasma,1,Whole Blood,0,Plasma,1,Plasma,1,NRTIs and/or NNRTIs,0,** Blood,0,Blood samples,0
Human Answer,38020274,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,** Yes,1,Yes,1
Human Answer,38020274,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a prospective cohort study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer,38020274,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,38020274,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"RTI, PI","Reverse transcriptase inhibitor classes (NRTIs and NNRTIs) used in RTI-based first-line regimens, and ritonavir-boosted protease inhibitors (PI/r) used in second-line regimens. Integrase strand transfer inhibitors (INSTIs) were not used/exposed in this cohort.",1,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",1,"NRTI, PI",1,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",1,"NRTI, PI, RTI",1,"NRTI, NNRTI",0,No,0,"NRTIs, NNRTIs",0,"NRTIs, NNRTIs",0,Not reported,0,"RTI, PI/r",1,"RTI, PI",1,No,0,"NRTI, NNRTI, PI",1,NRTI,0,"NRTI, NNRTI, PI, INSTI",1,NRTIs and/or NNRTIs,0,** NRTI,0,"NRTI, NNRTI",0
Human Answer,38020274,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Drugs mentioned as being used/examined in the cohort include NRTIs and NNRTIs such as tenofovir (TDF), lamivudine (3TC), zidovudine (AZT), abacavir (ABC), stavudine (d4T), and NNRTIs like nevirapine (NVP); and ritonavir-boosted protease inhibitors including lopinavir/ritonavir (LPV/r), atazanavir/ritonavir (ATV/r), and darunavir/ritonavir (DRV/r). Dolutegravir (DTG) / INSTIs were not used in this cohort.",0,No,1,No,1,"d4T, 3TC",0,Not Reported,1,Not reported,1,Not reported,1,"Stavudine (d4T), Lamivudine (3TC), Lopinavir (LPV/r)",0,Not specified,1,No,1,Not reported,1,"3TC, FTC, AZT, TDF, EFV",0,Not reported,1,"RTI, PI/r",0,Not reported,1,No,1,No,1,"TDF, AZT, 3TC",0,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, DTG, BIC, CAB, LEN",0,Not reported,1,"** D4T, 3TC, NVP",0,"D4T, 3TC, NVP",0
Human Answer,38022124,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** No,1,** No,1
Human Answer,38022124,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,** No,1
Human Answer,38022124,3,Were sequences from the paper made publicly available?,Boolean,No,No — there are no sequences reported and therefore none made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,** No,1
Human Answer,38022124,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported (no sequencing was performed or accession numbers given).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,** Not reported,1,** Not reported,1
Human Answer,38022124,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero — the study did not obtain samples for HIV sequencing.,1,0,1,0,1,116,0,0,1,Not reported,1,0,1,116,0,0,1,0,1,Not reported,1,116,0,116,0,0,1,116,0,0,1,0,1,116,0,116,0,116,0,** 116,0,** 116,0
Human Answer,38022124,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no sequenced samples; study was conducted in Turkey (Antalya).,1,No,1,No,1,Turkey,0,Turkey,0,Turkey,0,Turkey,0,Turkey,0,No,1,No,1,Not reported,1,Turkey,0,Turkey,0,Not reported,1,Turkey,0,No,1,No,1,Turkey,0,Not reported,1,Not reported,1,** Turkey,0,** Not reported,1
Human Answer,38022124,7,From what years were the sequenced samples obtained?,List,No,Not applicable — no sequencing performed; clinical data were collected between June 2020 and June 2022.,1,No,1,No,1,2020–2022,0,2020–2022,0,2020–2022,0,2020-2022,0,2020-2022,0,No,1,No,1,Not reported,1,2020-2022,0,2020-2022,0,Not reported,1,2020-2022,0,No,1,No,1,2020-2022,0,2020-2022,0,2020-2022,0,** 2020-2022,0,** 2020-2022,0
Human Answer,38022124,8,Were samples cloned prior to sequencing?,Boolean,No,No — samples were not cloned prior to sequencing (no sequencing was performed).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,** No,1
Human Answer,38022124,9,Which HIV genes were reported to have been sequenced?,List,No,None — the paper does not report sequencing of any HIV genes.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,** Not reported,1,** Not reported,1
Human Answer,38022124,10,What method was used for sequencing?,List,No,"Not applicable — no sequencing was performed, so no sequencing method was used or reported.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Sanger sequencing,0,Yes,0,** Not reported,1,** Not reported,1
Human Answer,38022124,11,What type of samples were sequenced?,List,No,Not applicable — no sequencing was performed; clinical measurements (HIV-1 RNA) imply plasma/blood samples were used for viral load testing.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"Plasma, whole blood",0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Plasma,0,Not reported,1,** Not reported,1,** Not reported,1
Human Answer,38022124,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — no sequences were obtained; the study reports virological outcomes but does not report sequencing of samples from individuals with virological failure.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,Not reported,1,** No,1,** No,1
Human Answer,38022124,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a retrospective observational (real-life) study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,** No,1
Human Answer,38022124,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report HIV sequences; it does report that many participants were treatment-experienced prior to switching to BIC/FTC/TAF.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,** No,1,** Yes,0
Human Answer,38022124,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not applicable for sequencing (no sequencing), but prior ART regimens reported include INSTIs (integrase strand transfer inhibitors) and NRTIs (nucleoside/nucleotide reverse transcriptase inhibitors); cobicistat (a pharmacokinetic booster) was also used as part of a combination.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,"NRTI, INSTI",0,"NRTI, INSTI",0,INSTI,0,No,1,Not reported,1,"INSTI, NRTI",0,"NRTIs, NNRTIs, INSTIs",0,Not reported,1,Not reported,1,No,1,No,1,"NRTIs, NNRTIs, INSTIs",0,"NRTI, NNRTI, PI, INSTI",0,No,1,** Not reported,1,"** INSTI, NRTI",0
Human Answer,38022124,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,No sequencing was done; prior drugs reported in the cohort include EVG/c/FTC/TAF (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) and DTG+TDF/FTC (dolutegravir + tenofovir disoproxil fumarate + emtricitabine).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,"EVG/c/FTC/TAF, DTG+TDF/FTC",0,"Stavudine, Lamivudine, Efavirenz, Tenofovir, Abacavir",0,"Bictegravir (BIC), Emtricitabine (FTC), Tenofovir (TAF)",0,No,1,Not reported,1,"EVG, FTC, TAF, DTG, TDF, FTC",0,"TDF, FTC, BIC",0,Not reported,1,Not reported,1,No,1,No,1,"Tenofovir, Emtricitabine, Elvitegravir, Dolutegravir",0,Not reported,1,No,1,** Not reported,1,"** EVG/c/FTC/TAF, DTG+TDF/FTC",0
Human Answer,38031075,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes.,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,38031075,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38031075,3,Were sequences from the paper made publicly available?,Boolean,No,No — there were no sequences generated to be made public.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1
Human Answer,38031075,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported (no sequencing was performed).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1
Human Answer,38031075,5,How many individuals had samples obtained for HIV sequencing?,Number,0,"None for sequencing; 2,253 participants had samples collected for viral load testing.",1,0,1,0,1,2253,0,0,1,Not reported,1,Not reported,1,Not reported,1,2253,0,0,1,Not reported,1,"2,253",0,"2,253.",0,Not reported,1,Not reported,1,0,1,2253,0,2253,0,2253,0,2253,0,"2,253",0,2253,0
Human Answer,38031075,6,From which countries were the sequenced samples obtained?,List,No,Not applicable for sequencing; samples were obtained in Sierra Leone.,1,No,1,No,1,Sierra Leone,0,Sierra Leone,0,Sierra Leone,0,Sierra Leone,0,Sierra Leone,0,Sierra Leone,0,No,1,Not reported,1,Sierra Leone,0,Sierra Leone.,0,Not reported,1,Not reported,1,No,1,Sierra Leone,0,Sierra Leone,0,Sierra Leone,0,Sierra Leone,0,Sierra Leone,0,Sierra Leone,0
Human Answer,38031075,7,From what years were the sequenced samples obtained?,List,No,Not applicable for sequencing; samples (for viral load) were collected between August 2022 and January 2023.,1,No,1,No,1,2022–2023,0,Not reported,1,2022-2023,0,August 2022 - January 2023,0,2022 to 2023,0,2022-2023,0,No,1,Not reported,1,2022-2023,0,2022-2023.,0,Not reported,1,Not reported,1,No,1,No,1,2022-2023,0,2022-2023,0,2022-2023,0,2022-2023,0,2022-2023,0
Human Answer,38031075,8,Were samples cloned prior to sequencing?,Boolean,No,No — sequencing was not performed (so no cloning occurred).,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1
Human Answer,38031075,9,Which HIV genes were reported to have been sequenced?,List,No,None — no HIV genes were sequenced in this study.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,HIV RNA.,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1
Human Answer,38031075,10,What method was used for sequencing?,List,No,Not applicable — no sequencing method was used or reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,PCR,0,RT-PCR/sequencing/genotyping,0,Yes,0,Not reported,1,Not reported,1
Human Answer,38031075,11,What type of samples were sequenced?,List,No,Not applicable — no sequencing performed; the study collected plasma derived from EDTA whole blood for viral load testing.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Plasma,0,No,1,Not reported,1,Plasma,0,Plasma or serum.,0,Not reported,1,Not reported,1,No,1,Plasma,0,Plasma,0,Plasma,0,"NRTIs, INSTIs",0,Plasma,0,Plasma,0
Human Answer,38031075,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — no sequencing was performed. The study did report individuals with detectable or low-level viremia while on ART.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes.,0,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,"Tenofovir, Lamivudine, Dolutegravir",1,Yes,0,Yes,0
Human Answer,38031075,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a cross-sectional observational survey, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38031075,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — no sequences were reported; however the study population predominantly consisted of individuals receiving ART.,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,Yes,0,No,1,Not reported,1,Yes,0,Yes.,0,Not reported,1,Not reported,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0
Human Answer,38031075,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable for sequencing; participants received NRTIs and either an INSTI (dolutegravir) or an NNRTI (efavirenz).,1,"NRTI, INSTI",0,No,1,"NRTI, INSTI",0,Not reported,1,"NRTI, INSTI",0,"NRTI, INSTI",0,"NRTI, INSTI",0,"NRTI, NNRTI, INSTI",0,No,1,Not reported,1,"INSTI, NNRTI",0,Not reported.,1,Not reported,1,Not reported,1,No,1,"NRTI, INSTI",0,"NRTIs, INSTIs",0,"NRTIs, INSTIs",0,No,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0
Human Answer,38031075,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Tenofovir, lamivudine, dolutegravir, and efavirenz were specifically mentioned.",0,"Tenofovir, Lamivudine, Dolutegravir",0,No,1,"Tenofovir, lamivudine, dolutegravir",0,Not reported,1,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, Lamivudine, Dolutegravir, Efavirenz",0,No,1,Not reported,1,"Dolutegravir, Efavirenz",0,Not reported.,1,Not reported,1,Not reported,1,No,1,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, Lamivudine, Dolutegravir",0,No,1,Not reported,1,"Tenofovir, Lamivudine, Dolutegravir, Efavirenz, Ritonavir, Lopinavir, Zidovudine, Atazanavir, Darunavir, Emtricitabine, Nevirapine, Didanosine",0
Human Answer,38033131,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1
Human Answer,38033131,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report any in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,38033131,3,Were sequences from the paper made publicly available?,Boolean,No,No — there are no sequences reported and thus none made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,Yes,0,No,1,No,1
Human Answer,38033131,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported (no sequencing performed).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not Reported,1,"The paper reports the following GenBank accession numbers: FJ800379–FJ800386, GQ477441-GQ477451, KP170487.",0,Not reported,1,Not reported,1
Human Answer,38033131,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero — no samples were obtained for HIV sequencing.,1,0,1,0,1,Not reported,1,0,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,492,0,492,0,Not reported,1,Not reported,1,0,1,0,1,492,0,Not Reported,1,492,0,492,0,492,0
Human Answer,38033131,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no sequencing was performed; the study population was from Ethiopia.,1,No,1,No,1,Ethiopia,0,Ethiopia,0,Ethiopia,0,Ethiopia,0,Ethiopia,0,No,1,No,1,Not reported,1,Ethiopia,0,Not reported,1,Not reported,1,Ethiopia,0,No,1,No,1,Not Reported,1,Not Reported,1,Ethiopia,0,South Africa,0,Not reported,1
Human Answer,38033131,7,From what years were the sequenced samples obtained?,List,No,"Not applicable — no sequencing was performed; clinical data cover January 1, 2015 to December 31, 2019.",1,No,1,No,1,2015–2019,0,2015–2019,0,2015–2019,0,2015 to 2019,0,2015-2019,0,No,1,No,1,Not reported,1,2015-2019,0,2015-2019,0,Not reported,1,2015-2019,0,No,1,No,1,2015-2019,0,Not Reported,1,2015-2019,0,2008-2012,0,Not reported,1
Human Answer,38033131,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — no sequencing or cloning was reported.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,No,1
Human Answer,38033131,9,Which HIV genes were reported to have been sequenced?,List,No,None — the paper does not report sequencing of any HIV genes.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,"PR, RT",0,Not reported,1
Human Answer,38033131,10,What method was used for sequencing?,List,No,Not applicable — no sequencing methods were reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not Reported,1,Yes,0,Not reported,1,Not reported,1
Human Answer,38033131,11,What type of samples were sequenced?,List,No,Not applicable — no samples were sequenced. The study used patient charts and viral load measurements from clinical records.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Plasma,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Patient charts,0,Not Reported,1,"NRTIs, NNRTIs, and PIs",0,Plasma,0,Not reported,1
Human Answer,38033131,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — no sequences were obtained from any individuals, including those with virological failure.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Yes,0,No,1,No,1,Yes,0,No,1,"AZT, 3TC, EFV, NVP, LPV/r, ATV/r, and DRV/r",1,Yes,0,No,1
Human Answer,38033131,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the patients were part of routine care and the study was a retrospective follow-up of clinical records, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1
Human Answer,38033131,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the paper does not report any HIV sequences; however, the participants were children and adolescents who had received ARV therapy (first-line ART).",1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1
Human Answer,38033131,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Not applicable for sequencing; among the study participants, NNRTI-based regimens (specifically NVP-based) were explicitly reported.",1,No,1,No,1,"NRTI, NNRTI",0,"NRTI, NNRTI",0,Not reported,1,"NRTI, NNRTI, PI",0,"NNRTI, Cotrimoxazole, Isoniazid",0,No,1,No,1,Not reported,1,"NRTI, NNRTI",0,Not reported,1,Not reported,1,NNRTI,0,No,1,No,1,NRTI,0,Not Reported,1,No,1,"NRTI, NNRTI, PI",0,Not reported,1
Human Answer,38033131,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable for sequencing; the paper explicitly mentions nevirapine (NVP)-based regimens and reports PMTCT history and prophylactic drugs (cotrimoxazole, isoniazid).",1,No,1,No,1,Nevirapine,0,Not reported,1,Not reported,1,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF)",0,"Nevirapine (NVP), Zidovudine (AZT)",0,No,1,No,1,Not reported,1,"AZT, 3TC, NVP",0,Not reported,1,Not reported,1,NVP,0,No,1,No,1,Not Reported,1,Not Reported,1,No,1,"Stavudine (D4T), Lamivudine (3TC), Lopinavir (LPV/r), Ritonavir (RTV), Abacavir (ABC), Didanosine (DDI), Zidovudine (AZT), Efavirenz (EFV)",0,Not reported,1
Human Answer,38058846,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Not explicitly — the paper reports HIV drug resistance testing results for three patients but does not explicitly state that HIV sequences from patient samples are reported.,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,38058846,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility (phenotypic) data.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer,38058846,3,Were sequences from the paper made publicly available?,Boolean,No,No — there is no indication that HIV sequences were deposited in public repositories.,1,No,1,No,1,Not Reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,** No,1,No,1
Human Answer,38058846,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,,1,Not reported,1,Not reported in the provided text,1,** Not reported,1,Not reported,1
Human Answer,38058846,5,How many individuals had samples obtained for HIV sequencing?,Number,3,Three individuals.,1,0,0,3,1,3,1,3,1,3,1,3,1,3,1,0,0,3,1,3,1,3,1,3.,1,3,1,3,1,0,0,0,0,No,0,3,1,3,1,** 3,1,3,1
Human Answer,38058846,6,From which countries were the sequenced samples obtained?,List,No,South Africa.,0,No,1,South Africa,0,South Africa,0,South Africa,0,South Africa,0,South Africa,0,South Africa,0,South Africa,0,South Africa,0,South Africa,0,South Africa,0,South Africa.,0,South Africa,0,Not reported,1,No,1,No,1,No,1,South Africa,0,Not reported,1,** South Africa,0,South Africa,0
Human Answer,38058846,7,From what years were the sequenced samples obtained?,List,No,The resistance testing for the cases occurred in 2022–2023 (testing confirmed in late 2022 and in 2023).,0,No,1,2021-2023,0,2020,0,2012–2023,0,2012–2023,0,2012-2022,0,2018-2022,0,No,1,"2012, 2020, 2022",0,2012-2023,0,2018-2023,0,Not reported.,1,2020-2023,0,Not reported,1,No,1,No,1,No,1,2020-2021,0,2020-2022,0,** 2022,0,2018-2022,0
Human Answer,38058846,8,Were samples cloned prior to sequencing?,Boolean,No,Not stated / no indication that samples were cloned prior to sequencing.,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,** No,1,No,1
Human Answer,38058846,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",Not specified in the provided text.,0,No,0,IN,0,Pol,0,Not reported,0,Not reported,0,IN (Integrase),0,IN,0,No,0,No,0,Integrase,0,Pol,0,IN.,0,"RT, PR, IN",1,"RT, IN",0,No,0,No,0,No,0,Pol,0,Pol,0,** Not reported,0,"PR, RT, IN",1
Human Answer,38058846,10,What method was used for sequencing?,List,No,Not specified in the provided text.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing,0,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Sanger sequencing,0,Sanger sequencing,0,** Not reported,1,"Sanger sequencing, Illumina sequencing",0
Human Answer,38058846,11,What type of samples were sequenced?,List,No,Not specified explicitly; implied plasma viral samples for resistance testing but sample type is not stated in the text.,1,No,1,Plasma,0,Not Reported,1,Not reported,1,Not reported,1,Plasma,0,Plasma,0,No,1,No,1,Plasma,0,Plasma,0,Plasma.,0,Plasma,0,Plasma,0,No,1,No,1,No,1,Plasma,0,Plasma,0,** Plasma,0,"Plasma, PBMC",0
Human Answer,38058846,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — all three cases had virological failure while on DTG-containing regimens when resistance testing was performed.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,38058846,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — they were patients managed in clinical care and included as a case series, not participants in a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,** No,1,Yes,0
Human Answer,38058846,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — at least two of the three cases had prior antiretroviral therapy exposure before the resistance testing.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,38058846,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI","Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs).",1,"NRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, PI",0,"NRTI, NNRTI",0,"NRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,INSTI,0,No,0,"Integrase inhibitors, Nucleoside reverse transcriptase inhibitors",0,"NRTIs, NNRTIs, INSTIs",0,INSTI.,0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI",0,No,0,No,0,"NRTI, INSTI",0,"NRTIs, NNRTIs",0,** Not reported,0,"NRTI, NNRTI, PI, INSTI",1
Human Answer,38058846,16,Which drugs were received by individuals in the study before sample sequencing?,List,"3TC, ABC, LPV, AZT, DTG, FTC, TDF, DRV, EFV, NVP","Drugs mentioned include lamivudine, abacavir, zidovudine, tenofovir, emtricitabine, efavirenz (likely in earlier regimen), nevirapine (infant prophylaxis and mentioned), lopinavir/ritonavir, darunavir/ritonavir, and dolutegravir (DTG) as part of TLD/TLD-like regimens.",1,"Lamivudine, Abacavir, Lopinavir, Ritonavir, Zidovudine, Dolutegravir, Tenofovir, Darunavir, Nevirapine",0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Lopinavir (LPV), Darunavir (DRV), Dolutegravir (DTG)",0,"Tenofovir, Emtricitabine, Darunavir, Ritonavir",0,"Lamivudine, Abacavir, Lopinavir/Ritonavir, Zidovudine, Tenofovir, Emtricitabine, Efavirenz",0,"Lamivudine, Zidovudine, Dolutegravir, Tenofovir, Emtricitabine, Darunavir, Ritonavir",0,"Lamivudine (3TC), Nevirapine, Efavirenz (EFV), Zidovudine (AZT), Abacavir (ABC), Lopinavir (LPV), Ritonavir (RTV), Tenofovir (TFV), Dolutegravir (DTG).",0,"Lamivudine (3TC), Abacavir (ABC), Lopinavir (LPV/r), Ritonavir (RTV)",0,Dolutegravir (DTG),0,No,0,"Dolutegravir, Lamivudine, Zidovudine, Abacavir, Tenofovir, Emtricitabine, Darunavir",0,"DTG, TDF, FTC, and other drugs",0,DTG.,0,"Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG)",0,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.",0,"Lamivudine, Abacavir, Lopinavir, Tenofovir, Emtricitabine, Efavirenz, TLD",0,No,0,No,0,"TDF, FTC, AZT, DTG",0,"Lamivudine, zidovudine, efavirenz",0,** Not reported,0,"3TC, NVP, EFV, D4T, AZT, LPV, ABC, ATZ, DTG, TDF",0
Human Answer,38072961,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — genotypic (Sanger) sequencing of HIV from patient CSF and plasma was performed.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,38072961,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No — the paper reports genotypic (Sanger) resistance testing, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,38072961,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report deposition of sequences in public databases.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,38072961,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,MN...,0,Not reported,1,Not reported,1,Not reported,1
Human Answer,38072961,5,How many individuals had samples obtained for HIV sequencing?,Number,1,One individual (single case report).,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1.,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1
Human Answer,38072961,6,From which countries were the sequenced samples obtained?,List,China,China.,1,No,0,China,1,China,1,China,1,China,1,China,1,China,1,No,0,No,0,China.,1,China,1,Not reported,0,Not reported,0,Not Found,0,No,0,No,0,China,1,China,1,Not reported,0,China,1,China,1
Human Answer,38072961,7,From what years were the sequenced samples obtained?,List,2022,2022 (sequencing performed during the relapse in mid-2022).,1,No,0,2022,1,2017–2022,1,Not reported,0,Not reported,0,2017-2022,1,2017 and onward,0,No,0,No,0,2022.,1,2022,1,2022,1,Not reported,0,Not reported,0,No,0,No,0,2022,1,2017-2022,1,Not reported,0,Not reported,0,2022,1
Human Answer,38072961,8,Were samples cloned prior to sequencing?,Boolean,No,No indication that samples were cloned prior to sequencing; standard Sanger population genotyping was reported.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported.,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1
Human Answer,38072961,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT","Protease and reverse transcriptase regions of pol (PI-, NNRTI-, and NRTI-associated regions).",1,"Protease, PR; Reverse transcriptase, RT; Nucleoside reverse transcriptase, NRTI",1,"PR, RT",1,"PR, RT",1,Not reported,0,Not reported,0,"PR, RT",1,"PR, RT",1,Not specified,0,No,0,Pol.,0,Pol,0,Pol,0,Not reported,0,"PR, RT, IN",1,No,0,No,0,Pol,0,"Pol, PR, RT",1,Not reported,0,Not reported,0,Not reported,0
Human Answer,38072961,10,What method was used for sequencing?,List,"Sanger sequencing, NGS",Sanger sequencing (genotypic drug resistance testing).,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Not reported,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,No,0,No,0,Sanger sequencing.,0,Sanger sequencing,0,Not reported,0,Sanger sequencing,0,Sanger sequencing,0,No,0,No,0,Sanger sequencing,0,Sanger sequencing,0,Not reported,0,Not reported,0,Not reported,0
Human Answer,38072961,11,What type of samples were sequenced?,List,"CSF, Plasma",Cerebrospinal fluid (CSF) and plasma samples from the patient.,1,Other,0,"CSF, Plasma",1,"Plasma, CSF",1,"Plasma, CSF",1,"CSF, Plasma",1,"Plasma, Cerebrospinal fluid (CSF)",1,"CSF, Plasma",1,"CSF, Plasma",1,No,0,CSF and plasma.,1,CSF and plasma,1,Plasma,0,Plasma,0,Plasma,0,CSF,0,No,0,CSF,0,Plasma,0,Not reported,0,CSF,0,CSF,0
Human Answer,38072961,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — sequencing was performed on samples from a patient experiencing virological failure/CSF viral escape while on ART.,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1
Human Answer,38072961,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this is an individual case report, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1
Human Answer,38072961,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — the patient had prior ART exposure and sequencing was performed on samples from that patient.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1
Human Answer,38072961,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI","Nucleoside reverse transcriptase inhibitors (NRTIs), a nonnucleoside reverse transcriptase inhibitor (NNRTI), and protease inhibitors (PIs).",1,"NRTI, PI",0,"NRTI, NNRTI, PI",1,"NRTI, PI",0,"NRTI, PI",0,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,"NRTI, PI, INSTI",0,No,0,"NRTIs, NNRTIs, and PIs.",1,"NRTIs, PIs, NNRTIs",1,"NRTIs, PIs, INSTIs",0,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI",1,No,0,"NRTI, PI",0,"NRTI, NNRTI",0,Not reported,0,"NRTI, NNRTI",0,"NRTI, NRTI, NNRTI",0
Human Answer,38072961,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, LPV, EFV","Tenofovir, lamivudine, efavirenz, and later lopinavir/ritonavir (tenofovir and lamivudine were continued across regimens).",1,"Tenofovir, Lamivudine, Lopinavir/Ritonavir",0,"Tenofovir (TFV), Lamivudine (3TC), Efavirenz (EFV), Lopinavir (LPV), Zidovudine (AZT), Dolutegravir (DTG)",1,"Tenofovir, Lamivudine, Lopinavir/Ritonavir, Zidovudine, Dolutegravir",0,"Tenofovir, Lamivudine, Lopinavir/Ritonavir, Zidovudine, Dolutegravir",0,"Tenofovir, Lamivudine, Efavirenz, Lopinavir/Ritonavir",1,"Tenofovir, Lamivudine, Efavirenz, Lopinavir/Ritonavir",1,"Tenofovir, Lamivudine, Efavirenz, Lopinavir/Ritonavir, Zidovudine, Dolutegravir",1,"Tenofovir, Lamivudine, Lopinavir/Ritonavir, Zidovudine, Dolutegravir",0,No,0,"Tenofovir, lamivudine, efavirenz, and lopinavir/ritonavir.",1,"tenofovir, lamivudine, lopinavir/ritonavir, efavirenz",1,"Tenofovir, lamivudine, lopinavir/ritonavir, dolutegravir",0,"Tenofovir, lamivudine, efavirenz, lopinavir/ritonavir",1,"Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG)",1,"Tenofovir, lamivudine, efavirenz, lopinavir/ritonavir, zidovudine, lamivudine, dolutegravir",1,No,0,"Tenofovir, lamivudine, lopinavir/ritonavir",0,"Tenofovir, Lamivudine, Efavirenz",0,Not reported,0,"Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV)",0,"Tenofovir, Lamivudine, Efavirenz",0
Human Answer,38090027,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,No,0,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,38090027,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer,38090027,3,Were sequences from the paper made publicly available?,Boolean,No,No (not reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Not Reported,1,No,1,No,1
Human Answer,38090027,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not Reported,1,Not reported,1,Not reported,1
Human Answer,38090027,5,How many individuals had samples obtained for HIV sequencing?,Number,5,Five patients had evaluable genotypic resistance tests.,1,0,0,0,0,1040,0,1040,0,Not reported,0,1040,0,1040,0,0,0,0,0,1040,0,1040,0,1040,0,Not reported,0,1040,0,No,0,0,0,1040,0,1040,0,1040,0,1040,0,358,0
Human Answer,38090027,6,From which countries were the sequenced samples obtained?,List,Italy,Italy.,1,No,0,No,0,Not reported,0,Italy,1,Not reported,0,Italy,1,Italy,1,No,0,No,0,Not reported,0,Not reported,0,Not Reported,0,Not reported,0,Not reported,0,No,0,No,0,Not reported,0,Italy,1,Not Reported,0,Not reported,0,Not reported,0
Human Answer,38090027,7,From what years were the sequenced samples obtained?,List,2019-2020,"Sequencing (GRT) was performed during the study follow-up period, with patient switches from June 2019 to June 2021 and follow-up/data freeze through 31 August 2022 (so samples were obtained during 2019–2022).",0,No,0,2019-2022,0,2019–2021,0,2019–2021,0,Not reported,0,2019-2021,0,2019-2021,0,No,0,No,0,2019-2021,0,2019-2021,0,2019-2021,0,Not reported,0,2019-2021,0,No,0,No,0,2019-2022,0,2019-2021,0,2019-2021,0,2019-2021,0,2019-2021,0
Human Answer,38090027,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No evidence of cloning.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer,38090027,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN","Protease, reverse transcriptase, and integrase regions were assayed (i.e., PR, RT and IN).",1,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,Not explicitly reported,0,Not reported,0,No,0,No,0,Not reported,0,Not reported,0,Not Reported,0,Not reported,0,"PR, RT, IN",1,No,0,No,0,Pol,0,Pol,0,No,0,HIV-RNA,0,"PR, RT, IN",1
Human Answer,38090027,10,What method was used for sequencing?,List,No,A validated in-house genotypic resistance testing method was used (details not specified in this paper).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Sanger sequencing,0,Yes,0,Not reported,1,"Sanger sequencing, Illumina sequencing",0
Human Answer,38090027,11,What type of samples were sequenced?,List,"Plasma, PBMC",Plasma HIV-RNA and PBMC (peripheral blood mononuclear cell) HIV-DNA.,1,No,0,"Plasma, PBMC",1,Not reported,0,"Plasma, PBMC",1,"Plasma, PBMC",1,Plasma,0,"Plasma, PBMC",1,No,0,No,0,"Plasma, PBMC",1,Not reported,0,Plasma,0,Not reported,0,"Plasma, PBMC",1,No,0,No,0,"Plasma, PBMC",1,Plasma,0,"NRTIs, NNRTIs, and INSTIs",0,Plasma,0,Plasma,0
Human Answer,38090027,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — GRTs were performed/evaluable in five patients who experienced virological failure.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,"Elvitegravir, cobicistat, and tenofovir alafenamide",0,Yes,1,Yes,1
Human Answer,38090027,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was an observational, retrospective cohort in routine clinical practice (though a small number later enrolled in clinical trials).",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38090027,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer,38090027,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI","Nucleoside reverse transcriptase inhibitors (NRTIs), integrase strand transfer inhibitors (InSTIs/INSTIs), protease inhibitors (PIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs).",1,"NRTI, INSTI",0,"NRTI, PI, INSTI, NNRTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,Not reported,0,"NRTI, INSTI",0,"NRTI, INSTI",0,INSTI,0,No,0,"Integrase inhibitors, NRTIs, NNRTIs",0,"NRTI, NNRTI, PI, INSTI",1,Not Reported,0,Not reported,0,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, INSTI",0,"Integrase inhibitor, protease inhibitor, non-nucleoside reverse transcriptase inhibitor",0,"NRTIs, NNRTIs, PIs",0,No,0,"Integrase inhibitor, protease inhibitor, non-nucleoside reverse transcriptase inhibitor",0,"NRTI, NNRTI, PI, INSTI",1
Human Answer,38090027,16,Which drugs were received by individuals in the study before sample sequencing?,List,"BIC, FTC, TAF, EVG","Reported drugs/regimens included elvitegravir/cobicistat/FTC/TAF (ECFTAF), bictegravir/emtricitabine/TAF (BFTAF), darunavir/cobicistat/FTAF (DcFTAF), dolutegravir (often with FTAF), rilpivirine/FTAF, emtricitabine (or lamivudine), tenofovir alafenamide (TAF), cobicistat and boosted protease inhibitors.",1,"Emtricitabine, Tenofovir Alafenamide, Elvitegravir",0,"Elvitegravir (EVG), Cobicistat (COBI), Emtricitabine (FTC), Tenofovir alafenamide (TAF), Darunavir (DRV), Dolutegravir (DTG), Rilpivirine (RPV)",0,Not reported,0,Not reported,0,Not reported,0,"Various ARV drugs including NNRTI and INSTI, specific drug names not provided.",0,Not reported,0,"Bictegravir (BIC), Emtricitabine (FTC), Tenofovir (TFV)",0,No,0,"Bictegravir, emtricitabine, tenofovir alafenamide, elvitegravir, darunavir, rilpivirine",1,"Bictegravir, emtricitabine, tenofovir alafenamide, elvitegravir",1,Not Reported,0,Not reported,0,"DOR, 3TC, TDF",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir",0,"Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide, darunavir, cobicistat, emtricitabine, tenofovir alafenamide, rilpivirine, emtricitabine, tenofovir alafenamide",0,"AZT, 3TC, FTC, TDF, ATV/r, DRV/r, MVC",0,No,0,"Elvitegravir, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, integrase inhibitors",0,"DTG, 3TC, RPV",0
Human Answer,38140553,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV-1 sequences obtained from patient samples (partial pol sequences covering protease and part of reverse transcriptase).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,38140553,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic drug resistance (DRM) analysis but does not report in vitro phenotypic drug susceptibility assays.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,38140553,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. All nucleotide sequences obtained were deposited in the Los Alamos HIV sequence database.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,38140553,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,GenBank accession numbers for the study sequences are not reported. The paper states sequences were deposited in the Los Alamos database but does not provide GenBank accession numbers.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,K03455,0,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.,0,Not reported,1,"ON989213-ON989341, OK584018, OK283056-OK283059",0
Human Answer,38140553,5,How many individuals had samples obtained for HIV sequencing?,Number,3178,3178 individuals (3178 partial pol sequences).,1,3178,1,3178,1,3178,1,3178,1,3178,1,3178,1,3178,1,3178,1,3178,1,3178,1,3178,1,3178.,1,3178,1,3178,1,3178,1,3178,1,3178,1,3178,1,3178,1,3178,1,134,0
Human Answer,38140553,6,From which countries were the sequenced samples obtained?,List,Russia,The sequenced samples were obtained from patients in the Russian Federation (various federal districts of Russia).,1,No,0,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia.,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Cyprus,0
Human Answer,38140553,7,From what years were the sequenced samples obtained?,List,2011-2020,Samples were obtained in the period 2011–2020.,1,2011-2020,1,2011 to 2020,1,2011–2020,1,2011–2020,1,2011–2020,1,2011-2020,1,2011 to 2020,1,2011-2020,1,2011-2020,1,2011-2020,1,2011-2020,1,2011-2020.,1,2011-2020,1,2011-2020,1,2011-2020,1,2011-2020,1,2011-2020,1,2011-2020,1,2011-2020,1,2011-2020,1,2017-2019,0
Human Answer,38140553,8,Were samples cloned prior to sequencing?,Boolean,No,No. Samples were amplified by nested PCR and directly Sanger-sequenced; no cloning step is reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer,38140553,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol",The pol gene region: HIV-1 protease (PR) and part of reverse transcriptase (RT) were sequenced.,0,"Protease, PR; Reverse transcriptase, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"PR, RT",0,"Protease, PR; Reverse transcriptase, RT",0,"PR, RT",0,"PR, RT",0,"Pol (PR, RT)",0,"PR, RT.",0,Pol,0,"PR, RT",0,"Protease, PR; Reverse transcriptase, RT",0,"PR, RT",0,Pol,0,Pol,0,Pol,0,Pol,0,"Near full length genome, Pol",0
Human Answer,38140553,10,What method was used for sequencing?,List,Sanger sequencing,Sanger sequencing (BigDye Terminator v3.1 and ViroSeq HIV-1 Genotyping System) of PCR amplicons was used.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing and Illumina sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,38140553,11,What type of samples were sequenced?,List,Plasma; PBMC; Whole Blood,"Blood plasma, peripheral blood mononuclear cells (lymphocytes), and frozen whole blood samples were sequenced (RNA from plasma and DNA from lymphocytes/whole blood as appropriate).",0,Plasma; PBMC; Whole Blood,1,Plasma; PBMC; Whole Blood,1,"Plasma, PBMC, Whole Blood",1,"Plasma, PBMC, Whole Blood",1,"Plasma, PBMC, Whole Blood",1,Blood plasma,0,"Plasma, PBMC, frozen whole blood",1,Plasma; PBMC; DBS; Whole Blood,1,"Plasma, PBMC, Whole Blood",1,"Plasma, PBMC, Whole Blood",1,"Plasma, PBMC, Whole Blood",1,"Plasma, PBMC, Whole Blood.",1,Not reported,0,Plasma; Lymphocytes; Whole blood,0,Plasma; PBMC; DBS; Whole Blood,1,"Plasma, PBMC, Whole Blood",1,"Plasma, PBMCs, and whole blood",1,"Plasma, PBMC, and whole blood",1,"Plasma, serum, PBMC, proviral DNA, and dried blood spots",0,"Blood plasma, peripheral blood mononuclear cells, and frozen whole blood",0,Plasma,0
Human Answer,38140553,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not explicitly reported. The paper states sequences came from patients both receiving ART and not on ART, but it does not explicitly state which sequences were from individuals with virological failure.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Not reported.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,38140553,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Patients were sampled as part of routine molecular genetic monitoring at federal and regional AIDS Centers, not as participants in a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38140553,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"Partially. The cohort includes patients both receiving ART and not on ART at the time of sampling, but the authors state they could not reliably determine past treatment history for all patients.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Not reported,1,Yes,0,Not reported.,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,38140553,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Individual-level drug class histories are not systematically reported. The study's resistance analyses focus on protease inhibitors (PIs), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs), and discussion references use of NNRTIs and NRTIs in Russian first-line regimens.",0,"NRTI, NNRTI",0,No,1,,1,,1,,1,Not reported,1,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",0,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,No,1,Not reported,1,"NRTIs, NNRTIs, and PIs",0,"NRTIs, NNRTIs, and PIs",0,Not reported,1,"NRTI, NNRTI",0
Human Answer,38140553,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Specific individual drug regimens are not reported. The manuscript mentions commonly used drugs/regimens in Russia such as efavirenz (EFV), lamivudine (3TC), emtricitabine (FTC), and discusses dolutegravir (DTG) as later introduced, but it does not provide participant-level drug lists.",1,No,1,No,1,,1,,1,,1,Not reported,1,"3TC, d4T, NVP, AZT, EFV",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN), GS-CA1, Lenacapavir (GS-6207)",0,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"AZT, 3TC, FTC, TDF, ATV, and DRV",0,"AZT, 3TC, EFV, and ATV",0,Not reported,1,"Lamivudine (3TC), Stavudine (d4T), Nevirapine (NVP), Zidovudine (AZT), Efavirenz (EFV)",0
Human Answer,38140649,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,38140649,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer,38140649,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,38140649,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,"OR605755-OR606279, OR613869-OR613875",OR605755-OR606279 and OR613869-OR613875.,1,"OR605755-OR606279, OR613869-OR613875",1,"OR605755-OR606279, OR613869-OR613875, E-MTAB-13563",1,"OR605755-OR606279, OR613869-OR613875",1,"OR605755-OR606279, OR613869-OR613875",1,"OR605755-OR606279, OR613869-OR613875",1,"OR605755-OR606279, OR613869-OR613875",1,"OR605755-OR606279, OR613869-OR613875",1,OR605755-OR606279 and OR613869-OR613875,1,"OR605755-OR606279, OR613869-OR613875",1,OR605755-OR606279 and OR613869-OR613875.,1,OR605755-OR606279 and OR613869-OR613875,1,OR605755-OR606279 and OR613869-OR613875.,1,"OR605755-OR606279, OR613869-OR613875",1,"OR605755-OR606279, OR613869-OR613875",1,OR605755-OR606279 and OR613869-OR613875,1,E-MTAB-13563,0,OR605755-OR606279 and OR613869-OR613875,1,OR605755-OR606279 and OR613869-OR613875,1,OR605755-OR606279 and OR613869-OR613875,1,"OR605755-OR606279, OR613869-OR613875",1,"OR605755-OR606279, OR613869-OR613875",1
Human Answer,38140649,5,How many individuals had samples obtained for HIV sequencing?,Number,270,270 individuals.,1,270,1,270,1,270,1,270,1,270,1,270,1,270,1,270,1,270,1,270.,1,270,1,270.,1,270,1,270,1,270,1,280,0,270,1,270,1,270,1,270,1,270,1
Human Answer,38140649,6,From which countries were the sequenced samples obtained?,List,Croatia,Primarily Croatia (patients were newly diagnosed in and reported Croatia as country of infection).,1,Croatia,1,Croatia,1,Croatia,1,Croatia,1,Croatia,1,Croatia,1,Croatia,1,Croatia,1,Croatia,1,"Croatia (and possibly other countries, but not specified).",1,Croatia,1,Croatia.,1,Croatia,1,Croatia,1,Croatia,1,Croatia,1,Croatia,1,Croatia,1,Croatia,1,Croatia,1,Croatia,1
Human Answer,38140649,7,From what years were the sequenced samples obtained?,List,2019-2022,From 2019 to 2022.,1,2019-2022,1,2019-2022,1,2019-2022,1,2019–2022,1,2019–2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022.,1,2019-2022,1,2019-2022.,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1,2019-2022,1
Human Answer,38140649,8,Were samples cloned prior to sequencing?,Boolean,No,No (no cloning step reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported.,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,38140649,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN, Pol","Protease (PR), partial reverse transcriptase (RT), and integrase (IN) regions of the pol gene.",1,"Protease, RT, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"Protease, Reverse transcriptase, Integrase",0,"PR, RT, IN",0,"Pol (including protease, reverse transcriptase, and integrase).",1,Pol (protease and reverse transcriptase regions),0,"Pol, including protease, reverse transcriptase, and integrase.",1,"PR, RT, IN",0,"PR, RT, IN",0,"Protease, RT, and IN",0,"PR, RT",0,Pol,0,"Pol, PR, RT, IN",1,Pol,0,"PR, RT, IN",0,"PR, RT, IN",0
Human Answer,38140649,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing",Sanger sequencing (BigDye Terminator) for initial genotyping and Illumina-based deep sequencing (MiniSeq) for NGS comparison.,1,Illumina sequencing,0,Sanger sequencing; Illumina sequencing,1,"Sanger sequencing, NGS (Illumina)",1,"Sanger sequencing, NGS",0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing; Next-generation sequencing (NGS),1,Illumina sequencing,0,Both Sanger sequencing and Next-Generation Sequencing (NGS).,1,Sanger sequencing and NGS (Illumina platform),1,Sanger sequencing and NGS using the Illumina platform.,1,Sanger sequencing,0,Sanger sequencing,0,Illumina sequencing,0,Illumina sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing and deep sequencing,0,Sanger sequencing,0,Sanger sequencing,0
Human Answer,38140649,11,What type of samples were sequenced?,List,Plasma,Plasma samples (HIV-1 RNA extracted from patient plasma).,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma.,1,Plasma,1,Plasma.,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,38140649,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer,38140649,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38140649,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No, sequences are from treatment-naïve individuals (no prior ARV).",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer,38140649,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,None (participants were treatment-naïve).,1,No,1,No,1,,1,,1,,1,,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,No,1,Not Reported.,1,,1,None.,1,,1,,1,No,1,No,1,,1,"NRTI, NNRTI, PI, INSTI",0,,1,Not reported,1,Not reported,1
Human Answer,38140649,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None (no antiretroviral drugs were received prior to sampling).,1,No,1,No,1,,1,,1,,1,,1,Not reported,1,"Abacavir (ABC), Zidovudine (AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Raltegravir (RAL), Elvitegravir (EVG), Dolutagravir (DTG), Bictegravir (BIC), Cabotagravir (CAB), Lenacapavir (LEN), GS-CA1, Lenacapavir (GS-6207)",0,No,1,Not Reported.,1,,1,None.,1,,1,,1,No,1,No,1,,1,"AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",0,,1,Not reported,1,Not reported,1
Human Answer,38140667,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No. This article is a literature review and does not report new HIV sequences from patient samples.,1,No,1,Yes,0,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,38140667,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not present original in vitro drug susceptibility data; it only references published findings and in vitro passage experiments reported elsewhere.,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,38140667,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper did not generate new sequences and therefore did not deposit sequences in public repositories.,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer,38140667,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported. The review does not provide any GenBank accession numbers because it did not generate new sequence data.,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,Not reported,1,Not reported,1
Human Answer,38140667,5,How many individuals had samples obtained for HIV sequencing?,Number,0,The review itself did not obtain samples; numbers of sequenced/genotyped individuals vary by the included studies (examples: 34 plasma samples sequenced in a Botswana study; 89 individuals successfully genotyped in a Malawi study; 167 genotypes obtained in a Mozambique study).,0,0,1,146,0,Not reported.,1,Not reported,1,Not reported,1,358,0,358,0,0,1,0,1,3219,0,Not reported,1,Not reported,1,358,0,358,0,0,1,0,1,3219 (from one study) and 928 (from another study),0,955,0,599,0,358,0,358,0
Human Answer,38140667,6,From which countries were the sequenced samples obtained?,List,No,"Sequenced samples reported in the reviewed studies came from multiple countries, including (but not limited to) France, Canada, Tanzania, Malawi, Brazil, Nigeria, Mozambique, Botswana, South Africa, Italy, Germany, Spain, Ukraine, and Poland.",0,No,1,"Canada, Tanzania, Brazil, Nigeria",0,Not reported.,1,Not reported,1,Not reported,1,"France, Canada",0,"France, Canada",0,No,1,No,1,"France, Canada, Tanzania, Malawi, Mozambique, Brazil, Nigeria, Spain, Italy, Germany, Botswana, and South Africa",0,"France, Tanzania, Malawi, Mozambique, and other countries",0,"France, Canada, Tanzania, Malawi, Mozambique, Brazil, Nigeria, and others",0,Spain,0,Spain,0,No,1,No,1,"France, Canada, Spain, Tanzania, Malawi, Brazil, Nigeria, Mozambique, and Botswana",0,"Ukraine, Poland",0,Multiple countries,0,"Colombia, Nigeria",0,Not reported,1
Human Answer,38140667,7,From what years were the sequenced samples obtained?,List,No,The review covers publications and congress data from 2013 to 2023 and includes primary studies with sampling years spanning at least 2012 through 2022 (examples: a French study 2019–2022; a Canadian study 2012–2014; German samples from 2017–July 2022).,0,No,1,"2012-2014, 2019, 2021, 2018",0,Not reported.,1,Not reported,1,Not reported,1,2015-2021,0,2015-2021,0,No,1,No,1,2012-2022,0,2012-2022,0,"2012, 2014, 2015, 2018, 2019, and others",0,2015-2021,0,2015-2021,0,2013-2023,0,No,1,2012-2022,0,2012-2014,0,2012-2023,0,2015-2021,0,Not reported,1
Human Answer,38140667,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported in this review. The paper does not provide details indicating that samples were cloned prior to sequencing.,1,No,1,No,1,Not reported.,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Yes (in one study),0,Yes,0,Yes,0,No,1,No,1
Human Answer,38140667,9,Which HIV genes were reported to have been sequenced?,List,No,"Primarily the integrase gene (INSTI-associated mutations) and, in many studies, reverse transcriptase and protease regions (RT and PR) were also reported/sequenced.",0,No,1,IN,0,Not reported.,1,Not reported,1,IN,0,"RT, IN",0,IN (Integrase),0,No,1,No,1,Integrase,0,IN,0,Integrase,0,"PR, RT, IN",0,"PR, RT, IN",0,Integrase,0,No,1,"Pol (in one study), and possibly other genes (not specified)",1,"Pol, PR, RT, IN",0,Pol,0,"PR, RT, IN",0,"PR, RT, IN",0
Human Answer,38140667,10,What method was used for sequencing?,List,No,"Not specified in this review. The paper does not uniformly report sequencing methodologies (e.g., Sanger versus next-generation sequencing) used in the primary studies.",1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,Not reported,1,Sanger sequencing,0,No,1,No,1,Not reported,1,Sanger sequencing,0,Sanger sequencing and NGS,0,Sanger sequencing,0,Sanger sequencing,0,No,1,No,1,"Sanger sequencing (in one study), and possibly other methods (not specified)",1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,"Sanger sequencing, Illumina sequencing",0
Human Answer,38140667,11,What type of samples were sequenced?,List,No,Viral plasma samples (from viremic individuals) were sequenced/genotyped in the primary studies cited in the review.,0,No,1,Plasma,0,Not reported.,1,Not reported,1,Not reported,1,Plasma,0,Plasma,0,No,1,No,1,Plasma,0,Plasma,0,Plasma and PBMCs,0,Plasma,0,"Plasma, PBMC",0,Plasma,0,No,1,"Plasma (in one study), and possibly other types of samples (not specified)",1,Plasma,0,Multiple types of samples,0,Plasma,0,Plasma,0
Human Answer,38140667,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,Yes. Many of the cited studies obtained sequences from individuals experiencing virologic failure on DTG-based or other INSTI-containing regimens.,0,No,1,Yes,0,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,38140667,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this paper is a literature review of real-world cohorts, case studies, and some clinical trials; the patients discussed come from a mix of study types, but the review itself does not enroll patients in a trial.",1,No,1,No,1,No.,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Yes (in some studies),0,Yes,0,Yes,0,No,1,No,1
Human Answer,38140667,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"Yes. The review includes many sequences/genotypes from treatment-experienced individuals, including those with prior exposure to NRTIs, NNRTIs, PIs, and first-generation INSTIs (RAL, EVG).",0,No,1,Yes,0,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,38140667,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"Individuals had received multiple drug classes prior to sequencing, including nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs).",0,No,1,"NRTI, INSTI",0,Not reported.,1,Not reported,1,Not reported,1,"NRTI, INSTI",0,"NRTI, INSTI",0,"INSTI, NRTI, NNRTI",0,No,1,"NRTIs, NNRTIs, PIs, and INSTIs",0,"NRTIs, NNRTIs, PIs, INSTIs",0,"NRTIs, NNRTIs, PIs, and INSTIs",0,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0,INSTI,0,No,1,"NRTIs, NNRTIs, PIs, and INSTIs",0,"NRTI, PI, INSTI",0,"NRTIs, NNRTIs, PIs, and INSTIs",0,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",0
Human Answer,38140667,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Specific drugs mentioned in the review include dolutegravir (DTG), raltegravir (RAL), elvitegravir (EVG), lamivudine (3TC), abacavir (ABC), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), rilpivirine (RPV), and others referenced as components of regimens.",0,No,1,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG), Rilpivirine (RPV)",0,Not reported.,1,Not reported,1,Not reported,1,"3TC, DTG, ABC, TAF, FTC, LPV, DRV",0,"Dolutegravir (DTG), Lamivudine (3TC)",0,"DTG, 3TC, RPV",0,No,1,"DTG, 3TC, ABC, TDF, FTC, EFV, NVP, and RPV",0,"DTG, 3TC, ABC, TDF, FTC, EFV, RPV, ATV, DRV, and other drugs",0,"Dolutegravir, raltegravir, elvitegravir, and others",0,"Dolutegravir (DTG), Lamivudine (3TC)",0,"Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG)",0,"Dolutegravir (DTG), Raltegravir (RAL), Elvitegravir (EVG)",0,No,1,"DTG, 3TC, ABC, TDF, FTC, RPV, and others",0,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0,Multiple drugs,0,"NRTI, NNRTI, PI, INSTI",0,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.",0
Human Answer,38142692,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,"Yes

""""

""""",0,Yes,0
Human Answer,38142692,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"No

""""

""""",1,No,1
Human Answer,38142692,3,Were sequences from the paper made publicly available?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,"No

""""

""""",1,No,1
Human Answer,38142692,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported / not applicable.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,"Not reported

""""

""""",1,Not reported,1
Human Answer,38142692,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero (no individuals had samples sequenced).,1,0,1,0,1,1214,0,1214,0,Not reported,1,1214,0,1214,0,0,1,0,1,Not reported,1,1214,0,Not reported,1,1214,0,74,0,0,1,0,1,1214,0,1214,0,1214,0,"1214

""""

""""",0,1214,0
Human Answer,38142692,6,From which countries were the sequenced samples obtained?,List,No,Not applicable (no sequences); study participants were from South Africa.,1,No,1,No,1,South Africa,0,South Africa,0,South Africa,0,South Africa,0,South Africa,0,No,1,No,1,Not reported,1,South Africa,0,South Africa,0,South Africa,0,Tanzania,0,No,1,South Africa,0,South Africa,0,South Africa,0,South Africa,0,"South Africa

""""

""""",0,South Africa,0
Human Answer,38142692,7,From what years were the sequenced samples obtained?,List,No,"Not applicable (no sequences); study sample period was Dec 1, 2019 to Nov 30, 2020.",1,No,1,No,1,2019–2020,0,2019–2020,0,2019–2020,0,2019-2020,0,2019-2020,0,No,1,No,1,Not reported,1,2019-2020,0,2019-2020,0,2019-2020,0,2019 to 2021,0,No,1,No,1,2019-2020,0,2019-2020,0,2019-2020,0,"2019-2020

""""

""""",0,2019-2020,0
Human Answer,38142692,8,Were samples cloned prior to sequencing?,Boolean,No,No (not applicable — no sequencing was performed).,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,"No

""""

""""",1,No,1
Human Answer,38142692,9,Which HIV genes were reported to have been sequenced?,List,No,None (no genes sequenced / not applicable).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Pol,0,Not reported,1,"RT, PR, IN",0,"PR, RT, IN",0,No,1,No,1,Not reported,1,"Pol, PR, RT",0,Pol,0,"RT

""""

""""",0,"PR, RT, IN",0
Human Answer,38142692,10,What method was used for sequencing?,List,No,Not applicable — no sequencing methods reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Sanger sequencing,0,No,1,No,1,Not reported,1,Sanger sequencing,0,Sanger sequencing,0,"Not reported

""""

""""",1,"Sanger sequencing, Illumina sequencing",0
Human Answer,38142692,11,What type of samples were sequenced?,List,No,Not applicable — no samples were sequenced. (Viral load testing was performed on plasma as part of routine care.),1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Plasma,0,No,1,No,1,Not reported,1,Plasma,0,Not reported,1,Not reported,1,Plasma,0,No,1,No,1,Patient samples,0,Plasma,0,Plasma,0,"Plasma

""""

""""",0,Plasma; DBS,0
Human Answer,38142692,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No sequences were obtained.,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,"Yes

""""

""""",0,Yes,0
Human Answer,38142692,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a retrospective observational cohort study using routine-care data, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"No

""""

""""",1,No,1
Human Answer,38142692,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No sequences reported; study participants had prior ARV exposure (mostly first-line TDF/XTC/EFV).,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,NRTIs and NNRTIs,1,"Yes

""""

""""",0,Yes,0
Human Answer,38142692,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).,0,"NRTI, INSTI",0,No,1,"NNRTIs, NRTIs",0,NRTIs,0,"NRTI, NNRTI",0,NNRTI,0,"NRTI, NNRTI",0,No,1,No,1,Not reported,1,NNRTI,0,"NRTI, NNRTI, PI",0,NNRTI,0,"NRTI, NNRTI, INSTI",0,No,1,No,1,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"AZT, 3TC, TDF, and EFV",0,"NRTI, NNRTI

""""

""""",0,"NRTI, NNRTI, INSTI",0
Human Answer,38142692,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Tenofovir disoproxil fumarate (TDF), emtricitabine or lamivudine (XTC), and efavirenz (EFV) or nevirapine (NVP) as first-line therapy.",0,"Tenofovir (TDF), Emtricitabine (XTC), Efavirenz (EFV), Nevirapine (NVP)",0,No,1,"EFV, NVP, TDF",0,TDF and EFV/NVP,0,"Tenofovir disoproxil fumarate (TDF), Emtricitabine (FTC), Efavirenz (EFV) / Nevirapine (NVP)",0,Not reported,1,"Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (XTC), Efavirenz (EFV), Nevirapine (NVP)",0,No,1,No,1,Not reported,1,"EFV, NVP",0,"AZT, 3TC, TDF, EFV, LPV/r",0,NNRTI-based regimens,0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF), Dolutegravir (DTG)",0,No,1,No,1,No,1,"TDF, XTC, EFV, NVP",0,No,1,"TDF, EFV, NVP",0,"TDF, XTC, EFV, NVP, AZT, LPV/r, DTG",0
Human Answer,38152686,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,38152686,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,No,1
Human Answer,38152686,3,Were sequences from the paper made publicly available?,Boolean,No,No — information is available only upon request; no public deposit is reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,** No,1,No,1
Human Answer,38152686,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1
Human Answer,38152686,5,How many individuals had samples obtained for HIV sequencing?,Number,1,One individual (single case report).,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,1,** 1,1,1,1
Human Answer,38152686,6,From which countries were the sequenced samples obtained?,List,No,Not explicitly stated; the report discusses Brazil and is likely from Brazil but the country of the patient is not explicitly reported.,0,No,1,No,1,Not reported,1,Not reported,1,Brazil,0,Brazil,0,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1
Human Answer,38152686,7,From what years were the sequenced samples obtained?,List,No,Not reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Not reported,1,"2010, 2018",0
Human Answer,38152686,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,** No,1,No,1
Human Answer,38152686,9,Which HIV genes were reported to have been sequenced?,List,IN,Integrase and reverse transcriptase (parts of the pol gene).,1,"Integrase, IN",1,"RT, IN",1,IN,1,IN,1,Not reported,0,IN,1,"IN, RT",1,"Integrase, Reverse transcriptase",1,"IN, RT",1,IN,1,IN,1,IN,1,IN,1,"RT, IN",1,Integrase,1,IN,1,Integrase,1,Pol,0,Integrase,1,** IN,1,"RT, IN",1
Human Answer,38152686,10,What method was used for sequencing?,List,No,Not specified beyond that genotyping was performed.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Not reported,1,"Sanger sequencing, Illumina sequencing",0
Human Answer,38152686,11,What type of samples were sequenced?,List,Plasma,"Not explicitly stated (likely plasma from the patient, but sample type is not reported).",1,No,0,Plasma,1,Not Reported,0,Not reported,0,Not reported,0,Blood/serum,0,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Plasma,1,Not reported,0,Plasma,1,Plasma,1,Plasma,1,No,0,Not reported,0,Plasma,1,Blood,0,** Plasma,1,"Plasma, PBMC",1
Human Answer,38152686,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,38152686,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,Yes,0
Human Answer,38152686,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer,38152686,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, INSTI","Nucleoside reverse transcriptase inhibitors (NRTIs), an integrase strand transfer inhibitor (INSTI), and a non-nucleoside reverse transcriptase inhibitor (NNRTI).",1,"NRTI, INSTI",1,"NRTI, NNRTI, INSTI",1,"NRTI, INSTI",1,NRTI,0,"NRTI, INSTI",1,"NRTI, PI",0,"NRTI, NNRTI, PI",0,"INSTI, NRTI",1,"NRTI, INSTI",1,"NRTI, INSTI",1,INSTI,0,INSTI,0,"NRTI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, INSTI",1,"NRTI, INSTI",1,"NRTI, NNRTI",0,INSTI,0,Integrase inhibitors,0,"** NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1
Human Answer,38152686,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, DTG","Tenofovir (TDF), Lamivudine (3TC), Dolutegravir (DTG), and Efavirenz (EFZ).",1,"Tenofovir, Lamivudine, Dolutegravir",1,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG), Efavirenz (EFZ)",1,"TDF, 3TC, DTG",1,"TDF, 3TC, DTG, EFZ, DRV, RTV",1,"Tenofovir, Lamivudine, Dolutegravir",1,"Tenofovir (TDF), Lamivudine (3TC), Dolutegravir (DTG)",1,"TDF, 3TC, DTG, ABC, LPV, EFV, RGV",1,"Dolutegravir (DTG), Tenofovir (TDF), Lamivudine (3TC)",1,"Tenofovir (TDF), Lamivudine (3TC), Dolutegravir (DTG)",1,"TDF, 3TC, DTG",1,Dolutegravir,0,Dolutegravir,0,"Tenofovir (TDF), Lamivudine (3TC), Dolutegravir (DTG)",1,"Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG)",1,"Tenofovir, Lamivudine, Dolutegravir",1,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG), Efavirenz (EFV)",1,"Tenofovir, Lamivudine, Dolutegravir",1,Dolutegravir,0,Dolutegravir,0,"** Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG)",1,"3TC, NVP, EFV, D4T, AZT, LPV, ABC, ATZ, DTG, TDF",1
Human Answer,38314093,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV-1 protease-reverse transcriptase (PR-RT) gene sequences obtained from patient samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,38314093,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No — the study reports genotypic resistance analysis and predicted drug sensitivity from sequence data, not in vitro phenotypic susceptibility assays.",1,Yes,0,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,38314093,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report public deposition of sequences (no GenBank accession numbers are provided).,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer,38314093,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported — no GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"The paper reports GenBank accession numbers for sequences generated in this study, which are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.",0,Not reported,1,Not reported,1
Human Answer,38314093,5,How many individuals had samples obtained for HIV sequencing?,Number,37,37 individuals had samples obtained for HIV sequencing.,1,195,0,37,1,37,1,37,1,37,1,195,0,195,0,195,0,37,1,37,1,37,1,195,0,Not reported,0,195,0,37,1,0,0,Not Reported,0,195,0,195,0,186257,0,195,0
Human Answer,38314093,6,From which countries were the sequenced samples obtained?,List,China,"China — samples were obtained from Meizhou People's Hospital in Meizhou, China.",1,No,0,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,China,1,Not reported,0,China,1,No,0,No,0,China,1,China,1,China,1,China,1,Not reported,0
Human Answer,38314093,7,From what years were the sequenced samples obtained?,List,2008-2019,Samples were collected between May 2008 and December 2019.,1,2008-2019,1,2008-2019,1,2008–2019,1,2008–2019,1,2008-2019,1,2008-2019,1,2018-2019,0,2008-2019,1,2018-2019,0,2008-2019,1,2008-2019,1,2008-2019,1,Not reported,0,2008-2019,1,2008-2019,1,No,0,2008-2019,1,2008-2019,1,2008-2019,1,2008-2019,1,2008-2019,1
Human Answer,38314093,8,Were samples cloned prior to sequencing?,Boolean,No,No — there is no indication that samples were cloned; cDNA was amplified and subjected to high-throughput sequencing.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer,38314093,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",The protease and reverse transcriptase (PR-RT) region of the pol gene was sequenced.,1,"Reverse transcriptase, RT",0,"PR, RT",1,"PR, RT",1,RT,0,"PR, RT",1,PR-RT,1,"PR (Protease), RT (Reverse Transcriptase)",1,No,0,"PR, RT",1,Pro-RT,1,"PR, RT",1,Pol,0,Not reported,0,"PR, RT",1,"Protease, Reverse transcriptase",1,No,0,"PR, RT",1,Pol,0,No,0,Not reported,0,Protease-reverse transcriptase (PR-RT),1
Human Answer,38314093,10,What method was used for sequencing?,List,NGS,PCR amplification of cDNA for the PR-RT region followed by high-throughput sequencing (next-generation sequencing) was used.,1,No,0,No,0,Not Reported,0,NGS,1,Not reported,0,High-throughput sequencing,0,High-throughput sequencing,0,No,0,NGS,1,Not reported,0,Not reported,0,Sanger sequencing,0,Not reported,0,High-throughput sequencing,0,Illumina sequencing,0,No,0,NGS,1,Sanger sequencing,0,Yes,0,Not reported,0,Not reported,0
Human Answer,38314093,11,What type of samples were sequenced?,List,Serum,Serum (blood) samples from HIV-infected individuals were sequenced.,1,Serum,1,Plasma,0,Serum,1,Blood,0,Not reported,0,Blood samples,0,Serum samples,1,Serum,1,Serum,1,Blood,0,Blood,0,Plasma,0,Not reported,0,Serum,1,Serum,1,No,0,Serum,1,Plasma,0,"NRTI, NNRTI, PI, INSTI",0,Serum samples,1,Serum,1
Human Answer,38314093,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — the sequenced samples came from untreated patients, not from individuals reported to have virological failure on treatment.",1,No,1,No,1,No,1,Yes,0,No,1,No,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,"AZT, 3TC, EFV, NVP, TDF, FTC, ATV, RTV, RAL, DTG, BIC, CAB, LEN, MVC",1,No,1,Not reported,1
Human Answer,38314093,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a retrospective observational study of routine laboratory samples, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1
Human Answer,38314093,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the sequences analyzed were from untreated patients; the paper does not report sequences from individuals with prior ARV exposure.,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1
Human Answer,38314093,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,"None — the sequenced individuals were untreated prior to sampling, so no ARV drug classes were received before sequencing.",1,"NRTI, NNRTI",0,"NRTI, NNRTI",0,,1,"NRTI, NNRTI",0,,1,"NRTIs, NNRTIs",0,"NRTIs, NNRTIs",0,"NRTIs, NNRTIs",0,No,1,,1,"NRTIs, NNRTIs",0,"NRTIs, NNRTIs, PIs",0,Not reported,1,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",0,No,1,"NRTIs, NNRTIs",0,"NRTIs, NNRTIs",0,No,1,"NRTIs, NNRTIs",0,Not reported,1
Human Answer,38314093,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,None — the sequenced individuals were untreated prior to sequencing and therefore had not received specific antiretroviral drugs before sample collection.,1,"Zidovudine (AZT), Lamivudine (3TC), Efavirenz (EFV), Nevirapine (NVP)",0,"Efavirenz (EFV), Nevirapine (NVP), Zidovudine (AZT), Lamivudine (3TC)",0,,1,"AZT, 3TC, EFV, NVP",0,,1,"Fördovudine (AZT), Lamivudine (3TC), Efavirenz (EFV), Nevirapine (NVP)",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",0,"AZT, 3TC, EFV, NVP",0,No,1,,1,Not reported,1,"AZT, 3TC, EFV",0,Not reported,1,"Efavirenz (EFV), Nevirapine (NVP), Zidovudine (AZT), Lamivudine (3TC)",0,"NRTI (Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC)), NNRTI (Nevirapine (NVP), Efavirenz (EFV)), PI (Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Derunavir (DRV))",0,No,1,"AZT, 3TC, EFV, NVP",0,"AZT, 3TC, EFV, NVP",0,No,1,"Efavirenz (EFV), Nevirapine (NVP), Zidovudine (AZT), Lamivudine (3TC)",0,Not reported,1
Human Answer,38427738,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — the paper reports sequencing of viral genomes derived from in vitro cell culture and molecular clones, not from patient-derived clinical samples.",1,No,1,No,1,Yes,0,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,38427738,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,"Yes — the paper reports extensive in vitro drug susceptibility and resistance assays (IC50/AUC, fold-change) for multiple antiretrovirals.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,38427738,3,Were sequences from the paper made publicly available?,Boolean,No,No explicit public sequence deposition is reported; the paper does not provide GenBank accession numbers and states that data are present in the paper/supplementary materials and materials are available upon request.,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not clearly reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer,38427738,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,None reported in the paper.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,"OQ336290 - OQ336294, MW48492, AF324493",0,No,1,No,1,Not Reported,1,Not Reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,"The accession numbers are not explicitly stated in the provided text, but the paper mentions that sequences were submitted to GenBank and provides accession numbers for the sequences.",0,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,"FJ800379–FJ800386, GQ477441-GQ477451, KP170487",0,Not reported,1,MN234327 - MN235714,0
Human Answer,38427738,5,How many individuals had samples obtained for HIV sequencing?,Number,0,Zero — no human/patient samples were obtained; sequencing was performed on in vitro cultures and molecular clones.,1,0,1,0,1,Not reported,1,0,1,Not reported.,1,600,0,6,0,0,1,0,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,100,0,Not reported,1,Not reported,1
Human Answer,38427738,6,From which countries were the sequenced samples obtained?,List,No,Not applicable — no patient-derived samples from countries were reported; sequencing was from in vitro viral cultures and lab/previously described isolates.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,"Spain, Switzerland",0,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,United States,0,United States,0,Not reported,1,"United States, Australia",0
Human Answer,38427738,7,From what years were the sequenced samples obtained?,List,No,Not applicable — no patient-derived sampling years are reported; sequencing was performed on in vitro passaged viruses and constructs without reporting sample collection years.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not specified,1,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,2010–2015,0,2004-2007,0,Not reported,1,2018-2021,0
Human Answer,38427738,8,Were samples cloned prior to sequencing?,Boolean,No,"For the initial sequencing of viral regions from infected cultures, PCR amplicons were directly sequenced (not cloned); however, env amplicons were cloned into molecular clones for subsequent functional analyses.",1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,No,1
Human Answer,38427738,9,Which HIV genes were reported to have been sequenced?,List,"Gag, Pol, Env, Nef, vpu","gag, pol, env, vpu and nef regions (with specific analyses of gag/NC, pol/RT/IN, env/gp120-gp41, and Nef noted throughout).",1,"Gag, Pol, Env, Vpu",0,"Gag, Pol, Env, Nef, vpu",1,"gag, pol, env, nef",0,"gag, pol, env, vpu",0,"Gag, Pol, Env.",0,"Gag, Pol, Env, Vpu",0,"Gag, pol, env, vpu",0,Envelope; Full genome; Near full length genome,0,"Gag, Pol, Env, Vpu",0,"Gag, Pol, Env, Nef",0,Pol,0,Env,0,Not reported,0,Not reported,0,Envelope,0,No,0,"Pol, PR, RT, IN, and Env",0,"Pol, PR, RT",0,Pol,0,IN,0,Full length genome,0
Human Answer,38427738,10,What method was used for sequencing?,List,No,Sanger sequencing of PCR amplicons (sequencing performed by commercial providers Psomagen or Poochon Scientific); constructed plasmids were also verified by Sanger sequencing.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not specified,1,Sanger sequencing,0,No,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Illumina sequencing,0,Illumina sequencing,0
Human Answer,38427738,11,What type of samples were sequenced?,List,No,Viral genomic DNA extracted from infected cell cultures (genomic/proviral DNA PCR amplicons) and sequences from constructed molecular clones (env amplicons cloned into proviral plasmids) were sequenced.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Laboratory-cultured HIV genomic DNA,0,Cultured HIV-1 strains,0,Plasma,0,No,1,"Virus-containing supernatants, Genomic DNA from infected cells",0,"Plasma, PBMC",0,Plasma,0,Not reported,1,Not reported,1,No,1,No,1,"Plasma, PBMC, and dried blood spots",0,"Plasma, PBMC",0,Plasma,0,Plasma,0,Plasma,0
Human Answer,38427738,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the study did not sequence viruses from individuals experiencing virological failure; it performed in vitro selection and mentions clinical observations from other studies but did not analyze patient-derived failure samples.,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,38427738,13,Were the patients in the study in a clinical trial?,Boolean,No,Not applicable — there were no patient participants or clinical trial subjects in this study.,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,Yes,0,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer,38427738,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report sequences from individuals with prior ARV exposure; all sequences derive from in vitro cultured viruses and lab/previously described isolates.,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,38427738,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable — there were no human individuals whose treatment histories were sequenced; the study exposed in vitro viruses to various antiretroviral classes including INSTIs and RT inhibitors during passaging.,1,No,1,No,1,,1,,1,None.,1,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, CCR5 antagonist, INSTI",0,INSTI,0,No,1,"INSTI, RT inhibitor",0,"NRTI, PI, INSTI",0,INSTI,0,Not reported,1,Not reported,1,No,1,No,1,"NRTI, NNRTI, PI, INSTI, CAI, and CCR5 antagonist",0,,1,"NRTIs, NNRTIs",0,"NRTI, NNRTI, INSTI, CCR5 antagonist",0,"NRTI, NNRTI, INSTI, CCR5 antagonist",0
Human Answer,38427738,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable — no individuals provided samples; in vitro experiments used specific drugs including dolutegravir (DTG), islatravir (EFdA), raltegravir (RAL), cabotegravir (CAB), emtricitabine (FTC), rilpivirine (RPV), efavirenz (EFV), darunavir (DRV), nelfinavir (NFV), T-20, BMS-378806, BI-224436, and LEN.",1,No,1,No,1,Not reported,1,,1,Not reported.,1,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Raltegravir (RAL)",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL)",0,INSTI,0,No,1,"DTG, EFdA",0,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0,"DTG, RAL, CAB",0,Not reported,1,Not reported,1,No,1,No,1,"AZT, 3TC, FTC, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, and lenacapavir",0,"AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC, IBA",0,"AZT, 3TC, EFV, ATV/r",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)",0
Human Answer,38864613,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No. The reported sequences derive from in vitro resistance-selection experiments (culture supernatants), not from patient samples.",1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer,38864613,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,"Yes. The paper reports extensive in vitro antiviral activity data (IC50 values and fold-changes) for ISL, LEN, and variants.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,38864613,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. Sequences from the resistance selection experiments were deposited in GenBank.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0
Human Answer,38864613,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,PP827803-PP828572,GenBank accession numbers reported: PP827803 -- PP828572.,1,PP827803 -- PP828572,1,PP827803 - PP828572,1,PP827803 -- PP828572,1,PP827803 -- PP828572,1,PP827803 – PP828572,1,PP827803 -- PP828572,1,PP827803 -- PP828572,1,No,0,PP827803--PP828572,1,PP827803 -- PP828572,1,PP827803 -- PP828572,1,PP827803 -- PP828572,1,PP827803 -- PP828572,1,PP827803 -- PP828572,1,PP827803 -- PP828572,1,PP827803 -- PP828572,1,PP827803 -- PP828572,1,PP827803 -- PP828572,1,PP827803 -- PP828572,1,"ON351529, ON351530, and ON351531",0,Not reported,0
Human Answer,38864613,5,How many individuals had samples obtained for HIV sequencing?,Number,0,None. No patient individuals were sampled; sequences derive from in vitro virus selection (cell culture wells).,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,0,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,0,1,0,1,Not reported,1,Not reported,1,"8,700",0,72,0,0,1
Human Answer,38864613,6,From which countries were the sequenced samples obtained?,List,No,Not applicable / Not reported. The sequences were derived from laboratory in vitro experiments and no country-of-origin for patient samples is reported.,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Japan,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1
Human Answer,38864613,7,From what years were the sequenced samples obtained?,List,No,Not reported / Not applicable. The paper does not provide collection years for the sequenced (in vitro) samples.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1
Human Answer,38864613,8,Were samples cloned prior to sequencing?,Boolean,No,No. Sequencing was performed by population-based Sanger sequencing of RT-PCR products rather than by cloning.,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,Yes,0,Yes,0,Not reported,1,Yes,0,No,1,No,1
Human Answer,38864613,9,Which HIV genes were reported to have been sequenced?,List,"RT, CA",The capsid (CA) region and reverse transcriptase (RT) region were sequenced.,1,"Capsid, CA; Reverse transcriptase, RT",1,"CA, RT",1,"CA, RT",1,Not Reported,0,Not reported,0,"RT, CA",1,Not reported,0,No,0,"CA, RT",1,"CA, RT",1,"Pol, IN",0,"CA, RT",1,"CA, RT",1,"CA, RT",1,No,0,"CA, RT",1,"CA, RT",1,"Pol, PR, RT",0,Not Reported,0,"PR, RT, IN, CA",1,"PR, RT, IN, CA",1
Human Answer,38864613,10,What method was used for sequencing?,List,Sanger sequencing,Population-based Sanger sequencing of RT-PCR amplicons (automated full-length sequencing) was used.,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0,Not Reported,0,Not reported,0,Sanger sequencing,1,Sanger sequencing,1,No,0,Sanger sequencing,1,Not reported,0,Not reported,0,Sanger sequencing,1,RT-PCR and automated population-based full-length sequencing,0,Not reported,0,No,0,No,0,NGS,0,Sanger sequencing,1,Yes,0,NGS,0,"Sanger sequencing, Illumina sequencing",1
Human Answer,38864613,11,What type of samples were sequenced?,List,No,Viral culture supernatant from wells with viral breakthrough in in vitro resistance selection experiments (MT4-GFP cell culture supernatants).,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Not applicable (in vitro cell samples),1,No,1,Culture supernatant,1,Not reported,1,"Plasma, PBMC",0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,"Proviral DNA, Plasma",0,"Plasma, PBMCs, proviral DNA",0,"Gag, Pol, Env",0,Plasma,0,Plasma,0
Human Answer,38864613,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. All sequences were obtained from in vitro resistance-selection experiments, not from patients experiencing virological failure on treatment.",1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,38864613,13,Were the patients in the study in a clinical trial?,Boolean,No,No. There were no patients in this study; it was an in vitro study using laboratory virus and cell culture.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,Yes,0,No,1
Human Answer,38864613,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The reported sequences are from in vitro-selected viruses and not from individuals with prior ARV exposure.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,38864613,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,Not applicable. No individuals were sampled; therefore no drug classes were received by study participants prior to sequencing.,1,No,1,No,1,,1,,1,Not reported,1,"NRTI, NNRTI, PI, INSTI, CAI",0,"NRTI, NNRTI, PI, INSTI",0,No,1,No,1,Not reported,1,"NRTI, PI, INSTI",0,"NRTI (ISL), CAI (LEN)",0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"NRTI, NNRTI, PI, INSTI",0,"NRTIs, NNRTIs, PIs, INSTIs",0,"NRTI, NNRTI, PI, INSTI, CAI",0,"NRTI, NNRTI, PI, INSTI",0
Human Answer,38864613,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,"Not applicable. No individuals were included; samples were generated in vitro. (In vitro compounds used included islatravir and lenacapavir and control antivirals such as efavirenz, indinavir, L-002254051, stavudine, and ribavirin.)",1,No,1,No,1,,1,Not Reported,1,Not reported,1,"Tenofovir (TAF), Emtricitabine (FTC), Darunavir (DRV), Dolutegravir (DTG), Doravirine, Ibalizumab (IBA)",0,"Tenofovir (TAF, TDF), Emtricitabine (FTC), Darunavir (DRV), Dolutegravir (DTG), Doravirine",0,No,1,No,1,Not reported,1,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0,"ISL, LEN",0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,"AZT, 3TC, FTC, TDF, ATV, DRV, MVC, CAB, LEN",0,"AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN",0,"Tenofovir (TFV), Emtricitabine (FTC), Darunavir (DRV), Dolutegravir (DTG), Doravirine (DOR), Ibalizumab (IBA), Lenacapavir (LEN)",0,"DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.",0
Human Answer – Yes/No questions,18715920,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — sequences derive from in vitro–selected laboratory strains and recombinant constructs, not from patient samples.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,18715920,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes — the paper reports in vitro antiviral susceptibility (EC50) and fold-change phenotypic data for selected and recombinant viruses against multiple integrase inhibitors.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,18715920,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report deposition of sequences in public databases or provide GenBank accession numbers.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,18715920,8,Were samples cloned prior to sequencing?,Boolean,No,"Population-based (direct) Sanger sequencing was used for virus populations (no cloning); separately, site-directed mutant (SDM) constructs were generated in plasmids and confirmed by sequencing (these constructs were cloned).",1,Yes,0,No,1,Yes,0,Yes,0,No.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1
Human Answer – Yes/No questions,18715920,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — the sequences derive from in vitro–selected laboratory viruses and recombinant constructs, not from patients with virologic failure.",1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Not reported,1,Not reported,1,Yes,0
Human Answer – Yes/No questions,18715920,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients in this study; the work was performed using cell lines and laboratory virus strains in vitro.,1,No,1,No,1,Not Reported,1,No,1,Not reported.,1,No,1,Yes,0,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,No,1,Not reported,1,Yes,0
Human Answer – Yes/No questions,18715920,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report sequences from treated individuals; sequences are from in vitro-selected viruses and recombinant constructs.,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,Not reported,1,Yes,0
Human Answer – Yes/No questions,19104010,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — the reported HIV sequences were derived from in vitro tissue-culture selections and cloned viral DNA, not from patient samples.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,19104010,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes — extensive in vitro antiviral activity and phenotypic resistance (EC50/IC50) data are reported.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,19104010,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report deposition of sequences in public databases or provide accession numbers.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,19104010,8,Were samples cloned prior to sequencing?,Boolean,Yes,Yes — PCR products were cloned into a plasmid and individual plasmid clones were sequenced.,1,No,0,No,0,Yes,1,Not Reported,0,Not reported.,0,Yes,1,No,0,No,0,No,0,Not reported.,0,Not reported,0,Not Reported,0,Not reported,0,Not reported,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0
Human Answer – Yes/No questions,19104010,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the sequences were from in vitro–selected viruses in tissue culture; there were no sequences reported from patients failing therapy.,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,Yes,0,No,1,No,1,No.,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,19104010,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the study used cell lines, primary cells from healthy donors, and in vitro experiments; it did not involve patients enrolled in a clinical trial.",1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,19104010,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the sequences were from laboratory-selected viruses and not from individuals with prior ARV exposure.,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,Yes,0,Yes,0,No,1,No.,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,21115794,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,21115794,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,21115794,3,Were sequences from the paper made publicly available?,Boolean,No,No (no deposition or accession numbers are reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,21115794,8,Were samples cloned prior to sequencing?,Boolean,No,"No for the integrase PCR products (sequencing was performed on PCR products); cloning was performed when constructing recombinant molecular clones for mutagenesis, but PCR products from infected cells were directly sequenced.",1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,21115794,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,21115794,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this publication reports preclinical in vitro work, not a clinical trial with patients.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,21115794,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,23749954,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — the study used laboratory-generated NL4-3 recombinant viruses and cell culture selections, not patient-derived sequences.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,,1
Human Answer – Yes/No questions,23749954,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No — the paper reports in vitro drug selection experiments (selection of resistance mutations) but does not present quantitative phenotypic drug susceptibility (e.g., IC50) data.",1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,We recently reported the preferential selection of the K65R resistance,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,,1
Human Answer – Yes/No questions,23749954,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report deposition of sequences or provide GenBank accession numbers.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,Yes,0,,1
Human Answer – Yes/No questions,23749954,8,Were samples cloned prior to sequencing?,Boolean,Yes,"Yes, laboratory clones (mutant NL4-3 plasmids/viruses) were generated by site-directed mutagenesis; however, no patient sample cloning prior to sequencing applies because no patient samples were sequenced.",1,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,No,0,No,0,Not reported,0,Yes,1,Yes,1,Not reported,0,No,0,Yes,1,No,0,Yes,1,Not Reported,0,Yes,1,No,0,,0
Human Answer – Yes/No questions,23749954,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the study did not include patient samples or sequences from individuals with virological failure.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,,1
Human Answer – Yes/No questions,23749954,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients enrolled in this study; it was an in vitro laboratory study using recombinant viruses.,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,Yes,0,Yes,0,,1
Human Answer – Yes/No questions,23749954,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report sequences from treated individuals; it discusses clinical findings from other studies but presents laboratory data from recombinant viruses.,1,No,1,No,1,Yes,0,No,1,,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Not reported,1,Not reported,1,Not reported,1,Yes,0,No,1,Not Reported,1,Yes,0,Yes,0,No,1,,1
Human Answer – Yes/No questions,24227862,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — the study reports experiments with site-directed mutant proviral clones and in vitro selections using CBMCs, not sequences derived from patient samples.",1,No,1,No,1,No,1,Yes,0,** Yes,0,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,24227862,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes — the paper reports in vitro phenotypic susceptibility assays in TZM-bl cells and biochemical assays with recombinant RT enzymes.,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,24227862,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report making sequences publicly available (no GenBank accession numbers or data-deposition statement are provided).,1,No,1,No,1,No,1,No,1,** No,1,Yes,0,Yes,0,No,1,No,1,No.,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,24227862,8,Were samples cloned prior to sequencing?,Boolean,Yes,Yes for the engineered constructs: proviral and RT expression plasmids were generated by site-directed mutagenesis and then sequenced to verify mutations; no patient-derived clones were described.,1,No,0,No,0,No,0,Not reported,0,** Not reported,0,Not reported,0,Not reported,0,No,0,No,0,Not reported.,0,Not reported,0,Not reported,0,Not reported,0,Not reported,0,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0
Human Answer – Yes/No questions,24227862,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the study did not obtain sequences from clinical patients with virological failure; experiments were laboratory-based.,1,No,1,No,1,Not reported,1,Yes,0,** Not reported,1,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,"Efavirenz, nevirapine, lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, and lenacapavir",1,Yes,0,Yes,0
Human Answer – Yes/No questions,24227862,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients enrolled in this study; it is an in vitro/biochemical study. (Clinical trials like ECHO and THRIVE are cited for context but are not the source of study participants.),1,No,1,No,1,No,1,No,1,** Not reported,1,Not reported,1,Yes,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0
Human Answer – Yes/No questions,24227862,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the study does not report patient-derived HIV sequences from individuals with prior ARV exposure; it is based on engineered viruses and in vitro selections, though it discusses prevalence of mutations in treatment-experienced patients.",1,No,1,No,1,Not reported,1,Yes,0,** Not reported,1,Yes,0,Yes,0,Yes,0,No,1,Yes.,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0
Human Answer – Yes/No questions,25637519,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,25637519,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,25637519,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report any public sequence deposition.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,25637519,8,Were samples cloned prior to sequencing?,Boolean,Yes,Yes — mutated RT sequences were generated in plasmid clones and positive clones were identified and sequenced.,1,No,0,No,0,Not reported,0,No,0,Not reported,0,No,0,Yes,1,Yes,1,No,0,Not reported,0,No,0,Not reported,0,Not reported,0,Not reported,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0
Human Answer – Yes/No questions,25637519,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — this study did not sequence samples from treatment-failure patients (although it cites other studies that found D404N in treatment-failure patients).,1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,25637519,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients enrolled or described in a clinical trial in this study.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,25637519,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — this study did not report sequences from treated individuals (it only references other reports of D404N in ART-experienced patients).,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,26246578,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,,1
Human Answer – Yes/No questions,26246578,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0
Human Answer – Yes/No questions,26246578,3,Were sequences from the paper made publicly available?,Boolean,No,No (not reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,,1
Human Answer – Yes/No questions,26246578,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable for patient samples; laboratory plasmid constructs and viral clones were generated by cloning for experiments.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported.,1,Yes,0,Not reported,1,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,,1
Human Answer – Yes/No questions,26246578,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — the study did not obtain or report sequences from individuals, including those with virological failure.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Not reported.,1,Yes,0,Yes,0,Yes,0,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Not reported,1,Yes,0,,1
Human Answer – Yes/No questions,26246578,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients in this study.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,No,1,No,1,,1
Human Answer – Yes/No questions,26246578,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the paper does not report sequences from individuals, regardless of treatment history.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported.,1,Yes,0,Yes,0,Yes,0,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,,1
Human Answer – Yes/No questions,26311878,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No. The study used lab-derived plasmids and viruses and sequenced PCR products from tissue-culture samples rather than patient-derived clinical samples.,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1
Human Answer – Yes/No questions,26311878,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,"Yes. The paper reports in vitro susceptibility (IC50) data for DTG, RAL, and EVG using cell-based assays.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,26311878,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report deposition of sequences to public databases or provide accession numbers.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,26311878,8,Were samples cloned prior to sequencing?,Boolean,No,"For the constructs used, yes: plasmids were generated by site-directed mutagenesis and verified by sequencing; clinical sample cloning was not performed because no patient samples were used.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Yes,0,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,26311878,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. The sequences reported were from laboratory constructs and tissue-culture selections, not from individuals experiencing virological failure.",1,No,1,No,1,Not reported,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,26311878,13,Were the patients in the study in a clinical trial?,Boolean,No,No. There were no patients in this study and no clinical trial involvement.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,26311878,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The paper does not present sequences from individuals with prior ARV exposure; it focuses on laboratory-generated viruses and in vitro selections.,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,26559830,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the study used lab-derived molecular clones and cell culture; no patient-derived HIV sequences are reported.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,26559830,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes — the paper reports in vitro phenotypic protease inhibitor (PI) susceptibility data (EC50s) using single-cycle cell culture assays.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** No,0,No,0
Human Answer – Yes/No questions,26559830,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report public deposition of sequences (no GenBank accession numbers); only that clones were sequenced and that primer sequences are available on request.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,26559830,8,Were samples cloned prior to sequencing?,Boolean,No,Yes — the study used molecular cloning and site-directed mutagenesis to create and sequence full-length plasmid clones.,0,No,1,No,1,Yes,0,Not reported,1,Yes.,0,Yes,0,No,1,Yes,0,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,** No,1,Yes,0
Human Answer – Yes/No questions,26559830,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the study did not sequence viruses from treated individuals or from cases of virological failure.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,26559830,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients in the study; experiments used laboratory cell lines and molecular clones.,1,No,1,No,1,Not Reported,1,No,1,Not reported.,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,No,1,** No,1,Yes,0
Human Answer – Yes/No questions,26559830,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the sequences reported derive from laboratory clones and not from individuals with prior ARV exposure.,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,27009474,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,"Yes
```",1,** Yes,1
Human Answer – Yes/No questions,27009474,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,"Yes
```",1,** Yes,1
Human Answer – Yes/No questions,27009474,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,"Yes
```",1,** Yes,1
Human Answer – Yes/No questions,27009474,8,Were samples cloned prior to sequencing?,Boolean,Yes,"Yes, infectious molecular clones were created and sequenced (clinical clone).",1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not Reported,0,Not Reported,0,Yes,1,No,0,Yes,1,No,0,Yes,1,No,0,Yes,1,Yes,1,"Yes
```",1,** Yes,1
Human Answer – Yes/No questions,27009474,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the patient reported in this paper was virologically suppressed (HIV-1 RNA <50 copies/ml) on therapy at the time of the INSTI resistance test.,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,No,1,"Yes
```",0,** Yes,0
Human Answer – Yes/No questions,27009474,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,"Yes
```",0,** Yes,0
Human Answer – Yes/No questions,27009474,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"The primary sequenced individual was treatment-naive at the time of sampling (transmitted resistance), but the paper references other sequences from raltegravir-experienced individuals in GenBank.",0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,"Yes
```",1,** Yes,1
Human Answer – Yes/No questions,27124362,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,27124362,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,27124362,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report making sequences publicly available.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,27124362,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — no sequencing was performed on patient-derived samples.,1,No,1,No,1,No,1,Not reported,1,Not reported.,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,27124362,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — the paper did not generate or report patient-derived sequences, although it discusses mutations that are observed in virological failures in prior studies.",1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,27124362,13,Were the patients in the study in a clinical trial?,Boolean,No,No — this study is an in vitro and structural study and did not involve patients or clinical trial participants.,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,27124362,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report any patient-derived sequences; it discusses and tests mutations that have been observed in individuals on ARV therapy in prior studies.,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,28559249,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,No — the paper reports patient-derived viral isolates and recombinant clones but does not present nucleotide sequence data in the text.,0,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes.,1,Yes,1,No,0,Yes,1,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,28559249,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,28559249,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report that sequences were deposited or provide accession numbers.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,Not Reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,28559249,8,Were samples cloned prior to sequencing?,Boolean,No,"Some viruses used in the study were derived from full-length plasmid molecular clones and a recombinant clone was constructed from a treated patient, but the paper does not report sequencing workflows or whether patient-derived samples were cloned specifically for sequencing.",1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not Reported.,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,28559249,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Yes — a recombinant clone (designated 4.7a) was derived from a patient receiving AZT, lamivudine (3TC), and ritonavir-boosted lopinavir (i.e., treatment-experienced).",0,No,1,Yes,0,Not reported,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,28559249,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there is no indication that the patients providing samples were enrolled in a clinical trial; sample collection was approved by institutional and national ethics committees.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not Reported.,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,Not reported,1,No,1,No,1
Human Answer – Yes/No questions,28559249,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"Yes — the recombinant clone 4.7a was derived from a patient receiving AZT, lamivudine (3TC), and ritonavir-boosted lopinavir, indicating prior ARV exposure.",0,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,29373677,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The paper reports genotypic analysis of the integrase gene from patient samples (PBMC DNA and plasma RNA) and identifies specific mutations (N155H, K156N, K211R, E212T).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,29373677,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes. The paper reports both cell-free and cell-based (culture) assays measuring IC50/EC50 for raltegravir and dolutegravir and other susceptibility readouts.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,29373677,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report deposition of sequences or provide public accession numbers.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,29373677,8,Were samples cloned prior to sequencing?,Boolean,No,No. The paper does not report cloning of patient samples prior to genotypic analysis.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,29373677,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes. Sequences/genotypic data were obtained from a patient who experienced virological failure on dolutegravir monotherapy (viral load became detectable).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,29373677,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The paper reports a single patient case and does not indicate enrollment in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,Yes,0
Human Answer – Yes/No questions,29373677,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. The patient had prior antiretroviral therapy including raltegravir and tenofovir/emtricitabine before the dolutegravir monotherapy and sequencing.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,30053052,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports patient-derived HIV sequences used to create chimeric viruses and to clone RT genes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,30053052,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes. The paper reports both cell-based phenotypic drug susceptibility assays (ex vivo) and cell-free biochemical (in vitro) susceptibility/IC50 assays.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,30053052,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report GenBank accession numbers or state that sequences were deposited in a public database.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,30053052,8,Were samples cloned prior to sequencing?,Boolean,No,"Yes. The gag-pol fragment was cloned into pNL43 to produce chimeric viruses, and RT genes were PCR-amplified and cloned for protein expression.",0,No,1,No,1,Yes,0,Yes,0,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Not reported.,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1
Human Answer – Yes/No questions,30053052,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Sequences (replication-competent viruses) were obtained from three patients with virological treatment failure, and those isolates harbored resistance mutations.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,30053052,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The patients were sampled from an HIV cohort at Karolinska University Hospital; there is no indication that they were participants in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1
Human Answer – Yes/No questions,30053052,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. Sequences were obtained from individuals with virological treatment failure (i.e., previously treated), and those isolates contained resistance mutations consistent with prior ARV exposure.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,30803972,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No. The paper does not report nucleotide sequence data from patient-derived samples; it reports phenotypic drug-susceptibility testing of virus isolates and site-directed mutant clones.,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,,1
Human Answer – Yes/No questions,30803972,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes. The paper reports in vitro drug susceptibility data (EC50 values and fold-resistance) obtained in a single-cycle culture-based assay.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,,0
Human Answer – Yes/No questions,30803972,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report that any sequences were deposited in public databases.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,,1
Human Answer – Yes/No questions,30803972,8,Were samples cloned prior to sequencing?,Boolean,No,"Not applicable for sequencing. The study used existing molecular clones and generated site-directed mutant clones, but it did not report cloning patient-derived sequences for sequencing.",1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,,1
Human Answer – Yes/No questions,30803972,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. The isolates tested in this study were from ART-naive individuals, and no sequences from treatment-failure patients were reported here.",1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,"TDF, FTC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB",1,Yes,0,,1
Human Answer – Yes/No questions,30803972,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. The study was an in vitro laboratory investigation using isolates and molecular clones, not a clinical trial.",1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,Not Reported,1,No,1,,1
Human Answer – Yes/No questions,30803972,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No. The isolates tested were from ART-naive individuals, and the paper does not report sequences from ARV-experienced individuals.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,Not reported,1,Not reported,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,,1
Human Answer – Yes/No questions,31988104,1,Does the paper report HIV sequences from patient samples?,Boolean,No,Yes. The study used patient-derived HIV isolates (patient samples) to generate viruses for phenotypic testing.,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,31988104,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes. The paper reports extensive in vitro phenotypic drug susceptibility data (EC50 fold-changes and viral breakthrough assays).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,31988104,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report GenBank accession numbers for patient-derived sequences; only GenBank numbers for reference plasmid clones are given.,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,31988104,8,Were samples cloned prior to sequencing?,Boolean,No,Yes. DNA fragments (from SDM and PCR of patient isolates) were cloned into plasmid backbones (pKSHX and pXXLAI) to generate viruses used in assays.,0,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,31988104,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not explicitly reported. The isolates are described as ART-experienced and many contain TAMs, but the paper does not state whether donors were experiencing virological failure at time of sampling.",1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,31988104,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The experiments used laboratory-created viruses and patient-derived isolates; the patient samples used to generate isolates are not described as coming from a clinical trial in this study.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,Not reported,1,Not reported,1,Yes,0,No,1
Human Answer – Yes/No questions,31988104,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,Yes. The paper explicitly states that patient-derived isolates were from ART-experienced individuals.,0,No,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,32601157,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — the study did not report sequencing of primary patient samples; it used engineered IN mutants, recombinant vectors, and some references to patient-derived IN sequences introduced into laboratory constructs, but no primary patient sequence datasets were reported.",1,No,1,No,1,No,1,Yes,0,No.,1,No,1,No,1,No,1,No,1,Yes.,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,32601157,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes — extensive in vitro drug susceptibility (antiviral potency) data are reported using single-round infectivity assays.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,32601157,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report making sequences publicly available (no accession numbers or database deposits are provided).,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,32601157,8,Were samples cloned prior to sequencing?,Boolean,No,Yes — IN coding sequences and mutant constructs were prepared in plasmid vectors (cloned/subcloned) and then sequenced to verify the constructs.,0,No,1,No,1,No,1,No,1,Not reported.,1,Not reported,1,No,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,32601157,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the study itself did not report sequencing of samples from individuals with virological failure; references are made to INSTI-experienced or clinical isolates in prior reports but no new patient failure-derived sequences are presented.,1,No,1,No,1,No,1,Not reported,1,No.,1,No,1,No,1,No,1,No,1,Yes.,0,Yes,0,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,32601157,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients enrolled in a clinical trial in this study; the work was laboratory-based using viral vectors and engineered mutants.,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,32601157,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the paper does not report sequences obtained from individuals with known prior ARV exposure; it focuses on engineered mutants and in vitro selections, though it discusses INSTI-experienced patients in the literature context.",1,No,1,No,1,Not reported,1,Not reported,1,No.,1,No,1,No,1,No,1,No,1,Yes.,0,Yes,0,Not reported,1,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,33855437,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,33855437,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes. Cell-based in vitro phenotypic assays measuring EC50 and fold-resistance were performed.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,33855437,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. Several isolates are listed with GenBank accession numbers.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0
Human Answer – Yes/No questions,33855437,8,Were samples cloned prior to sequencing?,Boolean,No,No evidence of cloning prior to sequencing was reported.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,33855437,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No clear evidence of sequencing from individuals with virological failure on treatment; most patient-derived isolates were from drug‑naive individuals, though one isolate (96USSN20) had baseline thymidine-analogue mutations.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,33855437,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The paper does not report that patients were enrolled in a clinical trial; samples were obtained with ethics approval and informed consent.,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Yes,0,No,1
Human Answer – Yes/No questions,33855437,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,Mostly no — the primary patient-derived isolates were from drug‑naive individuals; however one named isolate (96USSN20) had baseline thymidine-analogue mutations suggesting prior ARV exposure or transmitted resistance.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,34516245,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No. The paper reports sequences derived from laboratory virus stocks and cell culture passaging, not from patient samples.",1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,34516245,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,"Yes. The paper reports in vitro dose-response and EC50 data for EFdA and susceptibility testing against TDF and FTC, as well as in vitro biochemical assays.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,34516245,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. Mutation sequences were deposited in GenBank under accession numbers OK263149 to OK263162.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,34516245,8,Were samples cloned prior to sequencing?,Boolean,Yes,"Yes. PCR products spanning the full-length reverse transcriptase were cloned into pGEM-T and individual clones were sequenced (clonal sequencing), in addition to population sequencing.",1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,Not reported,0,Not reported,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0
Human Answer – Yes/No questions,34516245,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. The sequences were derived from laboratory-generated and passaged viruses, not from patients experiencing virological failure on treatment.",1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,34516245,13,Were the patients in the study in a clinical trial?,Boolean,No,No. There were no patients in this study and no clinical trial involvement; the work was laboratory-based.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not Reported,1,No,1,Yes,0
Human Answer – Yes/No questions,34516245,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No. The sequences are from lab-generated or passaged viruses; while some starting viruses carried resistance-associated mutations (e.g., K65R, M184V, AZT-resistance mutations), these were engineered or defined laboratory strains, not sequences from treated individuals.",1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,35730213,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,35730213,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,35730213,3,Were sequences from the paper made publicly available?,Boolean,No,No,1,No,1,"NRTI, NNRTI",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** Yes,0,No,1
Human Answer – Yes/No questions,35730213,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — no sequencing or cloning reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,35730213,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,Not applicable — no sequences reported; virologic failure was uncommon in cohort,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Yes,0,Not reported,1,No,1,No,1,No,1,Yes,0,No,1,No,1,** Yes,0,No,1
Human Answer – Yes/No questions,35730213,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — they were enrolled in a prospective, registered cohort study (DO-REAL)",1,No,1,No,1,Not reported,1,No,1,Not reported,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,"NRTI, NNRTI",1,** No,1,No,1
Human Answer – Yes/No questions,35730213,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — no sequences reported; participants included ART-experienced individuals transitioning from EFV to DTG,1,No,1,No,1,Not reported,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,EFV,1,** Yes,0,Yes,0
Human Answer – Yes/No questions,35913500,1,Does the paper report HIV sequences from patient samples?,Boolean,Uncertain,No. The paper does not report HIV sequence data or sequence alignments from patient samples; it reports clinical resistance testing results (a detected mutation) but provides no sequence files or sequence data.,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,35913500,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not report any in vitro phenotypic drug susceptibility assays or results.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,35913500,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not indicate that any HIV sequences were deposited in public repositories.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,** Yes,0,No,1
Human Answer – Yes/No questions,35913500,8,Were samples cloned prior to sequencing?,Boolean,No,"No. There is no report of cloning of samples prior to sequencing; in fact, no sequencing was reported.",1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,35913500,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes in the sense that clinical resistance testing detected a mutation in a viremic patient (one patient had the N155H mutation at baseline), but the paper does not provide sequence data files.",1,No,0,No,0,Yes,1,Not reported,0,No,0,Yes,1,Yes,1,No,0,No,0,Not reported,0,Yes,1,Yes,1,Yes,1,Not reported,0,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,35913500,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. This was a clinical demonstration project conducted in routine care, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,35913500,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Indirectly yes: the paper reports a detected resistance mutation (N155H) in a patient who was treatment experienced, but it does not provide sequence data.",0,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,Yes,1,Yes,1,No,0,No,0,Not reported,0,Yes,1,Yes,1,Yes,1,Not reported,0,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,35945163,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,No — the paper reports genotypic resistance-associated mutations/ART resistance profiles but does not report or deposit patient HIV sequences.,0,No,0,Yes,1,Yes,1,Not reported,0,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,No,0
Human Answer – Yes/No questions,35945163,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro phenotypic susceptibility assays.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** Yes,0,No,1
Human Answer – Yes/No questions,35945163,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not indicate that sequences were made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,** No,1,No,1
Human Answer – Yes/No questions,35945163,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,35945163,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — the paper reports resistance-associated mutations detected at discontinuation in individuals with incomplete virological response (virological failure).,1,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Not Reported,0,** Yes,1,No,0
Human Answer – Yes/No questions,35945163,13,Were the patients in the study in a clinical trial?,Boolean,No,No — participants were enrolled in a compassionate use programme and were explicitly ineligible for phase III clinical trials.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** Yes,0,No,1
Human Answer – Yes/No questions,35945163,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — many participants had prior ART exposure and resistance-associated mutations were reported; the paper includes participants with prior multiple ART regimens.,1,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,No,0,** Yes,1,No,0
Human Answer – Yes/No questions,36415058,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No. The paper reports an interview-based study and does not report HIV sequences from patient samples.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,36415058,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not report any in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36415058,3,Were sequences from the paper made publicly available?,Boolean,No,"No. There were no sequences generated or deposited, so none were made publicly available.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36415058,8,Were samples cloned prior to sequencing?,Boolean,No,No — not applicable. The study did not perform sequencing or cloning.,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1
Human Answer – Yes/No questions,36415058,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. The study selected individuals with HIV-RNA <50 copies/ml and no previous failure, so there were no sequences from individuals with virological failure (and no sequencing was performed).",1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36415058,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. The patients interviewed in this study were clinic outpatients, not participants in a clinical trial; the paper references the CARISEL Phase 3b trial as a separate study.",1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,Yes,0,No,1
Human Answer – Yes/No questions,36415058,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No sequences are reported. The paper does state that many individuals had long histories of ART (median 12.5 years), but no sequencing was performed on those individuals.",1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36454248,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV-1 pol sequences recovered from patient plasma samples (sequences obtained from 67 of 76 children/adolescents).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,36454248,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports predicted antiretroviral susceptibility based on genotypes (Stanford HIVdb), not in vitro phenotypic susceptibility assays.",1,Yes,0,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,Yes,0,No,1,No.,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,36454248,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. The sequences were submitted to GenBank.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,36454248,8,Were samples cloned prior to sequencing?,Boolean,No,No. PCR amplicons were purified and directly sequenced; there is no mention of cloning prior to sequencing.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported.,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,36454248,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Most treated individuals with sequences were experiencing virological failure (VL >50 copies/mL); specifically, 62 treated subjects were under virological failure and sequences were recovered from treated patients exhibiting virological failure.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,36454248,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The patients were under routine clinical follow-up at a hospital and enrolled with informed consent; they were not participants in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,36454248,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. The study includes sequences from ART-experienced (treated) individuals; 71 were treated at sampling and sequences were recovered from 62 treated individuals.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,36519389,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,** Yes,0,** Yes,0
Human Answer – Yes/No questions,36519389,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report any in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,** Yes,0
Human Answer – Yes/No questions,36519389,3,Were sequences from the paper made publicly available?,Boolean,No,No — no sequences were reported or made publicly available in this paper.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,** No,1
Human Answer – Yes/No questions,36519389,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable / Not reported — no sequencing (and thus no cloning) is described.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,** No,1,** No,1
Human Answer – Yes/No questions,36519389,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the paper does not report obtaining sequences; it does report HIV RNA elevations in some participants but no sequence data.,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** Yes,0,** Yes,0
Human Answer – Yes/No questions,36519389,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes — participants were randomized in the ADVANCE trial and CHARACTERISE is an extension evaluating switches; the trial received ethics and regulatory approvals.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Not reported,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,** Yes,1
Human Answer – Yes/No questions,36519389,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report any HIV sequences. The participants had received and been randomized to specific ART regimens prior to switching.,1,No,1,No,1,Yes,0,Not reported,1,Not reported,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Not reported,1,** Yes,0,** Yes,0
Human Answer – Yes/No questions,36571282,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,36571282,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,36571282,3,Were sequences from the paper made publicly available?,Boolean,No,No — sequences were not made openly public; data are available upon reasonable request.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Not reported,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,36571282,8,Were samples cloned prior to sequencing?,Boolean,No,No evidence of cloning; samples were sequenced by Sanger or NGS without cloning.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,36571282,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,36571282,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,** No,1,Yes,0
Human Answer – Yes/No questions,36571282,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,36597160,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes — the paper reports HIV genotypes (Sanger sequencing) performed on patient samples, including genotypes at baseline and at virologic failure.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36597160,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro phenotypic drug susceptibility testing data; it reports genotypic resistance (sequence-based) results only.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36597160,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not indicate that sequences were deposited in a public database and states that study data will not be shared publicly.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36597160,8,Were samples cloned prior to sequencing?,Boolean,No,No indication of cloning; genotyping was performed by Sanger sequencing without mention of cloning.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36597160,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — genotypic resistance results at the time of virologic failure were available for 6 of the 13 patients who experienced virologic failure.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,"Tenofovir, emtricitabine, efavirenz, lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir",0,Yes,1,Yes,1
Human Answer – Yes/No questions,36597160,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a retrospective multicenter observational (non-interventional) cohort study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,No,1
Human Answer – Yes/No questions,36597160,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes — the study enrolled treatment-experienced patients and reports genotypes from individuals with prior ARV exposure (many had prior NRTI, PI/r, NNRTI, or INSTI regimens).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,36645792,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports genotypic antiretroviral resistance testing (GART) performed on patient plasma samples (baseline and as needed during follow-up).,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes.,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36645792,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance testing and computational susceptibility prediction, but no in vitro phenotypic (laboratory) drug susceptibility assays are described.",1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36645792,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported. The paper does not state that sequences or accession numbers were deposited in public repositories.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No.,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,36645792,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported. There is no mention of cloning of samples prior to sequencing.,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported.,1,No,1,No.,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,36645792,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes. The study enrolled adults with virologic failure on first-line tenofovir-emtricitabine (or lamivudine)-efavirenz (TEE) and performed baseline and on-study GART for such participants.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Tenofovir, Emtricitabine, Efavirenz",0,Yes,1,Yes,1
Human Answer – Yes/No questions,36645792,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes. This was a randomized, double-blind, placebo-controlled, phase 2 clinical trial (ARTIST; ClinicalTrials.gov NCT03991013).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,36645792,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. Participants had previously received first-line antiretroviral therapy (tenofovir plus emtricitabine/lamivudine plus efavirenz) and sequencing was performed on their samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,36659824,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the study performed baseline HIV-1 resistance genotyping on participant samples.,1,No,0,No,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,,0
Human Answer – Yes/No questions,36659824,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report newly generated in vitro drug susceptibility (phenotypic) assay results; it only references published in vitro IC95 values used to interpret plasma concentrations.,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,,1
Human Answer – Yes/No questions,36659824,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report depositing sequences in public repositories or provide accession numbers.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,,1
Human Answer – Yes/No questions,36659824,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / no indication that samples were cloned prior to sequencing.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,,1
Human Answer – Yes/No questions,36659824,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes — resistance genotypic testing was recommended and performed in cases of virological non-response/failure, and the study reports no emergent resistance-associated mutations in those individuals.",1,No,0,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,No,0,No,0,Yes,1,Not reported,0,Yes,1,,0
Human Answer – Yes/No questions,36659824,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes — the study was a registered, prospective, multicentre, open-label single-arm clinical study (ClinicalTrials.gov NCT03858478).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,Yes,1,,0
Human Answer – Yes/No questions,36659824,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,No — previously treated individuals were excluded from the main ITT analyses and sequences from pretreated individuals are not reported in the results.,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,Yes,1,No,0,No,0,No,0,No,0,No,0,Yes,1,No,0,Yes,1,,0
Human Answer – Yes/No questions,36660819,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Not reported.,0,No,0,Not reported,0,Yes,1,No,0,No,0,Yes.,1,Yes,1,Yes,1,No,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,** No,0,Yes,1
Human Answer – Yes/No questions,36660819,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not present in vitro phenotypic susceptibility data.,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,Yes,0,No,1,No,1,No.,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,36660819,3,Were sequences from the paper made publicly available?,Boolean,No,No — sequences or accession numbers are not reported as publicly available.,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,36660819,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / no indication that cloning was performed.,1,No,1,No,1,Not reported,1,Not reported.,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No.,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,36660819,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes.,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,No,0,Yes,1,Yes,1,CAB and RPV,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,36660819,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,36660819,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,36694270,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer – Yes/No questions,36694270,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"No
```",1,No,1
Human Answer – Yes/No questions,36694270,3,Were sequences from the paper made publicly available?,Boolean,No,No (not reported).,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,"Yes, but the accession numbers are not provided.",0,"Yes
```",0,No,1
Human Answer – Yes/No questions,36694270,8,Were samples cloned prior to sequencing?,Boolean,No,No (no cloning reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"No
```",1,No,1
Human Answer – Yes/No questions,36694270,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer – Yes/No questions,36694270,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"No
```",1,No,1
Human Answer – Yes/No questions,36694270,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer – Yes/No questions,36706364,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports genotypic resistance testing (patient-derived sequences) from participants.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,36706364,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro phenotypic drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,36706364,3,Were sequences from the paper made publicly available?,Boolean,No,No — public availability of sequences is not reported in the paper.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** No,1,Yes,0
Human Answer – Yes/No questions,36706364,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No evidence of cloning prior to sequencing.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,36706364,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes — three participants underwent resistance testing during follow-up, including the two participants who met criteria for virological failure.",1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,No,0,Yes,1,Yes,1,"Tenofovir, Lamivudine/Emtricitabine, NNRTI",0,** Yes,1,Yes,1
Human Answer – Yes/No questions,36706364,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes — participants were enrolled in a single-arm, prospective, interventional study registered on ClinicalTrials.gov (NCT03991013).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,No,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,36706364,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes — participants had failed first-line ART consisting of tenofovir, lamivudine/emtricitabine and an NNRTI prior to switching to TLD, and genotypic resistance reflective of prior ARV exposure was reported.",1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,36738248,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The paper reports HIV sequences obtained from patient plasma samples, including both Sanger (SS) and next-generation (NGS, Illumina) sequences from participants in the Swiss HIV Cohort Study and Zurich Primary HIV Cohort.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36738248,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic resistance interpretation (in silico) using the Stanford database but does not report in vitro phenotypic (laboratory) drug susceptibility assays.,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36738248,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported as publicly deposited in GenBank; sequences are stored in internal cohort databases (SwissHIVGenomeDB and SHCS Drug Resistance Database).,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,No.,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,36738248,8,Were samples cloned prior to sequencing?,Boolean,No,No. The methods describe direct RT-PCR amplification of viral RNA into overlapping amplicons for sequencing (Sanger and Illumina) and do not describe cloning of samples prior to sequencing.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36738248,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Not reported,"Not explicitly reported. The paper reports ART status at sampling (20.4% on ART, 76.3% ART-naive) and analyzes resistance, but it does not explicitly state which sequences came from individuals with documented virological failure.",1,No,1,No,1,Not reported,1,No,1,Not reported,1,Yes,0,No,1,Yes,0,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,"TDF, FTC, EFV, NVP, ATV, DRV, RAL, DTG, BIC, CAB, LEN",1,Not reported,1,Yes,0
Human Answer – Yes/No questions,36738248,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Participants were enrolled in observational cohort studies (the Swiss HIV Cohort Study and the Zurich Primary HIV Cohort), not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36738248,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. The study includes ART-experienced individuals and assesses prior ARV exposure in relation to detected drug-resistance mutations.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Not reported,0,Yes,1
Human Answer – Yes/No questions,36751650,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36751650,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36751650,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No accession information provided.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,Not reported,1
Human Answer – Yes/No questions,36751650,8,Were samples cloned prior to sequencing?,Boolean,No,No; samples were amplified by nested PCR and directly Sanger-sequenced (no cloning reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,36751650,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,,1,No,1,No,1
Human Answer – Yes/No questions,36751650,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36751650,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No; participants had not received ART prior to sampling.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,36779485,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,** Yes,1
Human Answer – Yes/No questions,36779485,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** Yes,0,** Yes,0
Human Answer – Yes/No questions,36779485,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No accession information provided.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,** Yes,0
Human Answer – Yes/No questions,36779485,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No indication that samples were cloned prior to sequencing.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,** No,1,** No,1
Human Answer – Yes/No questions,36779485,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,** Yes,1
Human Answer – Yes/No questions,36779485,13,Were the patients in the study in a clinical trial?,Boolean,No,"No (retrospective cohort analysis, not a clinical trial).",1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,** No,1,** No,1
Human Answer – Yes/No questions,36779485,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes (the cohort of patients failing NNRTI-based ART had prior ARV exposure).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,** Yes,1
Human Answer – Yes/No questions,36795586,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No. The paper does not report HIV sequences from patient samples; HIV genotype testing was not available routinely and only sporadically available on a limited basis.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,36795586,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not report any in vitro drug susceptibility (phenotypic) data.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36795586,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not indicate that any sequences were made publicly available.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not Reported,1,No,1,No,1
Human Answer – Yes/No questions,36795586,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported. The paper provides no information about cloning of samples prior to sequencing.,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36795586,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Possibly yes but limited: targeted HIV genotype testing was sporadically available for CALHIV failing second-line ART, so some genotypes (and thus sequences) may have originated from individuals with virological failure, but these were limited and not reported in detail.",1,No,1,No,1,No,1,Not reported,1,No.,1,Not reported,1,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,"AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN, MVC",1,Yes,0,Yes,0
Human Answer – Yes/No questions,36795586,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. The study was a retrospective real-world cohort analysis of patients in routine clinical care, not a clinical trial.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1
Human Answer – Yes/No questions,36795586,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No sequences are reported. However, the cohort included many ART-experienced individuals and targeted genotyping (when done) was sometimes for those failing second-line ART.",1,No,1,No,1,Yes,0,Not reported,1,Not Reported.,1,Yes,0,Yes,0,Yes,0,No,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,36851704,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36851704,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36851704,3,Were sequences from the paper made publicly available?,Boolean,No,No (not reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1
Human Answer – Yes/No questions,36851704,8,Were samples cloned prior to sequencing?,Boolean,No,No (not reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Not Reported,1,No.,1,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36851704,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not explicitly reported; sequences were from individuals initiating or reinitiating ART with viral load >1000 copies/mL, some of whom reported prior ARV exposure, but the paper does not state that sequences came from people failing a current regimen.",1,No,1,Yes,0,Not reported,1,Not reported,1,Yes,0,Yes,0,Not reported,1,No,1,No,1,No.,1,Yes,0,Yes.,0,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1
Human Answer – Yes/No questions,36851704,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Not Reported,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36851704,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36851760,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer – Yes/No questions,36851760,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"No
```",1,No,1
Human Answer – Yes/No questions,36851760,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer – Yes/No questions,36851760,8,Were samples cloned prior to sequencing?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"No
```",1,No,1
Human Answer – Yes/No questions,36851760,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — sequences include samples from ART-treated children with virological failure; specifically 31 sequenced samples from ART-treated children with virological failure (20 from Benin and 11 from Mali).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Not Reported,0,"Yes
```",1,Yes,1
Human Answer – Yes/No questions,36851760,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,"No
```",1,No,1
Human Answer – Yes/No questions,36851760,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,"Yes
```",1,Yes,1
Human Answer – Yes/No questions,36920025,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — the reported sequences derive from in vitro cell-culture selections (NL4-3 clone and defined isogenic mutant virus pool), not from patient-derived clinical specimens.",1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes.,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1
Human Answer – Yes/No questions,36920025,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes — the paper reports in vitro viral infectivity EC50 measurements and enzymatic Ki and Km assays for wild-type and mutant proteases.,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36920025,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes — sequencing data are deposited in the NCBI SRA under BioProject PRJNA853351 and source datasets are available in the Carolina Digital Repository.,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,No,0,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36920025,8,Were samples cloned prior to sequencing?,Boolean,No,"Yes — some PCR products were cloned and sequenced, and Primer-ID MiSeq (next-generation) libraries were also generated for deep sequencing.",0,No,1,No,1,Yes.,0,No,1,Not reported,1,No,1,Yes,0,No,1,No,1,Yes.,0,Yes,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36920025,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — the sequences were derived from laboratory cell-culture selections of NL4-3 and defined isogenic mutant virus pools, not from patients experiencing treatment failure.",1,No,1,No,1,No.,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,36920025,13,Were the patients in the study in a clinical trial?,Boolean,No,No — there were no patients in this study and no clinical trial; experiments were performed with laboratory cell lines and molecular clones of HIV-1.,1,No,1,No,1,Not Reported.,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported.,1,Yes,0,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,36920025,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — sequences reported are from in vitro-selected laboratory viruses derived from NL4-3 and defined mutant pools, not from treated individuals.",1,No,1,No,1,No.,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,36931676,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36931676,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No direct in vitro susceptibility data are reported; the paper reports predicted phenotypic sensitivity.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36931676,3,Were sequences from the paper made publicly available?,Boolean,No,"No — sequences are stored in the registry and data (including sequences) are available upon reasonable request and after ethical approval, but no public deposition is reported.",1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No.,1,No,1,No.,1,Yes,0,Yes,0,No,1,No,1,Not Reported,1,No,1,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,36931676,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported.,1,Not reported,1,Not reported.,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,Not reported,1,Yes,0
Human Answer – Yes/No questions,36931676,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Not explicitly stated; the registry includes treatment-experienced patients and drug-resistance data, so sequences may include individuals with virological failure but the paper does not specifically report this.",1,No,0,Yes,1,No,0,Not reported,0,No,0,Not reported,0,No,0,No,0,No,0,Yes.,1,Yes,1,Not reported.,0,No,0,No,0,No,0,No,0,Not Reported,0,No,0,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36931676,13,Were the patients in the study in a clinical trial?,Boolean,No,"No, this is a prospective registry-based cohort (not a clinical trial).",1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,36931676,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes.,1,Yes,1,Not reported.,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36961945,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports sequencing of HIV from patient samples (blood plasma RNA by bulk genotyping and archived proviral DNA from PBMCs by NGS).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,36961945,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic drug resistance (NGS and bulk genotyping) but does not present in vitro (phenotypic) drug susceptibility assay data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,36961945,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported. The paper does not provide or cite public sequence deposits or accession numbers.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Not reported,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,36961945,8,Were samples cloned prior to sequencing?,Boolean,No,No. Samples were amplified by PCR/nested PCR and directly sequenced by NGS or bulk genotyping without cloning.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,36961945,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No. No participants experienced virologic failure after initiating ART during follow-up.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"3TC, FTC",1,** No,1,Yes,0
Human Answer – Yes/No questions,36961945,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Participants were enrolled in the San Diego Primary Infection Research Consortium (PIRC) observational cohort, not described as part of a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,36961945,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The sequencing was performed on samples from antiretroviral-naïve individuals (pre-ART).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,Yes,0,No,1,** Yes,0,Yes,0
Human Answer – Yes/No questions,36967989,1,Does the paper report HIV sequences from patient samples?,Boolean,No,Yes. The study used genotype data (patient-derived viral isolates) from the Stanford HIV drug resistance database.,0,No,1,No,1,No,1,No,1,** Not reported.,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes.,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,36967989,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,Yes. The study used genotype-phenotype data including fold-change in drug susceptibility (IC50/fold-change) from PhenoSense assay results.,0,Yes,0,No,1,No,1,No,1,** Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes.,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,** Yes,0,No,1
Human Answer – Yes/No questions,36967989,3,Were sequences from the paper made publicly available?,Boolean,No,"Partially. The processed data and code used in the study are made available on GitHub and Zenodo, and the underlying genotype-phenotype data originate from the publicly accessible Stanford HIV drug resistance database, but the paper does not report new sequence depositions (e.g., GenBank accessions).",1,Yes,0,No,1,Yes,0,Yes,0,** Yes.,0,Yes,0,Not reported,1,Yes,0,No,1,No,1,No,1,Yes.,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,36967989,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported. The paper does not describe any cloning of samples prior to sequencing.,1,No,1,No,1,No,1,No,1,** Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,36967989,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,Not reported. The paper does not state whether isolates came specifically from individuals with virological failure.,1,No,1,No,1,No,1,No,1,** Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes.,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,36967989,13,Were the patients in the study in a clinical trial?,Boolean,No,Not reported. The paper does not indicate that patients were enrolled in a clinical trial; data were obtained from an external database.,1,No,1,No,1,No,1,No,1,** Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** Yes,0,No,1
Human Answer – Yes/No questions,36967989,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,Not explicitly reported. The paper does not provide explicit statements about prior antiretroviral treatment histories for the individuals whose isolates were in the dataset.,1,No,1,No,1,No,1,No,1,** Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes.,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,36982978,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — this is a review article and does not report original HIV sequences from patient samples.,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Not explicitly stated,1,No,1,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,36982978,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"Yes — the review reports and summarizes in vitro susceptibility/phenotypic data from cited studies (EC50/IC50 values), but it does not present new experimental susceptibility data generated by the authors.",0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes.,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1
Human Answer – Yes/No questions,36982978,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report depositing any sequences in public databases.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1,No.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,36982978,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — the paper does not report generating or sequencing samples and therefore does not describe cloning prior to sequencing.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Yes,0,No,1,No,1,Not reported.,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36982978,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No sequences were obtained in this paper; however, the review discusses sequences and resistance mutations reported in the literature from individuals failing therapy (e.g., patients failing RAL-based regimens).",1,No,1,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,36982978,13,Were the patients in the study in a clinical trial?,Boolean,No,No — the paper is a review and did not enroll patients; it cites clinical trials and observational studies from the literature but did not conduct a trial itself.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Yes,0,No,1,No,1,Not reported.,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36982978,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the review does not present original sequences from previously treated individuals, though it discusses literature reporting sequences from treatment-experienced patients.",1,No,1,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37017009,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The study performed HIV genotyping and obtained sequences from patient plasma samples (809/899 specimens were successfully sequenced).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
""""",1,Yes,1
Human Answer – Yes/No questions,37017009,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance and predicted resistance profiles from sequence data, not direct in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"No
""""",1,No,1
Human Answer – Yes/No questions,37017009,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No evidence of public deposition was provided in the paper.,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Not Reported,1,"No
""""",1,Yes,0
Human Answer – Yes/No questions,37017009,8,Were samples cloned prior to sequencing?,Boolean,No,No. Samples were PCR-amplified and prepared as NGS libraries; cloning was not described.,1,No,1,No,1,Not reported,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,"No
""""",1,No,1
Human Answer – Yes/No questions,37017009,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Inclusion required recent evidence of virological failure (viral load ≥1000 copies/mL) in children on ART, and sequences were obtained from those participants.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not Reported,0,"Yes
""""",1,Yes,1
Human Answer – Yes/No questions,37017009,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. This was a cross-sectional facility-based observational study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not Reported,1,"No
""""",1,No,1
Human Answer – Yes/No questions,37017009,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. Participants were on ART for at least one year and prior/current regimen information (including PMTCT exposure) was collected and reported.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
""""",1,Yes,1
Human Answer – Yes/No questions,37029656,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer – Yes/No questions,37029656,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,"Yes
```",0,No,1
Human Answer – Yes/No questions,37029656,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No indication of public sequence deposition.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Not Reported,1,"No
```",1,No,1
Human Answer – Yes/No questions,37029656,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No indication that samples were cloned prior to sequencing.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,"No
```",1,No,1
Human Answer – Yes/No questions,37029656,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,"Yes
```",0,No,1
Human Answer – Yes/No questions,37029656,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,"No
```",1,No,1
Human Answer – Yes/No questions,37029656,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"No
```",1,No,1
Human Answer – Yes/No questions,37039023,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37039023,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37039023,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37039023,8,Were samples cloned prior to sequencing?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37039023,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"TDF, 3TC, EFV",1,No,1,No,1
Human Answer – Yes/No questions,37039023,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37039023,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37042390,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports sequencing (genotypic resistance testing) of patient-derived HIV samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,37042390,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic resistance testing and interpretation but does not report in vitro phenotypic (laboratory) drug susceptibility assays.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,37042390,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report that sequences were deposited in public databases or provide accession numbers.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Not Reported,1,** No,1,No,1
Human Answer – Yes/No questions,37042390,8,Were samples cloned prior to sequencing?,Boolean,No,"No. The methods describe RT-PCR, nested PCR, gel purification and direct Sanger sequencing, with no mention of cloning.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported.,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37042390,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Genotyping was performed on patients who did not attain virological suppression after 12 months, and sequencing was done on samples from those failing therapy (e.g., 12 of 13 failing at 12 months were genotyped).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not Reported,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,37042390,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. This was a single-centre observational study in programmatic (routine care) conditions, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,37042390,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. The cohort consisted of treatment-experienced patients who had prior first-line and second-line ART before initiation of third-line therapy, and sequencing included their viruses.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,37052343,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,"Yes
""""",0,Yes,0
Human Answer – Yes/No questions,37052343,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility (phenotypic) data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"No
""""",1,No,1
Human Answer – Yes/No questions,37052343,3,Were sequences from the paper made publicly available?,Boolean,No,No — there were no sequences reported and thus none made publicly available.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,"Yes
""""",0,Yes,0
Human Answer – Yes/No questions,37052343,8,Were samples cloned prior to sequencing?,Boolean,No,No — not applicable because no sequencing was performed.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,"No
""""",1,No,1
Human Answer – Yes/No questions,37052343,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — no sequences were obtained; the study did report virological failure events but did not sequence samples from those individuals.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Not reported,1,No,1,No,1,No,1,No,1,,1,"No
""""",1,Yes,0
Human Answer – Yes/No questions,37052343,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — participants were from observational cohorts (RESPOND), not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,"Yes
""""",0,Yes,0
Human Answer – Yes/No questions,37052343,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the study focused on ART‑naive individuals and did not report sequences.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,"No
""""",1,Yes,0
Human Answer – Yes/No questions,37071019,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,No,1,Yes,0,** Yes.,0,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37071019,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37071019,3,Were sequences from the paper made publicly available?,Boolean,No,No evidence of public deposition (no sequences appear to have been made publicly available).,1,No,1,No,1,No,1,No,1,** No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37071019,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable for patient samples; plasmid constructs were generated and amplified in bacteria prior to Sanger sequencing.,1,No,1,No,1,Not reported,1,No,1,** Not reported.,1,No,1,Yes,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37071019,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No sequences from such individuals were obtained in this study (the paper cites other studies reporting such cases).,1,No,1,No,1,Not reported,1,Yes,0,** Yes.,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37071019,13,Were the patients in the study in a clinical trial?,Boolean,No,No — this study did not include patients; it is laboratory-based. Clinical trials are only cited in the Discussion.,1,No,1,No,1,No,1,No,1,** No.,1,No,1,Yes,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,Yes,0,No,1,No,1,Not Reported,1,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37071019,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report sequences from individuals previously treated with antiretrovirals; patient cases are referenced from other studies.,1,No,1,No,1,Not reported,1,Yes,0,** Yes.,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37085698,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37085698,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No — only genotypic/in silico susceptibility interpretation was reported, not in vitro phenotypic assays.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37085698,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37085698,8,Were samples cloned prior to sequencing?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37085698,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not reported,1,Not reported,1
Human Answer – Yes/No questions,37085698,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37085698,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37104815,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV sequences from patient samples generated by Sanger and ultra-deep sequencing of the HIV-1 genome (RNA at failure and DNA at baseline).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0,Yes,1
Human Answer – Yes/No questions,37104815,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance (Sanger and UDS) and pharmacological drug concentration measurements, but does not report in vitro phenotypic drug susceptibility assay data.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,,1,No,1
Human Answer – Yes/No questions,37104815,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported. The paper does not provide GenBank accession numbers or state that sequence data were deposited in public repositories.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,,1,No,1
Human Answer – Yes/No questions,37104815,8,Were samples cloned prior to sequencing?,Boolean,No,No. The methods describe Sanger sequencing and ultra-deep (Illumina) sequencing without mention of cloning of samples prior to sequencing.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,,1,No,1
Human Answer – Yes/No questions,37104815,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes. Resistance sequencing (RNA at failure) was performed for the 10 participants who experienced virological failure (6 in the 4/7 arm and 4 in the 7/7 arm).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Tenofovir/emtricitabine, rilpivirine, darunavir/ritonavir",0,,0,Yes,1
Human Answer – Yes/No questions,37104815,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes. Participants were enrolled in the ANRS 170 QUATUOR open-label, randomized, multicentre, non-inferiority Phase III clinical trial (registered NCT03256422).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,,0,Yes,1
Human Answer – Yes/No questions,37104815,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. All participants were on continuous combination ART with sustained virological suppression (>12 months) at enrollment, and sequencing was performed on their RNA/DNA samples.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,,0,Yes,1
Human Answer – Yes/No questions,37112971,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The study reports HIV sequences obtained from patient samples (4481 PR-RT and 844 INT sequences).,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37112971,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic resistance interpretation derived from sequence data but does not report in vitro phenotypic (laboratory) drug susceptibility assays.,1,No,1,No,1,No,1,No,1,** No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37112971,3,Were sequences from the paper made publicly available?,Boolean,No,No. The sequence data are not publicly available; they are available on request from the corresponding author due to the RuHIV database privacy policy.,1,No,1,No,1,No,1,No,1,** No,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,Yes.,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37112971,8,Were samples cloned prior to sequencing?,Boolean,No,No. The methods describe direct genotyping (commercial kits and in-house methods) with Sanger or NGS sequencing and do not report any cloning prior to sequencing.,1,No,1,No,1,No,1,No,1,** No,1,No,1,No,1,No,1,No,1,Not reported.,1,Not reported,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37112971,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. The study population consisted of treatment-naïve patients, so sequences were not from individuals with virological failure on ART.",1,No,1,No,1,No,1,No,1,** No,1,No,1,Yes,0,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,,1,No,1,No,1
Human Answer – Yes/No questions,37112971,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Patients were not described as participants in a clinical trial; sequences originated from routine HIV DR testing, research and clinical projects, and outbreak investigations uploaded to the national database.",1,No,1,No,1,No,1,No,1,** No,1,No,1,No,1,No,1,No,1,Not reported.,1,Not reported,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37112971,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No. The study explicitly analyzed sequences from treatment-naïve individuals, so subjects had not previously received antiretroviral drugs prior to sampling.",1,No,1,No,1,No,1,No,1,** No,1,Yes,0,Yes,0,No,1,No,1,No.,1,No,1,No.,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37147875,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,37147875,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,Yes,1,No,0,Yes,1,No,0,No,0,Yes,1,No,0,No,0,No,0,No,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,37147875,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not Reported,1,** No,1,No,1
Human Answer – Yes/No questions,37147875,8,Were samples cloned prior to sequencing?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,Not Reported,1,** No,1,No,1
Human Answer – Yes/No questions,37147875,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,Not reported,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,37147875,13,Were the patients in the study in a clinical trial?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,Not Reported,1,** No,1,No,1
Human Answer – Yes/No questions,37147875,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,37272233,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37272233,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37272233,3,Were sequences from the paper made publicly available?,Boolean,No,No (no public deposition reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37272233,8,Were samples cloned prior to sequencing?,Boolean,No,No evidence of cloning; cloning is not reported.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported.,1,Not Reported,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37272233,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not explicitly reported as sequences from virological failure cases; however, some detected mutations (e.g., T215 revertants) are related to virological failure and some patients had prior ART exposure shortly before testing.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,"Zidovudine, lamivudine, emtricitabine, tenofovir, abacavir, efavirenz, nevirapine, lopinavir, atazanavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, and cabotegravir",1,Yes,0,Yes,0
Human Answer – Yes/No questions,37272233,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37272233,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,Yes — some individuals had prior ART exposure before sequencing.,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Yes,0,Yes,0,No,1,No,1,Yes.,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0
Human Answer – Yes/No questions,37279764,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV sequences obtained from patient samples (partial HIV-1 pol sequences).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37279764,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro (phenotypic) drug susceptibility assays; drug sensitivity changes were inferred from genotypic interpretation.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37279764,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes — sequences were deposited in GenBank and accession numbers are provided.,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,No,0
Human Answer – Yes/No questions,37279764,8,Were samples cloned prior to sequencing?,Boolean,No,No cloning prior to sequencing is reported.,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37279764,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — all individuals were treatment naive at enrolment, so sequences were not from persons with virological failure on treatment.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37279764,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the study involved newly diagnosed patients enrolled for surveillance/analysis, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37279764,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — sequences were from individuals who were treatment naive and had not previously received ARV drugs.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37327289,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37327289,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37327289,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37327289,8,Were samples cloned prior to sequencing?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37327289,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,,1,No,1,No,1
Human Answer – Yes/No questions,37327289,13,Were the patients in the study in a clinical trial?,Boolean,No,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37327289,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No (all participants were treatment-naive), although one sequence showed a pattern suggesting possible prior ARV exposure.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37340869,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The paper reports genotypic (sequence-based) analyses from participant samples, including identification of resistance-associated mutations and HIV-1 subtypes.",1,No,0,No,0,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,,0
Human Answer – Yes/No questions,37340869,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No—direct in vitro drug susceptibility (phenotypic) results are not presented in the main text (phenotypic analyses are only referenced as published elsewhere/supplementary).,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,,1
Human Answer – Yes/No questions,37340869,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported. The manuscript does not provide GenBank accession numbers or state that sequence data were deposited in a public repository.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,,1
Human Answer – Yes/No questions,37340869,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported. The main text does not describe cloning of samples prior to sequencing.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,,1
Human Answer – Yes/No questions,37340869,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Yes. Some sequence-derived findings relate to participants who experienced confirmed virologic failure (CVF); 23 participants had CVF and the analyses relate baseline sequence findings (e.g., preexisting RPV RAMs) to later CVF.",0,No,1,No,1,Not reported,1,Not reported,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Not reported,1,Yes,0,,1
Human Answer – Yes/No questions,37340869,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes. Participants were enrolled in randomized, multicenter, open-label phase 3/3b clinical trials (FLAIR, ATLAS, and ATLAS-2M).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,,0
Human Answer – Yes/No questions,37340869,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. Participants were virologically suppressed on antiretroviral therapy at randomization and had prior ARV exposure; the paper discusses historical genotypic evidence and retrospective proviral DNA analyses to detect archived resistance related to prior ARV use.,1,No,0,No,0,Not reported,0,Not reported,0,Not reported,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,,0
Human Answer – Yes/No questions,37358226,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** Yes,0,No,1
Human Answer – Yes/No questions,37358226,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,37358226,3,Were sequences from the paper made publicly available?,Boolean,No,No — no sequences were reported or made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,37358226,8,Were samples cloned prior to sequencing?,Boolean,No,"Not applicable — no sequencing was performed, so no cloning was reported.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,** No,1,No,1
Human Answer – Yes/No questions,37358226,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not applicable — no sequences were obtained; however, the cohort included individuals with virologic failure (e.g., pretransition VL >999 copies/mL).",1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,37358226,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the patients were part of a prospective open cohort receiving routine care (programmatic transitioning), not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,37358226,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report any HIV sequences. The study population consists of individuals who previously received ARV drugs (NNRTI- and NRTI-containing regimens) and transitioned to DTG.,1,No,1,No,1,Yes,0,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,37376649,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports proviral DNA genotyping (NGS) performed on baseline whole blood samples from participants.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0,Yes,1
Human Answer – Yes/No questions,37376649,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not report any in vitro phenotypic drug susceptibility assays; it reports proviral DNA genotypic resistance (NGS) data only.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,,1,No,1
Human Answer – Yes/No questions,37376649,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report deposition of sequences in public repositories or provide GenBank accession numbers; data availability refers to requesting anonymized participant data through a data request portal.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Not Reported,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,,1,No,1
Human Answer – Yes/No questions,37376649,8,Were samples cloned prior to sequencing?,Boolean,No,No evidence of cloning is reported; sequencing was performed by the GenoSure Archive NGS assay on proviral DNA from whole blood without mention of cloning.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,,1,No,1
Human Answer – Yes/No questions,37376649,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. Participants with recent virologic failure or a prior regimen switch for virologic failure were excluded, and baseline samples came from virologically suppressed participants.",1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,,1,No,1
Human Answer – Yes/No questions,37376649,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes. The data come from the randomized TANGO clinical trial (ClinicalTrials.gov NCT03446573).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0,Yes,1
Human Answer – Yes/No questions,37376649,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. Participants were on antiretroviral therapy prior to the switch and had prior ART histories; proviral DNA from these individuals was genotyped to detect archived resistance.,1,No,0,Yes,1,No,0,Yes,1,No,0,Yes,1,Yes,1,No,0,No,0,Not reported,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0,Yes,1
Human Answer – Yes/No questions,37381002,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — HIV sequences from patient samples were reported (pol gene sequences from 398 patients and ten near full-length genomes).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37381002,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper did not report in vitro phenotypic susceptibility assays; resistance was inferred from sequence analysis using the Stanford HIVdb.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37381002,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported — the paper does not provide GenBank accession numbers or state that sequences were deposited in a public database.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1
Human Answer – Yes/No questions,37381002,8,Were samples cloned prior to sequencing?,Boolean,No,No — there is no indication that samples were cloned; PCR products were sequenced directly (Sanger) or pooled and sequenced by NGS.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37381002,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — sequences were obtained from individuals with ART failure (virological failure; viral load ≥ 1000 copies/ml).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,"AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",0,Yes,1,Yes,1
Human Answer – Yes/No questions,37381002,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the study was retrospective and observational, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37381002,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — all sequenced individuals were people who had received antiretroviral therapy and experienced treatment failure.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37439411,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The study reports HIV-1 RNA protease/reverse transcriptase sequences (genotypes) retrieved from patient samples in the ARCA database; these include 5,982 treatment-naïve individuals and 28,505 genotypes from 9,387 treatment-experienced PLWH.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,37439411,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not report in vitro phenotypic susceptibility assays; it reports genotypic resistance interpreted via the Stanford HIVdb (genotypic susceptibility scoring).,1,Yes,0,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37439411,3,Were sequences from the paper made publicly available?,Boolean,No,"Partially: sequences were obtained from the public ARCA observational database, but the paper does not report deposition of sequence data to public repositories such as GenBank or provide accession numbers.",1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,37439411,8,Were samples cloned prior to sequencing?,Boolean,No,No indication of cloning; the paper does not report that samples were cloned prior to sequencing.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37439411,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Genotyping on RNA was performed in cases of virological failure with detectable viraemia, and the dataset includes many treatment-experienced individuals for whom genotypes were retrieved.",1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,37439411,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Patients were drawn from a public observational cohort (ARCA); the study is observational and real-life, not a clinical trial.",1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,37439411,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. The paper includes 28,505 genotypes from 9,387 treatment-experienced PLWH and defines PDR based on genotypes of experienced individuals with previous ARV exposure.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,37495103,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37495103,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37495103,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No accession numbers provided.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not Reported,1,No,1,No,1
Human Answer – Yes/No questions,37495103,8,Were samples cloned prior to sequencing?,Boolean,No,No (no cloning was reported).,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37495103,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not Reported,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37495103,13,Were the patients in the study in a clinical trial?,Boolean,No,No (they were clinic patients in a real-world setting).,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not Reported,1,No,1,No,1
Human Answer – Yes/No questions,37495103,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37498738,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports near full-length HIV-1 proviral sequences obtained from participant PBMCs using PCR and next-generation sequencing.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37498738,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not report in vitro phenotypic drug susceptibility assays; it reports genotypic/resistance mutation analysis from sequencing only.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37498738,3,Were sequences from the paper made publicly available?,Boolean,No,Not explicitly in the main text. Data availability is referenced but specific public sequence accession details are not provided in the main text and are said to be described in Supplementary Appendix 6.,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,Not reported,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,Not reported,1,Yes,0
Human Answer – Yes/No questions,37498738,8,Were samples cloned prior to sequencing?,Boolean,No,"No. Samples were not cloned; single-genome dilution and whole-genome amplification were used for single-provirus analysis and PCR amplicons were sequenced, but no cloning into vectors is described.",1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37498738,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No. Participants showed sustained virological suppression over 48 weeks and the paper reports no viral failure during the study; one individual with a detected mutation did not show viral failure over an additional 3 years.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"Dolutegravir, tenofovir, emtricitabine, lamivudine",1,Yes,0,No,1
Human Answer – Yes/No questions,37498738,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes. Participants were enrolled in the Early Simplified Study (ESS), a randomized clinical trial (NCT00537966) comparing switch to dolutegravir monotherapy versus continuation of cART.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37498738,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. The participants were early-treated individuals who had initiated combination ART prior to randomization and some sequences (e.g., transmitted DRMs) were from initial plasma before undergoing cART.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37515095,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV sequences obtained from patient samples (968 partial HIV-1 pol sequences from people living with HIV in Kazakhstan).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37515095,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance profiling using sequence-based analysis and Stanford HIVdb scoring, but does not report in vitro (phenotypic) drug susceptibility assays.",1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37515095,3,Were sequences from the paper made publicly available?,Boolean,No,No. The study states that study data are unavailable to protect patient confidentiality.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37515095,8,Were samples cloned prior to sequencing?,Boolean,No,"No. The methods describe RT-PCR and direct sequencing using AmpliSens HIV-Resist-Seq and an Applied Biosystems Genetic Analyzer, with no cloning step reported.",1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37515095,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not explicitly labeled as 'virological failure' in the paper; however, most sequences were from ART-experienced individuals and many sequences showed resistance to drugs on patients' regimens (consistent with treatment failure).",1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Yes,0,Not reported,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Yes,0
Human Answer – Yes/No questions,37515095,13,Were the patients in the study in a clinical trial?,Boolean,No,No. Participants were registered at a national clinical center and provided informed consent for blood sampling; there is no indication they were enrolled in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,968,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37515095,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. The majority of sequenced participants were ART-experienced and had received antiretroviral drugs prior to sequencing.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37515146,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV-1 sequences obtained from patient samples (379 sequences).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37515146,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance interpretation and predictive efficacy from HIVdb, not in vitro (phenotypic) susceptibility assays.",1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37515146,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. Sequence data were deposited in GenBank and made publicly available.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37515146,8,Were samples cloned prior to sequencing?,Boolean,No,No. Samples were amplified by RT-PCR and semi-nested PCR and directly sequenced; no cloning step is reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported.,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37515146,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. All sequenced individuals were ART-naïve (initiating ART) and had no prior history of ART, so sequences are not from people with virological failure on treatment.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,"AZT, 3TC, EFV, NVP, TDF, FTC, ATV, RTV, RAL, DTG, BIC, CAB, MVC, LEN",1,No,1,No,1
Human Answer – Yes/No questions,37515146,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. The study was a cross-sectional sentinel surveillance/analytical study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37515146,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No. The study excluded individuals with prior ART exposure, so reported sequences are from individuals without previous ARV treatment.",1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37520425,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37520425,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37520425,3,Were sequences from the paper made publicly available?,Boolean,Yes,"Yes, some sequences were deposited in GenBank.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37520425,8,Were samples cloned prior to sequencing?,Boolean,No,No — direct (population) sequencing was used rather than cloning.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37520425,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Sequencing was performed on samples from viremic individuals (VL ≥50 copies/mL), and some of those individuals had VL ≥1000 copies/mL, but it is not explicitly stated whether the successfully sequenced samples came from individuals meeting the virological failure definition (≥1000 copies/mL on two measurements).",1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37520425,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was an observational cohort study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37520425,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"No — treatment-experienced individuals were excluded; the report focuses on treatment-naive participants, so sequences were from those who had not previously received ART.",0,No,0,Yes,1,No,0,No,0,No,0,No,0,Yes,1,Yes,1,No,0,No.,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37537871,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV sequences derived from patient plasma samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37537871,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report phenotypic (in vitro) drug susceptibility assays; it reports genotypic resistance profiling inferred from sequence data.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37537871,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report deposition of patient-derived HIV sequences in public sequence repositories.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No.,1,No,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1
Human Answer – Yes/No questions,37537871,8,Were samples cloned prior to sequencing?,Boolean,No,No — samples were not cloned; viral RNA was reverse-transcribed and long-region PCR amplicons were directly sequenced.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37537871,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Not reported / unclear — the paper does not explicitly state whether sampled individuals were experiencing virological failure while on treatment.,1,Yes,1,No,0,Not reported,0,No,0,No,0,Yes,1,Yes,1,No,0,No,0,No.,0,Yes,1,Yes,1,No,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37537871,13,Were the patients in the study in a clinical trial?,Boolean,No,No — the patients were clinical samples obtained from a hospital; there is no indication they were enrolled in a clinical trial.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37537871,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Not reported / unclear — the paper does not provide explicit antiretroviral treatment histories for the sampled individuals.,0,No,0,No,0,Not reported,0,No,0,Not reported,0,Yes,1,Yes,1,No,0,No,0,No.,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37540331,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** No,1,Yes,0
Human Answer – Yes/No questions,37540331,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37540331,3,Were sequences from the paper made publicly available?,Boolean,No,No (no sequences reported and no public sequence deposition referenced).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37540331,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — no sequencing or cloning reported.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37540331,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — there were no sequences reported, and no virological failures occurred during the study.",1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not reported,1,Yes,0,No,1,No,1,Yes,0,Yes,0,** No,1,Yes,0
Human Answer – Yes/No questions,37540331,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes — participants were enrolled in a registered randomized open-label non-inferiority clinical trial.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,37540331,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report any HIV sequences; participants were treatment-experienced and on ART prior to enrollment.,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,37541705,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,No — the paper does not report patient-derived HIV sequences.,0,No,0,No,0,No.,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,Yes,1,Yes,1,No,0,No,0,No,0,No,0,,0,Yes,1,Yes,1,** No,0,No,0
Human Answer – Yes/No questions,37541705,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report any in vitro drug susceptibility data.,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37541705,3,Were sequences from the paper made publicly available?,Boolean,No,No — sequence or participant-level data were not made publicly available.,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37541705,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No information provided.,1,No,1,No,1,Not reported.,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,,1,No,1,No,1,** Not reported,1,No,1
Human Answer – Yes/No questions,37541705,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not reported. The paper notes one ART-naïve participant met the protocol definition of virologic failure, but it does not report sequences obtained from that or other failing participants.",1,No,1,No,1,No.,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,,1,Yes,0,Not reported in the provided text,1,** No,1,Yes,0
Human Answer – Yes/No questions,37541705,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes — participants were enrolled in an international phase I/II clinical trial (IMPAACT 2019, NCT03760458).",1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,,0,Yes,1,No,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,37541705,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"No — the paper does not report sequences, but most participants were treatment-experienced (previously received ARV drugs).",0,No,0,Yes,1,No.,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Not reported,0,Yes,1,Yes,1,Not reported,0,Not reported,0,Yes,1,No,0,,0,Yes,1,No,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,37546367,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. Partial HIV-1 pol sequences were obtained from patient plasma samples (2074 sequences from 3274 collected samples).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37546367,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The study reports genotypic resistance inferred from sequence data using the Stanford HIVdb, not direct in vitro phenotypic susceptibility assays.",1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37546367,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. The partial pol nucleotide sequences were submitted to GenBank.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37546367,8,Were samples cloned prior to sequencing?,Boolean,No,No. Samples were amplified by one-step RT-PCR and nested PCR and the PCR products were purified and Sanger-sequenced; no cloning step was reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37546367,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Not explicitly stated. Sequences were obtained from ART-experienced individuals with low-level viremia (viral load 200–1000 copies/mL) after at least 6 months of ART; the paper does not explicitly classify these individuals as virological failure cases.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,Yes,1,Not Reported,0,Yes,1,Not Reported,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37546367,13,Were the patients in the study in a clinical trial?,Boolean,No,No. This was a retrospective observational study using samples and data from routine care (National Free Antiretroviral Treatment Database).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37546367,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. Inclusion criteria required individuals to have received ART for at least 6 months prior to sampling; sequences therefore derive from ART-experienced individuals.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37554471,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0,Yes,0,No.,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,,1
Human Answer – Yes/No questions,37554471,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"The paper reports in vitro susceptibility testing for Mycobacterium avium-intracellulare and reports HBV resistance testing, but it does not report HIV in vitro drug susceptibility data.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,,1
Human Answer – Yes/No questions,37554471,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report making any sequences publicly available.,1,No,1,No,1,No,1,No,1,No.,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,,1
Human Answer – Yes/No questions,37554471,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported — no information about cloning prior to sequencing is provided.,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1,,1
Human Answer – Yes/No questions,37554471,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No HIV sequences were reported; the single patient did have virologic failure (high viral load) prior to CAB/RPV but no sequences were obtained or presented.,1,No,1,No,1,Yes,0,Yes,0,No.,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,,1
Human Answer – Yes/No questions,37554471,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the patient was treated clinically (a case report), not as part of a described clinical trial.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,,1
Human Answer – Yes/No questions,37554471,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No HIV sequences are reported; however, the patient described had extensive prior ARV exposure.",1,No,1,No,1,Yes,0,Yes,0,Yes.,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,,1
Human Answer – Yes/No questions,37573167,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37573167,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,Yes,0,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37573167,3,Were sequences from the paper made publicly available?,Boolean,No,No (not reported).,1,No,1,No,1,No.,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37573167,8,Were samples cloned prior to sequencing?,Boolean,No,No — cloning is not reported.,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37573167,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — sequences were from virologically suppressed individuals.,1,No,1,No,1,No.,1,Yes,0,No,1,No,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37573167,13,Were the patients in the study in a clinical trial?,Boolean,No,No — samples were from routine clinical practice (retrospective study).,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37573167,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37574435,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes — the paper reports and uses archived HIV genotypic resistance data (resistance-associated mutations) from patient samples, but it does not present raw sequence data or newly generated sequencing reads in the manuscript.",1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,37574435,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro phenotypic drug susceptibility testing results.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,** No,1,No,1
Human Answer – Yes/No questions,37574435,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not indicate that HIV sequences or accessioned sequence data were made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Not Reported,1,** No,1,No,1
Human Answer – Yes/No questions,37574435,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No indication that samples were cloned prior to sequencing.,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37574435,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — genotypic resistance data were collected for patients who experienced viral rebound (virologic failure) while on treatment prior to switching regimens.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Not Reported,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,37574435,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a single-center, retrospective cohort study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,37574435,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — the study population consisted of antiretroviral-experienced people with HIV who had been receiving ART prior to the observed viral rebound and genotypic resistance data were from these treatment-experienced individuals.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,37585352,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV-1 proviral sequences obtained from participant samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37585352,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,No — the paper does not report in vitro (phenotypic) drug susceptibility assays; it reports genotypic analysis and in silico resistance predictions.,0,Yes,1,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No.,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,No,0,Yes,1,No,0,No,0
Human Answer – Yes/No questions,37585352,3,Were sequences from the paper made publicly available?,Boolean,No,Partially — sequences are not deposited in a public repository within the paper but are available on request through the PANGEA consortium.,1,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37585352,8,Were samples cloned prior to sequencing?,Boolean,No,No — samples were not described as cloned; sequencing was performed on PCR amplicons by NGS and a single consensus was generated per participant.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37585352,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — sequences from individuals experiencing virological failure were not included.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37585352,13,Were the patients in the study in a clinical trial?,Boolean,Yes,"Yes — participants were recruited from the Botswana Combination Prevention Project (BCPP), a registered trial (ClinicalTrials.gov NCT01965470).",1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,Yes,1,Yes.,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37585352,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — the dataset includes 4524 sequences from ART-experienced (virally suppressed) individuals in addition to 1281 from treatment-naive individuals.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37593123,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV-1 pol gene sequences obtained from patient samples (ART-naïve HIV-positive individuals).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37593123,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper did not report in vitro (phenotypic) drug susceptibility data; it used genotypic prediction via the Stanford HIVdb.,1,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37593123,3,Were sequences from the paper made publicly available?,Boolean,No,"Partly — the study used sequences that were publicly available in databases (China CDC holdings, Los Alamos, and GenBank annotations), but the paper does not present new accession numbers or explicitly state deposition of new sequences.",1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,Not reported,1
Human Answer – Yes/No questions,37593123,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported; there is no indication that samples were cloned prior to sequencing.,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,No,1,No,1
Human Answer – Yes/No questions,37593123,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — sequences were from ART-naïve individuals, so none were from persons with virological failure on treatment.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37593123,13,Were the patients in the study in a clinical trial?,Boolean,No,No — the study compiled surveillance/repository sequences from ART-naïve individuals and does not describe enrollment in any clinical trial.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,No,1,No,1
Human Answer – Yes/No questions,37593123,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the study explicitly focused on ART-naïve individuals and did not include sequences from persons with prior ARV exposure.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37626789,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV-1 genotyping and sequencing of the pol gene from children with virologic failure.,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,37626789,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance (sequence-based inference) using the Stanford HIVDB algorithm, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,Yes,0,** No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37626789,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report public deposition of sequences; raw data are available from the corresponding author on request.,1,No,1,No,1,No,1,** No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37626789,8,Were samples cloned prior to sequencing?,Boolean,No,No indication of cloning; the manuscript does not report cloning prior to sequencing.,1,No,1,No,1,No,1,** No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No.,1,No,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37626789,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes. Sequencing/genotyping was performed specifically for children with virologic failure (two consecutive plasma viral loads ≥1000 copies/mL).,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"AZT, 3TC, TDF, FTC, EFV, and NVP",0,** Yes,1,Yes,1
Human Answer – Yes/No questions,37626789,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. The study was a longitudinal observational cohort (part of a national cohort study), not a clinical trial.",1,No,1,No,1,No,1,** No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,37626789,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. All sequenced individuals were children already on first-line ART for at least six months, so they had prior ARV exposure.",1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,37632026,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37632026,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper reports genotypic interpretation (predicted susceptibility) rather than in vitro phenotypic susceptibility assays.,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37632026,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37632026,8,Were samples cloned prior to sequencing?,Boolean,No,No — samples were PCR-amplified and directly sequenced; no cloning step is described.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37632026,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — all participants were experiencing virological failure on first- or second-line ART.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"AZT, 3TC, FTC, TDF, ABC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN, MVC",0,Yes,1,Yes,1
Human Answer – Yes/No questions,37632026,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a laboratory-based cross-sectional and analytical study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37632026,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — participants were previously treated and failing first- or second-line ART regimens.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37632071,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes.,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37632071,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37632071,3,Were sequences from the paper made publicly available?,Boolean,No,No — no sequences were reported or made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37632071,8,Were samples cloned prior to sequencing?,Boolean,No,No — not applicable; no sequencing or cloning was reported.,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No.,1,Not reported,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,No,1,No,1
Human Answer – Yes/No questions,37632071,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — no sequences were obtained. Some participants had prior detectable viremia (≥50 copies/mL) in the year before switch, but no sequencing was performed.",1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes.,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,"AZT, 3TC, FTC, TDF, EFV, NVP, RAL, DTG, BIC, CAB",1,Yes,0,Yes,0
Human Answer – Yes/No questions,37632071,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a retrospective cohort study of routine clinical practice, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37632071,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the paper does not report sequences. However, the participants were treatment-experienced and had received ARV drugs prior to switching.",1,No,1,No,1,Not reported,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes.,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0
Human Answer – Yes/No questions,37649807,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the study analyzed retrospective viral load (VL) program data and did not report HIV sequence data from patient samples.,1,No,1,No,1,Yes,0,No,1,Yes.,0,No,1,** No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37649807,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report any in vitro drug susceptibility assays or results.,1,No,1,No,1,No,1,No,1,No.,1,No,1,** No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37649807,3,Were sequences from the paper made publicly available?,Boolean,No,No — no sequences were reported or deposited; the study used existing VL program data and data are owned by the Kenyan Ministry of Health.,1,No,1,No,1,No,1,No,1,No.,1,No,1,** No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37649807,8,Were samples cloned prior to sequencing?,Boolean,No,"No — there was no sequencing performed, and therefore no cloning prior to sequencing.",1,No,1,No,1,Not Reported,1,Not Reported,1,Not reported.,1,Not reported,1,** Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37649807,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the study did not generate sequences. The cohort did include individuals with virologic non-suppression and virologic failure based on VL data.,1,No,1,No,1,Yes,0,No,1,Not reported.,1,No,1,** Not reported,1,Yes,0,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,"TDF, FTC, EFV, NVP, LPV/r, ATV/r, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, and LEN",1,Yes,0,Yes,0
Human Answer – Yes/No questions,37649807,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the study analyzed retrospective routine programmatic VL data from the national database, not a clinical trial.",1,No,1,No,1,No,1,No,1,No.,1,No,1,** No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37649807,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the paper does not report any HIV sequences. However, the analyzed cohort comprised people with prior ARV exposure.",1,No,1,No,1,Yes,0,No,1,Yes.,0,Yes,0,** Not reported,1,Yes,0,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0
Human Answer – Yes/No questions,37662576,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples; it uses protein structures from the PDB and molecular dynamics simulations.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37662576,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not present in vitro drug susceptibility assays; it reports computational molecular dynamics analyses of protease structures and cites resistance levels from the literature.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37662576,3,Were sequences from the paper made publicly available?,Boolean,No,"No — the paper does not report depositing sequences (e.g., GenBank accessions); it references PDB entries and provides a GitHub link for code.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37662576,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — no sequencing was performed and therefore no cloning for sequencing was performed.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37662576,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — the paper does not report sequences from individuals, including those with virological failure; it analyzes PDB structures and known resistance variants computationally.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37662576,13,Were the patients in the study in a clinical trial?,Boolean,No,Not applicable — there were no patients in this study; it is a computational/structural analysis using PDB data.,1,No,1,No,1,Not reported,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported (no specific information mentioned in the paper),1,Not reported,1,No,1,Yes,0
Human Answer – Yes/No questions,37662576,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report sequences from individuals with prior ARV exposure; it analyzes structural protease variants from PDB and discusses clinical drugs in the literature context.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37674678,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The paper reports HIV-1 pol gene sequences obtained from patient plasma samples and analyzes 1,161 successfully sequenced samples.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37674678,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance analysis using sequence-based interpretation algorithms, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37674678,3,Were sequences from the paper made publicly available?,Boolean,Yes,"No accession numbers are reported in the manuscript, and the Data availability statement indicates data must be deposited prior to publication but does not show deposited sequence identifiers.",0,Yes,1,No,0,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,Yes.,1,No,0,No,0,Yes,1,No,0,Yes,1,No,0,Yes,1,Yes,1,Not reported,0
Human Answer – Yes/No questions,37674678,8,Were samples cloned prior to sequencing?,Boolean,No,No. PCR products were directly sequenced after nested PCR; no cloning step is described.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37674678,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. All participants were ART-naïve with no history of antiretroviral therapy, so sequences were not from individuals with virological failure on treatment.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,,1,No,1,No,1
Human Answer – Yes/No questions,37674678,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Patients were recruited from voluntary counseling and testing clinics and the study was an observational surveillance study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37674678,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The study specifically enrolled ART-naïve individuals with no history of antiretroviral therapy.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1
Human Answer – Yes/No questions,37701387,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports baseline genotypic data (viral mutations) from patient samples (Rainbow study participants).,1,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,No,0,Yes,1,No,0,No,0,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37701387,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro phenotypic drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37701387,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report that sequences were deposited in public repositories.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37701387,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No information provided.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37701387,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — sequences described were from ART‑naive individuals at baseline, not from persons with virological failure on treatment.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37701387,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes — the Rainbow study was a prospective phase IV clinical trial (single-arm) and the LAPTOP study is described as an ongoing randomized controlled trial.,1,Yes,1,Yes,1,Not reported,0,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Not reported,0,No,0,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37701387,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,No — the sequences described (baseline genotypes) come from ART‑naive individuals.,0,No,0,No,0,No,0,No,0,No,0,Yes,1,No,0,No,0,No,0,No,0,No,0,No,0,Not reported,0,Not reported,0,No,0,No,0,No,0,Yes,1,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,37716367,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — this paper is a reporting guideline and does not present primary HIV sequence data from patient samples.,1,Yes,0,No,1,No,1,Yes,0,Not reported,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37716367,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37716367,3,Were sequences from the paper made publicly available?,Boolean,No,"No — there are no sequences reported in this paper, so none were made publicly available.",1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1
Human Answer – Yes/No questions,37716367,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / not applicable — the paper does not present laboratory methods applied to original samples and does not state that samples were cloned.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37716367,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,Not applicable / no — the paper does not present sequence data from individuals on treatment or with virological failure.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Not reported,1,Yes,0,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,No,1
Human Answer – Yes/No questions,37716367,13,Were the patients in the study in a clinical trial?,Boolean,No,No — this paper is a guideline and not a clinical trial report.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37716367,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report sequences from treated individuals.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Not reported,1,Yes,0,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,No,1
Human Answer – Yes/No questions,37755428,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the study reports HIV sequences generated from patient samples (dried blood spots) and successful quality-assured genotypes for PR/RT and integrase were obtained.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0,Yes,1
Human Answer – Yes/No questions,37755428,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No — the paper reports genotypic resistance predictions using the Stanford HIVdb algorithm, not phenotypic in vitro drug susceptibility testing.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,,1,No,1
Human Answer – Yes/No questions,37755428,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported — the paper does not state GenBank or other public accession deposition.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Not Reported,1,,1,No,1
Human Answer – Yes/No questions,37755428,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported — there is no mention of cloning; sequencing was performed by a Sanger-based method on extracted nucleic acids.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,,1,No,1
Human Answer – Yes/No questions,37755428,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — sequences were from ART-naive infants; the mother's virus was not sequenced despite her having detectable viral load before delivery.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not Reported,1,Yes,0,Not reported,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,,1,Yes,0
Human Answer – Yes/No questions,37755428,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the data derive from a national survey of HIV drug resistance, not a clinical trial.",1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,,1,No,1
Human Answer – Yes/No questions,37755428,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"Yes — although infants were ART-naive, the majority had prior exposure to antiretroviral drugs for PMTCT and some infants received prophylaxis (e.g., ZDV-based PNP); mothers had received ART including DTG-based regimens.",0,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,,1,Yes,0
Human Answer – Yes/No questions,37775947,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37775947,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37775947,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No accession information provided.,1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,Not reported,1,No,1
Human Answer – Yes/No questions,37775947,8,Were samples cloned prior to sequencing?,Boolean,No,No — cloning is not reported; samples were amplified and sequenced by NGS without mention of cloning.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37775947,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — sequences were from ART-naïve participants at baseline; they were not sampled while failing therapy.,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Yes.,0,Not Reported,1,Yes,0,Yes,0,Not reported,1,No,1,No,1,Yes,0,Yes,0,"Tenofovir, lamivudine, efavirenz, and lopinavir/ritonavir",1,Yes,0,Yes,0
Human Answer – Yes/No questions,37775947,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes — participants were enrolled in the START randomized clinical trial.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37775947,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the participants were antiretroviral therapy (ART)-naïve at enrollment.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37817087,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The paper reports HIV sequences obtained from patient samples (protease and reverse-transcriptase sequences from 4559 cases and protease, reverse-transcriptase and integrase sequences from 3097 cases) collected as plasma, serum or dried spots.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37817087,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance (sequence-based) interpreted with the Stanford HIVdb algorithm, not in vitro phenotypic drug susceptibility assays.",1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37817087,3,Were sequences from the paper made publicly available?,Boolean,No,No — sequences were not deposited in a public repository in the paper; the datasets including sequences are available from the corresponding author upon reasonable request.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37817087,8,Were samples cloned prior to sequencing?,Boolean,No,No. The methods describe PCR amplification of target regions and direct Illumina NGS (MiSeq) sequencing of amplicons; no cloning step is reported.,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37817087,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not specifically reported; the study analyzed new HIV diagnoses (primary/transmitted resistance), not persons selected for virological failure on treatment, although the authors note some treated cases abroad could be misclassified.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37817087,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Samples were collected as part of national surveillance reporting to the Robert Koch Institute, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37817087,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the study focuses on new diagnoses (primary/transmitted resistance). The authors note they cannot completely exclude that some cases previously treated abroad were misclassified as new diagnoses, but sequences from previously treated individuals are not specifically reported.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37823653,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37823653,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37823653,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No evidence of public deposition in the paper.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1,Not Reported,1,No,1,Not Reported.,1,No,1,No,1,No,1,No,1,Not Reported,1,"Yes, but accession numbers are not provided",0,Yes,0,Not reported,1,Yes,0
Human Answer – Yes/No questions,37823653,8,Were samples cloned prior to sequencing?,Boolean,No,No evidence of cloning; samples were amplified from proviral DNA and sequenced by NGS to produce a consensus.,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not Reported.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37823653,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — sequences from individuals experiencing virologic failure (VL >400 copies/mL) were included; 213 such individuals were analyzed.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37823653,13,Were the patients in the study in a clinical trial?,Boolean,No,"Yes — participants were enrolled in the Botswana Combination Prevention Project (BCPP), which is registered on ClinicalTrials.gov (NCT01965470).",0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Not Reported.,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37823653,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes — sequences from ART-experienced individuals were included (4,748 ART-experienced participants overall).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37872202,1,Does the paper report HIV sequences from patient samples?,Boolean,No,Yes. The study uses HIV env sequences derived from previously reported patient-derived isolates (including a transmitted/founder CRF01_AE T/F100 from participant 40100 of the RV217 cohort) and engineered env constructs.,0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes.,0,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37872202,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,Yes. The paper reports in vitro neutralization/drug susceptibility data for temsavir using single-round luciferase-expressing pseudovirus neutralization assays and reports IC50 values.,1,Yes,1,No,0,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0
Human Answer – Yes/No questions,37872202,3,Were sequences from the paper made publicly available?,Boolean,No,"Partially. Structural data (atomic models and EM maps) were deposited in PDB and EMDB, but no GenBank accession numbers for nucleotide sequences are reported in the Data availability statement.",1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,Yes.,0,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37872202,8,Were samples cloned prior to sequencing?,Boolean,No,Yes—env sequences used in the study were present in cloned expression plasmids and mutations were introduced by site-directed mutagenesis with confirmation by automated DNA sequencing.,0,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported.,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37872202,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No. The manuscript does not report sequences from individuals characterized as experiencing virological failure on antiretroviral therapy.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1,No,1,Not reported.,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37872202,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The manuscript does not describe enrolling patients in a clinical trial; it uses previously collected cohort-derived material (RV217 Early Capture HIV Cohort) and previously reported env constructs.,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37872202,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The paper does not report treatment histories or indicate that the source individuals had previously received antiretroviral drugs.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1,Not reported.,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37878637,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Yes
```",1,Yes,1
Human Answer – Yes/No questions,37878637,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"No
```",1,No,1
Human Answer – Yes/No questions,37878637,3,Were sequences from the paper made publicly available?,Boolean,No,"Partially — underlying study data are available on figshare, but the paper does not report GenBank accession numbers for the sequences.",1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,"Yes
```",0,Yes,0
Human Answer – Yes/No questions,37878637,8,Were samples cloned prior to sequencing?,Boolean,No,No; PCR products were directly sequenced (no cloning step reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,"No
```",1,No,1
Human Answer – Yes/No questions,37878637,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — sequences were obtained from participants experiencing virological failure (PVL ≥ 1000 RNA copies/mL) while on ART.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,"TDF, 3TC, EFV, ATV/r, DRV/r",0,"Yes
```",1,Yes,1
Human Answer – Yes/No questions,37878637,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the study was a cohort study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"No
```",1,No,1
Human Answer – Yes/No questions,37878637,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — participants were on ART (first- or second-line regimens) and some had prior exposure to PMTCT; sequences were obtained from these treated individuals.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,Yes,1,Yes,1,No,0,"Yes
```",1,Yes,1
Human Answer – Yes/No questions,37880705,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports patient-derived HIV-1 pol sequences (1070 sequences) from ART-naïve Ethiopian individuals.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37880705,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper reports genotypic (sequence-based) resistance analysis but does not report in vitro phenotypic drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37880705,3,Were sequences from the paper made publicly available?,Boolean,No,Yes — many sequences were publicly available via GenBank and sequences not found online were requested from study authors; the paper states sequences were downloaded from GenBank or obtained from authors.,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37880705,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported — the paper does not state that samples were cloned prior to sequencing.,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37880705,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — sequences were from ART-naïve individuals and studies among ART-experienced individuals were excluded.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,,1,No,1,No,1
Human Answer – Yes/No questions,37880705,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the paper is a pooled sequence analysis of observational studies/surveillance among ART-naïve individuals, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37880705,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the sequences analyzed come from ART-naïve individuals (i.e., individuals who had not previously received ARV drugs).",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1
Human Answer – Yes/No questions,37896785,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV-1 nucleotide sequences obtained from patient plasma samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37896785,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic resistance (sequence-based) analyses but does not report phenotypic (in vitro) drug susceptibility assays.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37896785,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. The nucleotide sequences were deposited in GenBank.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37896785,8,Were samples cloned prior to sequencing?,Boolean,No,No. The samples underwent RT‑PCR and direct Sanger sequencing; no cloning step is described.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37896785,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. 31 of the 61 women showed virological failure of ART, and their samples were included among the sequenced isolates.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not Reported,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37896785,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The paper describes an observational study of plasma samples from pregnant women seeking PMTCT; there is no indication that patients were enrolled in a clinical trial.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37896785,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. Sequences include samples from 31 women with virological failure of ART (i.e., previously treated individuals).",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37896860,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37896860,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37896860,3,Were sequences from the paper made publicly available?,Boolean,No,No — sequences/data are not publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37896860,8,Were samples cloned prior to sequencing?,Boolean,No,No evidence of cloning; sequencing was performed directly by Sanger methods.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37896860,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes — DRT was targeted to individuals with virologic failure (VL ≥ 1000 copies/mL), and the DRT results reported are from those with VF.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,"Abacavir, Zidovudine, Lopinavir/Ritonavir",0,Yes,1,Yes,1
Human Answer – Yes/No questions,37896860,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes — participants were enrolled in the Opt4Kids randomized controlled trial.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37896860,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — participants were on ART (on or initiating ART) and many had prior ARV exposure at time of sequencing.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37910452,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper is a systematic review/meta-analysis of ART adherence and does not report HIV sequences from patient samples.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,Yes,0
Human Answer – Yes/No questions,37910452,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37910452,3,Were sequences from the paper made publicly available?,Boolean,No,No — no HIV sequences are reported or made publicly available by this paper. The paper's shared data are adherence study data deposited to figshare and Dryad.,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,** No,1,Yes,0
Human Answer – Yes/No questions,37910452,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — no sequencing or cloning was reported.,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,** No,1,No,1
Human Answer – Yes/No questions,37910452,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the paper does not report any sequences; it discusses risk of treatment failure due to sub-optimal adherence but provides no virological failure sequencing data.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,** No,1,Yes,0
Human Answer – Yes/No questions,37910452,13,Were the patients in the study in a clinical trial?,Boolean,No,"Some included studies were randomized controlled trials, but the review as a whole is a meta-analysis of diverse study designs; no sequencing was associated with trial participants.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Not reported,1,** No,1,Yes,0
Human Answer – Yes/No questions,37910452,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report any HIV sequences from individuals (regardless of prior ARV exposure). It discusses individuals on ART in general but provides no sequence data.,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,Yes,0,** No,1,Yes,0
Human Answer – Yes/No questions,37914679,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV sequences (pre-existing low-frequency drug resistance mutations) detected from patient plasma samples using second-generation sequencing.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37914679,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility (phenotypic) assay data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37914679,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report that sequences were deposited in public databases or provide accession numbers.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not Reported,1,No,1,No,1
Human Answer – Yes/No questions,37914679,8,Were samples cloned prior to sequencing?,Boolean,No,No indication of cloning prior to sequencing is given; samples were amplified and directly analyzed by MiSeq.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37914679,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,Yes — sequences were obtained from both patients who later experienced virological failure and from those with successful virological response.,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,"AZT, 3TC, EFV, RPV",1,Yes,0,Yes,0
Human Answer – Yes/No questions,37914679,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a retrospective single-center observational study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Yes,0,No,1
Human Answer – Yes/No questions,37914679,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the study enrolled ART-naïve patients, so sequences were from individuals who had not previously received antiretroviral drugs.",1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,No,1,Yes,0,Yes,0
Human Answer – Yes/No questions,37920909,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports sequencing of HIV-1 integrase genes from patient samples (601 successful sequences).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,37920909,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The study reports genotypic resistance interpretation but does not report in vitro (phenotypic) drug susceptibility assays.,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37920909,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported. The paper does not provide GenBank accession numbers or state that sequences were deposited in a public database.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37920909,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported; no mention of cloning prior to sequencing is made.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,** No,1,No,1
Human Answer – Yes/No questions,37920909,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. All participants were ART-naïve with no prior antiviral treatment, so sequences were not from individuals with virological failure on treatment.",1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,** Yes,0,No,1
Human Answer – Yes/No questions,37920909,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The patients were recruited as outpatients and there is no indication they were enrolled in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37920909,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The study exclusively involved ART-naïve individuals with no prior antiviral treatment.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,** No,1,No,1
Human Answer – Yes/No questions,37938856,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV drug resistance mutation testing by sequencing on patient samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37938856,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper reports genotypic DRM testing (Sanger sequencing) but does not report in vitro phenotypic drug susceptibility assays.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37938856,3,Were sequences from the paper made publicly available?,Boolean,No,No evidence of public deposition of sequences is provided in the paper.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37938856,8,Were samples cloned prior to sequencing?,Boolean,No,No — there is no indication that samples were cloned prior to sequencing; Sanger sequencing is reported without mention of cloning.,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37938856,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes — DRM sequencing was performed on participants with viral load >1000 copies/ml (viraemia), i.e., virological failure while on ART.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37938856,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the study was a pre/post-intervention prospective cohort study, not a randomized clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37938856,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — most participants were on ART at enrolment and DRM testing was performed on viraemic individuals who had prior ART exposure.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37941373,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The study reports sequencing of the HIV-1 integrase (IN) gene from patient plasma samples, generating integrase sequence data for 1,032 patients.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37941373,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance analysis using sequencing and Stanford HIVdb interpretation, not in vitro phenotypic susceptibility assays.",1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37941373,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper does not report public deposition; data are available from the first author on reasonable request.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Not reported,1,No,1
Human Answer – Yes/No questions,37941373,8,Were samples cloned prior to sequencing?,Boolean,No,No. Samples were amplified by nested PCR and sequenced by Sanger dideoxy sequencing; no cloning step is described.,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37941373,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Sequences include samples from ART-treated individuals, including ART-ineffective patients (virological failure) and INSTI-treated patients with resistance.",1,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37941373,13,Were the patients in the study in a clinical trial?,Boolean,No,No. Patients were inpatients and outpatients at Chongqing Public Health Medical Center and not enrolled in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37941373,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. The study sequenced samples from 465 ART-treated individuals (and 102 INSTI-treated patients among them).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37946329,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,"Yes. The study amplified, sequenced, and analyzed partial pol and complete integrase gene-coding sequences from patient plasma samples; pol sequences were successfully obtained from 921 patients and integrase sequences from 751 patients.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,,0
Human Answer – Yes/No questions,37946329,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic resistance testing and predicted resistance via the Stanford HIVdb rather than in vitro phenotypic (cell-based) susceptibility assays.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,,1
Human Answer – Yes/No questions,37946329,3,Were sequences from the paper made publicly available?,Boolean,No,"Not explicitly reported. The paper states sequences were submitted to the Stanford HIVdb for analysis, but it does not state that raw sequences were deposited in public sequence repositories (e.g., GenBank) or provide accession numbers.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,,1
Human Answer – Yes/No questions,37946329,8,Were samples cloned prior to sequencing?,Boolean,No,No indication that samples were cloned prior to sequencing; the paper describes amplification and sequencing but does not mention cloning.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,,1
Human Answer – Yes/No questions,37946329,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. The study specifically targeted people living with HIV who were refractory to ART (viral load >200 copies/mL) and patients who failed ART; sequences derive from these virologically failing, treatment-experienced individuals.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,,0
Human Answer – Yes/No questions,37946329,13,Were the patients in the study in a clinical trial?,Boolean,No,No. The study appears observational/clinical-service–based and does not report enrollment in a clinical trial.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,,1
Human Answer – Yes/No questions,37946329,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. The study focused on ART-experienced patients who failed therapy, and analysis stratifies DRMs by ART regimen types and durations.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"NRTI, NNRTI, PI",0,Yes,1,,0
Human Answer – Yes/No questions,37957382,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The study reports single-genome near-full-length proviral sequences and plasma HIV-1 RNA sequences from participants.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37957382,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No. The paper reports genotypic resistance scoring and viral outgrowth assays, but it does not report classical in vitro phenotypic drug susceptibility assays.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37957382,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. Sequence data were submitted to GenBank under BioProject PRJNA973660.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0
Human Answer – Yes/No questions,37957382,8,Were samples cloned prior to sequencing?,Boolean,Yes,No. The study used limiting-dilution single-genome PCR (endpoint dilution) for near-full-length sequencing rather than cloning.,0,No,0,No,0,No,0,No,0,Not reported,0,No,0,No,0,No,0,No,0,Not reported,0,Not Reported,0,Not reported,0,No,0,No,0,No,0,No,0,No,0,Yes,1,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,37957382,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,"Yes. Sequences were obtained from individuals with persistent low-level viremia while on ART (non-suppressible viremia), i.e., viremia despite being on antiretroviral therapy.",1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,No,0,No,0,Not reported,0,Yes,1,Yes,1,No,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,37957382,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. The participants were enrolled in an observational study (with some comparators from cohort sources), not a clinical trial.",1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not Reported,1,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37957382,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes. All participants were ART-treated with a median ART duration of 10 years and were receiving at least two active antiretroviral drugs during NSV episodes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37966701,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** Not reported,1,No,1
Human Answer – Yes/No questions,37966701,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report any in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,37966701,3,Were sequences from the paper made publicly available?,Boolean,No,"No — no sequences were reported, and the study datasets are not publicly available.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,Not reported,1
Human Answer – Yes/No questions,37966701,8,Were samples cloned prior to sequencing?,Boolean,No,"Not applicable — no sequencing was performed, therefore no cloning was reported.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Yes,0,** No,1,Not reported,1
Human Answer – Yes/No questions,37966701,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — although four confirmed virologic failures occurred, resistance data/sequences were not available or reported.",1,No,1,No,1,Not reported,1,Not reported,1,No.,1,Not reported,1,Yes,0,No,1,No,1,Not reported,1,Yes,0,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,Yes,0,** Yes,0,No,1
Human Answer – Yes/No questions,37966701,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — patients were part of an observational cohort (routine clinical care, OPERA), not a clinical trial.",1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,"NRTI, NNRTI",1,** No,1,No,1
Human Answer – Yes/No questions,37966701,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the paper does not report any HIV sequences, including from individuals with prior ARV exposure.",1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,No,1,Not reported,1,** Yes,0,No,1
Human Answer – Yes/No questions,37973713,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV-1 protease and reverse transcriptase coding region sequences obtained from patients using Sanger sequencing.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37973713,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic resistance data but does not present in vitro (phenotypic) susceptibility testing results.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37973713,3,Were sequences from the paper made publicly available?,Boolean,No,"Partially. Sequences were submitted to the Stanford University HIV Drug Resistance Database, but no public GenBank accession numbers are reported.",1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,No,1,Yes.,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Not reported,1
Human Answer – Yes/No questions,37973713,8,Were samples cloned prior to sequencing?,Boolean,No,No. There is no indication that samples were cloned prior to sequencing; Sanger sequencing with ViroSeq was used.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37973713,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. All sequenced individuals were antiretroviral treatment–naïve at sampling, so sequences were not from cases of virological failure on therapy.",1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37973713,13,Were the patients in the study in a clinical trial?,Boolean,Yes,Yes. The study was registered as a clinical trial (NCT04636736) and received bioethics approval.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Not Reported,0,No.,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37973713,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The paper reports sequences from individuals with no prior history of antiretroviral therapy.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes.,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37976080,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The study reports HIV sequences obtained from patient plasma samples and generated sequence data for the PR/RT regions (pol gene).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,37976080,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The study reports genotypic resistance analysis (sequence-based interpretation) rather than in vitro phenotypic drug susceptibility assays.,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37976080,3,Were sequences from the paper made publicly available?,Boolean,No,"No specific sequence deposit (e.g., GenBank accession numbers) is reported; only web-accessible molecular network results are referenced.",1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** Yes,0,No,1
Human Answer – Yes/No questions,37976080,8,Were samples cloned prior to sequencing?,Boolean,No,No. The paper describes PCR amplification followed by direct Sanger sequencing and does not report cloning prior to sequencing.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37976080,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. The study targeted pretreatment individuals starting or restarting first-line ART; it was not a virological failure cohort, although 3.2% reported prior ARV exposure.",1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37976080,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. This was a multicenter observational cross-sectional surveillance study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,37976080,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes. The study included participants with prior ARV exposure (3.2% of participants), and their sequences were part of the dataset used for PDR analysis.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,37976185,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,37976185,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,37976185,3,Were sequences from the paper made publicly available?,Boolean,No,Not reported / No indication in the paper that sequences were made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,37976185,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No indication that samples were cloned prior to sequencing.,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,** No,1,No,1
Human Answer – Yes/No questions,37976185,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — sequences were baseline genotypes from newly diagnosed individuals, not from people with virological failure on ART.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Not reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,37976185,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,** No,1,Yes,0
Human Answer – Yes/No questions,37976185,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — sequences include individuals with prior PrEP exposure (antiretroviral drugs tenofovir and emtricitabine).,1,No,0,Yes,1,No,0,No,0,No,0,Yes,1,Not reported,0,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Not reported,0,No,0,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,37993493,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37993493,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No — the paper reports genotypic-inferred drug susceptibility, not direct in vitro phenotypic susceptibility assays.",1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37993493,3,Were sequences from the paper made publicly available?,Boolean,No,No — sequences were not deposited in a public repository; data are available on request from the corresponding author/DUCS database.,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes.,0,No,1,No,1,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG), Raltegravir (RAL), Elvitegravir(EVG), Bictegravir (BIC), cabotegravir (CAB), Lenacapavir (LEN)",1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37993493,8,Were samples cloned prior to sequencing?,Boolean,No,No — samples were not cloned; direct plasma-derived PCR products were Sanger-sequenced.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37993493,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — sequences were obtained from individuals with virological failure (defined as VL ≥1000 copies/mL) who were on ART.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,"Tenofovir, lamivudine, and dolutegravir",0,Yes,1,Yes,1
Human Answer – Yes/No questions,37993493,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a cross-sectional survey of routine care patients, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37993493,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,"Yes — the study reports sequences from treatment-experienced individuals who had been on ART (at least one year), mostly on DTG-based regimens and some with prior ART exposures.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,38005921,1,Does the paper report HIV sequences from patient samples?,Boolean,No,Yes. The paper uses amino acid sequences of HIV enzymes derived from clinical samples (from the Stanford HIV Drug Resistance Database) to build and evaluate prediction models.,0,Yes,0,Yes,0,Yes,0,Yes,0,** Yes,0,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes.,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,38005921,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"Yes. The study used phenotype (in vitro) resistance data from the Stanford database, with experimental resistance levels determined by the PhenoSense™ test system.",0,Yes,0,Yes,0,Yes,0,Yes,0,** Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes.,0,No,1,No,1,Yes,0,No,1,Yes,0,No,1,Yes,0,** Yes,0,Yes,0
Human Answer – Yes/No questions,38005921,3,Were sequences from the paper made publicly available?,Boolean,Yes,"Partially yes. The datasets used to build the models are provided in the Supplementary Materials and the web service is publicly available, but no separate GenBank depositions are specified in the paper.",0,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1,No,0,Yes,1,No,0,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,38005921,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported. The paper does not describe any cloning of samples prior to sequencing.,1,No,1,No,1,No,1,Not reported,1,** Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Yes,0,** No,1,Yes,0
Human Answer – Yes/No questions,38005921,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,Not reported. The paper does not state whether sequences correspond specifically to individuals who experienced virological failure on treatment.,1,No,1,No,1,No,1,No,1,** Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes.,0,Not reported,1,No,1,No,1,No,1,Yes,0,Not reported,1,"AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",1,** Not reported,1,Yes,0
Human Answer – Yes/No questions,38005921,13,Were the patients in the study in a clinical trial?,Boolean,No,"Not reported. The sequences were obtained from public genotype–phenotype databases and published studies, but the paper does not state that patients were enrolled in a clinical trial.",1,No,1,No,1,No,1,No,1,** Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,** No,1,Yes,0
Human Answer – Yes/No questions,38005921,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"Not explicitly reported. The paper uses datasets that include resistant and susceptible variants and models resistance to drugs, but it does not explicitly state patients' prior antiretroviral treatment histories.",1,No,1,No,1,Not reported,1,Not reported,1,** Not reported,1,Not reported,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes.,0,Not reported,1,Not reported,1,Yes,0,No,1,Yes,0,Not reported,1,No,1,** Yes,0,Yes,0
Human Answer – Yes/No questions,38020274,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,38020274,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No, not direct in vitro susceptibility assays; only predicted drug efficacy from genotypic data.",1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,38020274,3,Were sequences from the paper made publicly available?,Boolean,No,No evidence in the paper that sequences were made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,** No,1,Yes,0
Human Answer – Yes/No questions,38020274,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / no evidence of cloning prior to sequencing.,1,No,1,No,1,Not reported,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,38020274,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,** Yes,1,Yes,1
Human Answer – Yes/No questions,38020274,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a prospective cohort study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,38020274,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,38022124,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,** No,1,** No,1
Human Answer – Yes/No questions,38022124,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,** No,1
Human Answer – Yes/No questions,38022124,3,Were sequences from the paper made publicly available?,Boolean,No,No — there are no sequences reported and therefore none made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,** No,1
Human Answer – Yes/No questions,38022124,8,Were samples cloned prior to sequencing?,Boolean,No,No — samples were not cloned prior to sequencing (no sequencing was performed).,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,** No,1
Human Answer – Yes/No questions,38022124,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — no sequences were obtained; the study reports virological outcomes but does not report sequencing of samples from individuals with virological failure.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,Not reported,1,** No,1,** No,1
Human Answer – Yes/No questions,38022124,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a retrospective observational (real-life) study, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,** No,1,** No,1
Human Answer – Yes/No questions,38022124,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report HIV sequences; it does report that many participants were treatment-experienced prior to switching to BIC/FTC/TAF.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,** No,1,** Yes,0
Human Answer – Yes/No questions,38031075,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes.,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,38031075,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38031075,3,Were sequences from the paper made publicly available?,Boolean,No,No — there were no sequences generated to be made public.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1
Human Answer – Yes/No questions,38031075,8,Were samples cloned prior to sequencing?,Boolean,No,No — sequencing was not performed (so no cloning occurred).,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38031075,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — no sequencing was performed. The study did report individuals with detectable or low-level viremia while on ART.,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes.,0,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,"Tenofovir, Lamivudine, Dolutegravir",1,Yes,0,Yes,0
Human Answer – Yes/No questions,38031075,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a cross-sectional observational survey, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38031075,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — no sequences were reported; however the study population predominantly consisted of individuals receiving ART.,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,No,1,Yes,0,No,1,Not reported,1,Yes,0,Yes.,0,Not reported,1,Not reported,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0
Human Answer – Yes/No questions,38033131,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1
Human Answer – Yes/No questions,38033131,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report any in vitro drug susceptibility data.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38033131,3,Were sequences from the paper made publicly available?,Boolean,No,No — there are no sequences reported and thus none made publicly available.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38033131,8,Were samples cloned prior to sequencing?,Boolean,No,Not applicable — no sequencing or cloning was reported.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38033131,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — no sequences were obtained from any individuals, including those with virological failure.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Yes,0,No,1,No,1,Yes,0,No,1,"AZT, 3TC, EFV, NVP, LPV/r, ATV/r, and DRV/r",1,Yes,0,No,1
Human Answer – Yes/No questions,38033131,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — the patients were part of routine care and the study was a retrospective follow-up of clinical records, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38033131,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No — the paper does not report any HIV sequences; however, the participants were children and adolescents who had received ARV therapy (first-line ART).",1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Not reported,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1
Human Answer – Yes/No questions,38058846,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Not explicitly — the paper reports HIV drug resistance testing results for three patients but does not explicitly state that HIV sequences from patient samples are reported.,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,38058846,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No — the paper does not report in vitro drug susceptibility (phenotypic) data.,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,38058846,3,Were sequences from the paper made publicly available?,Boolean,No,No — there is no indication that HIV sequences were deposited in public repositories.,1,No,1,No,1,Not Reported,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,Yes,0,** No,1,No,1
Human Answer – Yes/No questions,38058846,8,Were samples cloned prior to sequencing?,Boolean,No,Not stated / no indication that samples were cloned prior to sequencing.,1,No,1,No,1,Not Reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,** No,1,No,1
Human Answer – Yes/No questions,38058846,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — all three cases had virological failure while on DTG-containing regimens when resistance testing was performed.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,38058846,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — they were patients managed in clinical care and included as a case series, not participants in a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,** No,1,Yes,0
Human Answer – Yes/No questions,38058846,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — at least two of the three cases had prior antiretroviral therapy exposure before the resistance testing.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,38072961,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — genotypic (Sanger) sequencing of HIV from patient CSF and plasma was performed.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38072961,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No — the paper reports genotypic (Sanger) resistance testing, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38072961,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report deposition of sequences in public databases.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38072961,8,Were samples cloned prior to sequencing?,Boolean,No,No indication that samples were cloned prior to sequencing; standard Sanger population genotyping was reported.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported.,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1
Human Answer – Yes/No questions,38072961,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — sequencing was performed on samples from a patient experiencing virological failure/CSF viral escape while on ART.,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1
Human Answer – Yes/No questions,38072961,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this is an individual case report, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,No,1,No,1
Human Answer – Yes/No questions,38072961,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes — the patient had prior ART exposure and sequencing was performed on samples from that patient.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1
Human Answer – Yes/No questions,38090027,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,No,0,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,No,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38090027,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,38090027,3,Were sequences from the paper made publicly available?,Boolean,No,No (not reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Not Reported,1,No,1,No,1
Human Answer – Yes/No questions,38090027,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported / No evidence of cloning.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38090027,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes — GRTs were performed/evaluable in five patients who experienced virological failure.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,No,0,Yes,1,Yes,1,Yes,1,"Elvitegravir, cobicistat, and tenofovir alafenamide",0,Yes,1,Yes,1
Human Answer – Yes/No questions,38090027,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was an observational, retrospective cohort in routine clinical practice (though a small number later enrolled in clinical trials).",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38090027,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Not reported,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,38140553,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes. The paper reports HIV-1 sequences obtained from patient samples (partial pol sequences covering protease and part of reverse transcriptase).,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38140553,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper reports genotypic drug resistance (DRM) analysis but does not report in vitro phenotypic drug susceptibility assays.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38140553,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. All nucleotide sequences obtained were deposited in the Los Alamos HIV sequence database.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38140553,8,Were samples cloned prior to sequencing?,Boolean,No,No. Samples were amplified by nested PCR and directly Sanger-sequenced; no cloning step is reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38140553,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"Not explicitly reported. The paper states sequences came from patients both receiving ART and not on ART, but it does not explicitly state which sequences were from individuals with virological failure.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Not reported.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38140553,13,Were the patients in the study in a clinical trial?,Boolean,No,"No. Patients were sampled as part of routine molecular genetic monitoring at federal and regional AIDS Centers, not as participants in a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38140553,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"Partially. The cohort includes patients both receiving ART and not on ART at the time of sampling, but the authors state they could not reliably determine past treatment history for all patients.",1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Not reported,1,Yes,0,Not reported.,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,38140649,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38140649,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38140649,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38140649,8,Were samples cloned prior to sequencing?,Boolean,No,No (no cloning step reported).,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported.,1,No,1,No.,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38140649,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,38140649,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38140649,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"No, sequences are from treatment-naïve individuals (no prior ARV).",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No.,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1
Human Answer – Yes/No questions,38140667,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No. This article is a literature review and does not report new HIV sequences from patient samples.,1,No,1,Yes,0,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,38140667,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No. The paper does not present original in vitro drug susceptibility data; it only references published findings and in vitro passage experiments reported elsewhere.,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38140667,3,Were sequences from the paper made publicly available?,Boolean,No,No. The paper did not generate new sequences and therefore did not deposit sequences in public repositories.,1,No,1,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38140667,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported in this review. The paper does not provide details indicating that samples were cloned prior to sequencing.,1,No,1,No,1,Not reported.,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Yes (in one study),0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38140667,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,Yes. Many of the cited studies obtained sequences from individuals experiencing virologic failure on DTG-based or other INSTI-containing regimens.,0,No,1,Yes,0,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,38140667,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this paper is a literature review of real-world cohorts, case studies, and some clinical trials; the patients discussed come from a mix of study types, but the review itself does not enroll patients in a trial.",1,No,1,No,1,No.,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Yes (in some studies),0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38140667,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,"Yes. The review includes many sequences/genotypes from treatment-experienced individuals, including those with prior exposure to NRTIs, NNRTIs, PIs, and first-generation INSTIs (RAL, EVG).",0,No,1,Yes,0,Yes.,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,38142692,1,Does the paper report HIV sequences from patient samples?,Boolean,No,No.,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,"Yes

""""

""""",0,Yes,0
Human Answer – Yes/No questions,38142692,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"No

""""

""""",1,No,1
Human Answer – Yes/No questions,38142692,3,Were sequences from the paper made publicly available?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,"No

""""

""""",1,No,1
Human Answer – Yes/No questions,38142692,8,Were samples cloned prior to sequencing?,Boolean,No,No (not applicable — no sequencing was performed).,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,No,1,Yes,0,"No

""""

""""",1,No,1
Human Answer – Yes/No questions,38142692,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No sequences were obtained.,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,Yes,0,"Yes

""""

""""",0,Yes,0
Human Answer – Yes/No questions,38142692,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a retrospective observational cohort study using routine-care data, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,"No

""""

""""",1,No,1
Human Answer – Yes/No questions,38142692,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No sequences reported; study participants had prior ARV exposure (mostly first-line TDF/XTC/EFV).,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,Yes,0,No,1,Yes,0,Yes,0,Yes,0,NRTIs and NNRTIs,1,"Yes

""""

""""",0,Yes,0
Human Answer – Yes/No questions,38152686,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,38152686,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,38152686,3,Were sequences from the paper made publicly available?,Boolean,No,No — information is available only upon request; no public deposit is reported.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,** No,1,No,1
Human Answer – Yes/No questions,38152686,8,Were samples cloned prior to sequencing?,Boolean,No,Not reported.,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,** No,1,No,1
Human Answer – Yes/No questions,38152686,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,38152686,13,Were the patients in the study in a clinical trial?,Boolean,No,No.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,** No,1,Yes,0
Human Answer – Yes/No questions,38152686,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,** Yes,1,Yes,1
Human Answer – Yes/No questions,38314093,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,Yes — the paper reports HIV-1 protease-reverse transcriptase (PR-RT) gene sequences obtained from patient samples.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38314093,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,"No — the study reports genotypic resistance analysis and predicted drug sensitivity from sequence data, not in vitro phenotypic susceptibility assays.",1,Yes,0,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38314093,3,Were sequences from the paper made publicly available?,Boolean,No,No — the paper does not report public deposition of sequences (no GenBank accession numbers are provided).,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38314093,8,Were samples cloned prior to sequencing?,Boolean,No,No — there is no indication that samples were cloned; cDNA was amplified and subjected to high-throughput sequencing.,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38314093,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No — the sequenced samples came from untreated patients, not from individuals reported to have virological failure on treatment.",1,No,1,No,1,No,1,Yes,0,No,1,No,1,Not reported,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,"AZT, 3TC, EFV, NVP, TDF, FTC, ATV, RTV, RAL, DTG, BIC, CAB, LEN, MVC",1,No,1,Not reported,1
Human Answer – Yes/No questions,38314093,13,Were the patients in the study in a clinical trial?,Boolean,No,"No — this was a retrospective observational study of routine laboratory samples, not a clinical trial.",1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38314093,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the sequences analyzed were from untreated patients; the paper does not report sequences from individuals with prior ARV exposure.,1,No,1,No,1,No,1,Yes,0,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38427738,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No — the paper reports sequencing of viral genomes derived from in vitro cell culture and molecular clones, not from patient-derived clinical samples.",1,No,1,No,1,Yes,0,No,1,No.,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38427738,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,"Yes — the paper reports extensive in vitro drug susceptibility and resistance assays (IC50/AUC, fold-change) for multiple antiretrovirals.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38427738,3,Were sequences from the paper made publicly available?,Boolean,No,No explicit public sequence deposition is reported; the paper does not provide GenBank accession numbers and states that data are present in the paper/supplementary materials and materials are available upon request.,1,No,1,No,1,No,1,No,1,No.,1,No,1,Not clearly reported,1,No,1,No,1,Not Reported,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,38427738,8,Were samples cloned prior to sequencing?,Boolean,No,"For the initial sequencing of viral regions from infected cultures, PCR amplicons were directly sequenced (not cloned); however, env amplicons were cloned into molecular clones for subsequent functional analyses.",1,No,1,No,1,No,1,No,1,Yes.,0,No,1,No,1,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,No,1
Human Answer – Yes/No questions,38427738,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,No — the study did not sequence viruses from individuals experiencing virological failure; it performed in vitro selection and mentions clinical observations from other studies but did not analyze patient-derived failure samples.,1,No,1,No,1,No,1,No,1,No.,1,No,1,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,38427738,13,Were the patients in the study in a clinical trial?,Boolean,No,Not applicable — there were no patient participants or clinical trial subjects in this study.,1,No,1,No,1,No,1,No,1,Not reported.,1,No,1,Yes,0,No,1,No,1,Not Reported,1,Not Reported,1,Not reported,1,No,1,Not reported,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,38427738,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No — the paper does not report sequences from individuals with prior ARV exposure; all sequences derive from in vitro cultured viruses and lab/previously described isolates.,1,No,1,No,1,No,1,No,1,No.,1,Yes,0,Yes,0,No,1,No,1,Yes,0,Yes,0,Yes,0,Not reported,1,Not reported,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,38864613,1,Does the paper report HIV sequences from patient samples?,Boolean,No,"No. The reported sequences derive from in vitro resistance-selection experiments (culture supernatants), not from patient samples.",1,No,1,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38864613,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,"Yes. The paper reports extensive in vitro antiviral activity data (IC50 values and fold-changes) for ISL, LEN, and variants.",1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38864613,3,Were sequences from the paper made publicly available?,Boolean,Yes,Yes. Sequences from the resistance selection experiments were deposited in GenBank.,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0
Human Answer – Yes/No questions,38864613,8,Were samples cloned prior to sequencing?,Boolean,No,No. Sequencing was performed by population-based Sanger sequencing of RT-PCR products rather than by cloning.,1,No,1,No,1,No,1,Not Reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,Not reported,1,No,1,Yes,0,Yes,0,Not reported,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,38864613,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,"No. All sequences were obtained from in vitro resistance-selection experiments, not from patients experiencing virological failure on treatment.",1,No,1,No,1,Not reported,1,No,1,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,38864613,13,Were the patients in the study in a clinical trial?,Boolean,No,No. There were no patients in this study; it was an in vitro study using laboratory virus and cell culture.,1,No,1,No,1,No,1,No,1,Not reported,1,Yes,0,Yes,0,No,1,No,1,Not reported,1,Not reported,1,Not reported,1,No,1,No,1,No,1,No,1,Not reported,1,Not reported,1,Not Reported,1,Yes,0,No,1
Human Answer – Yes/No questions,38864613,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,No. The reported sequences are from in vitro-selected viruses and not from individuals with prior ARV exposure.,1,No,1,No,1,Not reported,1,No,1,Not reported,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0,Yes,0,No,1,No,1,No,1,No,1,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
